<SEC-DOCUMENT>0001213900-23-024260.txt : 20230330
<SEC-HEADER>0001213900-23-024260.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230329215655
ACCESSION NUMBER:		0001213900-23-024260
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cadrenal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001937993
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880860746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41596
		FILM NUMBER:		23776979

	BUSINESS ADDRESS:	
		STREET 1:		822 A1A NORTH
		STREET 2:		SUITE 300
		CITY:			PONTE VEDRA
		STATE:			FL
		ZIP:			32082
		BUSINESS PHONE:		904-300-0701

	MAIL ADDRESS:	
		STREET 1:		822 A1A NORTH
		STREET 2:		SUITE 300
		CITY:			PONTE VEDRA
		STATE:			FL
		ZIP:			32082
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_cadrenalth.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:09 UTC 2023 -->
<html xmlns:cvkd="http://www.cadrenal.com/20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from ___ to ___</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-41596</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>CADRENAL THERAPEUTICS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its
charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 0.8pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 0.8pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>88-0860746</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of <br/> incorporation or organization)</span></td> <td>&#160;</td> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer <br/> Identification No.)</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">822 A1A North</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Suite 306</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Ponte Vedra</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric> 32082</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32082</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td>&#160;</td> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number, including
area code: <b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(904)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">300-0701</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; width: 2%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol(s)</b></span></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; width: 2%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 0.8pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding-right: 0.8pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVKD</span></ix:nonNumeric></td> <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding-right: 0.8pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Stock Market, LLC</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td style="padding-right: 0.8pt; text-align: center">&#160;</td> <td style="padding-right: 0.8pt; text-align: center">&#160;</td> <td style="padding-right: 0.8pt; text-align: center">&#160;</td> <td style="padding-right: 0.8pt; text-align: justify">&#160;</td> <td style="padding-right: 0.8pt; text-align: center">(The Nasdaq Capital Market)</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(g)
of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 43%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 6%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 39%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 12%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="padding-right: 0.8pt; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="padding-right: 0.8pt; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting common equity
held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#8217;s common stock on January 24,
2023, as reported by the Nasdaq Capital Market on such date was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">13,279,306</ix:nonFraction>. The registrant has elected to use January 24,
2023, which was the date of the closing of registrant&#8217;s initial public offering, as the calculation date because on June 30, 2022
(the last business day of the registrant&#8217;s mostly recently completed second fiscal quarter), the registrant was a privately-held
company. Shares of the registrant&#8217;s common stock held by each executive officer, director and holder of 5% or more of the outstanding
common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination
that certain persons are affiliates of the registrant for any other purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 29, 2023, there were <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">11,634,575</ix:nonFraction> shares of Common Stock,
$0.001 par value per share, outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DOCUMENTS INCORPORATED BY REFERENCE: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CADRENAL THERAPEUTICS, INC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#c_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><a href="#c_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="vertical-align: bottom; text-align: center">3</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_002i">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center">28</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_003">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center">64</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_004">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center">64</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_005">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center">64</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_006">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center">64</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_007">PART II</a></b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_008">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_009">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; text-align: center">68</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_010">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center">69</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_011">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_012">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center">F-1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_013">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: center">76</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_014">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center">76</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_015">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center">76</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_016">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom; text-align: center">76</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_017">PART III</a></b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_018">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center">77</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_019">Executive Compensation</a>
    </span></td>
    <td style="vertical-align: bottom; text-align: center">83</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center">91</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_021">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_022">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center">95</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_023">PART IV</a></b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_024">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center">96</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_025">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center">96</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This Annual Report on Form&#160;10-K (this
&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933,
as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&#160;I,
Item&#160;1. &#8220;Business,&#8221; Part&#160;I, Item&#160;1A. &#8220;Risk Factors,&#8221; and Part&#160;II, Item&#160;7. &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report
in some cases you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221;
&#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and
are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>You should refer to Item&#160;1A. &#8220;Risk
Factors&#8221; section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially
from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking
statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all. We do not undertake any obligation to update any forward-looking statements. Unless the context requires otherwise,
references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Cadrenal,&#8221; refer to Cadrenal Therapeutics,&#160;Inc.
and its subsidiaries.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>This Annual Report
also contains market data related to our business and industry. These market data include projections that are based on a number of assumptions.
If these assumptions turn out to be incorrect, actual results may differ from the projections based on these assumptions. As a result,
our markets may not grow at the rates projected by these data, or at all. The failure of these markets to grow at these projected rates
may harm on our business, results of operations, financial condition and the market price of our common stock.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note Regarding Company References</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout this Annual Report, &#8220;Cadrenal,&#8221;
&#8220;the Company,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to Cadrenal Therapeutics, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business faces significant risks and uncertainties
of which investors should be aware before making a decision to invest in our common stock. If any of the following risks are realized,
our business, financial condition and results of operations could be materially and adversely affected. The following is a summary of
the more significant risks relating to the Company. A more detailed description of our risk factors is set forth below under the caption
&#8220;Risk Factors&#8221; in Item 1A in Part I of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Financial Position
and Need for Capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We have a limited operating history, a history of losses and expect
to continue to incur losses<i>;</i></td>
</tr>
     </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our cash and the proceeds from our initial public offering will only fund our operations for a limited time;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We will need to
                                            raise additional capital.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Product Development, Regulatory
Approval, Manufacturing and Commercialization</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business is dependent upon the success of tecarfarin, which requires additional clinical testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of our current data for tecarfarin are the results of clinical trials conducted by third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our development efforts may not generate data sufficient to support regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we complete our clinical trials, we may not receive regulatory approval for tecarfarin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast Track designation and Orphan Drug Designation by the FDA does not assure FDA approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain regulatory approval, we may not enjoy marketing exclusivity and we may face development, regulatory or labeling difficulties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials are very expensive, time-consuming and difficult to design and implement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may experience delays in the enrollment of patients in any or all of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If tecarfarin is approved, our success depends on our commercialization efforts and market acceptance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never submitted an NDA to the FDA or comparable applications to other regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After approval of tecarfarin, it will remain subject to regulatory obligations&#160;&#160;and other restrictions ;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to federal and state obligations and regulations applicable to our marketing practices;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently do not have an agreement with a third-party manufacturer to produce tecarfarin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the manufacturer fails to comply with stringent regulations, we may face delays;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face substantial competition;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious adverse effects may be identified with respect to our products, which may harm our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently enacted and future legislation may affect marketing approval and commercialization of tecarfarin; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject to penalties if we violate healthcare fraud and abuse laws or price reporting laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to generate product revenues will be diminished if our products sell for inadequate prices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will rely on third parties to conduct all of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have limited distribution, marketing, support and sales capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our employees, contractors, consultants, commercial partners and vendors may engage in misconduct;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are not successful establishing a sales force, our ability to generate sales and profits will be limited;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to rely on collaborations with third parties to commercialize, market and promote our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future growth depends, in part, on our ability to penetrate foreign markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ongoing COVID-19 global health crisis may impact our planned operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with regulations regarding the treatment of animals could increase our costs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Company-Related Risks</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Our business depends
                                            upon our ability to attract and keep senior management and key scientific personnel;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We will need to
                                            increase the size of our organization, and we may experience difficulties managing this;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">If product liability
                                            lawsuits are brought against us, we may incur substantial liabilities;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Computer system
                                            failures could be costly and expose us to litigation and government enforcement actions;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Acquisitions of other businesses could harm our operating results;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Declining general
                                            economic or business conditions may have a negative impact on our business.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We may be unable
                                            to obtain and maintain market exclusivity or patent protection for tecarfarin;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">To date, we have
                                            not engaged intellectual property counsel to conduct a freedom to operate analysis;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We may become involved in intellectual property lawsuits, which could
be costly and time consuming;</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Patent law changes
                                            in the United States and other jurisdictions could diminish the value of patents;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Patent protection depends on compliance with requirements imposed by governmental patent agencies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may not be able to enforce our intellectual property rights throughout the world;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Patent terms may be inadequate to protect our competitive position on our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Ownership of Our Common
Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">An active public trading market for our common stock may not develop or be sustained;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We cannot be assured that we will be able to maintain our listing on the Nasdaq Capital Market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our stock price has been extremely volatile;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">If favorable research or reports about us are not published our stock price could decline;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our officers, directors, and principal stockholders exercise significant control over our Company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">As a &#8220;controlled company&#8221; we may choose to be exempt from certain corporate governance requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Future sales of common stock could depress the market price of our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our charter documents have anti-takeover provisions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Claims for indemnification by our directors and officers may reduce our available funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We do not intend to pay dividends in the foreseeable future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Certain members of our management team have limited experience managing a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We will incur significant increased costs as a result of operating as a public company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We are an emerging growth company and may avail ourselves of reduced disclosure requirements or extended transition periods for complying with new or revised accounting standards.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are focused on developing tecarfarin, a novel
therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients
with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. We secured the rights to tecarfarin on
April 1, 2022 via an asset purchase agreement from HESP LLC, a wholly owned subsidiary of Horizon Technology Finance Corporation. HESP
LLC acquired the assets of Espero BioPharma, Inc., or Espero, including tecarfarin, in an assignment for the benefit of creditors in
which the creditor, Horizon Technology Finance Corporation and Horizon Credit II LLC (collectively, Horizon), a secured lender of Espero,
designated HESP LLC as the assignee of Espero&#8217;s assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin is an anticoagulant that uses a drug
design process which targets a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib.
Tecarfarin has been evaluated in eleven (11) human clinical trials conducted by its previous owners and other third parties in over 1,003
individuals (269 patients were treated for at least six months and 129 patients were treated for one year or more). In Phase 1, Phase
2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic
kidney disease, or CKD. In the Phase 2/3 trial, EMBRACE-AC, the largest tecarfarin trial with 607 patients having completed it, only
1.6% of the blinded tecarfarin subjects suffered from major bleeding and there were no thrombotic events. Five patients died during the
trial, but only one death due to intracerebral hemorrhage was considered to be possibly related to the tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019, the United States Food and Drug Administration,
or FDA, provided input on the Phase 3 trial design for tecarfarin, which was submitted by Espero, the previous owner of tecarfarin. We
intend to submit our Phase 3 trial design to the FDA using the same protocol that was submitted by Espero. Assuming the FDA accepts our
Phase 3 trial design, we intend to commence the Phase 3 pivotal trial in the first half of 2024. However, there can be no assurance that
the trial design will be accepted by the FDA. We are pursuing regulatory approval of tecarfarin as an individual treatment, although
we might evaluate, in consultation with the FDA, other potential uses in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2019, the FDA granted orphan drug designation,
or ODD, for tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients with ESRD and AFib. The FDA grants
ODD status to drugs that are intended for the treatment, diagnosis, or prevention of rare diseases or conditions, which are defined as
a disease or condition that affects fewer than 200,000 people in the U.S. The ODD program provides a drug developer with certain benefits
and incentives, including a seven-year period of U.S. marketing exclusivity from the date of marketing authorization, waiver of FDA user
fees, and tax credits for clinical research. The granting of an orphan drug designation does not alter the FDA&#8217;s regulatory requirements
to establish safety and effectiveness of a drug through adequate and well-controlled studies to support approval and commercialization.
Furthermore, orphan drug designation does not indicate or guarantee FDA approval of the New Drug Application, or NDA, and we might not
receive exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin was developed by researchers using
a retrometabolic drug design process which targets a different metabolic pathway than the most commonly prescribed drugs for the treatment
of thrombosis and AFib. &#8220;Drug metabolism&#8221; refers to the process by which a drug is inactivated by the body and rendered easier
to eliminate or to be cleared by the body. Most approved drugs, including warfarin, the only FDA-approved Vitamin K antagonists, or VKAs,
which is a prescribed drug for the treatment of thrombosis, are metabolized in the liver through a pathway known as the Cytochrome CYP450
system, or CYP450, by the enzymes known as CYP2C9 and CYP3A4. By using a different metabolic pathway, tecarfarin eliminates or minimizes
the CYP450 metabolism in the liver. Patients taking multiple medications that interact with CYP2C9, or CYP3A4 or those with impaired
kidney function, can experience an overload in the pathway, creating a bottleneck that often leads to insufficient clearance, which results
in a toxic build-up of one or more drugs. In some instances, patients taking multiple medications metabolized by the same CYP450 pathway
may experience decreased efficacy of one or more of the medications due to rapid metabolism or increased drug effect and/or toxicity
due to enzyme induction. Patient-specific genetic differences can also hinder drug clearance in the CYP450 pathway. Our product candidate
tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450
pathways. We believe this may allow elimination by large capacity and non-saturable tissue esterase pathways that exist throughout the
body rather than just in the liver.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin is an orphan designated, vitamin K
antagonist, oral, once-daily anticoagulant in the same drug class as warfarin designed for use in patients requiring chronic VKA anticoagulation,
to prevent systemic thromboembolism of cardiac origin in patients with ESRD and AFib. The prevailing treatment for thrombosis is with
an oral anticoagulant, either a VKA, like warfarin, or non-vitamin K oral anticoagulant (&#8220;NOAC&#8221;). VKAs block the production
of vitamin K-dependent blood clotting factors, such that the blood is &#8220;thinned,&#8221; preventing clots, while NOACs directly block
the activity of certain of these clotting factors. Tecarfarin, like warfarin, is a VKA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vitamin K epoxide Reductase Complex subunit 1
(VKORC1) is a significant enzyme for effective clotting. VKORC1 reduces vitamin K epoxide to its active form (Vitamin K), which is the
rate-limiting step in the physiological process of vitamin K recycling. Vitamin K serves as a cofactor for normal function of several
clotting/anticoagulation factors including Factors II, VII, IX and X and Proteins C, S, and Z. VKORC1 genetic deficiencies result in
increased sensitivity to VKAs, which results in an increase in the risk of significant hemorrhaging. We believe tecarfarin has similar
potency for VKORC1 inhibition as warfarin, but it is an investigational new drug, and we must demonstrate it is safe and effective for
its proposed indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AFib is the most common arrhythmia, with its
incidence and prevalence increasing over the last 20 years. AFib is associated with an approximate five-fold increased risk of stroke.
The risk of developing AFib increases in patients with CKD. According to 2021 estimates by the Centers for Disease Control and Prevention,
or CDC, approximately 15% of the U.S. adult population, or 37 million people, have CKD. An estimated 0.4% of people in the U.S. suffer
from Stage 4 CKD and 0.1% of people in the U.S. have ESRD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients with ESRD and AFib represent a spectrum
of disorders involving both the heart and kidneys (known as cardiorenal syndrome or CRS) in which acute or chronic dysfunction in one
organ may induce acute or chronic dysfunction in the other organ. These patients have typically been excluded from randomized clinical
trials because the approved therapies for AFib have metabolic profiles that may increase drug exposures thereby increasing the known
risks and challenges in managing these patients. The presence of either CKD or AFib, increases the risk of serious thromboembolic adverse
clinical outcomes, such as stroke and death. Antithrombotic therapy is typically recommended to decrease this risk in AFib patients,
but there are no approved treatment options for patients with ESRD and AFib. Warfarin may cause substantial harm in these patients. Low-dose
apixaban (Eliquis) was approved by the FDA for use in ESRD patients on hemodialysis based upon limited pharmacokinetic data by 8 subjects,
despite that randomized trials to date of apixaban versus warfarin for AFib excluded patients with severe and end-stage kidney disease.
The RENAL-AF (Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation) was terminated early in 2019
by its sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are more than 809,000 Americans with ESRD,
with approximately 70% on dialysis, according to the United States Renal Data System. Approximately 150,000 ESRD patients also have AFib.
AFib nearly doubles the anticipated mortality and increases the stroke risk by approximately five-fold in these patients. There is evidence
that AFib is an independent risk factor for developing ESRD in CKD patients. Both diseases share common risk factors including hypertension,
diabetes, vascular disease, and advancing age. Cardiovascular disease contributes to more than half of all deaths among patients with
ESRD. According to the Annual Data Report published by the United States Renal Data System, total Medicare spending for patients with
ESRD reached $51 billion in 2019, accounting for approximately 7% of the Medicare paid claims costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have licensed out the rights to tecarfarin
for several Asian markets including China, to Lee&#8217;s Pharmaceutical Holdings Limited, an integrated research-driven and market-oriented
biopharmaceutical publicly listed company based in Hong Kong with over 25 years&#8217; experience in the pharmaceutical industry in China.
Lee&#8217;s Pharmaceutical Holdings Limited is developing tecarfarin as an anti-thrombotic for patients with mechanical heart valves.
In 2020 and 2021, Lee&#8217;s Pharmaceutical Holdings Limited completed two Phase 1 studies in China and Hong Kong and is currently preparing
for its Phase 2 trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/>&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><b>*</b></td><td style="text-align: justify">The rights to tecarfarin for several Asian markets including
China have been out licensed to Lee&#8217;s Pharmaceutical, a publicly listed company based in Hong&#160;Kong, who is developing tecarfarin
as an anti-thrombotic&#160;for patients with mechanical heart valves.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Members of our management team have extensive
experience in drug discovery, development and commercialization and have held senior leadership positions at a number of pharmaceutical
and biotechnology companies. We also benefit from our broad network of established relationships with leaders in the industry and medical
community.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As more fully set forth in our risk factors,
we are a clinical development biopharmaceutical company with a limited operating history. We have a history of operating losses and expect
to continue to incur substantial losses for the foreseeable future. Our cash and the proceeds from our initial public offering will only
fund our operations for a limited time. The proceeds from our initial public offering are insufficient to allow us to fully fund our
planned pivotal Phase 3 clinical trial. We will need to raise additional capital for the initiation of enrollment of patients and completion
of the planned pivotal Phase 3 trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to tecarfarin, we have two issued
U.S. patents directed to tecarfarin. While the patents currently expire in 2024, we expect to seek extensions of patent terms. In the
United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years
beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during
the period of extension). We also intend to seek exclusivity for our proprietary product candidates through market and data exclusivity
granted by regulatory agencies in the United States and other countries. Further, as discussed above, the ODD program provides a drug
developer with certain benefits and incentives, including a seven-year period of U.S. marketing exclusivity from the date of marketing
authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we have engaged intellectual property counsel
to assist in protecting our patent ownership rights, to date, we have not had intellectual property counsel conduct a freedom to operate
analysis regarding our tecarfarin product. As a result, we cannot be certain that we will not be exposed to third party legal claims,
liabilities and/or litigation actions when we seek to develop, make and market products using our tecarfarin technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Trials</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin has been evaluated in 11 human clinical
trials in over 1,003 individuals which includes eight Phase 1 trials, two Phase 2 trials and one Phase 2/3 trial evaluating the efficacy
and safety of tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a Phase 2/3 randomized and blinded trial sponsored
by ARYx Therapeutics, Inc. in 2008, 607 patients with indications for chronic anticoagulation were treated with either tecarfarin or
warfarin. The Time in Therapeutic Range, or TTR, with tecarfarin was similar to that with well-managed warfarin and tecarfarin appeared
to have a favorable safety profile and be well tolerated with only 1.6% of the blinded tecarfarin subjects suffering from major bleeding
and no thrombotic events. When thrombotic and major bleeding events during the blinded period were combined, a numerical imbalance favoring
tecarfarin over warfarin was seen (warfarin 11 subjects, 3.6%; tecarfarin 5 subjects, 1.6%). The trial however did not meet its primary
endpoint as superiority of tecarfarin over warfarin as measured by TTR was not demonstrated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a subsequent Phase 1 study with 23 patients
with CKD sponsored by Armetheon, Inc. in 2016, the metabolism of warfarin was inhibited, but not tecarfarin. The safety of repeated dosing
of tecarfarin in CKD patients remained unknown. However, if the pharmacokinetic findings of this single-dose study are present with repeated
dosing, tecarfarin may lead to dosing that is more predictable than warfarin in CKD patients who require anticoagulation therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Events</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track Designation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2023, the FDA designated as a
Fast Track development program the investigation of tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients
with ESRD and AFib. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious
conditions and fill an unmet medical need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initial Public Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On January 24, 2023,
we completed our initial public offering of 1,400,000 shares of our common stock at a public offering price of $5.00 per share, generating
gross proceeds of $7,000,000. Our shares of common stock commenced trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on January
20, 2023 under the symbol &#8220;CVKD.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with our
initial public offering, on January 19, 2023, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
Boustead Securities, LLC, as representative of the underwriters (the &#8220;Representative&#8221;), a form of which was previously filed
as an exhibit to our registration statement on Form&#160;S-1, as amended (File No.&#160;333-267562), which was declared effective by
the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 19, 2023 (the &#8220;Registration Statement&#8221;).&#160;Pursuant
to the Underwriting Agreement, we agreed to issue to the underwriters a five-year warrant (the &#8220;Representative&#8217;s Warrant&#8221;)
to purchase an aggregate of 84,000 shares of our common stock, which is equal to six percent (6%) of the shares of common stock sold
in the initial public offering. Such Representative&#8217;s Warrant has an exercise price of $6.00, which is equal to 120% of the public
offering price of the common stock in the initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with the
closing of the initial public offering, we entered into separate indemnification agreements with each of our directors (we had previously
entered into separate indemnification agreements with each of our executive officers). The indemnification agreements, in addition to
our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, require us to indemnify our directors, executive
officers and certain controlling persons to the fullest extent permitted by Delaware law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Resale Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a separate prospectus (the &#8220;Resale
Prospectus&#8221;), dated January 19, 2023, 1,704,783 shares of our common stock have been registered for resale by certain of our shareholders
(the &#8220;Selling Shareholders&#8221;). We did, and will not, receive any proceeds from the sales by the Selling Stockholders of the
securities set forth in the Resale Prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to build a biopharmaceutical company
with a foundation of product candidates that significantly advance patient care in cardiorenal diseases. Key elements of our strategy
are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Complete the clinical
                                            development of and seek FDA approval for tecarfarin. We intend to initiate our pivotal Phase
                                            3 clinical trial in the first half of 2024, subject to completion of our initial public offering
                                            and funding from additional financings, which we believe will be our remaining pivotal trial
                                            based upon the latest feedback that the prior owner of tecarfarin had with the FDA in 2019.
                                            ACTOR AF: Anti-Coagulation with Tecarfarin on Outcomes in Renal disease and Atrial Fibrillation
                                            is designed as a Phase 3, 492-patient, Randomized, Double-Blind, Placebo-Controlled Outcomes
                                            Study of Tecarfarin vs. Placebo in Subjects with End-Stage Renal Disease and Atrial Fibrillation
                                            not Currently Treated with Chronic Oral Anticoagulation. If we are able to complete the Phase
                                            3 clinical trial and we are able to obtain FDA approval of our NDA, we believe tecarfarin
                                            can be an alternative treatment for patients who are currently without an approved treatment.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">If we obtain FDA
                                            approval of our NDA for our first indication, we intend to seek to expand the label for tecarfarin
                                            through a supplemental NDA. We intend to explore the full potential of tecarfarin in additional
                                            indications, including the treatment of patients with Left Ventricular Assist Devices (LVADs)
                                            and Mechanical Heart Valves (MHVs) who require chronic anticoagulation. A LVAD is an implantable
                                            pump attached to the heart, connecting the apex of the left ventricle to the ascending aorta.
                                            LVADs are intended to treat patients suffering from advanced heart failure. MHVs are a type
                                            of prosthetic heart valve constructed of durable materials such as titanium or carbon that
                                            can potentially last a patient&#8217;s lifetime. Despite their high durability, MHVs are
                                            associated with an increased risk of developing blood clots that may interrupt blood flow
                                            and travel to various organs (thromboembolism). Oral anticoagulation therapy with a vitamin
                                            K antagonist (warfarin) continues to be the recommended treatment option for patients implanted
                                            with an MHV based on the 2014 American Heart Association/American College of Cardiology Guidelines.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We intend to partner
                                            and/or in-license and/or acquire clinical and pre-clinical stage cardiorenal products to
                                            augment our current pipeline which consists of one investigational product.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Create a commercial
                                            infrastructure for our product candidates. If tecarfarin is approved by the FDA, we intend
                                            to expand our commercial infrastructure and hire and train a focused and dedicated specialty
                                            cardiorenal salesforce which we believe can efficiently cover the top prescribing physicians
                                            and approximately 3,000 anticoagulation clinics in the U.S., which presently monitor patients
                                            on warfarin. If approved, we intend to initially target our tecarfarin commercialization
                                            efforts at the two largest dialysis providers in the U.S., DaVita Kidney Care and Fresenius
                                            Medical Care. DaVita maintains more than 2,800 brick-and-mortar dialysis centers in the U.S.,
                                            while Fresenius&#8217; North America subsidiary owns more than 2,500 on the continent &#8212;
                                            together accounting for more than 70% of the entire U.S. market.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Retrometabolic Drug Design Process</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We utilize a retrometabolic drug design process
to design product candidates that follow a metabolic pathway that we believe will confer significant clinical advantages over existing
drugs metabolized by the CYP450 pathway. &#8220;Drug metabolism&#8221; refers to the process by which a drug is inactivated by the body
and rendered easier to eliminate or to be cleared by the body. Most approved drugs are metabolized in the liver through the CYP450 pathway
by the enzymes known as CYP2C9 and CYP3A4. The CYP450 metabolic pathway has limited capacity, and patients taking multiple medications
that interact with CYP2C9, or those with impaired kidney function, can experience an overload in the pathway, creating a bottleneck causing
insufficient clearance, which results in a toxic build-up&#160;of one or more drugs. In some instances, patients taking multiple medications
that interact with CYP2C9 may also experience that a drug is eliminated too quickly from the body, reducing the efficacy of the drug.
Patient-specific&#160;genetic differences can also hinder drug clearance in the CYP450 pathway. Our product candidates were designed
so that they follow a metabolic pathway distinct from or in addition to the CYP450 pathway, eliminating or minimizing the CYP450 metabolism
by the liver, and are instead or additionally eliminated by large capacity and non-saturable&#160;tissue esterase pathways that exist
throughout the body rather than just in the liver. We believe that the use of these alternative pathways can minimize the impact of drug-to-drug&#160;interactions,
impaired kidney function and genetic variability, on the metabolism of our drugs, thereby ultimately minimizing clearance-related&#160;safety
issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the retrometabolic design process,
we first design a metabolite, which we refer to as the &#8220;ideal metabolite,&#8221; that is non-toxic, pharmacologically inactive,
water soluble and rapidly eliminated from the body through a pathway distinct from the CYP450 pathway. This ideal metabolite becomes
the foundation upon which we develop a limited series of potential molecular drug candidates that have the same pharmacology and function
as the original drug. We then test the potential drug candidates we have created preclinically to assess whether the candidates have
the same activity as the original drug and to ensure the candidates break down properly to the ideal metabolite. This process allows
us to identify the drug candidates that would be best suited for further clinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By designing drugs that break down to the ideal
metabolite, and accordingly, are not cleared through the CYP450 pathway, we create product candidates that we believe would reduce many
of the safety risks and complications that patients experience with drugs that are cleared through the CYP450 pathway. As a result, we
believe there may be better compliance with a tecarfarin treatment regimen, if approved by FDA, which may also result in increased efficacy
for the patients taking our drug product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Investigational Product Candidate</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tecarfarin for Use in Patients with ESRD
and AFib</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ESRD and AFib Current Treatment Landscape</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thrombosis is the formation or presence of a
blood clot (a thrombus) within a blood vessel that blocks normal blood flow. A formed thrombus can detach from the vessel or heart atrium
wall, resulting in a thromboembolism that causes a blockage of the blood flow to vital organs, such as the brain, heart and lungs. According
to the CDC, each year, approximately 800,000 people in the U.S.&#160;experience a new or recurrent stroke, of which approximately 87%
are ischemic strokes, which are caused by either a thrombotic event or embolism, in which blood flow to the brain is blocked. In addition,
the CDC estimates that as many as 900,000 people in the U.S.&#160;could be affected by venous thromboembolism (blood clotting in the
veins) or a pulmonary embolism (blood clotting in the lungs) each year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The American Heart Association estimates that
5&#160;million Americans suffer from heart-valve&#160;disease, which forces the heart to work harder to pump blood and can lead to heart
failure and sudden death. The disease can be present at birth or result from infections, heart attacks or other heart conditions. Further,
more than 182,000 heart valve replacements are performed every year in the U.S.&#160;Mechanical heart valves also create a risk of thrombotic
events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The prevailing treatment for patients at risk
of thrombosis is an oral anticoagulant, or OAC, of which there are two common types: vitamin K antagonists, or VKAs, and non-vitamin&#160;K
oral anticoagulants, or NOACs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Vitamin K Antagonists: Warfarin</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vitamin K antagonists, or VKAs, are substances
that block the production of vitamin K-dependent&#160;blood clotting factors such that the blood is &#8220;thinned,&#8221; preventing
clots. VKAs are used as anticoagulants in the treatment of thrombosis. For patients treated with a VKA, the international normalized
ratio, or INR, a system established by the World Health Organization and the International Committee on Thrombosis and Hemostasis, is
a commonly available, inexpensive measure of the body&#8217;s coagulation status. Each VKA patient&#8217;s dose must be individualized,
based on a target range for his or her INR test. The percentage of time that a patient&#8217;s INR is maintained within his or her target
range is known as the time in therapeutic range, or TTR.&#160;TTR is a well-established&#160;FDA metric used to evaluate anticoagulation
control (safety and efficacy) of a VKA based on prothrombin time and the INR.&#160;When used as a therapy, VKAs are titrated to a patient&#8217;s
individual INR range and that patient is expected to visit a clinic for regular INR monitoring. A higher TTR reflects better anticoagulation
control and is related to improved clinical outcomes, including rates of death, bleeding, myocardial infarction, stroke and systemic
embolism, and a TTR measure of &#8805; 70% is generally accepted as the goal for stable anticoagulation with a VKA.&#160;When patients are
above their individual INR range, they are at higher risk for bleeding, due to reduced clotting ability, while patients are below their
target INR range are at higher risk for thrombotic events. Potential benefits of monitoring INR include ascertaining patient compliance
with their drug treatment regimen, the ability to detect when dose adjustments are needed and maintaining safety and efficacy of the
drug treatment. TTR is predictive of adverse events, including mortality, stroke and myocardial infarction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As depicted in the chart below, higher TTR is
generally correlated with higher survival rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_003.jpg" style="height: 225pt; width: 307.5pt"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Source: Currie et al. Heart 2006 (92)&#160;196-200</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Higher TTR levels are also associated with better
kidney functioning, as measured by estimated glomerular filtration rate (eGFR), as reported by the Journal of the American Heart Association
in 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_004.jpg" style="height: 158.25pt; width: 228.75pt"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VKAs are reversible, meaning that in cases of
over-anticoagulation, vitamin K or fresh frozen plasma, or a combination, can be administered to bring patients back down into their
INR range.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warfarin is currently one VKA treatment option
for thrombosis in the U.S.&#160;and has been in use since the 1950s. However, as reported by the National Center for Biotechnology Information,
there are many adverse events associated with warfarin, including bleeding, skin necrosis and hair loss, and warfarin has been reported
as number three on the list of drugs implicated in adverse effects causing hospital admission due to its many drug-to-drug&#160;interactions.
Due to these side effects and the increasing use of NOACs, the use of warfarin has decreased during the last decade.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Limitations of Warfarin Treatment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warfarin has significant safety risks stemming
from its metabolic process, including its elimination pathway. Other drawbacks of warfarin are widely recognized such as narrow therapeutic
range, slow onset and offset of action causing difficulty to manage during peri-invasive&#160;procedures, and multiple drug and food
interactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warfarin&#8217;s efficacy and safety profile
are affected by its metabolism and elimination characteristics and various interactions with other drugs. Warfarin is metabolized through
the CYP450 pathway, primarily by the CYP2C9 enzyme, and approximately 15% of clinically used drugs are metabolized by the same enzyme,
including certain anticoagulants, antiplatelets and non-steroidal&#160;anti-inflammatory&#160;drugs, or NSAIDS.&#160;Patients taking
warfarin and on CYP2C9 interacting drugs may experience either or both of, warfarin being eliminated by the body too quickly, thereby
decreasing its anticoagulation effect, or warfarin being eliminated by the body too slowly, resulting in excessive and dangerous thinning
of the blood. In both of these situations, increased monitoring is required and dose adjustments are often necessary. Patients who take
both warfarin and these CYP2C9 interacting drugs also have an increased risk of being outside their individual INR target range and experiencing
lower or higher TTR.&#160;For these patients, their CYP2C9 interacting drugs must be used with caution, or at times, their use must cease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warfarin&#8217;s efficacy and safety profile
are also affected by genetic mutations that lead to a lower activity of the CYP2C9 enzyme, the primary enzyme used to eliminate warfarin
from the body. Clinical studies have shown that these persons require lower dosages of warfarin and are at an increased risk of anticoagulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, warfarin is commonly used in patients
with non-valvular&#160;AFib and in patients with valvular heart diseases (VHD) with AFib. However, as reported by an article published
by the Egyptian Heart Journal on March&#160;28, 2022, an analysis of 6,454 patients with AFib taking warfarin showed that almost 50%
of the time the INR was outside the target range of 2&#8211;3, leading to a higher risk of bleeding and thrombotic complications. The
major adverse effect associated with warfarin is bleeding. Major and fatal bleeding events occur at rates of 7.2 and 1.3 per 100 patient-years,
respectively, according to a meta-analysis&#160;of 33 studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INR should be more frequently monitored in patients
with impaired kidney function. Patients with impaired kidney function have a decreased ability to metabolize drugs through the CYP450
pathway, and accordingly have an increased risk of being outside their individual INR target range and experiencing lower TTR.&#160;Further,
according to an article published by Frontiers in Medicine in January&#160;2021, warfarin was associated with an increase in the risk
of major bleeding without reduction in stroke/thromboembolism or mortality in patients with end-stage&#160;CKD requiring dialysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of some or all of the above, and
other factors, trials have shown that patients treated with warfarin often experience TTRs lower than 70%, the generally accepted TTR
threshold representing stable anticoagulation. In a 2019 study conducted to evaluate the TTR of 300 patients on long-term&#160;warfarin
for non-valvular&#160;AFib, as reported by an article published in Health and Quality of Life Outcomes on October&#160;20, 2020, 75.5%
of patients had a poor TTR with a mean of only 39.5%, with the mean TTR of all patients in the study being 47%. In another study of 406
AFib patients conducted in Lithuania to evaluate the quality of warfarin as anticoagulation therapy, more than half (57.3%) of INR values
were outside of the target range and the median TTR was only 40%, with only 20% of patients having a TTR greater than or equal to 65%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Vitamin&#160;K Oral Anticoagulants (NOACs)
or Direct Acting Oral Anticoagulants (DOACs)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-vitamin&#160;K oral anticoagulants, or NOACs,
or DOACs, are a form of OAC treatment that inhibits certain blood clotting factors. While VKAs block the synthesis of vitamin K-dependent&#160;blood
clotting factors, NOACs block the activity of these clotting factors. There are two classes of NOACs, oral direct thrombin inhibitors
and oral direct factor Xa inhibitors. Currently, there are only four NOACs approved by the FDA for use outside of a hospital setting:
apixaban (the generic name for Eliquis), dabigatran (the generic name for Pradaxa), rivaroxaban (the generic name for Xarelto) and edoxaban
(the generic name for Savaysa). NOACs are generally more rapid in onset and offset of action than VKAs, have few strong drug-to-drug&#160;interactions
and do not require INR monitoring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Limitations of NOAC Treatment for Patients
with ESRD and AFib</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOACs have been approved in the U.S.&#160;for
the treatment of specific oral anticoagulation indications; however, there are anticoagulation indications for which NOACs are warned
against use or are not recommended for use, including for anticoagulation treatment in patients with mechanical heart valves. NOACs do
not have the same broad label indication as warfarin and are only indicated for some thrombosis indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Proposed Solution: Tecarfarin for Treatment
of ESRD and AFib</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin, our lead investigational product
candidate, is a VKA, once-daily&#160;OAC designed for use in patients with ESRD and AFib. Tecarfarin was designed using a retrometabolic
drug design which targets a different metabolic pathway than the most commonly prescribed drugs for the treatment of thrombosis and AFib.
Like warfarin, tecarfarin will also require INR monitoring. Due to its retrometabolic design, tecarfarin is eliminated by large capacity
and non-saturable&#160;tissue esterase pathways that exist throughout the body, rather than just in the liver. This is a metabolic pathway
that is distinct from the CYP450 pathway and infrequently used by other medications, which could potentially reduce the risk for drug-to-drug&#160;interactions.
Moreover, unlike warfarin, we do not believe tecarfarin&#8217;s metabolism is affected by CYP2C9 genetic variant alleles or by kidney
function.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the metabolic process and related safety
issues with warfarin and the limited treatment indications for which NOACs are approved, we believe there is a significant thrombosis
patient population in need of an alternative anticoagulation treatment. The lack of stable and predictable anticoagulation control is
particularly problematic in large underserved patient subpopulations with risk factors such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Patients treated
                                            with CYP2C9 interacting drugs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Patients with
                                            severely impaired kidney function;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Patients with
                                            genetic variant alleles for CYP2C9; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Patients with
                                            mechanical heart valve implants.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tecarfarin Clinical Program</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin has been evaluated in eleven clinical
trials: eight Phase&#160;1 trials, two Phase&#160;2 trials and one Phase&#160;2/3 trial evaluating the efficacy and safety of tecarfarin.
We are currently planning to commence what we believe to be our remaining pivotal Phase&#160;3 trial in the first half of 2024. A readout
of the two-year&#160;animal carcinogenicity study is expected to be completed in first half of 2024. We will also conduct any further
trials as may be required by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the clinical trials conducted to
date with tecarfarin is shown below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Study Number</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Study Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Study<br/> Population</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> Exposed</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date started</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date&#160;completed</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Sponsor</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 9%; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">ZK-TEK-201905</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="vertical-align: top; width: 32%; font-weight: bold; text-align: left">Multiple-dose tolerance and PK-PD study of tecarfarin</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: left">Healthy Chinese Volunteers</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; font-weight: bold; text-align: center">40</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; font-weight: bold; text-align: center">2020</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: center">January&#160;2021</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: center">Zhaoke Pharmaceutical (Guangzhou) Co., Ltd</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">LP-HK-001</td><td style="font-weight: bold">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1, Sequential Cohort, Single-dose escalation study</td><td style="font-weight: bold">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy Chinese Volunteers</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">40</td><td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June&#160;2018</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">July&#160;2019</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Lee&#8217;s Pharmaceutical (Hong Kong) Limited</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-512</td><td style="font-weight: bold">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 pharmacokinetic study in chronic kidney disease
    subjects</td><td style="font-weight: bold">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Chronic kidney disease subjects; healthy volunteers</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">23</td><td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November&#160;2015</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">May&#160;2016</td><td style="font-weight: bold">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">Armetheon, Inc.</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Study Number</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Study Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Study<br/> Population</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number<br/> Exposed</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date started</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date completed</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Sponsor</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 9%; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-505</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 32%; font-weight: bold; text-align: left">Phase&#160;2/3 randomized, blinded head-to-head
    anticoagulation in broad indications (EMBRACE-AC)</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: left">Patients (all indications)</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; width: 9%; font-weight: bold; text-align: center">609</td><td style="vertical-align: top; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 9%; font-weight: bold; text-align: center">June&#160;2008</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: center">December&#160;2009</td><td style="text-align: left; width: 1%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-509</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Pilot Phase&#160;2 study for trial methodology to be used in
    CLN-505</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Patients (all indications)</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">50</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">January&#160;2008</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">August&#160;2008</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-504</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;2a open-label anticoagulation in AFib</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Patients Requiring Oral Anticoagulation</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">66</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">December&#160;2006</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">October&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-508</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 DDI study with amiodarone</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy volunteers</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">19</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">July&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">September&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-507</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 DDI study with fluconazole</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy volunteers</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">20</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">June&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">August&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-503</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 Dose titration to target</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy volunteers</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">28</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">October&#160;2006</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">January&#160;2007</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-502</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 Effect on INR in multiple dose response</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy volunteers</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">42</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">November&#160;2005</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">July&#160;2006</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; text-indent: -10pt; padding-left: 10pt; vertical-align: top">CLN-501 &amp; CLN-501.X</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Phase&#160;1 Safety and human pharmacokinetics</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left">Healthy volunteers</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: top; font-weight: bold; text-align: center">66</td><td style="vertical-align: top; font-weight: bold; text-align: left">&#160;</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">August&#160;2005</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">April&#160;2006</td><td style="text-align: left; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: center">ARYx Therapeutics, Inc.</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Phase&#160;2 Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-504: </b>Trial CLN-504&#160;was an open-label&#160;study
in which 66 patients with AFib were treated with tecarfarin for a period of six&#160;weeks, with the option of continuing treatment for
an additional six&#160;weeks. The trial, which was conducted by our predecessor company that owned the rights to tecarfarin, was primarily
designed to determine an optimal dosing regimen and monitoring schedule and to describe the efficacy and explore the quality of anticoagulation
as measured by TTR for INR.&#160;Before the trial, warfarin-treated&#160;patients had a mean TTR of 59.4%. After the initial three&#160;weeks
of dose titration, the tecarfarin-treated&#160;patients were within the target INR range 71.4% of the time (p&lt;0.001). The most commonly
reported treatment-related&#160;adverse events, or TEAEs, were mild hemorrhagic complications of anticoagulation, such as bruising and
nosebleed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were two deaths after trial drug treatment
was completed: one patient died due to idiopathic pulmonary fibrosis and pneumonia two&#160;weeks following his last dose of tecarfarin,
and one patient died due to bronchial carcinoma two&#160;weeks following his last dose of tecarfarin. These deaths were not attributed
to tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-509: </b>The CLN-509&#160;trial was a
pilot Phase 2 study to assess clinical trial methodology to be used in CLN-505, in patients having a variety of clinical indications
requiring chronic oral anticoagulation, as measured by INR. Fifty patients, including patients with AFib, some of whom were already taking
warfarin and some of whom had not, received daily doses of tecarfarin ranging from 1 mg to 60 mg to maintain their INR value (the INR
varied based upon the patient&#8217;s condition). The objectives of evaluating safety and INR control in patients with a variety of clinical
indications for chronic oral anticoagulation and assessing the feasibility of tecarfarin treatment in multiple dose strengths were met.
INR control was shown for patients with atrial fibrillation, venous thromboembolic disease, prosthetic heart valves, and cardiomyopathy.
There were no off-target&#160;adverse events due to tecarfarin and there were no clinically important safety signals in other measures
of safety. The results of this trial resulted in the development of the clinical trial methodology for the Phase 2/3 trial (EMBRACE-AC).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-505&#160;(EMBRACE-AC): </b>The Phase&#160;2/3
CLN-505&#160;trial, referred to as the EMBRACE-AC&#160;trial, was a multi-center, randomized, stratified, double-blind, parallel group,
active control trial for a minimum period of six&#160;months and up to one year designed to compare the quality of anticoagulation of
tecarfarin and warfarin as determined by TTR.&#160;Dosing of study drugs was managed by a centralized dose control center. In total,
609 patients were enrolled and of those, 607 patients completed the trial and of these, 304 patients received warfarin and 303 patients
received tecarfarin. The EMBRACE-AC&#160;trial did not achieve statistical significance on its primary endpoint and the results of the
primary analysis showed that tecarfarin was not superior to warfarin as measured by TTR.&#160;However, the TTR observed in patients taking
tecarfarin (72.3%) was numerically similar to patients taking warfarin (71.5%) (difference of 0.8%; p=0.51).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of its original design, the EMBRACE-AC&#160;trial
included analyses of INR measurements while patients were temporarily off their trial drug due to other medical reasons. Subsequently
a post-hoc&#160;analysis was conducted in which we excluded INR values collected during these periods and showed that the percentage
of TTR was higher on tecarfarin (68.8%) than on warfarin (66.4%) (difference of 2.3%; p&lt;0.04).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-hoc&#160;analyses were conducted in other
patient subgroups in our EMBRACE-AC&#160;trial. The following chart depicts the findings of the analysis of the study and the degree
to which TTR% on tecarfarin was higher than on warfarin:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_005.jpg" style="height: 169.5pt; width: 390pt"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In the 179 patients
                                            taking CYP2C9 interacting drugs, the TTR of patients taking tecarfarin was similar to that
                                            of patients taking warfarin (72.2% and 69.9%, respectively; p=0.15).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In the 55 patients
                                            taking CYP2C9 interacting drugs who also had a CYP2C9 genetic variant allele, the TTR of
                                            patients taking tecarfarin was similar to that of patients taking warfarin (76.5% and 69.5%,
                                            respectively; p=0.09).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In the 84 patients
                                            with mechanical heart valve implants, the TTR of patients taking tecarfarin was similar to
                                            that of patients taking warfarin (68.4% and 66.3%, respectively; p=0.51).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential benefit of tecarfarin over warfarin
as measured by TTR was not demonstrated in EMBRACE-AC.&#160;However, the TTR observed in patients taking tecarfarin in the trial, and
in the subpopulations described above, were numerically similar to the TTR observed in the patients taking warfarin, and the TTR observed
in patients taking tecarfarin demonstrated stable anticoagulation. The TTR in patients treated with warfarin exceeded previously reported
TTR rates observed in patients taking warfarin, which are typically in the 50% to 65% range, which we believe was due to the use of dose
control centers in the administration of the trial. When dose control centers are used in the administration of warfarin, large teams
of medical professionals are able to closely monitor patients and mitigate many of the drug-to-drug&#160;and genetic variant-related&#160;limitations
of the drug that are not easily managed in real world settings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EMBRACE-AC&#160;also provided information for
dosing and dose adjustments for tecarfarin. The average daily doses required of both tecarfarin and warfarin was analyzed in patients
who had poor, intermediate or extensive metabolism capacity of the CYP2C9 enzyme. Patients with poor metabolism capacity of the CYP2C9
enzyme who were treated with warfarin required a significantly lower average daily dose compared to those patients with extensive CY2C9
enzyme metabolism capacity. In contrast, as depicted below, the required dosage of tecarfarin did not vary significantly based on the
patient&#8217;s CYP2C9 activity level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_006.jpg" style="height: 137.25pt; width: 376.5pt"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin appeared to be well tolerated with
only 1.6% of the blinded tecarfarin subjects suffering from major bleeding and no thrombotic events. When thrombotic and major bleeding
events during the blinded period were combined, a numerical imbalance favoring tecarfarin over warfarin was seen (warfarin 11 subjects,
3.6%; tecarfarin 5 subjects, 1.6%). The safety data from EMBRACE-AC&#160;showed comparable rates of adverse events between the two treatment
groups. TEAEs were reported for 93.2% of patients who received tecarfarin and 90.5% of patients who received warfarin. TEAEs reported
by &#8805;10% of patients in either treatment group were nasopharyngitis (18.6% and 19.3%, blinded tecarfarin and warfarin, respectively),
contusion (15.6% and 14.8%, respectively), epistaxis (8.1% and 11.1%, respectively), upper respiratory tract infection (10.7% and 10.8%,
respectively), diarrhea (10.1% and 9.2%, respectively) and headache (10.7% and 8.9%, respectively). Most TEAEs were mild (32.2%, tecarfarin
and 30.2%, warfarin) or moderate (45.0% and 46.6%, respectively) in severity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trial had some limitations. The TTR with
warfarin achieved in Embrace-AC&#160;was much higher than that typically seen in clinical trials and as compared to &#8220;real-world&#160;practice,&#8221;
exceeding 71% on an interpolated basis in both treatment arms. The most likely reason stemmed from the dosing of study drugs which was
managed by a centralized dose control center, which had access to genotyping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Five patients died during the trial, with four
deaths occurring during the double-blind&#160;period: one patient (tecarfarin; off drug) died due to mantle cell lymphoma, pneumonia
and sepsis; one patient (tecarfarin; on drug) died due to cardiorespiratory arrest and myocardial infarction; one patient (warfarin;
off drug) died due to metastatic colon cancer; one patient (warfarin; off drug) died due to lung cancer; and one patient (not randomized)
died due to intracerebral hemorrhage. The patient who died due to intracerebral hemorrhage was considered to be possibly related to the
study drug, but the remaining four deaths were not attributed to the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the blinded period of the trial, five
patients on tecarfarin and six patients on warfarin experienced major bleeding events. The occurrence of major bleeding events for both
tecarfarin and warfarin was lower when compared to prior anticoagulation trials. Among warfarin-treated&#160;patients, there were five
thrombotic events (two ischemic strokes, two deep vein thromboses and one pulmonary embolism), while there were no such events among
tecarfarin-treated&#160;patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Phase&#160;1 Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-501: </b>Trials CLN-501&#160;and CLN-501.X
evaluated the safety tolerability of tecarfarin in a total of 64 healthy volunteers. The studies were sufficiently similar in their requirements
and study populations to be combined and analyzed together. The primary differences between the studies were the study drug formulation
(CLN-501&#160;used a solution formulation while study 501.X used tablets) and the range of single doses studied. In CLN-501, cohorts
of 6 eligible subjects were randomly assigned to receive tecarfarin at one of eight ascending dose levels between 0.2 and 10.0 mg or
placebo. In CLN-501.X, similar cohorts received tecarfarin at one of three ascending dose levels (20.0, 30.0, or 40.0 mg) or placebo.
The studies demonstrated that there were no apparent differences between pharmacokinetics parameters after tecarfarin was administered
at single doses from 0.2 to 10.0 mg as an oral solution or at single doses from 20.0 to 40.0 mg as an oral solid tablet formulation and
that tecarfarin was well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-502: </b>Trial CLN-502&#160;evaluated
tecarfarin pharmacokinetics, dose range, and duration of dosing that would attain a stead steady state INR of 1.7 to 2.0 and would give
stead-state&#160;plasma concentrations of tecarfarin. Forty-two&#160;healthy volunteer subjects were randomized and received either&#160;1,&#160;3,&#160;6,&#160;10,&#160;20,&#160;30,
or 40 mg of tecarfarin or placebo (the 3 and 6 mg cohorts were discontinued after one week due to lack of pharmacodynamic effect). The
study successfully determined the active dose of tecarfarin and provided the pharmacokinetic and pharmacodynamic basis for subsequent
multidose trials. Doses of 20 mg and above brought subjects into the target INR range of 1.7 to 2.0, with the 40 mg dose bringing all
subjects into the target range within one week of dosing. The trial demonstrated that tecarfarin was well-tolerated&#160;at all doses
studied as assessed by adverse events, vital signs, electrocardiography, and laboratory testing, and that a loading dose of 40 mg could
be appropriate for initiating anticoagulation in Phase II trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-503: </b>Trial CLN-503&#160;evaluated
the safety and tolerability of tecarfarin versus warfarin when administered alone and in combination with amiodarone as measured by INR
in 28 healthy subjects. During the first phase, subjects were administered tecarfarin or warfarin for 10 days, with doses titrated daily
to achieve a target INR range of 1.5 to 2.0. Subjects who remained within the target INR range without requiring a dose change continued
to the next phase with amiodarone, with all subjects receiving 200 mg amiodarone twice daily in addition to tecarfarin or warfarin. The
primary objectives of the trial were completely met. Both tecarfarin and warfarin were well-tolerated, both alone and in the presence
of amiodarone. There were no safety signals as ascertained by adverse event reports, clinical laboratory testing, vital sign measurement,
and by electrocardiography. The quality of anticoagulation was good for both cohorts and a target INR was reached and maintained during
the 3-day&#160;maintenance period. The results of the trial suggested the use of the same INR therapeutic range for tecarfarin as is
recommended for warfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-507: </b>Trial CLN-507&#160;evaluated
the effects of co-administration&#160;of fluconazole, a drug that blocks the activity of the CYP450 enzyme, with either 50&#160;mg tecarfarin
or 17.5&#160;mg warfarin in 20 healthy volunteers. The trial demonstrated that co-administration&#160;of fluconazole did not affect the
metabolism or elimination of tecarfarin. In contrast, the co-administration&#160;of fluconazole prolonged the half-life&#160;of warfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-512: </b>Trial CLN-512&#160;evaluated
the effects of severe chronic kidney dysfunction on the metabolism and elimination of tecarfarin and warfarin. Thirteen patients with
severe kidney dysfunction (stage 4 chronic kidney disease, or CKD) and 10 healthy volunteers (matched for age, weight, gender and CYP2C9
genotype) were administered 30&#160;mg tecarfarin and 10&#160;mg warfarin in a randomized crossover design. The trial demonstrated that
tecarfarin&#8217;s elimination from the body was not affected by severe kidney dysfunction: the half-life&#160;and the amount of drug
in the body were similar in people with CKD and healthy patients. In contrast, the plasma concentration and half-life&#160;of warfarin
was increased in patients with CKD, with warfarin&#8217;s exposure increasing 44% in these patients. These effects were exaggerated in
patients with CYP2C9 genetic variant alleles and in those who required concomitant CYP2C9 interacting drugs. At the conclusion of the
trial, the safety of repeated dosing of tecarfarin in CKD patients remained unknown. However, overall, the results of this study suggest
that no adjustment in the dose of tecarfarin is needed for patients with CKD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CLN-508: </b>Trial CLN-508&#160;evaluated
the effects of co-administration&#160;of 400&#160;mg amiodarone with either 50&#160;mg tecarfarin or 17.5&#160;mg warfarin in 19 healthy
volunteers, nine on tecarfarin and 10 on warfarin. Amiodarone, a drug used to treat irregular heartbeat, is a moderately potent inhibitor
of CYP2C9 metabolism and is frequently used as a treatment for AFib in combination with warfarin. The effects of amiodarone on the pharmacokinetics
of warfarin and tecarfarin showed that the exposure was increased to about the same extent for both drugs. The exposure of R-warfarin&#160;increased
by 27% and the exposure for S-warfarin&#160;increased by 38%. The exposure of tecarfarin increased by approximately 31%. These changes
in exposure did not result in any changes in INR in either the tecarfarin or the warfarin cohorts and demonstrated that tecarfarin behaved
similarly to warfarin when administered in combination with amiodarone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>An&#160;Open-label, Phase&#160;1, Sequential
Cohort,&#160;Single-Dose&#160;Escalation Study to Assess the Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Study Protocol: LP-HK-001&#160;completed in July&#160;2019</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This was an open-label, phase&#160;1, sequential
cohort, single-dose&#160;escalation study conducted in China to assess the safety and tolerability of tecarfarin (ATI-5923) in healthy
Chinese volunteers. The study site enrolled up to a total of 40 subjects. Ten (10)&#160;healthy Chinese subjects received tecarfarin
(ATI-5923) at each dose level (i.e., 10&#160;mg, 20&#160;mg, 30&#160;mg and 40&#160;mg).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The safety assessment results of this study were
consistent with the results of CLN-501&#160;study, and there was no safety risk after single dose administration of 10mg~40mg tecarfarin.
AEs with higher incidence rate included headache and dizziness, and such AEs were graded as mild in severity. Tecarfarin showed a promising
safety and tolerability profile in Chinese subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the results in this open-labelled, single-dose&#160;escalation,
phase 1 study of tecarfarin, the following conclusions were made:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Single dose administration of tecarfarin in dose
level ranging from 10&#160;mg to 40&#160;mg had no clinically significant effect on coagulation function. However, a slightly increasing
trend in INR and PT values were observed with dose escalation. A slightly decreasing trend in coagulation factors&#160;II,&#160;VII and&#160;X
were observed with dose escalation. Tecarfarin showed a promising safety and tolerability profile in Chinese subjects. The results of
this study warrant further multiple-dose&#160;pharmacokinetic studies in the Chinese population. We do not believe we can extrapolate
this data to other populations, including the United&#160;States, but other trials were performed in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A&#160;Multiple-Dose, Safety and Tolerability
PK/PD Study of Tecarfarin in Healthy Chinese Volunteers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Study Protocol:<i>&#160;</i>ZK-TEK-201905&#160;completed
in January&#160;2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This was a multiple-dose&#160;phase 1 pharmacokinetic-pharmacodynamic&#160;study
conducted in China to assess the safety and tolerability of tecarfarin in healthy Chinese volunteers. The study site enrolled up to a
total of 40 subjects. Ten&#160;(10)&#160;healthy Chinese subjects received tecarfarin once-daily&#160;on fasting every morning for 14&#160;days
at each dose level (i.e., 10&#160;mg, 20&#160;mg, 30&#160;mg and 40&#160;mg).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin was well tolerated in Chinese volunteers
without serious adverse events in both single ascending dose and multiple ascending dose (&#8220;MAD&#8221;) studies. There was only
one treatment related adverse event (hematochezia) that resulted in early withdrawal in the MAD 40mg cohort. Exposure levels of tecarfarin
were generally dose proportional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Summary of Tecarfarin Clinical Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical and preclinical trials of tecarfarin
have demonstrated lack of drug-to-drug&#160;interactions with tecarfarin, predictable clearance that is independent of CYP450 blood clotting
factors and any genetic variation in these factors, and the lack of impact of kidney function on clearance of tecarfarin. In the largest
and longest of the clinical trials, EMBRACE-AC, tecarfarin and warfarin were found to have similar major and overall bleeding risks.
In EMBRACE-AC, warfarin-treated&#160;patients had five thrombotic events, while there were no such events among tecarfarin-treated&#160;patients.
When thrombotic and major bleeding events were combined, a trend favoring tecarfarin over warfarin was seen (five tecarfarin patients
(1.6%) compared to 11 warfarin patients (3.6%)). We will conduct further studies and intend to submit this data to FDA in the NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Upcoming Pivotal Phase&#160;3 Trial: CLN-515
(ACTOR AF)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the second half of 2023, we intend to commence
our Phase&#160;3, randomized, double-blind, placebo-controlled&#160;study of tecarfarin in subjects with ESRD and AFib not currently
treated with chronic oral anticoagulation. The study will assess the safety and efficacy of evaluate the efficacy and safety of tecarfarin
(target INR 2.0-3.0) in subjects with ESRD (stage 5 &#8212;&#160;eGFR &lt; 15 mL/min/1.73 mm2) and AFib. Subjects must have chronic paroxysmal,
persistent or permanent AFib documented. All subjects will undergo genetic testing for VKORC1 prior to randomization, which will also
be used for stratification at the time of randomization. Subjects will be randomly assigned to receive either blinded tecarfarin or placebo
in a 1:1 ratio. Approximately 540 subjects (270 per arm) will be enrolled in the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An enrollment period of 15&#160;months is anticipated.
A 10% dropout rate (48 subjects) is anticipated resulting in 492 evaluable subjects. All subjects enrolled in the study will remain on
study drug until the last subject enrolled completes a minimum of 12&#160;months of therapy or until the required number of adjudicated
major adverse cardiovascular events (death, ischemic stroke, pulmonary embolus, and/or myocardial infarction) have been obtained, whichever
is later. The primary efficacy assessment is time to first major adverse cardiovascular event, or MACE.&#160;There will be approximately
125 study sites in the United&#160;States and Canada, with other trial sites to be determined. Based upon internal statistical projections,
assuming the Phase&#160;3 clinical trial is powered at 80%, the study is expected to demonstrate a treatment effect of 25%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="image_007.jpg" style="height: 135pt; width: 384.75pt"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sub-License</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Lee&#8217;s Pharmaceutical Holdings Limited
License</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September&#160;2015, China Cardiovascular
Focus Ltd., a wholly owned subsidiary of Lee&#8217;s Pharmaceutical Holdings Limited, or LPH, entered into an agreement (the &#8220;LPH
License&#8221;) with Armetheon for the license, development and commercialization of our tecarfarin compound in China, Hong&#160;Kong,
Macau, Taiwan and Thailand (the &#8220;Territory&#8221;). In October&#160;2017, Armetheon merged with Espero BioPharma, Inc., or Espero.
The assets owned by Espero were assigned to HESP LLC in a court-approved&#160;assignment for the benefit of creditors. On April&#160;1,
2022 we acquired from HESP LLC, pursuant to an asset purchase agreement, the assets related to tecarfarin, including the LPH License.
Under the terms of the LPH License, LPH provided a non-refundable&#160;up-front&#160;payment of $1&#160;million and agreed, during the
term of the agreement, not to develop, manufacture or commercialize a competitive product in the Territory. Conversely, we agreed not
to develop, manufacture or commercialize a competitive product in the Territory. If all potential development, regulatory and commercial
milestones under the LPH License are met, we are entitled to receive payments of approximately $52.0&#160;million. In addition, we are
also entitled to receive royalties between 9% to 15% of the net sales of tecarfarin in certain specified markets. The LPH License expires
on a country-by-country&#160;basis within the Territory, upon the latest of the expiration of the last intellectual property covering
the tecarfarin compound in such country of the Territory, or the twelfth anniversary of the first commercial sale of tecarfarin in such
country of the Territory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have a manufacturing infrastructure
and do not intend to develop one. We intend to contract with third parties for the production and packaging of our products and product
candidates. With respect to tecarfarin, we are negotiating a contract with a third-party&#160;contract pharmaceutical manufacturer to
perform the work necessary to develop a validated manufacturing process and to scale up for commercial production. However, we have not
entered into any long-term&#160;supply agreements or commercialization partnership with these vendors. We anticipate that certain of
the manufacturing sites for our products and product candidates may be in locations outside of the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the drug substances used in our product
candidate are manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable
to acquire supplies from an alternative supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It
could also require significant time and expense to redesign our manufacturing processes to work with another company. If approved by
the FDA, we anticipate that we will be able to enter into agreements with suppliers to formulate and distribute tecarfarin on commercially
reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of our product candidates are approved
by the FDA or other regulatory authorities, we intend to commercialize our products by leveraging our existing commercial infrastructure
and hiring and training a small and dedicated cardiorenal salesforce to commercialize our products in the U.S., and possibly other major
markets. In addition, we anticipate entering into a variety of distribution agreements and commercial partnerships in those territories
where we do not establish an internal sales force, including if we expand outside of the U.S.&#160;We expect that our specialized commercial
cardiovascular team would be comprised of experienced marketing and sales management professionals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon data of untreated patients with ESRD
and AFib (40,823) and orphan drug pricing of $65 per&#160;day (or $23,400 annually) derived from a 2019 study commissioned by us (adjusted
for inflationary increases in the per&#160;day pricing), and assuming that we receive FDA approval of tecarfarin, we estimate that the
annual U.S.&#160;market revenue potential for tecarfarin is approximately $1&#160;billion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been several randomized trials to
definitively assess the treatment effects of apixaban compared with VKAs in the population dependent on dialysis. The RENAL-AF&#160;(Trial
to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation) was terminated early in 2019 by its sponsor. In
addition, the AXADIA study (Compare Apixaban and Vitamin-K&#160;Antagonists in Patients With Atrial Fibrillation and End-Stage&#160;Kidney
Disease), which is currently recruiting patients, will randomize patients to apixaban 2.5&#160;mg twice daily versus phenprocoumon. The
randomization of study drug and blinded event adjudication in these trials will help to minimize bias and confounding, and will better
elucidate the risks and benefits of standard versus low-dose&#160;apixaban. Neither of these trials are adequately powered to address
the important questions relating to intracerebral hemorrhage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new
drugs is highly competitive. We face competition with respect to developing our current product candidate, and we will face competition
with respect to any products that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. We are seeking to develop tecarfarin as a marketable VKA, once-daily&#160;OAC
for chronic anticoagulation, and we are seeking to develop as a marketable oral drug for the treatment and prevention of refractory AFib.
If we succeed in developing the lead indication or additional indications, we will face substantial competition. Existing anticoagulant
treatments for thrombosis include warfarin and NOACs such as Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and Savaysa
(edoxaban) for specific indications. The entry of the first generic NOACs, starting with Boehringer Ingelheim&#8217;s loss of U.S., Japanese
and Canadian patent protection for Pradaxa (dabigatran) in November&#160;2018 and the remaining NOACs by 2024, could increase competition
and reduce the total dollars spent on the treatment of thrombosis, as a result of lower generic drug pricing. The next generation of
anticoagulants in development, Factor&#160;XI inhibitors, are currently in Phase&#160;2 studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these named products are marketed by
some of the largest and most successful pharmaceutical companies worldwide. The companies that market these products have substantially
more resources than we do and substantially more experience developing and marketing pharmaceuticals. We may not be able to successfully
compete with these existing products. Potential competitors also include academic institutions, government agencies and other public
and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing and commercialization of competing drugs and potentially competing drugs. Our competitors are developing or
may be attempting to develop therapeutics for our target indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Factors affecting competition in these markets
include the financial, research and development, testing, and marketing strengths of individual competitors, trends in industry consolidation,
consumers&#8217; product options, product quality, price, technology, reputation, customer service capabilities and access to market
partners and customers. Eliquis is manufactured and distributed by Bristol Myers Squibb, amiodarone is manufactured and distributed by
several companies, including Sanofi, Baxter, and Pfizer, Pradaxa is manufactured and distributed by Boehringer Ingelheim, Xarelto is
manufactured and distributed by Janssen Pharmaceuticals, and Savaysa is manufactured and distributed by Daiichi Sankyo. Each of these
organizations has a long operating history, extensive resources, strong brand recognition and large customer base. As a result, we expect
they will be able to devote greater resources than we can to the manufacture, promotion and sale of their products, receive greater resources
and support than we will from market partners and independent distributors, initiate and withstand substantial price competition, and
take advantage more readily than we could of acquisition and other strategic market opportunities. In addition, these or other organizations
could succeed in developing new products that perform better or more cost-effectively&#160;than our products and product candidates in
their respective markets. Moreover, changes in health trends, diet or other factors could substantially reduce the commercial attractiveness
or viability of anti-anginal, anticoagulant, anti-arrhythmic&#160;and anti-platelet&#160;products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The high level of competition in these markets
could result in pricing pressure, reduced margins, the inability of our product candidates to achieve market acceptance and other impediments
to commercial success. As a result, there can be no assurance that we will be able to complete the development of competitive products
and commercialize them on a competitive basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mergers and acquisitions in the pharmaceutical,
biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors.
Smaller or early-stage&#160;companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to,
or necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success will significantly depend upon our
ability to obtain and maintain patent and other intellectual property and proprietary protection for our drug candidates, including market
and data exclusivity granted by regulatory agencies and composition-of-matter, dosage and formulation patents, as well as patent and
other intellectual property and proprietary protection for our novel biological discoveries and other important technology inventions
and know-how. In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological innovation to develop
and maintain our competitive position. We protect our proprietary information, in part, using confidentiality agreements with our commercial
partners, collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality
agreements or invention assignment agreements with our commercial partners and selected consultants. Despite these measures, any of our
intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive advantages. For more information, please see &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two issued U.S.&#160;patents directed
to tecarfarin. The expiration dates of the patents are 2024 for both our composition of matter patent and our method of treatment patent,
not including any possible patent term extension. Foreign patents corresponding to the tecarfarin patents expire in 2025. If our patents
expire, we may not be able to adequately protect our intellectual property, and competitors may be able to erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, in the U.S., the term of a patent covering
an FDA-approved&#160;drug may be eligible for a patent term extension under the Hatch-Waxman&#160;Act as compensation for the loss of
patent term during the FDA regulatory review process. The period of extension may be up to five&#160;years beyond the expiration of the
patent, but cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one
patent among those eligible for an extension may be extended. For patents that might expire during the application phase, the patent
owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up
to four times. For each interim patent extension granted, the post-approval&#160;patent extension is reduced by one year. The director
of the United&#160;States Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent
extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.
Provisions are available in certain other jurisdictions to extend the term of a patent that covers an approved drug or to provide data
exclusivity. For example, data exclusivity in the EU may be available for 10&#160;years from approval and in Japan for eight&#160;years
from approval. It is possible that issued U.S.&#160;patents covering tecarfarin may be entitled to patent term extensions. If our product
candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover
the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however,
there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should
be granted, and even if granted, the length of such extensions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a list of our U.S.&#160;and
foreign patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tecarfarin Patents</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Country</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patent No.<br/> (Application No.)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Type of Patent<br/> Protection</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">U.S.A.</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7666902</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">02/23/2010</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Method of treatment</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2024</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">U.S.A.</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7253208</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">08/07/2007</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 21%; text-align: center">U.S.A.</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">7285671</td><td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 19%; text-align: center">10/23/2007</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    of matter (chloro derivative)<sup>(1)</sup></span></td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 19%; text-align: center">April&#160;8, 2024</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Australia</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2005233614</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">7/12/2012</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Austria</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Belgium</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Belgium</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Brazil</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI0508392-3</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Canada</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2559568</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">5/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">China</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1950353-B<br/>
                                            (200580012074.6)</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">6/1/2011</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Cyprus</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Denmark</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Denmark</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">Europe</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1735296<br/>
                                            (05733799.0)</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Europe</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2161261<br/>
                                            (09175606.4)</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Finland</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Finland</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">France</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">France</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Germany</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">602005018181.4</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Germany</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">602005041073.2</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Great Britain</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Great Britain</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Greece</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3071104</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Hong Kong</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1105200</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">3/9/2012</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Hong Kong</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1138265</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">5/23/2014</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">India</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250594<br/>
                                            (2793/KOLNP/2006)</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">1/11/2012</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Ireland</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Ireland</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Israel</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">178122</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">5/4/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of Matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Italy</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">502010901815570</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Italy</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">502013902212109</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Japan</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">5036532</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">7/13/2012</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Luxembourg</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Luxembourg</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">Mexico</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">274321<br/>
                                            (PA/a/2006/011637)</span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">3/3/2010</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Monaco</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Composition of matter</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Monaco</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Use</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  </table><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">This patent is not directed to tecarfarin, but rather
                                            is a derivative of tecarfarin.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patent No.<br/> (Application No.)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Type of Patent<br/> Protection</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: center">Netherlands</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">1735296</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 19%; text-align: center">12/9/2009</td><td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: center">Composition of matter</td><td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Netherlands</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td>&#160;</td>
    <td style="text-align: center">Use</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Norway</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">338837</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">10/24/2016</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Philippines</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-2006-501866</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">11/19/2010</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Portugal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Russia</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2335501-C2</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">10/10/2008</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Russia</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2495034-C2</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">10/10/2013</td><td>&#160;</td>
    <td style="text-align: center">Method of Treatment</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">South Africa</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2006/07667</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">11/28/2007</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">South Korea</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-1203124</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">11/14/2012</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Spain</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Spain</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">09175606.4</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td>&#160;</td>
    <td style="text-align: center">Use</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Sweden</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Sweden</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td>&#160;</td>
    <td style="text-align: center">Use</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">Switzerland</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1735296</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">12/9/2009</td><td>&#160;</td>
    <td style="text-align: center">Composition of matter</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Switzerland</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2161261</td><td style="text-align: left">&#160;</td>
    <td style="text-align: center">8/28/2013</td><td>&#160;</td>
    <td style="text-align: center">Use</td><td>&#160;</td>
    <td style="text-align: center">April&#160;8, 2025</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Data Exclusivity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If tecarfarin is approved by the FDA, we expect
to receive five years of data exclusivity, often referred to as new chemical entity exclusivity, for our tecarfarin NDA, so long as FDA
has not approved a drug containing the same active moiety as tecarfarin. It is possible that the FDA may disagree with our position and
not approve tecarfarin or grant new chemical exclusivity to our NDA for tecarfarin. Assuming the FDA approves tecarfarin and new chemical
entity exclusivity is granted, during the five-year&#160;period, no generic applicant can file an abbreviated drug application referencing
our NDA for tecarfarin, unless the generic applicant challenges a patent listed in the FDA Orange Book for the referenced NDA, in which
case the generic applicant can file after four years. If the patent is asserted against the generic applicant within 45 days of receipt
of a required notice letter by the generic applicant, the generic abbreviated drug application cannot be approved by FDA for up to thirty
months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of
substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could
include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or untitled letters,
product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product development and marketing activities
are subject to extensive regulation by various government authorities, including the FDA, other federal, state and local agencies and
comparable regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical&#160;development,
testing, manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
Generally, before a new drug can be sold, considerable data demonstrating its quality, safety and efficacy must be obtained, organized
into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority. The data are often
generated in two distinct development states: pre-clinical&#160;and clinical.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among other matters, U.S.&#160;and foreign anti-corruption,
anti-money&#160;laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade
Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors,
and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper
payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial
criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and
fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of
government agencies or government-affiliated&#160;hospitals, universities, and other organizations. We also expect our non-U.S.&#160;activities
to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners,
even if we do not explicitly authorize or have prior knowledge of such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Development of Drugs in the United&#160;States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmaceutical products must be approved by the
FDA before they may be legally marketed in the United&#160;States. Pharmaceutical product development for a new product or certain changes
to an approved product in the U.S.&#160;typically involves pre-clinical&#160;laboratory and animal tests, the submission to the FDA of
an investigational new drug application, or IND, which must become effective before clinical testing may commence, and adequate and well-controlled&#160;clinical
trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA
pre-market&#160;approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon
the type, complexity and novelty of the product or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pre-clinical&#160;development stage generally
involves synthesizing the active component, developing the formulation and determining the manufacturing process, as well as carrying
out non-human&#160;toxicology, pharmacology and drug metabolism trials that support subsequent clinical testing. These pre-clinical&#160;laboratory
and animal tests must comply with federal regulations and requirements, including the FDA&#8217;s good laboratory practices regulations.
A drug&#8217;s sponsor must submit the result of the pre-clinical&#160;tests, together with manufacturing information, analytical data
and any available clinical data or literature and a proposed clinical protocol to the FDA as part of an IND application. A 30-day&#160;waiting
period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented
on nor questioned the IND within this 30-day&#160;period, the clinical trial proposed in the IND may begin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials involve the administration of
the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must
be conducted (i)&#160;in compliance with federal regulations, including good clinical practices, or GCPs, an international standard meant
to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; and (ii)&#160;under
protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be
evaluated. Each protocol involving testing on U.S.&#160;patients and subsequent protocol amendments must be submitted to the FDA as part
of the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials to support NDAs for marketing
approval can generally be divided into three sequential phases that may overlap, Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical
trials. In Phase&#160;1, generally, small numbers of healthy volunteers are initially exposed to single escalating doses and then multiple
escalating doses of the product candidate. The primary purpose of these trials is to assess the metabolism, pharmacologic action and
general safety of the drug. Phase&#160;2 trials typically involve trials in disease-affected&#160;patients to determine the dose required
to produce the desired benefits, common short-term&#160;side effects and risks. Phase&#160;2 trials are typically well-controlled, closely
monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred patients. Phase&#160;3
trials are intended to gather the additional information about effectiveness and safety in a larger number of patients, typically at
geographically dispersed clinical trial sites, that is needed to evaluate the overall benefit-risk&#160;relationship of the drug and
to provide an adequate basis for physician labeling. Phase&#160;3 trials usually include from several hundred to several thousand patients
and are closely controlled and monitored. In many cases, the FDA requires two adequate and well-controlled&#160;Phase&#160;3 clinical
trials to demonstrate the efficacy of the drug. A single Phase&#160;3 trial with other confirmatory evidence may be sufficient in some
instances. In addition to these Phase&#160;1-3&#160;trials, other trials may be conducted to gather additional safety, pharmacokinetic
and pharmacodynamic information. Pharmaceutical products with active ingredients that are the same as or similar to those already approved
by the FDA may have more streamlined development programs than new chemical entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may order the temporary, or permanent,
discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being
conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. Trials must be conducted
in accordance with GCPs and reporting of study progress and any adverse experiences is required. The study protocol and informed consent
information for patients in clinical trials must also be submitted to an institutional review board, or IRB, responsible for overseeing
trials at particular sites and protecting human research trial patients. An independent institutional review</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">board may also suspend or terminate a trial once
initiated, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Accordingly, we cannot be sure that
submission of an IND, will result in the FDA allowing clinical trials to begin, or that once begun, issues will not arise that could
cause the trial to be suspended or terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-approval&#160;trials, sometimes referred
to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. Sometimes, these trials are used to gain additional
experience from the treatment of patients in the intended therapeutic condition. In certain instances, the FDA may mandate the performance
of Phase&#160;4 trials. In other situations, post-approval&#160;trials aim to gain additional indications for a medication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes to some of the conditions established
in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission
and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically
requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA
supplements as it does in reviewing NDAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Review and Approval in the United&#160;States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following Phase&#160;3 trial completion, data
are analyzed to determine safety and efficacy, with any final such determination to be made by the FDA.&#160;Data are then submitted
to the FDA in an NDA, along with proposed labeling for the product and information about the manufacturing and testing processes and
facilities that will be used to ensure product quality. The cost of preparing and submitting an NDA is substantial. Manufacturers may
be assessed up to five program fees for a fiscal year for prescription drug products identified in a single approved NDA.&#160;These
fees are typically increased annually. In the United&#160;States, FDA approval of an NDA must be obtained before marketing a new drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has 60&#160;days from its receipt of
an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the
application is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth&#160;review.
The FDA has agreed to certain performance goals in the review of NDAs. Most applications for standard review drug products are reviewed
within 10 to 12&#160;months; most applications for priority review drugs are reviewed in six to eight&#160;months. Priority review can
be applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy exists.
The review process for both standard and priority review may be extended by the FDA for three additional&#160;months to consider certain
late-submitted&#160;information, or information intended to clarify information already provided in the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may also refer applications for novel
drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&#160;&#8212;&#160;typically
a panel that includes clinicians and other experts&#160;&#8212;&#160;for review, evaluation, and a recommendation as to whether the application
should be approved. The FDA is not bound by the recommendations of advisory committees, but it generally follows such recommendations.
Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.&#160;Additionally,
the FDA will inspect the facility or the facilities at which the drug is manufactured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may conduct a pre-approval&#160;inspection
of the manufacturing facilities for the new product to determine whether they comply with current good manufacturing practice requirements.
The FDA will not approve the product unless compliance with current good manufacturing practices, or GMPs, is satisfactory and the NDA
contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the FDA evaluates the NDA and the manufacturing
facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application.
If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue
an approval letter. The FDA has committed to reviewing such resubmissions in two to six&#160;months depending on the type of information
included.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk
evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include
medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU.&#160;ETASU can include,
but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability
of the drug. Moreover, product approval may require substantial post-approval&#160;testing and surveillance to monitor the drug&#8217;s
safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems
are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pediatric Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Pediatric Research Equity Act, or PREA,
NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant
pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective.
The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not
apply to any drug for an indication for which orphan designation has been granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Best Pharmaceuticals for Children Act, or
BPCA, provides NDA holders a six-month&#160;extension of any exclusivity&#160;&#8212;&#160;patent or non-patent&#160;&#8212;&#160;for
a drug if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the
use of a new drug in the pediatric population may produce health benefits in that population, the FDA&#8217;s written request for pediatric
studies, and the applicant&#8217;s agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications
under the BPCA are treated as priority applications, with all of the benefits that designation confers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Designation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant
orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects
fewer than 200,000 individuals in the United&#160;States. Orphan product designation must be requested before submitting an NDA.&#160;After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by
the FDA.&#160;Orphan product designation does not convey any advantage in or shorten the duration of regulatory review and approval process.
It also does not suggest FDA approval or exclusivity. The first NDA applicant to receive FDA approval for a particular active ingredient
to treat a particular disease with FDA orphan drug designation is entitled to a seven-year&#160;exclusive marketing period in the U.S.&#160;for
that product, for that indication. In addition to the potential period of exclusivity, orphan designation makes a company eligible for
grant funding of up to $500,000 per year for four&#160;years to defray costs of clinical trial expenses, tax credits for clinical research
expenses and potential exemption from the FDA application user fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orphan drug exclusivity means the FDA may not
approve any other applications to market the same drug for the same indication for seven&#160;years, except in limited circumstances,
such as (i)&#160;the drug&#8217;s orphan designation is revoked; (ii)&#160;its marketing approval is withdrawn; (iii)&#160;the orphan
exclusivity holder consents to the approval of another applicant&#8217;s product; (iv)&#160;the orphan exclusivity holder is unable to
assure the availability of a sufficient quantity of drug; or (v)&#160;a showing of clinical superiority to the product with orphan exclusivity
by a competitor product. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition,
or the same drug for a different disease or condition. If a drug designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan drug exclusivity. There has been recent litigation concerning FDA&#8217;s
interpretation of the orphan drug exclusivity provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accelerated Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a variety of pathways under which applicants
may seek expedited approval from FDA, including Fast Track, breakthrough therapy, priority review and accelerated approval. Fast Track
is a process designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and
fill an unmet medical need. Drugs that receive Fast Track designation may be eligible for more frequent communications and meetings with
the FDA to discuss the drug&#8217;s development plan, including the design of the proposed clinical trials, use of biomarkers and the
extent of data needed to support approval. Drugs with Fast Track designation may also qualify for accelerated approval and priority review
of new drug applications if relevant criteria are met. However, Fast Track designation may be withdrawn by the FDA if the FDA believes
that the designation is no longer supported by data emerging in the clinical trial process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA accelerated approval program provides
for early approval of drugs based on a drug on a clinical trial(s)&#160;showing that the drug meets a surrogate or an intermediate clinical
endpoint rather than a clinical benefit endpoint. Accelerated approval is possible for drugs for serious conditions that fill an unmet
medical need. Under priority review, the FDA reviews an application in six months rather than ten months after it is accepted for filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A surrogate endpoint used for accelerated approval
is a marker, such as a laboratory measurement, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit.
Likewise, an intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the
clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. Because it sometimes can take many&#160;years
for a drug trial to show a clinical benefit, the use of a surrogate endpoint or an intermediate clinical endpoint can significantly shorten
the time required to complete clinical trials and obtain FDA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a drug receives an accelerated approval, the
company that sponsored the application must conduct a post-approval&#160;trial to confirm the anticipated clinical benefit. These trials
are known as Phase&#160;4 or post-approval&#160;confirmatory trials. If the confirmatory trial shows that the drug actually provides
a clinical benefit, then the FDA grants traditional approval for the drug. Failure to conduct required post-approval&#160;studies, or
confirm a clinical benefit during post-marketing&#160;studies, will allow the FDA to withdraw the drug from the market on an expedited
basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.&#160;If
the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead
to removing the drug from the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Drug Development in Europe</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, our future products may
also be subject to extensive regulatory requirements. Similar to the United&#160;States, the marketing of medicinal products is subject
to the granting of marketing authorizations by regulatory agencies. Also, as in the United&#160;States, the various phases of pre-clinical&#160;and
clinical research in the European Union are subject to significant regulatory controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Review and Approval in the European Union</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, approval of new medicinal
products can be obtained through one of three processes: the mutual recognition procedure, the centralized procedure and the decentralized
procedure. We intend to determine which process we will follow, if any, in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mutual Recognition Procedure: </i>An applicant
submits an application in one European Union member state, known as the reference member state. Once the reference member state has granted
the marketing authorization, the applicant may choose to submit applications in other concerned member states, requesting them to mutually
recognize the marketing authorizations already granted. Under this mutual recognition process, authorities in other concerned member
states have 55&#160;days to raise objections, which must then be resolved by discussion among the concerned member states, the reference
member state and the applicant within 90&#160;days of the commencement of the mutual recognition procedure. If any disagreement remains,
all considerations by authorities in the concerned member states are suspended and the disagreement is resolved through an arbitration
process. The mutual recognition procedure results in separate national marketing authorizations in the reference member state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Centralized Procedure: </i>This procedure
is currently mandatory for products developed by means of a biotechnological process and optional for new active substances and other
&#8220;innovative medicinal products with novel characteristics.&#8221; Under this procedure, an application is submitted to the European
Agency for the Evaluation of Medical Products. Two European Union member states are appointed to conduct an initial evaluation of each
application. These countries each prepare an assessment report that is then used as the basis of a scientific opinion of the Committee
on Proprietary Medical Products. If this opinion is favorable, it is sent to the European Commission, which drafts a decision. After
consulting with the member states, the European Commission adopts a decision and grants a marketing authorization, which is valid throughout
the European Union and confers the same rights and obligations in each of the member states as a marketing authorization granted by that
member state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Decentralized Procedure: </i>The most recently
introduced of the three processes for obtaining approval of new medicinal processes in the European Union, the decentralized procedure
is similar to the mutual recognition procedure described above, but with differences in the timing that key documents are provided to
concerned member states by the reference member state, the overall timing of the procedure and the possibility of, among other things,
&#8220;clock stops&#8221; during the procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Post-Marketing&#160;Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following approval of a new product, a pharmaceutical
company and the approved product are subject to continuing regulation by the FDA and other regulatory authorities, including, among other
things, monitoring and recordkeeping activities, reporting to applicable regulatory authorities of adverse experiences with the product,
providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and
complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer&#160;advertising,
restrictions on promoting drugs for uses or in patient populations not described in the drug&#8217;s approved labeling (known as &#8220;off-label&#160;use&#8221;),
and limitations on industry-sponsored&#160;scientific and educational activities. Although physicians may prescribe legally available
drugs for off-label&#160;uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the approved
labeling. Modifications or enhancements to the products or labeling or changes of site of manufacture are often subject to the approval
of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. The FDA regulations require
the products be manufactured in specific approved facilities and in accordance with current good manufacturing practices, and NDA holders
must list their products and register their manufacturing establishments with the FDA.&#160;These regulations also impose certain organizational,
procedural and documentation requirements with respect to manufacturing and quality assurance activities. Drug manufacturers and other
entities involved in the manufacture and distribution of approved drugs are subject to periodic unannounced inspections by the FDA and
certain state agencies for compliance with current good manufacturing practice and other laws. NDA holders using contract manufacturers,
laboratories or packagers are responsible for the selection and monitoring of qualified firms. These firms are subject to inspections
by the FDA at any time, and the discovery of violative conditions could result in enforcement actions that interrupt the operation of
any such facilities or the ability to distribute products manufactured, processed or tested by them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulatory Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing, sales, promotion and other activities
following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the
United&#160;States, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human
Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational
Safety&#160;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. These laws and regulations
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The federal healthcare
                                            program anti-kickback&#160;law which prohibits, among other things, persons from soliciting,
                                            receiving or providing remuneration, directly or indirectly, to induce either the referral
                                            of an individual, for an item or service or the purchasing or ordering of a good or service,
                                            for which payment may be made under federal healthcare programs such as the Medicare and
                                            Medicaid programs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Federal false
                                            claims laws which prohibit, among other things, individuals or entities from knowingly presenting,
                                            or causing to be presented, claims for payment from Medicare, Medicaid, or other government
                                            reimbursement programs that are false or fraudulent. The government may assert that a claim
                                            including items or services resulting from a violation of the federal healthcare program
                                            anti-kickback&#160;law or related to off-label&#160;promotion constitutes a false or fraudulent
                                            claim for purposes of the federal false claims laws;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Federal Physician
                                            Payments Sunshine Act within the Affordable Care Act, or the ACA, and its implementing regulations,
                                            require that certain manufacturers of drugs, devices, biological and medical supplies for
                                            which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
                                            Program (with certain exceptions) to report on an annual basis information related to certain
                                            payments or other transfers of value made or distributed to physicians and teaching hospitals,
                                            or to entities or individuals at the request of, or designated on behalf of, the physicians
                                            and teaching hospitals and certain ownership and investment interests held by physicians
                                            and their immediate family members, with the information made publicly available on a searchable
                                            website; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Health Insurance
                                            Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology
                                            for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes
                                            certain requirements relating to the privacy, security and transmission of individually identifiable
                                            health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards
                                            directly applicable to &#8220;business associates&#8221;&#160;&#8212;&#160;independent contractors
                                            or agents of covered entities that receive or obtain protected health information in connection
                                            with providing a service on behalf of a covered entity. HITECH also created four new tiers
                                            of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly
                                            applicable to business associates and possibly other persons, and gave state attorneys general
                                            new authority to file civil actions for damages or injunctions in federal courts to enforce
                                            the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing
                                            federal civil actions.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Applicable child-resistant&#160;packaging
                                            requirements under the U.S.&#160;Poison Prevention Packaging Act.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Lanham Act
                                            and federal antitrust laws.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">State law equivalents
                                            of each of the above federal laws, such as anti-kickback&#160;and false claims laws, which
                                            may apply to items or services reimbursed by any third-party&#160;payer, including commercial
                                            insurers, and state laws governing the privacy and security of health information in certain
                                            circumstances, many of which differ from each other in significant ways and often are not
                                            preempted by federal laws, thus complicating compliance efforts. In addition, several states
                                            now require prescription drug companies to report expenses relating to the marketing and
                                            promotion of drug products and to report gifts and payments to individual physicians in these
                                            states. Other states prohibit various other marketing-related&#160;activities, and still
                                            other states require the posting of information relating to clinical studies and their outcomes.
                                            In addition, California, Connecticut, Massachusetts and Nevada require pharmaceutical companies
                                            to implement compliance programs and/or marketing codes. Several additional states are considering
                                            similar proposals. Compliance with these laws is difficult and time consuming, and companies
                                            that do not comply with these state laws face civil penalties.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distribution of pharmaceutical products is subject
to additional requirements and regulations, including extensive record-keeping, licensing, traceability, and storage and security requirements
intended to prevent the unauthorized sale of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-Party&#160;Payer Coverage and Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any of our drug candidates that ultimately may obtain regulatory approval. In both the United&#160;States
and foreign markets, our ability to commercialize our product candidates successfully, and to attract commercialization partners for
our product candidates, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party&#160;payers,
including, in the United&#160;States, governmental payers such as the Medicare and Medicaid programs, managed care organizations, and
private health insurers. Medicare is a federally funded program managed by the CMS, through local fiscal intermediaries and carriers
that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid
is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise
uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid
and each state creates specific regulations that govern its individual program. Each payer has its own process and standards for determining
whether it will cover and reimburse a procedure or particular product. Private payers often rely on the lead of the governmental payers
in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant
gating issue for successful introduction of a new product. The competitive position of some of our products will depend, in part, upon
the extent of coverage and adequate reimbursement for such products and for the procedures in which such products are used. Prices at
which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and
other payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The United&#160;States Congress and state legislatures
may, from time to time, propose and adopt initiatives aimed at cost containment, which could impact our ability to sell our products
and product candidates profitably. For example, in the first quarter of 2018, President Trump signed a law requiring pharmaceutical companies
to pay for a substantially larger percentage of the coverage gap, or the so-called&#160;&#8220;donut hole,&#8221; between regular and
catastrophic Medicare Part&#160;D prescription drug coverage, a change that is estimated to have a multi-billion-dollar&#160;effect on
brand-name&#160;drug companies. Additional changes could be made in the future to governmental healthcare programs and many other laws
that could significantly impact the success of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of pharmaceuticals continues to generate
substantial governmental and third-party&#160;payer interest. We expect that the pharmaceutical industry will experience pricing pressures
due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals.
Our results of operations could be adversely affected by current and future healthcare reforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some third-party&#160;payers also require pre-approval&#160;of
coverage for new or innovative devices or drugs before they will reimburse healthcare providers that use such drugs. While we cannot
predict whether any proposed cost-containment&#160;measures will be adopted or otherwise implemented in the future, the announcement
or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our products and product
candidates and operate profitably.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in some foreign countries, the proposed
pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country
to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member
state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement
limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically,
products launched in the European Union do not follow price structures of the United&#160;States and generally tend to be significantly
lower.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among other matters, U.S.&#160;and foreign anti-corruption,
anti-money&#160;laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade
Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors,
and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper
payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial
criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and
fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of
government agencies or government-affiliated&#160;hospitals, universities, and other organizations. We also expect our non-U.S.&#160;activities
to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners,
even if we do not explicitly authorize or have prior knowledge of such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Human&#160;Capital-Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">As of March 28, 2023, we had three full-time&#160;employees as well
as several independent contractors. Our employees are not represented by labor unions or covered by collective bargaining agreements.
We consider our relationship with our employees to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0"><b>Our Corporate Background and Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as a Delaware corporation
on January 25, 2022 and secured the rights to tecarfarin on April 1, 2022 via an asset purchase agreement (the &#8220;Asset Purchase
Agreement&#8221;) from HESP LLC. HESP LLC acquired the assets of Espero BioPharma, Inc., or Espero, from Horizon Technology Finance Corporation
and Horizon Credit II LLC (collectively, Horizon), a secured lender of Espero, including tecarfarin and the other assets of Espero in
an assignment for the benefit of creditors. Quang Pham, our Chief Executive Officer, was the Chief Executive Officer of Espero and consultant
to HESP LLC from July 2020 to December 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
822 A1A North, Suite 306, Ponte Vedra, Florida 32082, and our telephone number is (904) 300-0701. Our website address is <i>www.cadrenal.com</i>.
The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and
you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding
whether to purchase our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Our website address
is www.cadrenal.com.&#160;&#160;We will file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K,
proxy statements and other materials with the SEC. We are subject to the informational requirements of the Exchange Act and will file
or furnish reports, proxy statements and other information with the SEC. Such reports and other information filed by the Company with
the SEC are available free of charge on our website at http://cadrenal.com/investors/SEC filings. Information contained on, or that can
be accessed through, our website is not incorporated by reference into this Annual Report, and you should not consider information on
our website to be part of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The SEC also maintains
a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with
the SEC at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &#8220;emerging growth company&#8221;
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we remain an emerging growth company,
we may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to other
public companies. These provisions include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reduced obligations
                                            with respect to financial data, including presenting only two years of audited financial
                                            statements and selected financial data, and only two years of related Management&#8217;s
                                            Discussion and Analysis of Financial Condition and Results of Operations disclosure in our
                                            initial registration statement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an exemption from
                                            the auditor attestation requirement in the assessment of our internal control over financial
                                            reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reduced disclosure
                                            about executive compensation arrangements in our periodic reports, registration statements
                                            and proxy statements; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">exemptions from
                                            the requirements to seek non-binding advisory votes on executive compensation or stockholder
                                            approval of any golden parachute arrangements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of some or all of these
provisions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the
last day the fiscal year following the fifth anniversary of the completion of our initial public offering, (ii) the last day of the first
fiscal year in which our annual gross revenues exceed $1.235 billion, (iii) the date on which we have, during the immediately preceding
three-year period, issued more than $1.0 billion in non-convertible debt securities and (iv) the date on which we are deemed to be a
large accelerated filer under the rules of the SEC, or the SEC. We may choose to take advantage of some but not all of these reduced
burdens. For example, we have taken advantage of the reduced reporting requirements with respect to disclosure regarding our executive
compensation arrangements, have presented only two years of audited financial statements and only two years of related &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus, and have taken advantage
of the exemption from auditor attestation on the effectiveness of our internal control over financial reporting. To the extent that we
take advantage of these reduced burdens, the information that we provide stockholders may be different than you might obtain from other
public companies in which you hold equity interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the JOBS Act permits emerging growth
companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies. We have elected to use this extended transition period. As a result of this election, our timeline to comply with new or revised
accounting standards will in many cases be delayed as compared to other public companies that are not eligible to take advantage of this
election or have not made this election. Therefore, our financial statements may not be comparable to those of companies that comply
with the public company effective dates for these accounting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting company&#8221;
as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of
the scaled disclosures available to smaller reporting companies. To the extent that we continue to qualify as a &#8220;smaller reporting
company&#8221; as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company,
certain of the exemptions available to us as an &#8220;emerging growth company&#8221; may continue to be available to us as a &#8220;smaller
reporting company,&#8221; including exemption from compliance with the auditor attestation requirements pursuant to SOX and reduced disclosure
about our executive compensation arrangements. We will continue to be a &#8220;smaller reporting company&#8221; until we have $250 million
or more in public float (based on our Common Stock) measured as of the last business day of our most recently completed second fiscal
quarter or, in the event we have no public float (based on our Common Stock) or a public float (based on our Common Stock) that is less
than $700 million, annual revenues of $100 million or more during the most recently completed fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_002i"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Investors should
carefully consider the risks described below before deciding whether to invest in our securities. If any of the following risks actually
occur, our business, financial condition or results of operations could be adversely affected. In such case, the trading price of our
common stock could decline and you could lose all or part of your investment. Our actual results could differ materially from those anticipated
in the forward-looking statements made throughout this Annual Report a result of different factors, including the risks we face described
below.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Position and
Need for Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical development biopharmaceutical
company with a limited operating history.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a recently formed company and have had
limited operations to date. We have to complete clinical trials and receive regulatory approval of new drug applications, or NDAs, before
commercial sales of our product candidates can commence. The likelihood of success of our business plan must be considered in light of
the problems, substantial expenses, difficulties, complications and delays frequently encountered in connection with building and expanding
clinical development pharmaceutical businesses and the regulatory and competitive environment in which we operate. Pharmaceutical product
development is a highly speculative undertaking, involves a substantial degree of risk and is a capital-intensive business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, you should consider our prospects
in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the later stage of development,
especially clinical pharmaceutical companies such as ours. Potential investors should carefully consider the risks and uncertainties
that a company with a limited operating history will face. In particular, potential investors should consider that we cannot assure you
that we will be able to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successfully complete
                                            the clinical trials necessary to obtain regulatory approval for the marketing of our product
                                            candidate, tecarfarin;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">secure acceptance
                                            of our product candidate in the medical community and with third-party payors and consumers;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if approved for
                                            commercial sale, launch commercial sales of our product candidate, whether alone or in collaboration
                                            with others;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successfully build
                                            an internal sales force meeting our requirements for the marketing and sale of our product
                                            candidate, tecarfarin;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successfully manufacture
                                            our clinical product and establish commercial drug supply;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">secure market
                                            exclusivity and/or adequate intellectual property protection for our product candidate;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">attract and retain
                                            an experienced management, board and scientific advisory team;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successfully implement
                                            or execute our current business plan, and we cannot assure you that our business plan is
                                            sound; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">raise sufficient
                                            funds in the capital markets to effectuate our business plan.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we cannot successfully execute any one of
the foregoing, our business may not succeed and your investment will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history upon
which to evaluate our ability to commercialize our product candidate</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development-stage company and our success
is dependent upon our ability to obtain regulatory approval for and commercialize our product candidate, tecarfarin, and we have not
demonstrated an ability to perform the functions necessary for the approval or successful commercialization of any product candidate.
We have yet to demonstrate our ability to overcome the risks frequently encountered in our industry and are still subject to many of
the risks common to such enterprises, including our ability to implement our business plan, market acceptance of our proposed business
and lead product, under-capitalization, cash shortages, limitations with respect to personnel, financing and other resources, competition
from better funded and experienced companies, and uncertainty of our ability to generate revenues. In fact, though individual team members
have experience running clinical trials and our Chief Executive Officer has been involved with the development of tecarfarin for five
years, as a company we have yet to prove that we can successfully run a clinical trial. There is no assurance that our activities will
be successful or will result in any revenues or profit, and the likelihood of our success must be considered in light of the stage of
our development. In addition, no assurance can be given that we will be able to consummate our business strategy and plans, or that financial,
technological, market, or other limitations may force us to modify, alter, significantly delay, or significantly impede the implementation
of such plans. We have insufficient results for investors to use to identify historical trends. Investors should consider our prospects
in light of the risk, expenses and difficulties we will encounter as an early stage company. Our revenue and income potential is unproven
and our business model is continually evolving. We are subject to the risks inherent to the operation of a new business enterprise, and
cannot assure you that we will be able to successfully address these risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a history of operating losses and
expect to continue to incur substantial losses for the foreseeable future. We may never become profitable or, if achieved, be able to
sustain profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have not generated any revenue from
operations and we expect to continue to incur significant operating losses in connection with the development and sale of tecarfarin.
We may continue to incur operating losses until such time, if ever, as we are able to achieve sufficient levels of revenue from operations.
Our ability to achieve profitability will depend on regulatory approval of our product candidate and if approved, the market acceptance
of our product offering and our capacity to develop, introduce and sell our product to our targeted markets. There can be no assurance
that we will ever generate significant sales or achieve profitability. Accordingly, the extent of future losses and the time required
to achieve profitability, if ever, cannot be predicted at this point.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we succeed in developing and commercializing
one or more product candidates, we expect to incur substantial losses for the foreseeable future and may never become profitable. We
also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will increase substantially
in the foreseeable future as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">continue to undertake
                                            the pivotal clinical trial for our product candidate;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">seek regulatory
                                            approvals for our product candidate;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">implement additional
                                            internal systems and infrastructure; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">hire additional
                                            personnel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to generate revenue or achieve
profitability in the future. Our failure to achieve or maintain profitability would likely negatively impact the value of our securities
and could prevent us from continuing as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we can secure such arrangements, we may
continue to have obligations and expenses that exceed the revenue generated by these marketed products. In addition, we could incur significant
development and other expenses if we were to make alterations to the manufacturing process for tecarfarin, for preparation and submission
of a supplemental NDA for such alterations, if required by the FDA, and in connection with the launch of tecarfarin, if approved. Further,
as we pursue FDA approval for tecarfarin, we expect that our research and development expenses will continue to increase significantly
as we advance our pivotal Phase 3 clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our cash and the proceeds of our initial
public offering will only fund our operations for a limited time, and we will need to raise additional capital to fund our planned pivotal
Phase 3 clinical trial and to support our development and commercialization efforts for our product candidate, tecarfarin.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not succeed in raising additional funds on
acceptable terms, we will be unable to commence our planned Phase 3 pivotal clinical trial or obtain approval of our product candidate
from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego
sales and marketing efforts, and forego licensing in attractive business opportunities. We estimate that we will require a total of $45
million for the completion of our planned pivotal Phase 3 clinical trial and other expenditures that we will need to incur in order to
file our NDA. We intend to use approximately $3 million of the proceeds from our initial public offering to fund CMC preparation, research
and development and other trial preparation expenses required for the initiation of our planned pivotal Phase 3 clinical trial, therefore,
we will require at least $42 million of additional funding to enroll patients and complete our first Phase 3 clinical trial. Additionally,
we estimate that we will require $13 million for general and administrative expenses anticipated to be incurred over the next three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will also need to raise additional capital
to expand our business to meet our long-term business objectives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our existing cash, which includes
the net proceeds from our initial public offering will be sufficient in the aggregate to meet our anticipated cash requirements for at
least the next twelve months. We will, however, require additional financing as we continue to execute our business strategy, including
that we will require additional funds for the initiation of enrollment of patients and completion of the planned pivotal Phase 3 trial.
Our liquidity may be negatively impacted as a result of a research and development cost increases in addition to general economic and
industry factors. We anticipate that, to the extent that we require additional liquidity, it will be funded through the incurrence of
other indebtedness, additional equity financings or a combination of these potential sources of liquidity. In addition, we may raise
additional funds to finance future cash needs through grant funding and/or corporate collaboration and licensing arrangements. If we
raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. Debt financing, if
available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights
to our products, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. The covenants
under future credit facilities may limit our ability to obtain additional debt financing. We cannot be certain that additional funding
will be available on acceptable terms, or at all. Any failure to raise capital in the future could have a negative impact on our financial
condition and our ability to pursue our business strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our present and future capital requirements will
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the outcome, timing
                                            and cost of our Phase 3 clinical trial to obtain regulatory approval for tecarfarin in the
                                            United States;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the degree and
                                            rate of market adoption of our products, if approved;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the emergence
                                            of new, competing technologies and products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs of R&amp;D
                                            activities we undertake to develop new products and indications;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs of commercialization
                                            activities, including sales, marketing and manufacturing;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs of building
                                            an internal sales force meeting our requirements for the marketing and sale of our product
                                            candidates, if approved;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to
                                            collaborate with third parties on the development and commercialization of our product candidates
                                            and products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the level of working
                                            capital required to support our growth; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our need for additional
                                            personnel, information technology or other operating infrastructure to support our growth
                                            and operations as a public company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently have any arrangements or
credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise sufficient additional capital
on acceptable terms, or at all. We anticipate that the additional funding we require will be funded through the incurrence of other indebtedness,
additional equity financings or a combination of these potential sources of liquidity We may seek additional capital through a combination
of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, including issuing shares of our common stock or
other securities and incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity
financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders to waive certain
rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay,
scale back or eliminate the development of business opportunities and our operations and financial condition may be materially adversely
affected. We can provide no assurances that any additional sources of financing will be available to us on favorable terms, if at all.
In addition, if we are unable to secure sufficient capital to fund our operations, we might have to enter into strategic collaborations
that could require us to share commercial rights to our products or product candidates with third parties in ways that we currently do
not intend or on terms that may not be favorable to us. If we choose to pursue additional indications and/or geographies for any of our
products or product candidates or otherwise expand more rapidly than we presently anticipate, we may also need to raise additional capital
sooner than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Product Development, Regulatory
Approval, Manufacturing and Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is dependent upon the success
of our investigational product candidate, tecarfarin, which requires additional clinical testing before we can seek regulatory approval
and potentially launch commercial sales. We do not own any other product candidates or have any other products in clinical development.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business and future success depends upon
our ability to obtain regulatory approval of and then successfully commercialize our product candidate, tecarfarin. Tecarfarin is in
late clinical stage development. Our main focus and the investment of a significant portion of our efforts and financial resources is
expected to be in the development of our only product candidate, tecarfarin, for which we are currently planning a Phase 3 clinical trial
with approximately 492 patients in the United States. We believe that the proceeds from our initial public offering will not provide
us with sufficient funds to initiate or complete this pivotal Phase 3 clinical trial. Even though we are pursuing a registration pathway
based on specific FDA input and guidance, there are many uncertainties known and unknown that may affect the outcome of the trial. These
include adequate patient enrollment, adequate supply of our product candidate, potential changes in the regulatory landscape, the results
of the trial being successful, and FDA acceptance of the data to support approval. We also rely on third parties to conduct the appropriate
clinical trials, and their failure to perform in accordance with applicable law would have a negative effect on our regulatory submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success depends heavily on our ability
to successfully manufacture, develop, obtain regulatory approval, and commercialize tecarfarin, which may never occur. We currently generate
no revenues from our product candidate, and we may never be able to develop or commercialize a marketable drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>All of our current data for our product
candidate are the results of clinical trials conducted by third parties and do not necessarily provide sufficient evidence that our products
are viable as potential pharmaceutical products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We possess toxicology, pharmacokinetic, and other
preclinical data and clinical data on tecarfarin from studies and trials conducted several years ago by third parties. As of now, tecarfarin
has been tested in eleven clinical trials and is now in preparations to enter a pivotal Phase 3 trial. There is no guarantee that Phase
1 or Phase 2 results can or will be replicated by the pivotal Phase 3 study. Further, as the clinical trials were conducted by third
parties, and were completed prior to our ownership of the technology, we cannot be assured that such trials were conducted in compliance
with applicable statutes, rules, regulations and guidelines applicable to such trials. Although the FDA concurred with our recommended
endpoints in correspondence that it had with Espero in 2019, and Espero submitted the protocol we plan to use to FDA in 2019, we have
not received FDA input on our Phase 3 protocol. The FDA agreed in principle that &#8220;a single registration trial that combines these
populations may be acceptable.&#8221; However, there can be no assurance that the planned protocol will be accepted by FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Previous clinical trials using tecarfarin have
had different trial designs, doses, parameters and endpoints than the planned Phase 3 clinical trial that is expected to serve as a basis
for approval of tecarfarin. We plan to use a fixed dose in future clinical trials that we believe provides good coverage given the dose
ranges tested clinically; however, it is possible that the dose selected will not be the optimal dose and so drug effects may be limited
or not be demonstrated sufficiently in clinical testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As all of our clinical trials to date were
conducted by third parties, we cannot be assured that such clinical trials were in compliance with applicable laws, rules and regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not acquire tecarfarin until April of
2022, and do not have first-hand knowledge of how the Phase 1 and Phase 2 clinical trials were completed. As such, we cannot be assured
that such clinical trials were conducted in full compliance with applicable laws, rules and regulations. While we are not aware of any
issues in relation to such trials and the performance thereof, we cannot be assured that we may learn in the future that there was a
failure to abide by such laws, rules and regulations, which could potentially expose us to issues with regards to our Phase 3 clinical
trials or otherwise create risks unknown to us with regards to our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our efforts to develop our product candidate
may not generate data sufficient to support an application for regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the global burden of cardiovascular disease,
investment in cardiovascular drug development has stagnated over the past two decades, with relative underinvestment compared with other
therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular
outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically meaningful
cardiovascular endpoints. In addition, clinical trials are difficult to design and implement, can take many years to complete and are
uncertain as to outcome. Success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will
be successful, and interim results of a clinical trial do not necessarily predict final results. For example, in the Phase 2/3 EMBRACE-AC
trial of tecarfarin conducted by ARYx Therapeutics, Inc., a predecessor company to Espero, tecarfarin did not reach statistical significance
on its primary endpoint, superiority to warfarin as measured by time in TTR. There is no guarantee that later trials, including ACTOR
AF, will reach statistical significance on their endpoints, or demonstrate superiority to warfarin or any other therapy. A failure of
one or more of clinical trials can occur at any stage of testing. Our product candidate may prove to have undesirable or unintended side
effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use with
respect to one or all intended indications. In addition, we may experience other numerous unforeseen events during, or as a result of,
the clinical trial process that could delay or prevent our ability to continue development. Development stage risks include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">although we have
                                            FDA minutes documenting Espero&#8217;s correspondence with the FDA regarding tecarfarin,
                                            the FDA minutes are from 2019, are not binding on FDA, and our expectations regarding such
                                            plans may be out of date and not be in line with current market dynamics and the FDA or comparable
                                            foreign regulatory authorities or institutional review boards, or IRBs, may disagree with
                                            the design or implementation of our clinical trial and refuse to let them proceed;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we may not be
                                            able to provide acceptable evidence of the safety and efficacy of our product candidates
                                            or an acceptable benefit/risk profile for our product candidate;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we may not be
                                            able to successfully manufacture drug supplies for our clinical trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the results of
                                            our clinical trial may not be satisfactory or may not meet the level of statistical or clinical
                                            significance required by the FDA, European Medicines Agency, or EMA, or other comparable
                                            foreign regulatory authorities to demonstrate effectiveness;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we may not be
                                            able to determine the optimal dosing of our product candidates; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">patients in our
                                            clinical trial may suffer adverse effects that are deemed related to our product candidates,
                                            leading us or regulatory authorities to stop clinical trial temporarily or permanently.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If unacceptable safety concerns or other adverse
events arise in the development of a product candidate, our clinical trials could be suspended or terminated or the FDA or comparable
foreign regulatory authorities could order us to cease clinical trials or deny approval of such product candidate for any or all targeted
indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the
trial or result in potential product liability claims. Inadequate training in recognizing or managing the potential side effects of a
product candidate could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we successfully complete our clinical
trials, we may not receive regulatory approval for tecarfarin, and we may not be able to commercialize our product candidate and our
ability to generate revenue will be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research, testing, manufacturing, labeling,
packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products are
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations
differ from country to country. We are not permitted to market our product candidate in the United States until we receive approval of
an NDA from the FDA and in non-U.S. markets until we receive the requisite approval from comparable regulatory agencies in such countries.
Of the large number of drugs in development, only a small number are submitted for approval to the FDA through an NDA and even fewer
are eventually approved for commercialization. In 2020 and 2021, the FDA approved only three new molecular entities to treat cardiovascular/vascular
diseases. We may not succeed at gaining regulatory approval, which would materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receipt of necessary regulatory approval is subject
to a number of risks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the data collected
                                            from pre-clinical and clinical trials may not be sufficient to support the submission of
                                            an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the FDA or comparable
                                            foreign regulatory authorities may fail to approve the manufacturing processes or facilities
                                            of third-party manufacturers with which we contract for clinical and commercial supplies;
                                            and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the relevant laws,
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering our clinical data insufficient for approval.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that regulators will agree
with our assessment of the results of our clinical trials or that such trials will be considered by regulators to have shown safety or
efficacy of our product candidates. For example, while we currently intend to conduct future clinical trials of tecarfarin with a primary
endpoint of reduction of major cardiac adverse events (MACE), we cannot assure you that the FDA will consider it to be a clinically meaningful
endpoint. The FDA, EMA and other regulators have substantial discretion in the approval process and may refuse to accept any application
or may decide that our data are insufficient for approval and require additional clinical trials, or pre-clinical or other trials. In
addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory
approval of a product candidate. Failure to obtain regulatory marketing approval for our product candidates in any indication will prevent
us from commercializing the product candidate, and our ability to generate revenue will be materially impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of obtaining regulatory approvals
is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things, the
type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory approval is sought and the substantial
discretion of the regulatory authorities. Changes in regulatory review for a submitted product application may cause delays in approval
or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily mean that a product candidate will
receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to obtain approval in one jurisdiction
may negatively impact our ability to seek or gain approval in a different jurisdiction. Obtaining foreign regulatory approvals and compliance
with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the
introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or
fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential
of tecarfarin or any future product candidates will be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track designation by the FDA may not
actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product candidate is intended for the treatment
of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this
condition, the sponsor may apply for FDA Fast Track designation. However, a Fast Track designation does not ensure that the product candidate
will receive marketing approval or that approval will be granted within any particular timeframe. As a result, while we have received
Fast Track designation for tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients with ESRD and AFib,
we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA
may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval,
we will still face ongoing regulatory requirements and tecarfarin may face future development and regulatory difficulties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we receive regulatory approval of tecarfarin
or any future product candidates, we will be subject to ongoing regulatory obligations, such as post market surveillance and current
good manufacturing practice (&#8220;GMP&#8221;) requirements, and continued regulatory review, which may result in significant additional
expense. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with
product candidates. In addition, third parties on whom we rely must comply with regulatory requirements, and any non-compliance on their
part may negatively impact our business, assuming we obtain regulatory authorization at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any regulatory approvals that we receive for
product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a
Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) program in order to approve product candidates, which could entail requirements
for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA could also require a boxed warning, sometimes referred to as a Black Box
Warning on the product label to identify a particular safety risk, which could affect commercial efforts to promote and sell the product.
In addition, if the FDA or a comparable foreign regulatory authority approves product candidates, the manufacturing processes, labeling,
packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for product candidates
will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with current GMPs and current good clinical practices (&#8220;GCPs&#8221;)
for any clinical trials that we conduct post-approval. We are also subject to certain user fees imposed by the regulatory agencies. Later
discovery of previously unknown problems with product candidates, including adverse events of unanticipated severity or frequency, or
with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among
other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">import alerts
                                            or automatic detentions;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">restrictions on
                                            the marketing or manufacturing of product candidates, withdrawal of the product from the
                                            market, or product recalls;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">fines, warning
                                            letters or holds on clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refusal by the
                                            FDA to approve pending applications or supplements to approved applications filed by us or
                                            suspension or revocation of approvals;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">labeling changes;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">product seizure
                                            or detention, or refusal to permit the import or export of product candidates;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">injunctions or
                                            the imposition of civil or criminal penalties; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">inability to obtain
                                            government contracts.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA&#8217;s and other regulatory authorities&#8217;
policies may change, such as those required by the 21<sup>st </sup>Century Cures Act, and additional government regulations may be enacted
that could prevent, limit or delay regulatory approval of tecarfarin or any future product candidates. In addition, it is unclear what
changes, if any, the new presidential administration may bring. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials are very expensive, time-consuming
and difficult to design and implement.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the regulatory process, we must conduct
clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities.
As we advance tecarfarin or any future product candidates we expect that our expenses will increase. The number and design of the clinical
trials that will be required varies depending upon product candidate, the condition being evaluated, current medical strategies and the
trial results themselves. Therefore, it is difficult to accurately estimate the cost of the clinical trials. Clinical trials are very
expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time consuming. We estimate that clinical trials of product candidates including tecarfarin, will take at least several
years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. The commencement and completion of clinical trials may be delayed or prevented by several factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">unforeseen safety
                                            issues;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">failure to determine
                                            appropriate dosing;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">greater than anticipated
                                            cost of our clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">failure to demonstrate
                                            effectiveness during clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">slower than expected
                                            rates of subject recruitment or difficulty obtaining investigators, particularly during COVID-19;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">subject drop-out
                                            or discontinuation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">import delays
                                            of clinical trial materials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">inability to monitor
                                            subjects adequately during or after treatment;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">third party contractors,
                                            including, without limitation, CROs and manufacturers, failing to comply with regulatory
                                            requirements or meet their contractual obligations to us in a timely manner</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reaching agreements
                                            with prospective CROs, and trial sites, both of which can be subject to extensive negotiation
                                            and may vary significantly among different CROs and trial sites;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">insufficient or
                                            inadequate supply or quality of product candidates or other necessary materials to conduct
                                            our trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">potential additional
                                            safety monitoring, or other conditions required by FDA or comparable foreign regulatory authorities
                                            regarding the scope or design of our clinical trials, or other studies requested by regulatory
                                            agencies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">problems engaging
                                            Institutional Review Boards (&#8220;IRBs&#8221;), to oversee trials or in obtaining and maintaining
                                            IRB approval of studies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">imposition of
                                            clinical hold or suspension of our clinical trials by regulatory authorities; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">inability or unwillingness
                                            of medical investigators to follow our clinical protocols.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we or the FDA may suspend or terminate
our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA finds deficiencies
in our Investigational New Drug, or IND, submissions or the conduct of these trials. Therefore, we cannot predict with any certainty
when, if ever, future clinical trials will commence or be completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delays in the enrollment of patients in
any or all of our clinical trials could increase our development costs and delay completion of our clinical trials and associated regulatory
submissions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to initiate or continue clinical
trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these
trials as required by the FDA or other regulatory authorities. COVID-19 will likely make this even more challenging. Even if we are able
to enroll a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development
costs for our product candidates may increase, and the completion of our trials may be delayed or our trials could become too expensive
to complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if approved, tecarfarin may not have
labeling that allows us to successfully commercialize it.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of tecarfarin and any
of our future product candidates will depend in significant measure upon our ability to obtain approval from the FDA and other regulatory
authorities of labeling describing a product candidate&#8217;s expected features or benefits. Regulatory authorities may approve tecarfarin
for fewer or more limited indications than we request or may approve tecarfarin with labeling that does not include the labeling claims
necessary or desirable for the successful commercialization of that indication. Failure to achieve approval from the FDA or other regulatory
authorities of product labeling containing certain types of information on features or benefits of our products will prevent or substantially
limit our advertising and promotion of such features in order to differentiate our product candidates or any future product candidates
from those products already existing in the market. This may make it difficult or impossible to achieve commercial success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our product candidate is approved, our
success depends on our commercialization efforts, which may not be achieved. If we are unable to commercialize our product candidate,
or experience significant delays in doing so, our business could be materially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will invest a significant portion of our efforts
and financial resources into the development and commercialization of tecarfarin. Product revenues from our product candidate, tecarfarin,
which will not be realized until after regulatory approval, if ever, will depend on the successful development, regulatory approval and
eventual commercialization of these product candidates. The success of our product candidate will depend on several factors, including
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">receipt of marketing
                                            approvals for our product candidate from the FDA and similar regulatory authorities outside
                                            the United States;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">obtaining product
                                            indications, other labeling information and product attributes that are acceptable and attractive
                                            to the medical community, third-party payors and patients;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to
                                            manufacture product commercially at acceptable costs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">establishing and
                                            maintaining commercial manufacturing arrangements with third parties;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successfully commercializing
                                            our product candidate, if approved, whether alone or in collaboration with others;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a continued acceptable
                                            safety profile of the product candidate following approval; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">obtaining, maintaining,
                                            enforcing and defending intellectual property rights and claims and available product exclusivities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not achieve one or more of these factors
in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidate,
which would materially harm our business. In addition, even if we obtain regulatory approvals for tecarfarin, the timing or scope of
any approval may prohibit or reduce our ability to commercialize tecarfarin successfully. For example, if the approval process takes
too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance.
Also, any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render
tecarfarin not commercially viable. For example, regulatory authorities may grant approval contingent on the performance of costly post-marketing
clinical trials or, outside the U.S., they may not accept or approve the price we intend to charge for tecarfarin. Further, the FDA or
comparable foreign regulatory authorities may place conditions on approvals, such as risk management plans and Risk Evaluation and Mitigation
Strategies, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a
proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician
communication plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA may also require a REMS for an approved product when new safety information emerges. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription or dispensing of tecarfarin. Moreover, product approvals
may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing of the product. Any
of the foregoing scenarios could materially harm the commercial success of tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our potential future product candidate,
tecarfarin, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical
community necessary for commercial success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of any potential future
product candidates, including tecarfarin, for which we may obtain marketing approval from the FDA or other regulatory authorities will
depend upon their acceptance by the medical community and third-party payors as clinically useful, cost-effective and safe. The degree
of market acceptance of any drug depends on a number of factors, such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">effectively competing
                                            with other therapies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the prevalence
                                            and severity of any side effects;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">success of patients
                                            in well-controlled clinical trials compared to real-world success of patients post FDA approval;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to
                                            educate and increase physician awareness of the benefits of our products relative to competing
                                            drugs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the willingness
                                            of physicians and healthcare organizations to change their current treatment practices, especially
                                            with respect to warfarin, a drug that is dominant in the market and with which physicians
                                            and healthcare organizations have 60 years of familiarity;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the willingness
                                            of hospitals and hospital systems to include our product candidates as treatment options;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">efficacy and potential
                                            advantages compared to alternative treatments;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the price we charge
                                            for our product candidates;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">interpretations
                                            of the results of our clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the status of
                                            our products on the formularies of third-party payers;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">convenience and
                                            ease of administration compared to alternative treatments;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the willingness
                                            of the target patient population to try new therapies and of physicians to prescribe these
                                            therapies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the willingness
                                            of the target patient population to pay for our products, including co-pays under their health
                                            coverage plans;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the accuracy of
                                            the international normalized ratio, or INR, testing and whether such testing can be conducted
                                            at home or in a medical facility such as a doctor&#8217;s office. A prothrombin time, or
                                            PT, is a test used to help detect and diagnose a bleeding disorder or excessive clotting
                                            disorder; the INR is calculated from a PT result and is used to monitor how well an anticoagulant
                                            medication such as tecarfarin is working to prevent thrombosis;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the strength of
                                            marketing and distribution support; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the availability
                                            of third-party coverage and adequate reimbursement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The failure to attain market acceptance among
the medical community, patients and third-party payors may have an adverse impact on our operations and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never submitted an NDA to the FDA
or comparable applications to other regulatory authorities and we may not be successful in achieving approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never submitted an NDA to the FDA or
comparable applications to other regulatory authorities and expect to rely on consultants and third-party contract research organizations,
or CROs, with expertise in this area to assist us in this process. Securing FDA approval requires the submission of pre-clinical, clinical
and/or pharmacokinetic data, information about product manufacturing processes and inspection of facilities and supporting information
to the FDA for each therapeutic indication to establish a product candidate&#8217;s safety and efficacy for each indication. Regulatory
authorities in other jurisdictions impose similar requirements. If we are unable to successfully complete the approval process with the
FDA or comparable applications of other regulatory authorities, our business will not be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Designation does not translate
to approval and, even if we obtain FDA approval, we may not enjoy marketing exclusivity or other expected benefits.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we have been granted orphan drug designation
for tecarfarin, this does not mean FDA will approve the NDA. Even if we obtain FDA approval, we may not be able to obtain or maintain
orphan drug exclusivity for tecarfarin. We may not be the first to obtain marketing approval of tecarfarin designation for the orphan-designated
indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the
United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the
FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of
the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for
a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties
may be approved for the same condition, or the competitive product is otherwise outside the scope of exclusivity. Even after an orphan
drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes
that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care
or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation
neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or
approval process, nor does it prevent competitors from obtaining approval of the same product candidate for indications other than those
in which orphan drug designation have been granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>After approval of tecarfarin, tecarfarin
will remain subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional risk
and expense.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drug products remain subject to the jurisdiction
of the FDA and non-U.S. regulatory authorities after they have been approved. Even if we obtain regulatory approval of tecarfarin, the
FDA and other regulatory authorities may impose significant restrictions on its indicated uses or marketing or the conditions of approval,
or impose ongoing requirements for potentially costly and time-consuming post-approval trials, including Phase 4 clinical trials, and
post-market surveillance to monitor safety and efficacy. Our product candidate, if approved, as well as our marketed products are subject
to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising,
promotion, sampling, recordkeeping and reporting of adverse events and other post-market information. These requirements include registration
with the FDA and continued compliance with current Good Manufacturing Practices requirements, or cGMPs, and current Good Clinical Practices
requirements, or GCPs, for any clinical trials that we conduct post-approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>After approval, our products could be subject
to labeling and other restrictions and we may be required to withdraw from the market or be subject to penalties if we fail to comply
with regulatory requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The product labeling, advertising and promotion
of our products and our product candidates, if approved, are subject to regulatory requirements and continuing regulatory review. Government
authorities, including the FDA and the Office of the Inspector General of the Department of Health and Human Services, or OIG, strictly
regulate the promotional claims and activities that may be made about prescription products. A drug product may not be promoted for uses
that are inconsistent with the product&#8217;s approved labeling. If we receive marketing approval for tecarfarin, physicians may nevertheless
legally prescribe our products to their patients in a manner that is inconsistent with the approved labeling. However, if we are found
to have promoted such off-label uses, we may become subject to significant liability and government fines. The federal government has
extracted very large settlements and levied very large civil and criminal fines against companies for alleged improper promotion, has
enjoined companies from engaging in off-label promotion, and made companies agree to onerous multi-year corporate integrity agreements.
The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct
is changed or curtailed. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability
claims and increase our product liability exposure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject, directly or indirectly,
to federal and state obligations and regulations applicable to our marketing practices. If we are unable to comply, or have not complied,
with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our marketing and sales operations are subject
to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes and false
claims laws. With respect to sales and marketing activities by us or any future partner, advertising and promotional materials must comply
with FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in other
countries. We also are subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including,
without limitation, the U.S. Federal Healthcare Program Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact,
among other things, most of our interactions with customers, including our proposed sales, marketing, and scientific/educational grant
programs. We are also subject to complex laws and regulation regarding reporting and payment obligations as a result of our participation
in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, and other government
drug programs. All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition
laws. Similar requirements exist in many of these areas in other countries. If investigated, we could be forced to incur substantial
expense responding to the investigation and defending our actions. If unsuccessful in our defense, we could be found to be in violation
and subject to substantial fines and penalties,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently do not have an agreement with
a third-party manufacturer for the production of tecarfarin and intend to rely upon third parties to produce our product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have an agreement with any
third-party manufacturers for the production of tecarfarin and there can be no assurance that we will be able to enter into an agreement
on acceptable terms. If an agreement is not entered into, we may experience longer manufacturing lead times for any purchase orders we
place with a manufacturer under purchase orders. We intend to rely on third-party manufacturers to produce tecarfarin for our clinical
studies who are expected to purchase materials from third-party vendors and transport the materials necessary to produce tecarfarin,
such as the required reagents and containers. If a third-party manufacturer was to experience any prolonged disruption for our manufacturing,
or face enforcement scrutiny by regulatory authorities, we could be forced to seek additional third-party manufacturing contracts, thereby
increasing our development costs and negatively impacting our timelines and any commercialization costs. If we change manufacturers at
any point during the development process or after approval of a product candidate, we will be required to demonstrate comparability between
the product manufactured by the old manufacturer and the product manufactured by the new manufacturer. If we are unable to do so, we
may need to conduct additional clinical trials with product manufactured by the new manufacturer, thereby delaying our NDA submission
or approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the manufacturer upon which we rely
fails to comply with stringent regulations, we may face delays in the development and commercialization of, or be unable to meet demand
for, our product candidates and may lose potential revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any problems or delays our contract manufacturers
experience in preparing for commercial-scale manufacturing of a product candidate or component may result in a delay in product development
timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture
commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment
of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results
of operations, stock price and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, manufacturers of drug products and
their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance
with cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents. Although
we do not have day-to-day control over our contract manufacturers&#8217; compliance with these requirements, we are responsible for ensuring
compliance with such requirements. Our failure, or the failure of our contract manufacturers, to comply with applicable regulations could
result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal
of approvals, revocation of licenses, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any
of which would significantly and adversely affect supplies of our product candidates and our business. If a contract manufacturer&#8217;s
facilities do not pass a pre-approval inspection or do not have a cGMP compliance status acceptable to the FDA or a comparable foreign
regulatory authority, our product candidate will not be approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, application holders must obtain
FDA approval for product and manufacturing changes, depending on the nature of the change. Moreover, in the United States, the distribution
of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. In addition, our marketed
products will have to comply with the Drug Supply Chain Security Act of 2013, which requires drug companies to enable electronic tracking
of their products though the U.S. supply chain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any deviations from regulatory requirements may
also require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the
temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility. Any such remedial measures
imposed upon us or third parties with whom we contract could materially harm our business. Any delays in obtaining products or product
candidates that comply with the applicable regulatory requirements may result in delays to product approvals, and commercialization.
It may also require that we conduct additional trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face substantial competition, which
may result in others discovering, developing or commercializing competing products more successfully than we do, or, perhaps obtaining
approval before our product and, potentially delaying our approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new
drugs is highly competitive. We face competition with respect to developing our current product candidates, and we will face competition
with respect to any products that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. We are seeking to develop tecarfarin as a marketable VKA, once-daily
OAC designed to treat and prevent thrombosis for ESRD patients with AFib. If we succeed in developing tecarfarin, we shall face substantial
competition. Traditionally, the drug of choice for CKD/ESRD patients has been warfarin. The reasoning for such therapy is that warfarin
undergoes extensive hepatic metabolism into inactive compounds, theoretically posing less risk to the renally impaired patient. Randomized
trials to date of apixaban versus warfarin for AFib excluded patients with severe and end-stage kidney disease, calculated creatinine
clearance &lt;25 mL per minute. The FDA cautiously extended apixaban use to patients with ESRD on hemodialysis based on limited pharmacokinetic
data by 8 subjects. Additionally, the lower limit for creatinine clearance has been adjusted for rivaroxaban for stroke prevention in
AFib, thereby permitting use in the ESRD population. The remaining two DOACs, dabigatran and edoxaban, are approved for use with dosage
adjustment in moderate-severe CKD for stroke prevention. However, the net benefit of anticoagulation with apixaban or warfarin in the
ESRD population is controversial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019, RENal Hemodialysis Patients Allocated
Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial was terminated early by the sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AXADIA is an investigator-driven, prospective,
parallel-group, single country, multi-center phase IIIb trial to assess the safety of apixaban versus the VKA phenprocoumon in patients
with non-valvular AFib and ESRD on hemodialysis treatment. The trial will be conducted in about 25-30 sites in Germany with an estimated
completion date of July 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Strategies for the Management of Atrial Fibrillation
in patients Receiving Dialysis (SAFE-D) is a pilot trial in Toronto, Canada to evaluate the feasibility of conducting a randomized controlled
trial comparing anticoagulation strategies in patients with AFib receiving dialysis (either hemodialysis or peritoneal dialysis). The
trial was estimated to have been completed by December 31, 2022 (final data collection date for primary outcome measure).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these named products are marketed by
some of the largest and most successful pharmaceutical companies. The companies that market these products have substantially more resources
than we do and substantially more experience developing and marketing pharmaceuticals. We may not be able to successfully compete with
these existing products. Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing
and commercialization of competing drugs and potentially competing drugs. Our competitors are or may be attempting to develop therapeutics
for our target indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Factors affecting competition in these markets
include the financial, research and development, testing, and marketing strengths of individual competitors, trends in industry consolidation,
consumers&#8217; product options, product quality, price and technology, reputation, customer service capabilities and access to market
partners and customers. Eliquis is manufactured and distributed by Bristol Myers Squibb, amiodarone is manufactured and distributed by
several companies including Sanofi, Baxter, and Pfizer, Pradaxa is manufactured and distributed by Boehringer Ingelheim, Xarelto is manufactured
and distributed by Janssen Pharmaceuticals, and Savaysa is manufactured and distributed by Daiichi Sankyo. Each of these organizations
has a long operating history, extensive resources, strong brand recognition and large customer bases. As a result, we expect they will
be able to devote greater resources than we can to the manufacture, promotion and sale of their products; receive greater resources and
support than we will from market partners and independent distributors; initiate and withstand substantial price competition; and take
advantage more readily than we could of acquisition and other strategic market opportunities. In addition, these or other organizations
could succeed in developing new products that perform better or more cost-effectively than our products and product candidates in their
respective markets. Moreover, changes in health trends, diet or other factors could substantially reduce the commercial attractiveness
or viability of the markets for anti-anginal, anticoagulant, anti-arrhythmic and anti-platelet products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The high level of competition in these markets
could result in pricing pressure, reduced margins, the inability of our product candidates to achieve market acceptance and other impediments
to commercial success. As a result, there can be no assurance that we will be able to complete the development of competitive products
and commercialize them on a competitive basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mergers and acquisitions in the pharmaceutical,
biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large
and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to,
or necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If serious adverse effects are identified
with respect to any of our product candidates or any of our approved products, we may need to modify or abandon our development of that
product candidate, discontinue sale of an approved product, or change our labeling to reflect new safety risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is impossible to guarantee when, or if, any
of our product candidates will prove safe enough to receive regulatory approval. It is impossible to guarantee that safety issues that
may arise during development will not significantly decrease the commercial potential of our product candidates. In addition, there can
be no assurance that our clinical trials will identify all relevant safety issues. Known or previously unidentified adverse effects can
adversely affect regulatory approvals or marketing of approved products. In such an event, we might need to abandon marketing efforts
or development of that product or product candidate or enter into a partnership to continue development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Serious adverse events have occurred in the clinical
trials of our product candidate. For example, major hemorrhages occurred in 1.6% of the blinded tecarfarin patients randomized in the
EMBRACE-AC trial. We expect that additional patients will experience serious adverse events in our future clinical trials and during
marketing if our products are approved. Design features of ACTOR AF, such as using a smaller number of patients and using MACE clinical
outcomes as an endpoint, may produce results that show an imbalance in adverse events between treatment groups, when no such imbalance
truly exists, or may not permit an assessment of the risk of rare events (due to the overall reduced size of the safety database), either
of which could lead the FDA to require additional studies to demonstrate the safety of tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a regulatory agency discovers adverse events
of unanticipated severity or frequency it may impose restrictions on that product or us, including requiring withdrawal of the product
from the market. Among other legal and administrative actions, a regulatory agency may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">mandate modifications
                                            to product labelling or promotional materials or require us to provide corrective information
                                            to healthcare practitioners;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">withdraw any regulatory
                                            approvals;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">place any ongoing
                                            clinical trials on clinical hold;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refuse to approve
                                            pending applications or supplements to approved applications filed by us, our partners or
                                            our potential future partners;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">impose restrictions
                                            on operations, including costly new manufacturing, licensing or packaging requirements; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">seize or detain
                                            products or require a product recall.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the occurrence of any of the foregoing,
even if promptly remedied, could (1) negatively impact the perception of us or the relevant product among the medical community, patients
or third-party payors and (2) result in product liability litigation that could result in the company paying substantial amounts of money
in settlements or verdicts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently enacted and future legislation
may increase the difficulty and cost for us to obtain marketing approval of and commercialize tecarfarin and affect the prices we may
obtain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent
or delay marketing approval for tecarfarin, restrict or regulate post-approval activities and affect our ability to profitably sell tecarfarin.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance
or interpretations will be changed, or what the impact of such changes on the marketing approvals of tecarfarin, if any, may be. In addition,
increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as
well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, under the Medicare Modernization
Act, or MMA, Medicare Part D provides coverage to the elderly and disabled for outpatient prescription drugs by approving and subsidizing
prescription drug plans offered by private insurers. The MMA also authorizes Medicare Part D prescription drug plans to use formularies
where they can limit the number of drugs that will be covered in any therapeutic class. The Part D plans use their formulary leverage
to negotiate rebates and other price concessions from drug manufacturers. Also under the MMA, Medicare Part B provides coverage to the
elderly and disabled for physician-administered drugs on the basis of the drug&#8217;s average sales price, a price that is calculated
according to regulatory requirements and that the manufacturer reports to Medicare quarterly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Congress and the Centers for Medicare &amp;
Medicaid Services, or CMS, the agency that administers the Medicare program, from time to time consider legislation, regulations, or
other initiatives to reduce drug costs under Medicare Parts B and D. For example, under the 2010 Affordable Care Act, drug manufacturers
are required to provide a 50% discount on prescriptions for branded drugs filled while the beneficiary is in the Medicare Part D coverage
gap, also known as the &#8220;donut hole.&#8221; The Bipartisan Budget Act of 2018 increased the manufacturer&#8217;s subsidy under the
program from 50% to 70% of the negotiated price, beginning in 2019. There have been legislative proposals to repeal the &#8220;non-interference&#8221;
provision of the MMA to allow CMS to leverage the Medicare market share to negotiate larger Part D rebates. Further cost reduction efforts
could decrease the coverage and price that we receive for tecarfarin and could seriously harm our business. Private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under the
Medicare program may result in a similar reduction in payments from private payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2010 Affordable Care Act is intended to broaden
access to health Insurance and reduce or constrain the growth of healthcare spending. Further, the Affordable Care Act imposes a significant
annual fee on companies that manufacture or import branded prescription drug products. It also increased the amount of the rebates drug
manufacturers must pay to state Medicaid programs, required that Medicaid rebates be paid on managed Medicaid utilization, and increased
the additional rebate on &#8220;line extensions&#8221; (such as extended-release formulations) of solid oral dosage forms of branded
products. The law also contains substantial provisions affecting fraud and abuse compliance and transparency, which may require us to
modify our business practices with healthcare practitioners, and incur substantial costs to ensure compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many members of the Republican Party have consistently
opposed the Affordable Care Act since it was signed. Efforts to repeal the Act have been attempted numerous times and some portions of
the Act have been amended in 2017 and 2018. It is unclear whether further amendments or repeal will be effectuated and what the effect
on the healthcare sector will be. In addition to potential changes to the Affordable Care Act, there are indications that the Medicaid
and Medicare programs may be restructured, which could lead to revisions in coverage and reimbursement of prescription drugs. While we
are unable to predict what legislation, if any, may potentially be enacted, to the extent that future changes affect how our product
candidates could be paid for and/or reimbursed by the government and private payers, our business could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, other legislative changes have been
proposed and adopted in the United States since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 included,
among other things, provisions that have led to 2% across-the-board reductions in Medicare payment amounts. Several states have adopted
or are considering adopting laws that require pharmaceutical companies to provide notice prior to raising prices and to justify price
increases. We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value
of certain development projects and reduce our profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we market any of our products in a manner
that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal
penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and other government authorities enforce
laws and regulations that require that the promotion of pharmaceutical products be consistent with the approved prescribing information.
While physicians may prescribe an approved product for a so-called &#8220;off-label&#8221; use under the practice of medicine, it is
unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any company
which engages in such conduct may be subject to significant liability. Similarly, industry codes in the European Union and other foreign
jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries enforce violations
of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with our label, regulatory
agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute other civil or criminal enforcement
proceedings. In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare
fraud and abuse laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These
laws include the U.S. Federal Healthcare Program Anti-Kickback Statute, U.S. False Claims Act and similar state laws. Because of the
breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to
challenge under one or more of these laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Federal Healthcare Program Anti-Kickback
Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in
return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable
under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted broadly to apply to arrangements
between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there
are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and
safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may
be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not, in all cases, meet all of the criteria
for safe harbor protection from anti-kickback liability. Moreover, recent health care reform legislation has strengthened these laws.
For example, the Affordable Care Act, among other things, amends the intent requirement of the U.S. Federal Healthcare Program Anti-Kickback
Statute and criminal health care fraud statutes; a person or entity no longer needs to have actual knowledge of this statute or specific
intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services
resulting from a violation of the U.S. Federal Healthcare Program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the U.S. False Claims Act. Federal false claims laws, including the U.S. False Claims Act, impose criminal and civil penalties, including
through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented,
to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal
an obligation to pay money to the federal government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over the past few years, pharmaceutical and other
healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as: allegedly
providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services
inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion
that caused claims to be submitted to Medicare or Medicaid for non-covered, off-label uses; using a charity as an illegal conduit to
cover the copays of Medicare patients; and submitting inflated best price information to the Medicaid Drug Rebate Program to reduce liability
for Medicaid rebates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other restrictions under applicable U.S. federal
and state healthcare laws and regulations may include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the federal Health
                                            Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil
                                            liability for, among other things, knowingly and willfully executing or attempting to execute
                                            a scheme to defraud any healthcare benefit program or making false statements relating to
                                            healthcare matters;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">HIPAA, as amended
                                            by the Health Information Technology for Economic and Clinical Health, or HITECH, Act and
                                            its implementing regulations, also imposes obligations, including mandatory contractual terms,
                                            on certain types of people and entities with respect to safeguarding the privacy, security
                                            and transmission of individually identifiable health information;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the federal Physician
                                            Payment Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics,
                                            and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s
                                            Health Insurance Program, with specific exceptions, to report payments and other transfers
                                            of value to physicians and teaching hospitals, as well as certain ownership and investment
                                            interests held by physicians and their immediate family, which includes annual data collection
                                            and reporting obligations; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">analogous state
                                            and foreign laws and regulations, such as state anti-kickback and false claims laws, may
                                            apply to sales or marketing arrangements and claims involving healthcare items or services
                                            reimbursed by non-governmental third-party payors, including private insurers.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures to federal and state agencies. State and foreign laws also govern the privacy
and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. Tracking and reporting may be burdensome and require a significant expenditure
to comply with applicable requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to generate product revenues
will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to commercialize our products, alone
or with collaborators, will depend in part on the extent to which reimbursement will be available from:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">government and
                                            health administration authorities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">private health
                                            maintenance organizations and health insurers; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">other healthcare
                                            payers.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients generally expect that products such
as ours are covered and reimbursed by third-party payors for all or part of the costs and fees associated with their use. If such products
are not covered and reimbursed then patients may be responsible for the entire cost of the product, which can be substantial. Therefore,
health care providers generally do not prescribe products that are not covered and reimbursed by third-party payors in order to avoid
subjecting their patients to such financial liability. The existence of adequate coverage and reimbursement for the products by government
and private insurance plans is central to the acceptance of tecarfarin and any future products we provide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the past several years, third-party payors
have undertaken cost-containment initiatives including different payment methods, monitoring health care expenditures, and anti-fraud
initiatives. For some governmental programs, such as Medicaid, coverage and reimbursement differ from state to state, and some state
Medicaid programs may not pay an adequate amount for tecarfarin or any of our other products or may make no payment at all. Furthermore,
the health care industry in the United States has experienced a trend toward cost containment as government and private insurers seek
to control health care costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Therefore,
we cannot be certain that our services will be reimbursed at a level that is sufficient to meet our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining coverage and reimbursement approval
of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to
the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given
product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments
that patients find unacceptably high. Patients are unlikely to use tecarfarin or any future product candidates unless coverage is provided
and reimbursement is adequate to cover a significant portion of the cost of tecarfarin or any future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to seek approval to market tecarfarin
and future product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign
jurisdictions for tecarfarin or any future product candidates, we will be subject to rules and regulations in those jurisdictions. In
some foreign countries, particularly those in the European Union, the pricing of drugs is subject to governmental control. In these countries,
pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate.
In addition, market acceptance and sales of product candidates will depend significantly on the availability of adequate coverage and
reimbursement from third-party payors for product candidates and may be affected by existing and future health care reform measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors, whether domestic or foreign,
or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United
States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that
could impact our ability to sell our products profitably. In particular, in the Affordable Care Act, as amended by the Health Care and
Education Affordability Reconciliation Act, among other things, revised the methodology by which rebates owed by manufacturers to the
state and federal government for covered outpatient drugs, including product candidates, under the Medicaid Drug Rebate Program are calculated,
increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug
Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers
to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s
comparative effectiveness research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been, and likely will continue to
be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare
and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, particularly
in light of the new presidential administration in the United States, and any proposed changes to healthcare laws that could potentially
affect our clinical development or regulatory strategy. The continuing efforts of the government, insurance companies, managed care organizations
and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the demand for
                                            tecarfarin, or future product candidates, if we obtain regulatory approval;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to
                                            set a price that we believe is fair for our products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to
                                            generate revenue and achieve or maintain profitability;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the level of taxes
                                            that we are required to pay; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the availability
                                            of capital.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any reduction in reimbursement from Medicare,
Medicaid or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our
future profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will rely on third parties and consultants
to conduct all of our clinical trials. If these third parties or consultants do not successfully carry out their contractual duties,
comply with regulatory requirements, or meet expected deadlines, we may be unable to obtain regulatory approval for any future product
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will rely on medical institutions, clinical
investigators, contract laboratories, collaborative partners and other third parties, such as CROs, to conduct clinical trials on our
product candidates. The third parties with whom we may contract for execution of any of our future clinical trials may play a significant
role in the conduct of these trials and the subsequent collection and analysis of data. These third parties would not be our employees,
and except for contractual duties and obligations, we would have limited ability to control the amount or timing of resources that they
devote to any of our future programs. Although we may rely on these third parties to conduct our clinical trials, we would remain responsible
for ensuring that each of our preclinical trials and clinical trials is conducted in accordance with applicable legal requirements, the
investigational plan and the protocol. Moreover, whether we conduct trials ourselves or hire third parties to do so, the FDA and other
similar regulatory authorities require us to comply with GCPs when we conduct, monitor, record and report the results of clinical trials
to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of
the potential risks of participating in clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the execution of clinical trials,
and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions
to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover,
these third parties may also have relationships with other commercial entities, some of which may compete with us. If the third parties
or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not
meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data
they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need
to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly
or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were
to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for and will not be able to, or may be delayed
in our efforts to, successfully commercialize any future product candidates being tested in such trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have limited distribution,
marketing, support and sales capabilities and plan to rely on third-party distribution partners for the distribution, marketing, support
and sales of our products which could delay or limit our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to utilize third-party service providers
for the distribution and marketing and sales of our product candidates, if approved. Upon launch, we intend to promote utilizing third
party collaborations in addition to building our own commercial infrastructure in anticipation of the approval of tecarfarin. Reliance
on third-party service providers may prevent our direct control of key aspects of those critical functions including regulatory compliance,
import and export operations, supply chain security, warehousing and inventory management, distribution, contract administration, invoicing,
sales deductions administration, accounts receivable management and call center management. Any future distribution partners may hold
significant control over important aspects of the commercialization of our products, including market identification, regulatory compliance,
marketing methods, pricing, composition of sales force and promotional activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to control the amount and
timing of resources that any future third-party distribution partners may devote to our products, or prevent any third-party from pursuing
the development of alternative technologies or products that compete with our products, except to the extent our contractual arrangements
protect us against such activities. Also, we may not be able to prevent any other third-party from withdrawing its support of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If third-party service providers fail to comply
with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities or otherwise
fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver product to meet commercial
demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample
accountability and regulatory monitoring, including adverse event reporting, safety database management and other product maintenance
services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market
our products could be jeopardized or we could be subject to regulatory sanctions, and any indemnity we may receive from such third-party
service providers could be limited by such provider&#8217;s ability to pay and otherwise might not be sufficient to cover all losses
we may experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to the risk of employee fraud
or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these
parties could include intentional, reckless and/or negligent conduct that fails to: (i) comply with the laws of the FDA and other similar
foreign regulatory bodies; (ii) provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies;
(iii) comply with manufacturing standards we have established; (iv) comply with healthcare fraud and abuse laws in the United States
and similar foreign fraudulent misconduct laws; or (v) report financial information or data accurately or to disclose unauthorized activities
to us. Any such misconduct or noncompliance could negatively affect the FDA&#8217;s review of our regulatory submission, including delaying
approval or disallowance of certain information to support the submission, and/or delay a federal or state healthcare programs or a commercial
insurer&#8217;s determination regarding the availability of future reimbursement for product candidates. If we obtain FDA approval of
any product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase
significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other
things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and
education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements
in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s),
certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper
use of information obtained in the course of patient recruitment for clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is not always possible to identify and deter
employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare
laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices
may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws
and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties,
damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could
adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of
any product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned
above, among other foreign laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We intend to establish a sales force to
market our product candidates. If we are not successful in doing so, our ability to generate sales and profits will be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although certain of our employees have commercialization
experience, as a company we do not have an internal sales force and we currently have only limited commercial capabilities. We intend
to establish an internal specialty cardiorenal sales force for the promotion and sale of tecarfarin, if approved. Establishing a pharmaceutical
sales force is a difficult undertaking. Experienced and competent sales representatives and sales managers must be recruited, hired,
trained, assigned appropriate territories, managed and compensated in such a way that they can achieve success in selling products to
a sophisticated audience of healthcare professionals who frequently have little or no time to spend with sales personnel. In addition,
our prospective sales force must compete against the sales forces of some of the largest and most successful pharmaceutical companies
in the world, who will be promoting competing products. If we fail to hire and field a high-quality sales force, we may be unable to
generate expected revenues and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are significant expenses and
risks involved with establishing our own sales and marketing capabilities, including our ability to hire, retain and appropriately incentivize
qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage
a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. For example,
if we recruit any sales representatives or establish marketing capabilities prior to commercial launch and the commercial launch is delayed
or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly,
and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own internal sales force,
we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment
our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into
such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. To the extent
we commercialize our product candidates by entering into agreements with third-party collaborators, we may have limited or no control
over the sales, marketing and distribution activities of these third parties, in which case our future revenues would depend heavily
on the success of the efforts of these third parties. If we are not successful in commercializing tecarfarin or any future product candidates,
either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we could incur
significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We plan to rely on collaborations and license
arrangements with third parties to commercialize, market and promote our marketed products which may limit our ability to generate revenue
and adversely affect our profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to rely on collaboration and other agreements
with third parties with third parties with respect to our product candidates and future marketed products. Our current or any future
collaborations or license arrangements may not be successful. With respect to the product candidates we have licensed, including our
rights to tecarfarin in China, we depend upon collaborations with third parties to develop these product candidates in the licensed territories
and we will depend substantially upon third parties to commercialize these product candidates. If we are unable to maintain current collaborations
or enter into additional collaborations with established pharmaceutical or pharmaceutical service companies to provide the services we
need, we may not be able to successfully commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future growth depends, in part, on
our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although our focus as this time is primarily
on the U.S. market, our future profitability will depend, in part, on our ability to commercialize tecarfarin in foreign markets for
which we intend to rely on collaborations with third parties. If we commercialize tecarfarin in foreign markets, we would be subject
to additional risks and uncertainties, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our customers&#8217;
                                            ability to obtain reimbursement in foreign markets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our inability
                                            to directly control commercial activities because we are relying on third parties;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the burden of
                                            complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">different medical
                                            practices and customs in foreign countries affecting acceptance in the marketplace;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">import, export
                                            and foreign licensing requirements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">different packaging
                                            and labeling requirements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">longer accounts
                                            receivable collection times;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">longer lead times
                                            for shipping;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">language barriers
                                            for technical training;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">differing and/or
                                            reduced protection of intellectual property rights in some foreign countries;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">foreign currency
                                            exchange rate fluctuations; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the interpretation
                                            of contractual provisions governed by foreign laws in the event of a contract dispute.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign sales of tecarfarin could also be adversely
affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs, any
of which may adversely affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The ongoing COVID-19 global health crisis
may impact our planned operations, including our pivotal Phase 3 clinical trial</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the World Health Organization
declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple
countries, including throughout the United States. We may experience disruptions as a result of the pandemic if the pandemic continues
or increases in severity, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">unwillingness
                                            of potential study participants to enroll in our pivotal Phase 3 clinical trial and/or visit
                                            healthcare facilities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">postponement of
                                            enrollment in our pivotal Phase 3 clinical trial</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">postponement of
                                            the initiation of our pivotal Phase 3 clinical trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">diversion of healthcare
                                            resources away from the conduct of clinical trials, including the diversion of hospitals
                                            serving as our clinical trial sites and hospital staff supporting the conduct of our clinical
                                            trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">interruption of
                                            key clinical trial activities, such as clinical site visits by study participants and clinical
                                            trial site monitoring, due to limitations on travel imposed or recommended by federal or
                                            state governments, employers and others;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">limitations in
                                            employee resources that would otherwise be focused on the conduct of our pivotal Phase 3
                                            clinical trial, including because of sickness of employees or their families or the desire
                                            of employees to avoid contact with large groups of people;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">delays in receiving
                                            approval from local regulatory authorities to initiate our pivotal Phase 3 clinical trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">delays in clinical
                                            sites receiving the supplies and materials needed to conduct our pivotal Phase 3 clinical
                                            trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">interruption in
                                            global shipping that may affect the manufacture and transport of clinical trial materials,
                                            such as investigational drug product used in our clinical trial;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes in local
                                            regulations as part of a response to the COVID-19 coronavirus outbreak which may require
                                            us to change the ways in which our pivotal Phase 3 clinical trial is conducted, which may
                                            result in unexpected costs, or to discontinue the clinical trial altogether;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">delays in necessary
                                            interactions with local regulators, ethics committees and other important agencies and contractors
                                            due to limitations in employee resources or forced furlough of government employees; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">delay in the timing
                                            of interactions with the FDA due to absenteeism by federal employees or by the diversion
                                            of their efforts and attention to approval of other therapeutics or other activities related
                                            to COVID-19.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business and the business of the suppliers
of our clinical product candidate is expected to be materially and adversely affected by the pandemic. While we are currently not experiencing
material delays, such events could result in the delay or complete or partial closure of clinical trial sites or one or more manufacturing
facilities which could impact our supply of our clinical product candidate. In addition, it could impact economies and financial markets,
resulting in an economic downturn that could impact our ability to raise capital or slow down potential partnering relationships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effects of the governmental orders may negatively
impact productivity, disrupt our business and delay our pivotal Phase 3 clinical trial program and timelines, the magnitude of which
will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in
the ordinary course.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the COVID-19 outbreak could disrupt
our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management
and other employees who elect not to come to work due to the illness affecting others in our office, or due to quarantines. The COVID-19
illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of
directors, and making it more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings
for the management of our affairs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global outbreak of the virus continues to
rapidly evolve. The extent to which the virus may continue to impact our business and clinical trials will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration
of the outbreak, travel restrictions and social distancing in the United States, business closures or business disruptions and the effectiveness
of actions taken in the United States and other countries to contain and treat the disease. We do not yet know the full extent of potential
delays or impacts on our business, operations, or the global economy as a whole. While the spread of COVID-19 may eventually be contained
or mitigated, there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur, or that the global
economy will recover, either of which could seriously harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we are currently not experiencing any delays,
we may in the future experience delays. These delays may result in the need for trials to be redesigned and may impact whether they will
be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the COVID-19 pandemic, delays
in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable
terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to
participate in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Manufacturing considerations for clinical
development candidates may include an expected several month lead time following a decision to commence any clinical trial(s) and capacity
considerations of our third-party contract manufacturers to provide clinical supply of our product candidates could cause delays in clinical
trials. Furthermore, due to the COVID-19 pandemic, many manufacturers have been prioritizing the manufacture of COVD-19 related products,
increasing the manufacturing lead times for non-COVID-19 related products. Many factors affect patient enrollment, including the size
of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing clinical
trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether to offer their
patients enrollment in clinical trials of our product candidates versus treating these patients with commercially available drugs that
have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product
development and timeliness and approval process and delay our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with governmental regulations
regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization
of our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Animal Welfare Act, or AWA, is the federal
law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations
that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most
notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom
we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own
regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations,
and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment
of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Company-Related Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to attract and keep senior management
and key scientific personnel, we may be unable to successfully develop tecarfarin or any future product candidates, conduct our clinical
trials and commercialize our product candidates or any future products we develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management team has expertise in many different
aspects of fundraising, drug development and commercialization. We believe that our future success is highly dependent upon the contributions
of our senior management, particularly Quang Pham, our Chief Executive Officer. We do not have an insurance policy on the life of our
Chief Executive Officer and we do not have &#8220;key person&#8221; life insurance policies for any of our other officers or advisors.
The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion
of our planned clinical trials or the commercialization of tecarfarin or any other future products we develop, which could adversely
affect our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to hire additional personnel, including
experienced marketing and sales representatives, as we expand our clinical development and commercial activities. We could experience
difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals
field is intense due to the limited number of individuals who possess the skills and experience required by our industry. Other pharmaceutical
companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer
history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some
of these characteristics may be more appealing to high-quality candidates than what we have to offer. We may not be able to attract and
retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject
to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that
their former employers own their research output. If we are unable to continue to attract and retain high-quality personnel, the rate
and success at which we can develop and commercialize product candidates could be limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to increase the size of our
organization, and we may experience difficulties in managing this growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 27, 2023, we had three employees
who work full-time as well as several independent contractors. We will need to continue to expand our managerial, operational, finance
and other resources to manage our operations, commercialize tecarfarin or any other product candidates, if approved, and continue our
development activities. Our management and personnel systems and facilities currently in place may not be adequate to support this future
growth. Our need to effectively execute our growth strategy requires that we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">manage any of
                                            our future clinical trials effectively;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">identify, recruit,
                                            retain, incentivize and integrate additional employees;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">manage our internal
                                            development efforts effectively while carrying out our contractual obligations to third parties;
                                            and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">continue to improve
                                            our operational, financial and management controls, reporting systems and procedures.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to our limited financial resources and our
limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs
and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development
and strategic objectives or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
as a result of the clinical testing of tecarfarin and any of our future product candidates. We will face further risk if we commercialize
tecarfarin or any of our product candidates. For example, we may be sued if any product we sell or any product we develop allegedly causes
injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims
may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence,
strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial losses or be required to limit commercialization of our products.
Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome,
liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">decreased demand
                                            for our product candidates or products we develop, including tecarfarin;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">termination of
                                            clinical trial sites or entire trial programs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">injury to our
                                            reputation and significant negative media attention;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">withdrawal of
                                            clinical trial participants or cancellation of clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant costs
                                            to defend the related litigation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a diversion of
                                            management&#8217;s time and our resources;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">substantial monetary
                                            awards to trial participants or patients;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">regulatory investigations,
                                            product recalls, withdrawals or labeling, marketing or promotional restrictions;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">loss of revenue;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the inability
                                            to commercialize any products we develop; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a decline in our
                                            share price.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our inability to obtain and maintain sufficient
product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent
or inhibit the commercialization of tecarfarin or any future products that we develop. We currently carry product liability insurance
covering our marketed products and our clinical trials. Although we maintain such insurance, any claim that may be brought against us
could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in
excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject
to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement
that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient
capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient
amounts to protect us against losses. If and when we obtain approval for marketing tecarfarin, we intend to expand our insurance coverage
to include the sale of tecarfarin, however, we may be unable to obtain this liability insurance on commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations would suffer
in the event of computer system failures.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the implementation of security measures,
our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware,
natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyber-attacks or cyber-intrusions, including by computer hackers, foreign governments, and cyber-terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or
future product development programs. For example, the loss of clinical trial data from completed or any future ongoing or planned clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation,
and the further development of our product candidates could be delayed.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any failure to maintain the security of
information relating to our patients, customers, employees and suppliers, whether as a result of cybersecurity attacks or otherwise,
could expose us to litigation, government enforcement actions and costly response measures, and could disrupt our operations and harm
our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the pre-clinical and clinical
development, sales and marketing of our products and services, we may from time to time transmit confidential information. We also have
access to, collect or maintain private or confidential information regarding our clinical trials and the patients enrolled therein, employees,
and suppliers, as well as our business. Cyberattacks are rapidly evolving and becoming increasingly sophisticated. It is possible that
computer hackers and others might compromise our security measures, or security measures of those parties that we do business with now
or in the future, and obtain the personal information of patients in our clinical trials, vendors, employees and suppliers or our business
information. A security breach of any kind, including physical or electronic break-ins, computer viruses and attacks by hackers, employees
or others, could expose us to risks of data loss, litigation, government enforcement actions, regulatory penalties and costly response
measures, and could seriously disrupt our operations. Any resulting negative publicity could significantly harm our reputation, which
could cause us to lose market share and have an adverse effect on our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may acquire other businesses or form
joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217;
ownership, increase our debt or cause us to incur significant expense.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our business strategy, we may pursue
acquisitions of businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our technology and industry
experience to expand our offerings or other capabilities. Though certain company personnel have business development and corporate transaction
experience, including with licensing, mergers and acquisitions, and strategic partnering, as a company we have no experience with acquiring
other companies and limited experience with forming strategic alliances and joint ventures. We may not be able to find suitable partners
or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions,
we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent
liabilities. Any future acquisitions also could result in significant write-offs or the incurrence of debt and contingent liabilities,
any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an
acquired company also may disrupt ongoing operations and require management resources that would otherwise focus on developing our existing
business. We may experience losses related to investments in other companies, which could have a material negative effect on our results
of operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may
not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To finance any acquisitions or joint ventures,
we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If the price
of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock
as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings.
Additional funds may not be available on terms that are favorable to us, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Declining general economic or business
conditions may have a negative impact on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Continuing concerns over U.S. health care reform
legislation and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the United
States and other countries have contributed to increased volatility and diminished expectations for the global economy. These factors,
combined with low business and consumer confidence, could precipitate an economic slowdown and recession. Additionally, political changes
in the U.S. and elsewhere in the world have created a level of uncertainty in the markets. If the economic climate does not improve or
deteriorate, our business, as well as the financial condition of our suppliers and our third-party payors, could be adversely affected,
resulting in a negative impact on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, due to increasing inflation, operating
costs for many businesses have increased and, in the future, could impact demand or pricing manufacturing of our drug candidates or services
providers, employee wages.&#160;Inflation rates, particularly in the United States, have increased recently to levels not seen in years,
and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our
ability to access credit or otherwise raise capital. In addition, the Federal Reserve has raised, and may again raise, interest rates
in response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the
effect of further increasing economic uncertainty and heightening these risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actual events involving reduced or limited liquidity,
defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services
industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may
in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, was closed by the California
Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.&#160; Although
we did not have any cash or cash equivalent balances on deposit with Silicon Valley Bank, uncertainty and liquidity concerns in the broader
financial services industry remain and the failure of Silicon Valley Bank and its potential near- and long-term effects on the biotechnology
industry and its participants such as our vendors, suppliers, and investors, may also adversely affect our operations and stock price.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are actively monitoring the effects these disruptions
and increasing inflation could have on our operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These conditions make it extremely difficult for
us to accurately forecast and plan future business activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
sufficient exclusivity and/or patent protection for our product candidates, or if the scope of the exclusivity or patent protection is
not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize
our product candidates successfully may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in large part on our ability
to obtain and maintain exclusivity for our proprietary product candidates through market and data exclusivity granted by regulatory agencies
in the United States and other countries with respect to our proprietary product candidates as well as through patent protection. If we
do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive advantage we may have,
which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in
the United States and abroad related to our novel product candidates that are important to our business. The patent application and approval
process are expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent position of pharmaceutical companies
generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date
in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical
compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result,
the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the other requirements for patentability
are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the
United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind
the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months
after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our
patents, or that we were the first to file for patent protection of such inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, because the issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability, our patents may be challenged in the courts or patent offices
in the United States and abroad. For example, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent
and Trademark Office, or USPTO, or become involved in post-grant review procedures, oppositions, derivations, reexaminations, <i>inter
partes</i> review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of
others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future patent applications may not result
in patents being issued which protect our product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries
may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not
protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts
the patentability of methods of treatment of the human body more than United States law does.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if our patent applications issue as patents,
they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise
provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative
technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or
otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by
submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these
circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any
of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors
are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection
against competing products or processes sufficient to achieve our business objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depending upon the timing, duration and conditions
of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension
under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved
product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may
not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise
fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain
patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights
for that product will be shortened compared to expectations and our competitors may obtain approval to market competing products sooner.
As a result, our revenue from applicable products could be reduced, possibly materially. Further, if this occurs, our competitors may
take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier
than might otherwise be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>To date, we have not engaged intellectual
property counsel to conduct a freedom to operate analysis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we have engaged intellectual property counsel
to assist in protecting our patent ownership rights, to date, we have not had intellectual property counsel conduct a freedom to operate
analysis regarding our tecarfarin product. As a result, we cannot be certain that we will not be exposed to third party legal claims,
liabilities and/or litigation actions when we seek to develop, make and market products using our tecarfarin technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our patents, trademarks,
copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents,
in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding,
there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have
the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is
upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from
using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding
involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude
our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely
affect our competitive business position, business prospects and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similarly, if we assert trademark infringement
claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted
trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such
trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we establish infringement, the court may
decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be
an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can
be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically
last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion
of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends, in part, on our
ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary
rights of third parties. If any third-party patents or patent applications are found to cover our product candidates or their methods
of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available
on commercially reasonable terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a substantial amount of intellectual
property litigation in the pharmaceutical industry, and we may become party to, or threatened with, litigation or other adversarial proceedings
regarding intellectual property rights with respect to our product candidates, including interference and other administrative proceedings
before the USPTO. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The
outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical
industry has produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents
cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation
is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or
methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we
may not be able to do this. In the United States, proving invalidity (except in proceedings before the USPTO) requires a showing of clear
and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings,
we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these
proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring
these actions to a successful conclusion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are found to infringe a third-party&#8217;s
intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the
infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able
to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive,
thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages,
including treble damages and attorney&#8217;&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement
could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially
harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes to the patent law in the United
States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with other pharmaceutical companies,
our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical
industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent
reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed
into law in September 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes
to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more
efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed
the U.S. patent system into a &#8220;first to file&#8221; system. The first-to-file provisions, however, only became effective in March
2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the
Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties
and costs surrounding the enforcement or defense of our or our collaboration partner&#8217;&#8217; issued patents, all of which could
harm our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States
and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the
U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents
could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees on any issued patent
are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent application process. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in
accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could
result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions
within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain
the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to enforce our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing, prosecuting and defending patents on our
product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ
in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained
patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain
patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products
in jurisdictions where we do not have any issued or licensed patents or where any future patent claims or other intellectual property
rights may not be effective or sufficient to prevent them from competing with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, our ability to protect and enforce our
intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws
of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws
of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property
rights in certain foreign jurisdictions. This could make it difficult for us to stop the infringement of our patents or the misappropriation
of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner
must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain
countries outside the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection,
if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proceedings to enforce our patent rights in foreign
jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of
our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure
that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly,
our efforts to protect our intellectual property rights in such countries may be inadequate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent terms may be inadequate to protect
our competitive position on our products for an adequate amount of time.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. With respect to tecarfarin, we have two issued U.S. patents directed to tecarfarin. The expiration dates
of the patents are 2024 for both a composition of matter patent and a method of treatment patent. We expect to seek extensions of patent
terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price
Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of
the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However,
the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries,
may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may
grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development
and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims by third parties
asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that many of the people that we
expect to hire as employees, including our one current employee, were previously employed at other pharmaceutical companies. Some of these
employees may have executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with
such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in
their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade
secrets or other proprietary information, of any such third-party. Litigation may be necessary to defend against such claims. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or
sustain damages. Such intellectual property rights could be awarded to a third-party, and we could be required to obtain a license from
such third-party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or
at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, while we typically require our employees,
consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that
we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in
prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even
if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction
to our senior management and scientific personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>An active public trading market for our
common stock may not be maintained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to our initial public offering consummated
on January 24, 2023, there was no public market or active private market for trading shares of our common stock. Our common stock is currently
traded on the Nasdaq Capital Market, but we can provide no assurance that we will be able to maintain an active trading market. The lack
of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable.
The lack of an active market may also reduce the price of shares of common stock. An inactive market may impair our ability to raise capital
by selling shares and our ability to use our capital stock to acquire other companies or technologies. We cannot predict the prices at
which our common stock will trade.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot be assured that we will be able
to maintain our listing on the Nasdaq Capital Market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our securities are listed on The Nasdaq Capital
Market, a national securities exchange. We cannot be assured that we will continue to comply with the rules, regulations or requirements
governing the listing of our common stock on Nasdaq or that our securities will continue to be listed on Nasdaq in the future. If Nasdaq
should determine at any time that we fail to meet Nasdaq requirements, we may be subject to a delisting action by Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Nasdaq delists our securities from trading
on its exchange at some future date, we could face significant material adverse consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited availability of market quotations for our securities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reduced liquidity with respect to our securities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a determination that our common stock is a &#8220;penny stock&#8221;
which will require brokers trading in our ordinary shares to adhere to more stringent rules, possibly resulting in a reduced level of
trading activity in the secondary trading market for our ordinary shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited amount of news and analyst coverage for our company;
and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a decreased ability to issue additional securities or obtain
additional financing in the future.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our stock price has fluctuated in the past,
has recently been volatile and may be volatile in the future, and as a result, investors in our common stock could incur substantial losses.
</i></b>Investors should consider an investment in our common stock risky and invest only if they can withstand a significant loss and
wide fluctuations in the market value of their investment. Investors who purchase our common stock may not be able to sell their shares
at or above the purchase price. Our stock price has been volatile and may be volatile in the future. In addition, the ongoing COVID-19
pandemic has caused broad stock market and industry fluctuations. The stock market in general and the market for biotechnology companies
in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.
As a result of this volatility, investors may experience losses on their investment in our common stock. Some of the factors that may
cause the market price of our common stock to fluctuate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">adverse results or delays in our clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the timing or delay of achievement of our clinical, regulatory,
partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the receipt of
regulatory approval or the establishment or termination of a commercial partnership for one or more of our product candidates;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">announcement of FDA approval or non-approval of our product
candidates or delays in the FDA review process;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">actions taken by regulatory agencies with respect to our
product candidates, our clinical trials or our sales and marketing activities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the commercial success of any product approved by the FDA
or its foreign counterparts;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">regulatory developments in the United States and foreign
countries;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes in the structure of healthcare payment systems;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any intellectual property infringement lawsuit involving
us;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">announcements of technological innovations or new products
by us or our competitors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">market conditions for the biotechnology or pharmaceutical
industries in general;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes in financial estimates or recommendations by securities
analysts;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">sales of large blocks of our common stock;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">sales of our common stock by our executive officers, directors
and significant stockholders;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">direct sales of our common stock through financing arrangements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">restatements of our financial results and/or material weaknesses
in our internal controls;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the loss of any of our key scientific or management personnel;
and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">announcements regarding the ongoing exploration of the strategic
options available to us.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock markets in general, and the markets
for biotechnology stocks in particular, have experienced extreme volatility and price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of particular companies. These broad market and industry factors may seriously harm the
market price of our common stock, regardless of our operating performance. In the past, class action litigation has often been instituted
against companies whose securities have experienced periods of volatility in market price. Any such litigation brought against us could
result in substantial costs, which would hurt our financial condition and results of operations, divert management&#8217;s attention and
resources, and possibly delay our clinical trials or commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If financial or industry analysts do not
publish research or reports about our business or if they issue inaccurate or unfavorable commentary or downgrade our common stock, our
stock price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our common stock will be
influenced by the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts
or the content and opinions included in their reports. As a new public company, we may be slow to attract research coverage, and the analysts
who publish information about our common stock will have had relatively little experience with our company, which could affect their ability
to accurately forecast our results and make it more likely that we fail to meet their estimates. In the event we obtain industry or financial
analyst coverage, if any of the analysts who cover us issue an inaccurate or unfavorable opinion regarding our stock price, our stock
price would likely decline. In addition, the stock prices of many companies in the biopharmaceutical industry have declined significantly
after those companies have failed to meet, or often times failed to exceed, the financial guidance publicly announced by the companies
or the expectations of analysts. If our financial results fail to meet, or significantly exceed, our announced guidance or the expectations
of analysts or public investors, analysts could downgrade our common stock or publish unfavorable research about us. If one or more of
these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets,
which in turn could cause our stock price or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our officers, directors, and principal stockholders
exercise significant control over our Company, and may be able to control our management and operations, acting in their best interests
and not necessarily those of other stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers, directors and principal
stockholders who beneficially own more than 5% or more of our outstanding common stock, in the aggregate, beneficially own shares representing
approximately 70.1% of our outstanding capital stock. Quang Pham, our Chief Executive Officer, beneficially owns 54.15% of our outstanding
capital stock. As a result, Mr. Pham alone and together with these other stockholders, acting together, may be able to significantly influence
any matters requiring approval by our stockholders, including the election of directors, the approval of mergers or other business combination
transactions. The interests of this group of stockholders may not always coincide with our interests or the interests of other stockholders.
The significant concentration of stock ownership may adversely affect the trading price of our common stock due to the perception that
conflicts of interest may exist or arise. Therefore, you should not invest in reliance on your ability to have any control over our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;controlled company&#8221; under
the rules of the Nasdaq Capital Market, we may choose to exempt our company from certain corporate governance requirements that could
have an adverse effect on our public stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a &#8220;controlled company&#8221; as defined
under the Nasdaq Stock Market Rules, because Quang Pham, our Chief Executive Officer and principal stockholder, beneficially owns 54.15%
of our common shares and will be able to exercise 54.15% of the total voting power of our issued and outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As long as Mr. Pham individually owns at least
50% of the voting power of our company, we are a &#8220;controlled company&#8221; as defined under Nasdaq Listing Rules. For so long as
we are a controlled company under that definition, we are permitted to elect to rely, and may rely, on certain exemptions from corporate
governance rules, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an exemption from the rule that a majority of our board of
directors must be independent directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an exemption from the rule that the compensation of our CEO
must be determined or recommended solely by independent directors; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an exemption from the rule that our director nominees must
be selected or recommended solely by independent directors.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, you may not have the same protection
afforded to stockholders of companies that are subject to these corporate governance requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not intend to rely on the &#8220;controlled
company&#8221; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future. If we elect to rely on
the &#8220;controlled company&#8221; exemption, a majority of the members of our board of directors might not be independent directors
and our nominating and corporate governance and compensation committees might not consist entirely of independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of common stock by our officers
and directors and principal stockholders or others of our common stock, or the perception that such sales may occur, could depress the
market price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of a substantial number of shares of our
common stock, particularly sales by our directors, executive officers and principal stockholders could adversely affect the market price
of our common stock and may make it more difficult to sell common stock at a time and price that you deem appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the shares of common stock sold in our
initial public offering and the shares of our common stock by the selling stockholders in the resale offering will be freely tradable
without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares
held by our affiliates as defined in Rule 144 under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A substantial majority our outstanding shares
of common stock are currently restricted from resale as a result of market standoff and &#8220;lock-up&#8221; agreements. These shares
will become available to be sold 181 days after January 19, 2023, with respect to shareholders holding 1% of more of our outstanding securities
prior to consummation of our initial public offering and 366 days after January 19, 2023, with respect to directors and executive officers.
Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities
Act and various vesting agreements. In addition, the underwriters may, in their sole discretion, release all or some portion of the shares
subject to market standoff or lock-up agreements prior to the expiration of the lock-up period. Sales of a substantial number of such
shares upon expiration of the market standoff and lock-up agreements, or the perception that such sales may occur, or early release of
these agreements, could cause our market price to fall or make it more difficult for you to sell your common stock at a time and price
that you deem appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have registered the offer and sale of shares
of common stock that have been issued or reserved for future issuance under our equity compensation plans on a Form S-8 registration statement.
As a result, such shares can be freely sold in the public market upon issuance, subject to the market standoff or lock-up agreements or
unless they are held by &#8220;affiliates,&#8221; as that term is defined in Rule 144 of the Securities Act. If the holders of these shares
choose to sell a large number of shares, they could adversely affect the market price for our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also issue shares of our common stock or
securities convertible into shares of our common stock from time to time in connection with a financing, acquisition, investment or otherwise.
Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to
decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions in our charter
documents, and under Delaware law, could make an acquisition of our company more difficult, limit attempts by our stockholders to replace
or remove our current management and limit the market price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions in our amended and restated certificate
of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management.
Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">authorize our board of directors to issue, without further
action by the stockholders, shares of undesignated preferred stock with terms, rights, and preferences determined by our board of directors
that may be senior to our common stock;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">require that any action to be taken by our stockholders be
effected at a duly called annual or special meeting and not by written consent;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">specify that special meetings of our stockholders can be
called only by our board of directors, the chairperson of our board of directors, or our Chief Executive Officer;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">establish an advance notice procedure for stockholder proposals
to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">prohibit cumulative voting in the election of directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">establish that our board of directors is divided into three
classes &#8212; Class I, Class II, and Class III &#8212; with each class serving staggered three-year terms;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide that, so long as our board of directors is classified,
directors may only be removed for cause;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide that vacancies on our board of directors may be filled
only by a majority of directors then in office, even though less than a quorum; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">require the approval of our board of directors or the holders
of two-thirds of our outstanding shares of voting stock to amend our bylaws and certain provisions of our certificate of incorporation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions may frustrate or prevent any
attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members
of our board of directors, which is responsible for appointing the members of our management. In addition, we are governed by the provisions
of Section 203 of the Delaware General Corporation Law, which generally, subject to certain exceptions, prohibits a Delaware corporation
from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years
following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Any of the foregoing provisions could limit
the price that investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers
of our company, thereby reducing the likelihood that you would receive a premium for your shares of our common stock in an acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated certificate of
incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware or the federal district court
for the District of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could result in increased
costs for our stockholders to bring a claim and could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes
with us or our directors, officers or employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and amended and restated bylaws provide that, unless the Company consents in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court
for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for (i) any derivative action or proceeding
brought on our behalf; (ii) any action asserting a claim of breach of fiduciary duty owed by, any director, officer, employee or agent
of the Company to the Company or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the Delaware
General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv) any action
asserting a claim against us or any director, officer of employee that is governed by the internal affairs doctrine of the law of the
State of Delaware; provided that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of
subject matter jurisdiction, or the Company consents in writing to the selection of an alternative forum, such action may be brought in
another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and
restated bylaws also provide that the federal district courts of the United States of America is the exclusive forum for the resolution
of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision
will not apply to claims brought to enforce any liability or duty created by the Exchange Act. Nothing in our amended and restated certificate
of incorporation or amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims
in state or federal court, subject to applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe these provisions may benefit us by
providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable,
particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other
forums and protection against the burdens of multi-forum litigation. However, this choice of forum provision could result in increased
costs for our stockholders to bring a claim and could may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that
it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits
with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and
the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217;
certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions
to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid,
a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there
can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice
of forum provision that is contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable
or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could
adversely affect our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Claims for indemnification by our directors
and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available
to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws, provide that
we will indemnify our directors and executive officers, in each case to the fullest extent permitted by Delaware law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as permitted by Section 145 of the
DGCL, our amended and restated bylaws and the indemnification agreements that we have entered into with each of our current executive
officers and intend to enter into with our directors and certain other officers, among other things provide that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We will indemnify our directors and executive officers for
serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request,
to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal
proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We may, in our discretion, indemnify employees and agents
in those circumstances where indemnification is permitted by applicable law.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We will be required to advance expenses, as incurred, to
our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay
such advances if it is ultimately determined that such person is not entitled to indemnification.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The rights conferred in our bylaws will not be exclusive.
We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, claims for indemnification by our
directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of
money available to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends in the
foreseeable future. As a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common
stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business
and do not anticipate paying any dividends on our common stock in the foreseeable future. Any determination to pay dividends in the future
will be at the discretion of our board of directors. Consequently, your only opportunity to achieve a return on your investment in our
company will be if the market price of our common stock appreciates and you sell your shares at a profit. There is no guarantee that the
price of our common stock that will prevail in the market will ever exceed the price that you pay. For additional information about our
dividend policy, see the section entitled &#8220;Dividend policy&#8221; elsewhere in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain members of our management team have
limited experience managing a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the members of our management team have
limited experience managing a publicly traded company, interacting with public company investors, and complying with laws pertaining to
public companies. Our management team may not successfully or efficiently manage our transition to being a public company subject to significant
regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and
investors. These new obligations and constituents will require significant attention from our senior management and could divert their
attention away from the day-to-day management of our business, which could adversely affect our business, financial condition, and operating
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant increased costs
as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we have incurred and will
continue to incur legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements
of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are required to comply with the applicable requirements of
the Sarbanes-Oxley Act of 2002, or SOX, and the Dodd-Frank Wall Street Reform and Consumer Protection Act, or Dodd-Frank. The listing
requirements of the Nasdaq Stock Market, and the rules of the SEC require that we satisfy certain corporate governance requirements. Our
management and other personnel are required to devote a substantial amount of time to ensure that we comply with all of these requirements.
Moreover, the reporting requirements, rules and regulations have increased our legal and financial compliance costs and will make some
activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy
our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the
increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract
and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain
types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we will be required to maintain
internal control over financial reporting and to report any material weaknesses in such internal controls. Beginning with the second annual
report on Form 10-K that we will be required to file with the SEC, Section 404 requires an annual management assessment of the effectiveness
of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal
control over financial reporting are complex and require significant documentation, testing, and possible remediation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have not identified any material weaknesses
in our review of our internal controls for the purpose of providing the reports required by these rules. In the future, if we identify
material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404
of the Sarbanes-Oxley Act in a timely manner, or if we are unable to assert that our internal control over financial reporting is effective,
investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could
decline, and we could also become subject to investigations by the stock exchange on which our common stock is listed, the SEC or other
regulatory authorities, which could require additional financial and management resources. In addition, as a public company we will be
required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial
results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from Nasdaq or other adverse consequences
that would materially harm our business and reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For so long as we remain an emerging growth company
as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable
to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor
attestation requirements of Section 404. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal
year (i) following the fifth anniversary of the completion of our initial public offering, (ii) in which we have total annual gross revenue
of at least $1.235 billion, or (iii) in which we are deemed to be a large accelerated filer, which means the market value of our common
stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30<sup>th</sup>, and (2) the date on which we have issued
more than $1.0 billion in non-convertible debt during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an emerging growth company and we
cannot be certain if (i) the reduced disclosure requirements or (ii) extended transition periods for complying with new or revised accounting
standards applicable to emerging growth companies will make our common stock less attractive to investors. In addition, as a smaller reporting
company we will also have reduced disclosure requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an emerging growth company. Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply
to private companies. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies until
the earlier of the date we (i) are no longer an emerging growth company, or (ii) affirmatively and irrevocably opt out of the extended
transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with
new or revised accounting pronouncements as of public company effective dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, for as long as we continue to be
an emerging growth company, we intend to take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock
less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may
be a less active trading market for our common stock and our stock price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; ">We are also a &#8220;smaller reporting company&#8221;
as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of the
scaled disclosures available to smaller reporting companies. To the extent that we continue to qualify as a &#8220;smaller reporting company&#8221;
as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the
exemptions available to us as an &#8220;emerging growth company&#8221; may continue to be available to us as a &#8220;smaller reporting
company,&#8221; including exemption from compliance with the auditor attestation requirements pursuant to SOX and reduced disclosure about
our executive compensation arrangements. We will continue to be a &#8220;smaller reporting company&#8221; until we have $250 million or
more in public float (based on our Common Stock) measured as of the last business day of our most recently completed second fiscal quarter
or, in the event we have no public float (based on our Common Stock) or a public float (based on our Common Stock) that is less than $700
million, annual revenues of $100 million or more during the most recently completed fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="c_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1B. Unresolved Staff Comments.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Properties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters are located at 822
A1A North, Suite 306, Ponte Vedra, Florida 32082, which are leased pursuant to a Lease Agreement dated October 15, 2022 with Veranda III
Partners, Ltd. (the &#8220;Lease Agreement&#8221;). The Lease Agreement has an initial term of 24 months commencing on November 1, 2022.
The monthly rent is $2,170. We&#160;believe that these headquarters are adequate for our current operations and needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Legal Proceedings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not currently a party to any material legal proceedings. We
may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims
or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and
the safety or efficacy of our products. Any of these claims could subject us to costly litigation. If this were to happen, the payment
of any such awards could have a material adverse effect on our business, financial condition and results of operations. Additionally,
any such claims, whether or not successful, could damage our reputation and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Mine Safety Disclosures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Market for Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock has traded on the Nasdaq Capital
Market under the symbol &#8220;CVKD&#8221; since January 20, 2023. The last price of our common stock as reported on the Nasdaq Capital
Market on March 28, 2023 was $1.37 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stockholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have two classes of stock, undesignated preferred
stock, par value $0.001 per share, and common stock, par value $0.001 per share. No shares of preferred stock have been issued or are
outstanding. As of March 28, 2023, we had twenty-four (24) common stock stockholders of record. The number of holders of record is based
on the actual number of holders registered on the books of our transfer agent and does not reflect holders of shares in &#8220;street
name&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained
by depository trust companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid any cash dividends on our common
stock to date, and do not anticipate paying such cash dividends in the foreseeable future. Whether we declare and pay dividends is determined
by our Board of Directors at their discretion, subject to certain limitations imposed under Delaware corporate law. The timing, amount
and form of dividends, if any, will depend on, among other things, our results of operations, financial condition, cash requirements and
other factors deemed relevant by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted the Cadrenal Therapeutics,
Inc. 2022 Equity Incentive Plan, (the &#8220;Initial Plan&#8221;), on July&#160;11, 2022, which was later amended and restated on October&#160;16,
2022, for purposes of clarifying the application of certain of the rules of the Initial Plan to awards approved before such amendment
and restatement of the Initial Plan and to facilitate the transition to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan (the &#8220;Successor Plan&#8221;) for the issuance and approval of awards after consummation of our initial public offering. On
October&#160;16, 2022, the Board adopted and the Company&#8217;s stockholders approved the Cadrenal Therapeutics, Inc. 2022 Successor
Equity Incentive Plan (the &#8220;2022 Plan&#8221;), which is a successor to and continuation of the Initial Plan. The 2022 Plan became
effective on January 19, 2023, upon effectiveness of the Registration Statement at which time it replaced the Initial Plan, except with
respect to awards outstanding under the Initial Plan. No further awards are available for grant under the Initial Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information as of
December 31, 2022 with respect to shares of our common stock that may be issued under our existing equity compensation plans, which as
of December 31, 2022 was only the Initial Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Securities<br/> to be Issued<br/> upon<br/> Exercise<br/> of<br/> Outstanding<br/> Equity Compensation Plan Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price of<br/> Outstanding<br/> Equity Compensation Plan Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Securities<br/> Remaining<br/> Available for<br/> Future<br/> Issuance<br/> Under Equity<br/> Compensation<br/> Plans<br/> (excluding<br/> securities<br/> reflected in<br/> the first<br/> column)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">810,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">--</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">--</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">--</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,100,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">810,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2022 Successor Equity Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Executive Compensation and Director
Compensation&#8212;Employee Benefit and Stock Plans&#8212;2022 Successor Equity Incentive Plan&#8221; in Part III, Item 11 for a description
of the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January 25, 2022 (inception), we have not issued unregistered
securities to any person, except as described below. None of these transactions involved any underwriters, underwriting discounts or commissions,
except as specified below, or any public offering, and, unless otherwise indicated below, we believe that each transaction was exempt
from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated
thereunder, and/or Regulation S promulgated thereunder regarding offshore offers and sales. All recipients had adequate access, though
their relationships with the Company, to information about the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Original Issuance of Stock</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 25, 2022, we issued 7,500,000 shares
of common stock, pursuant to a subscription agreement, to Quang Pham, our Chief Executive Officer, of which 4,500,000 were subsequently
transferred to related trusts, of which Mr. Pham&#8217;s child is a beneficiary and Mr. Pham is the trustee with sole voting and disposition
power with respect to the shares owned by the Trusts. Mr. Pham paid a total of $7,500 for such founders shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 17, 2022, we issued 450,000 shares of restricted
common stock, pursuant to a restricted stock purchase agreement, to Matthew Szot, our Chief Financial Officer, which shares shall vest
quarterly over a period of two (2) years, subject to certain adjustments, as provided in the Restricted Stock Purchase Agreement dated
May 17, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, we issued a restricted stock
grant of 46,875 shares of common stock to a consultant, which fully vested on October 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, we granted stock options to
purchase 650,000 shares of common stock at an exercise price of $0.64 per common share. The stock option grants were issued to directors,
members of the Scientific Advisory Board, and other consultants to us and vest in periods ranging over one to three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued stock options to
purchase 300,000 shares of common stock to Douglas Losordo, our Chief Medical Officer. The options have an exercise price of $0.64 per
common share and will vest quarterly over a period of two (2) years, subject to certain adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued 40,000 shares of
common stock to a consultant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued 40,000 shares of
common stock to Steven Zelenkofske, a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued stock options to
purchase an aggregate of 100,000 shares of common stock to members of the Scientific Advisory Board. The options have an at an exercise
price of $0.64 per common share and will vest over a period of three (3) years, with 33.33% vesting on the first anniversary of the effective
date and thereafter 1/36 on a monthly basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2022, we issued 50,000 shares
of common stock to John Murphy, a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2022, we issued stock grants totaling
137,000 shares of common stock to various consultants for services. These shares were fully vested upon the date of grant. 70,000 of the
shares were subsequently returned and cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2022, we issued stock options to
purchase 50,000 shares of common stock to a director. The options have an exercise price of $5.00 per common share and will vest over
a three-year period, with 33.33% vesting on the first anniversary of the effective date, and thereafter 1/36 on a monthly basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Convertible Promissory Notes and Related Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2022, we issued a convertible promissory
note in the amount of $500,000 (the &#8220;March 2022 Note&#8221;). The March 2022 Note accrued interest at 5% and had a maturity date
of March 1, 2025 (&#8220;March Note Maturity Date&#8221;). The March 2022 Note provided that the principal amount due under the March
2022 Note (and, at the Company&#8217;s option, any accrued but unpaid interest under the March 2022 Note) would be automatically converted,
on or before the March Note Maturity Date, into equity securities issued and sold at the initial closing of our next equity financing
(&#8220;Next Equity Securities&#8221;) in a single transaction or a series of related transactions yielding gross proceeds to us of at
least $3,000,000 (the &#8220;Next Equity Financing&#8221;). The March 2022 Note was initially convertible into shares of common stock
at a conversion price equal to the quotient obtained by dividing (i) the entire principal amount of the March 2022 Note plus (if applicable)
any accrued but unpaid interest under the March 2022 Note by (ii) eighty percent (80%) of the price per share of the Next Equity Securities
sold in the Next Equity Financing. In the event of a Change of Control which occurs prior to repayment in full of the March 2022 Note,
immediately prior to the Change of Control, the outstanding principal and any accrued but unpaid interest on the March 2022 Note would
have converted directly into our common equity (or directly into proceeds paid to the holders of our common equity in connection with
the Change of Control) at a price per share that is 80% of the price per share of common equity paid at the Change of Control. In December
2022 we amended the conversion price of the March 2022 Note to $1.00 per share. Upon consummation of our initial public offering, the
March 2022 Note was converted into 514,792 shares of our common stock, which are unregistered securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2022, we issued a convertible promissory
note in the amount of $50,000 (the &#8220;June 2022 Note&#8221;). The June 2022 Note accrued interest at 6% and had a maturity date of
June 13, 2025 (&#8220;June Note Maturity Date&#8221;). The June 2022 Note provided that the principal amount due under the June 2022 Note
(and, at the Company&#8217;s option, any accrued but unpaid interest under the June 2022 Note) would be automatically converted, on or
before the June Note Maturity Date, into Next Equity Securities in the Next Equity Financing. The June 2022 Note was initially convertible
into shares of common stock at a conversion price equal to the quotient obtained by dividing (i) the entire principal amount of the June
2022 Note plus (if applicable) any accrued but unpaid interest under the June 2022 Note by (ii) sixty percent (60%) of the price per share
of the Next Equity Securities sold in the Next Equity Financing. In the event of a Change of Control which occurs prior to repayment in
full of the June 2022 Note, immediately prior to the Change of Control, the outstanding principal and any accrued but unpaid interest
on the June 2022 Note would have converted directly into our common equity (or directly into proceeds paid to the holders of our common
equity in connection with the Change of Control) at a price per share that is 60% of the price per share of common equity paid at the
Change of Control. In December 2022 we amended the conversion price of the June 2022 Note to $1.00 per share. Upon consummation of our
initial public offering, the March 2022 Note was converted into 50,908 shares of our common stock, which have been registered for resale
in the Resale Prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2022, we closed the first tranche
of a private placement (the &#8220;Private Placement&#8221;) pursuant to which we issued convertible promissory notes in the aggregate
principal amount of $450,000 (the &#8220;First Tranche Private Placement Notes&#8221;) and received gross proceeds of $450,000. The private
placement offering was for up to $2,000,000 of convertible promissory notes and was to terminate upon the sale of all $2,000,000 of convertible
promissory notes or July 31, 2022 subject to extension until August 31, 2022, in the sole discretion of the placement agent and us. We,
together with the placement agent, determined to extend the Private Placement to August 31, 2022. On August 22, 2022, we issued a convertible
promissory note pursuant to the Private Placement in the principal amount of $50,000 (the &#8220;Second Tranche Private Placement Note&#8221;)
and received gross proceeds of $50,000. The Private Placement was further extended to September 30, 2022, after obtaining the consent
of the investors in the Private Placement to date. On September 13, 2022, we issued convertible promissory notes in the aggregate principal
amount of $75,000 (together with the First Tranche Private Placement Notes, and the Second Tranche Private Placement Note the &#8220;Private
Placement Notes&#8221;) and received gross proceeds of $75,000. The Private Placement Notes accrued interest at 6% and had a maturity
date of September 13, 2025 (the third anniversary of the last closing of the Private Placement Notes). The principal amount due under
the Private Placement Notes (any accrued but unpaid interest under the Private Placement Notes was waived pursuant to the terms thereof)
were automatically converted into shares of our common stock upon the consummation of the initial public offering. The Private Placement
Notes were initially convertible into shares of common stock at a conversion price equal to the quotient obtained by dividing (i) the
entire principal amount of the Private Placement Notes plus (if applicable) any accrued but unpaid interest under the Private Placement
Notes by (ii) sixty percent (60%) of the initial offering price per share subject to adjustment in the event of a subsequent issuance
of securities by us at a price per share less than the conversion price. Upon the issuance of the November Notes and November Warrants
the conversion price was reduced to $1.00 per share. Upon consummation of our initial public offering, the Private Placement Notes were
converted into 575,000 shares of our common stock, 525,000 of which have been registered for resale in the Resale Prospectus, and 50,000
of which remain unregistered securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boustead Securities, LLC acted as the placement
agent for the Private Placement and received a commission equal to 7% of the gross proceeds received by us from the sale of the Private
Placement Notes, a non-accountable expense allowance equal to 1% of the gross proceeds received by us from the sale of the Private Placement
Notes and five-year warrants, as amended, to purchase an aggregate of 11,500 shares of our common stock at an exercise price equal to
60% of the initial public offering price per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Convertible Promissory Notes and Related
Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2022, we closed a $250,000 note
offering (the November Private Placement) pursuant to which we sold to two accredited investors units consisting of (i) notes in the aggregate
principal amount of $250,000, which accrued interest at the rate of 10% and were repayable at the time of the completion of the initial
public offering (the November Notes) and (ii) warrants to purchase up to an aggregate of 250,000 shares of common stock exercisable at
$1.00 per share which were automatically exercisable into shares of our common stock upon the consummation of the initial public offering
(the November Warrants). The principal amount of the November Notes was repaid upon the consummation of the initial public offering out
of the proceeds of the automatic exercise of the November Warrants, resulting in the issuance of an aggregate of 250,000 shares of our
common stock to the investors, all of which have been registered for resale in the Resale Prospectus. The interest owed on the November
Notes was paid in cash in February 2023, at which time the November Notes were satisfied in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boustead Securities, LLC acted as the placement
agent for the November Private Placement and received a commission equal to 7% of the gross proceeds received by us from the sale of the
November Notes, a non-accountable expense allowance equal to 1% of the gross proceeds received by us from the sale of the November Notes
and five-year warrants to purchase shares of our common stock in an amount equal to 6% of the shares of common stock underlying the securities
issued in the November Private Placement at an exercise price of $1.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On January 24, 2023,
we consummated our initial public offering of 1,400,000 shares of our common stock at a public offering price of $5.00 per share, generating
gross proceeds of $7.0 million which resulted in net proceeds to us of approximately $5.4 million, after deducting underwriting discounts
and commissions of $490,000, underwriter non-accountable expenses of $70,000, and offering-related transaction costs of approximately
$1.0 million. None of the expenses associated with the initial public offering were paid to directors, officers, persons owning ten percent
or more of any class of equity securities, or to their associates, or to our affiliates. Our shares of common stock commenced trading
on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on January 20, 2023 under the symbol &#8220;CVKD.&#8221; The offering has terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with our
initial public offering, on January 19, 2023, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
Boustead Securities, LLC, as representative of the underwriters (the &#8220;Representative&#8221;), a form of which was previously filed
as an exhibit to our registration statement on Form&#160;S-1, as amended (File No.&#160;333-267562), which was declared effective by the
SEC on January 19, 2023 (the &#8220;Registration Statement&#8221;).&#160;<span>Pursuant to the Underwriting
Agreement, we agreed to issue to the underwriters a five-year warrant (the &#8220;Representative&#8217;s Warrant&#8221;) to purchase an
aggregate of 84,000 shares of our common stock, which is equal to six percent (6%) of the shares of common stock sold in the</span> initial
public offering<span>. Such Representative&#8217;s Warrant has an exercise price of $6.00, which is equal
to 120% of the public offering price of the common stock in the </span>initial public offering<span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There has been no material change in the planned use
of proceeds from our initial public offering as described in our final prospectus filed with the SEC on January 23, 2023 pursuant to Rule&#160;424(b)(4),
of $3 million of proceeds to be used for CMC preparation, research and development, and other trial preparation expenses necessary for
initiation of our planned Phase&#160;3 pivotal trial and $2.4 million of proceeds to be used for working capital, including payments made
to officers in accordance with the terms of their employment agreements and payment to Phamace, LLC, a consulting firm of which Quang
Pham, our Chief Executive Officer, is the sole member, as described in Part III, Item 13 &#8220;Certain Relationships and Related Transactions,
and Director Independence.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;7. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following discussion of our financial
condition and results of operations should be read in conjunction with the audited financial statements and notes thereto for the&#160;period
ended December&#160;31, 2022 found in this Annual Report. In addition to historical information, the following discussion contains forward-looking
statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward-looking statements
by using words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221;
&#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions.
Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks
including, but not limited to, those set forth under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are focused on developing tecarfarin, a novel
therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients
with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. We secured the rights to tecarfarin on
April 1, 2022 via an asset purchase agreement from HESP LLC, a wholly owned subsidiary of Horizon Technology Finance Corporation. HESP
LLC acquired the assets of Espero BioPharma, Inc., or Espero, including tecarfarin, in an assignment for the benefit of creditors in which
the creditor, Horizon Technology Finance Corporation and Horizon Credit II LLC (collectively, Horizon), a secured lender of Espero, designated
HESP LLC as the assignee of Espero&#8217;s assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin is an anticoagulant that uses a drug
design process which targets a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib.
Tecarfarin has been evaluated in eleven (11) human clinical trials conducted by its previous owners and other third parties in over 1,003
individuals (269 patients were treated for at least six months and 129 patients were treated for one year or more). In Phase 1, Phase
2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic
kidney disease, or CKD. In the Phase 2/3 trial, EMBRACE-AC, the largest tecarfarin trial with 607 patients having completed it, only 1.6%
of the blinded tecarfarin subjects suffered from major bleeding and there were no thrombotic events. Five patients died during the trial,
but only one death due to intracerebral hemorrhage was considered to be possibly related to the tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019, the United States Food and Drug Administration,
or FDA, provided input on the Phase 3 trial design for tecarfarin, which was submitted by Espero, the previous owner of tecarfarin. We
intend to submit our Phase 3 trial design to the FDA using the same protocol that was submitted by Espero. Assuming the FDA accepts our
Phase 3 trial design, we intend to commence the Phase 3 pivotal trial in the second half of 2023. However, there can be no assurance that
the trial design will be accepted by the FDA. We are pursuing regulatory approval of tecarfarin as an individual treatment, although we
might evaluate, in consultation with the FDA, other potential uses in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2019, the FDA granted orphan drug designation,
or ODD, for tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients with ESRD and AFib. The FDA grants
ODD status to drugs that are intended for the treatment, diagnosis, or prevention of rare diseases or conditions, which are defined as
a disease or condition that affects fewer than 200,000 people in the U.S. The ODD program provides a drug developer with certain benefits
and incentives, including a seven-year period of U.S. marketing exclusivity from the date of marketing authorization, waiver of FDA user
fees, and tax credits for clinical research. The granting of an orphan drug designation does not alter the FDA&#8217;s regulatory requirements
to establish safety and effectiveness of a drug through adequate and well-controlled studies to support approval and commercialization.
Furthermore, orphan drug designation does not indicate or guarantee FDA approval of the New Drug Application, or NDA, and we might not
receive exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin was developed by researchers using
a retrometabolic drug design process which targets a different metabolic pathway than the most commonly prescribed drugs for the treatment
of thrombosis and AFib. &#8220;Drug metabolism&#8221; refers to the process by which a drug is inactivated by the body and rendered easier
to eliminate or to be cleared by the body. Most approved drugs, including warfarin, the only FDA-approved Vitamin K antagonists, or VKAs,
which is a prescribed drug for the treatment of thrombosis, are metabolized in the liver through a pathway known as the Cytochrome CYP450
system, or CYP450, by the enzymes known as CYP2C9 and CYP3A4. By using a different metabolic pathway, tecarfarin eliminates or minimizes
the CYP450 metabolism in the liver. Patients taking multiple medications that interact with CYP2C9, or CYP3A4 or those with impaired kidney
function, can experience an overload in the pathway, creating a bottleneck that often leads to insufficient clearance, which results in
a toxic build-up of one or more drugs. In some instances, patients taking multiple medications metabolized by the same CYP450 pathway
may experience decreased efficacy of one or more of the medications due to rapid metabolism or increased drug effect and/or toxicity due
to enzyme induction. Patient-specific genetic differences can also hinder drug clearance in the CYP450 pathway. Our product candidate
tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450
pathways. We believe this may allow elimination by large capacity and non-saturable tissue esterase pathways that exist throughout the
body rather than just in the liver.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin is an orphan designated, vitamin K
antagonist, oral, once-daily anticoagulant in the same drug class as warfarin designed for use in patients requiring chronic VKA anticoagulation,
to prevent systemic thromboembolism of cardiac origin in patients with ESRD and AFib. The prevailing treatment for thrombosis is with
an oral anticoagulant, either a VKA, like warfarin, or non-vitamin K oral anticoagulant (&#8220;NOAC&#8221;). VKAs block the production
of vitamin K-dependent blood clotting factors, such that the blood is &#8220;thinned,&#8221; preventing clots, while NOACs directly block
the activity of certain of these clotting factors. Tecarfarin, like warfarin, is a VKA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vitamin K epoxide Reductase Complex subunit 1
(VKORC1) is a significant enzyme for effective clotting. VKORC1 reduces vitamin K epoxide to its active form (Vitamin K), which is the
rate-limiting step in the physiological process of vitamin K recycling. Vitamin K serves as a cofactor for normal function of several
clotting/anticoagulation factors including Factors II, VII, IX and X and Proteins C, S, and Z. VKORC1 genetic deficiencies result in increased
sensitivity to VKAs, which results in an increase in the risk of significant hemorrhaging. We believe tecarfarin has similar potency for
VKORC1 inhibition as warfarin, but it is an investigational new drug, and we must demonstrate it is safe and effective for its proposed
indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AFib is the most common arrhythmia, with its incidence
and prevalence increasing over the last 20 years. AFib is associated with an approximate five-fold increased risk of stroke. The risk
of developing AFib increases in patients with CKD. According to 2021 estimates by the Centers for Disease Control and Prevention, or CDC,
approximately 15% of the U.S. adult population, or 37 million people, have CKD. An estimated 0.4% of people in the U.S. suffer from Stage
4 CKD and 0.1% of people in the U.S. have ESRD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients with ESRD and AFib represent a spectrum
of disorders involving both the heart and kidneys (known as cardiorenal syndrome or CRS) in which acute or chronic dysfunction in one
organ may induce acute or chronic dysfunction in the other organ. These patients have typically been excluded from randomized clinical
trials because the approved therapies for AFib have metabolic profiles that may increase drug exposures thereby increasing the known risks
and challenges in managing these patients. The presence of either CKD or AFib, increases the risk of serious thromboembolic adverse clinical
outcomes, such as stroke and death. Antithrombotic therapy is typically recommended to decrease this risk in AFib patients, but there
are no approved treatment options for patients with ESRD and AFib. Warfarin may cause substantial harm in these patients. Low-dose apixaban
(Eliquis) was approved by the FDA for use in ESRD patients on hemodialysis based upon limited pharmacokinetic data by 8 subjects, despite
that randomized trials to date of apixaban versus warfarin for AFib excluded patients with severe and end-stage kidney disease. The RENAL-AF
(Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation) was terminated early in 2019 by its sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are more than 809,000 Americans with ESRD,
with approximately 70% on dialysis, according to the United States Renal Data System. Approximately 150,000 ESRD patients also have AFib.
AFib nearly doubles the anticipated mortality and increases the stroke risk by approximately five-fold in these patients. There is evidence
that AFib is an independent risk factor for developing ESRD in CKD patients. Both diseases share common risk factors including hypertension,
diabetes, vascular disease, and advancing age. Cardiovascular disease contributes to more than half of all deaths among patients with
ESRD. According to the Annual Data Report published by the United States Renal Data System, total Medicare spending for patients with
ESRD reached $51 billion in 2019, accounting for approximately 7% of the Medicare paid claims costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have licensed out the rights to tecarfarin
for several Asian markets including China, to Lee&#8217;s Pharmaceutical Holdings Limited, an integrated research-driven and market-oriented
biopharmaceutical publicly listed company based in Hong Kong with over 25 years&#8217; experience in the pharmaceutical industry in China.
Lee&#8217;s Pharmaceutical Holdings Limited is developing tecarfarin as an anti-thrombotic for patients with mechanical heart valves.
In 2020 and 2021, Lee&#8217;s Pharmaceutical Holdings Limited completed two Phase 1 studies in China and Hong Kong and is currently preparing
for its Phase 2 trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As more fully set forth in our risk factors, we are a clinical development
biopharmaceutical company with a limited operating history. We have a history of operating losses and expect to continue to incur substantial
losses for the foreseeable future. Our cash and the proceeds of our initial public offering will only fund our operations for a limited
time. The proceeds from our initial public offering are insufficient to allow us to commence and complete our planned Phase&#160;3 clinical
trial and submit our NDA. We will need to raise additional capital for the initiation of enrollment of patients and completion of the
planned pivotal Phase 3 trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to tecarfarin, we have two issued
U.S. patents directed to tecarfarin. While the patents currently expire in 2024, we expect to seek extensions of patent terms. In the
United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years
beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during
the period of extension). We also intend to seek exclusivity for our proprietary product candidates through market and data exclusivity
granted by regulatory agencies in the United States and other countries. Further, as discussed above, the ODD program provides a drug
developer with certain benefits and incentives, including a seven-year period of U.S. marketing exclusivity from the date of marketing
authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we have engaged intellectual property counsel
to assist in protecting our patent ownership rights, to date, we have not had intellectual property counsel conduct a freedom to operate
analysis regarding our tecarfarin product. As a result, we cannot be certain that we will not be exposed to third party legal claims,
liabilities and/or litigation actions when we seek to develop, make and market products using our tecarfarin technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Trials</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tecarfarin has been evaluated in 11 human clinical
trials in over 1,003 individuals which includes eight Phase 1 trials, two Phase 2 trials and one Phase 2/3 trial evaluating the efficacy
and safety of tecarfarin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a Phase 2/3 randomized and blinded trial sponsored
by ARYx Therapeutics, Inc. in 2008, 607 patients with indications for chronic anticoagulation were treated with either tecarfarin or warfarin.
The Time in Therapeutic Range, or TTR, with tecarfarin was similar to that with well-managed warfarin and tecarfarin appeared to have
a favorable safety profile and be well tolerated with only 1.6% of the blinded tecarfarin subjects suffering from major bleeding and no
thrombotic events. When thrombotic and major bleeding events during the blinded period were combined, a numerical imbalance favoring tecarfarin
over warfarin was seen (warfarin 11 subjects, 3.6%; tecarfarin 5 subjects, 1.6%). The trial however did not meet its primary endpoint
as superiority of tecarfarin over warfarin as measured by TTR was not demonstrated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a subsequent Phase 1 study with 23 patients
with CKD sponsored by Armetheon, Inc. in 2016, the metabolism of warfarin was inhibited, but not tecarfarin. The safety of repeated dosing
of tecarfarin in CKD patients remained unknown. However, if the pharmacokinetic findings of this single-dose study are present with repeated
dosing, tecarfarin may lead to dosing that is more predictable than warfarin in CKD patients who require anticoagulation therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Events</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track Designation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2023, the FDA designated as a Fast
Track development program the investigation of tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients
with ESRD and AFib. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions
and fill an unmet medical need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initial Public Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On January 24, 2023,
we consummated our initial public offering of 1,400,000 shares of our common stock at a public offering price of $5.00 per share, generating
gross proceeds of $7,000,000. Our shares of common stock commenced trading on the Nasdaq on January 20, 2023 under the symbol &#8220;CVKD.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with our
initial public offering, on January 19, 2023, we entered into the Underwriting Agreement with the Representative, a form of which was
previously filed as an exhibit to the Registration Statement, which was declared effective by the SEC on January 19, 2023.&#160;<span>Pursuant
to the Underwriting Agreement, we agreed to issue to the underwriters the Representative&#8217;s Warrant to purchase an aggregate of 84,000
shares of our common stock, which is equal to six percent (6%) of the shares of common stock sold in the </span>initial public offering<span>.
Such Representative&#8217;s Warrant has an exercise price of $6.00, which is equal to 120% of the public offering price of the common
stock in the</span> initial public offering<span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with the
closing of the initial public offering, we entered into separate indemnification agreements with each of our directors (we had previously
entered into separate indemnification agreements with each of our executive officers). The indemnification agreements, in addition to
our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, require us to indemnify our directors, executive
officers and certain controlling persons to the fullest extent permitted by Delaware law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Resale Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Resale Prospectus, dated January
19, 2023, 1,704,783 shares of our common stock have been registered for resale by the Selling Shareholders. We did, and will not, receive
any proceeds from the sales by the Selling Stockholders of the securities set forth in the Resale Prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fiscal Year Ended December 31, 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our results of
operations for the period January&#160;25, 2022 (inception) to December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022<br/> (inception)<br/>
 through<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,307,503</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392,859</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,266</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,701,628</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,701,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense, amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,913</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,905,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,012,701</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,714,329</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and administrative expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses were $2,307,503 for the period
January 25, 2022 (inception) to December 31, 2022. General and administrative expenses included $791,247 of stock-based compensation,
$936,437 of personnel-related expenses, $180,536 of contract labor, $115,000 in consulting fees, $30,871 of patent renewal fees, $68,226
in accounting fees, and $185,186 of other expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and development expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses were $392,859
for the period January 25, 2022 (inception) to December 31, 2022. Research and development expenses included $200,000 of acquired intangible
assets, $20,095 of transaction costs which are expensed as in-process research and development, $136,802 of stock-based compensation,
and $35,962 of consulting services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Change in fair value of derivative liabilities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determined that the redemption features in
the convertible notes contained rights and obligations for conversion contingent upon a potential future financing event or a change in
control. Thus, the embedded put options were bifurcated from the face value of the convertible notes and accounted for as derivative liabilities
to be remeasured at the end of each reporting period with the change in the fair value included in other expense, in the accompanying
statement of operations and comprehensive loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The derivative liabilities were considered a level 3 fair value financial
instrument and were measured at the reporting period ended December 31, 2022. We recorded a non-cash charge of $3,905,596 for the period
January 25, 2022 (inception) to December 31, 2022. This charge represented the increase in the fair value of the derivative liabilities
since the issuance of the respective financial instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrent with the closing of the initial public offering in January
2023, the note holders converted the debt into common stock, accordingly, the derivative financial liabilities will be de-recognized and
reclassified to stockholders&#8217; equity (deficit) on January 24, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception, we have incurred losses and negative
cash flows from operations. To date, we have funded our operations from the proceeds of the sale of convertible notes, the November Notes
and the November Warrants, as well as our recently completed initial public offering in January 2023. We had a net loss of $6,714,329
for the period January&#160;25, 2022 (inception) to December 31, 2022 which included $4,901,824 of non-cash expenses. Cash used in operations
for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $1,204,770. As of March 27, 2023, we had cash of $4.1 million
and no debt. Our current cash is sufficient to fund our operations for at least the next twelve&#160;months, however, we expect to require
additional funding to commence and complete our planned Phase&#160;3 clinical trial and submit our NDA, the cost of which we anticipate
will be approximately $45&#160;million. In order to fund the commencement and completion of our Phase&#160;3 clinical trial, we intend
to raise additional funds through equity and debt financings. However, there can be no assurance that we will be able to complete any
additional equity or debt financings on terms acceptable to the Company or at all. If we are unable to raise additional funding to meet
our working capital needs in the future, we will be forced to delay or reduce the scope of our research programs and/or limit or cease
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We estimate that we will require a total of $45&#160;million
for the completion of our planned pivotal Phase&#160;3 clinical trial and other expenditures that we will need to incur in order to file
our NDA.&#160;We intend to use approximately $3 million of the proceeds from our IPO to fund CMC preparation, research and development
and other trial preparation expenses necessary for commencement of our planned pivotal Phase&#160;3 clinical trial, therefore, we will
require at least $42 million of additional funding to enroll patients and complete our pivotal Phase&#160;3 clinical trial. In addition,
we estimate that we will require $15 million for general and administrative expenses anticipated to be incurred over the next three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our cash flows
for the period presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,204,770</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,279</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,239,635</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,586</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Cash, beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Cash, end of period</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">32,586</td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period January&#160;25, 2022 (inception)
to December 31, 2022, cash used in operating activities was $1,204,770. Net loss adjusted for the non-cash items as detailed on the statement
of cash flows used $1,812,505 in cash, and the changes in operating assets and liabilities as detailed on the statement of cash flows
provided $607,735 in cash primarily from a $404,897 increase in accounts payable and an $863,622 increase in accrued liabilities partially
offset by a $672,295 increase in deferred equity offering costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period January&#160;25, 2022 (inception)
to December 31, 2022, net cash provided by financing activities was $1,239,635, primarily consisting of the $1,011,964 of net proceeds
from the issuance of convertible notes and $219,721 of net proceeds from the issuance of a non-convertible promissory note and warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Estimates </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion and analysis of our financial
condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted
accounting principles in the United&#160;States, or GAAP.&#160;The preparation of these financial statements requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at
the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based
on our historical experience and on various other factors that we believe are reasonable under the circumstances, that results of which
form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimated under different assumption or conditions. While our significant accounting policies are
described in more detail in the notes to our financial statements, we believe that the following accounting policies are critical to understanding
our historical and future performance, as these policies relate to the more significant areas involving managements judgements and estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Acquisitions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate acquisitions of assets and other similar
transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first
applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single
identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further
determination is required as to whether or not we have acquired inputs and processes that have the ability to create outputs, which would
meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition
is a business combination or an acquisition of assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
We also evaluate which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted
for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities
assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an
asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative
fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (&#8220;IPR&amp;D&#8221;)
asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development
project. For an IPR&amp;D asset to have an alternative future use: (a)&#160;we must reasonably expect that we will use the asset acquired
in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;our use of the asset acquired is not
contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner
in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&amp;D that have no alternative use
are expensed to research and development. Asset acquisitions may include contingent consideration arrangements that encompass obligations
to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized
until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated
to the assets acquired on a relative fair value basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Nonrefundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period January 25, 2022 (inception) to
December 31, 2022, our research and development expenses were comprised primarily of the cost of the tecarfarin asset and related transaction
costs as well as stock-based compensation expense and consulting services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Derivative Financial Instruments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate all of our agreements to determine
if such instruments have derivatives or contain features that qualify as embedded derivatives. We account for certain redemption features
that are associated with convertible notes as liabilities at fair value and adjust the instruments to their fair value at the end of each
reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in
the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive loss for each reporting
period while such instruments are outstanding. The embedded derivative liability is valued using a probability-weighted expected return
model. If we repay the note holders or if, during the next round of financing, the note holders convert the debt into equity, the derivative
financial liability will be de-recognized on that date. Derivative instrument liabilities are classified in the balance sheet as current
or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12&#160;months of the
balance sheet date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We measure our stock-based awards granted to employees,
consultants and directors based on the estimated fair values of the awards and recognize the compensation over the requisite service period.
We use the Black-Scholes option-pricing model to estimate the fair value of our stock option awards. Stock-based compensation is recognized
using the straight-line method. As the stock compensation expense is based on awards ultimately expected to vest, it is reduced by forfeitures.
We account for forfeitures as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our equity awards granted through the date of
this filing have an estimated grant date fair value of approximately $2.1 million which will be expensed over the requisite service period
of each respective stock-based award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determination of the Fair Value of Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of our common stock for purposes
of stock-based awards has been determined by our board of directors. Because there has been no public market for our common stock until
the closing of our initial public offering on January 24, 2023, and in the absence of arm&#8217;s-length transactions in our common stock
with independent third parties, the board of directors has determined the fair value of our common stock with the assistance of an independent
third-party valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice
Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of our common stock on
each grant date, we considered numerous objective and subjective factors, including, but not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">independent third-party valuation as of May 31, 2022;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our current and expected operating and financial performance,
including our level of available capital resources;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the value of our tangible and intangible assets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">market conditions affecting comparable public companies,
as reflected in comparable companies&#8217; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the illiquidity of our common stock by virtue of being a
private company, and the resulting discount for lack of marketability;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the business risks we face;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the experience of management and the board of directors</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and certain
accruals. We evaluate our estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those
estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OFF-BALANCE SHEET ARRANGEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not have during the period presented, and
we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Item 7A. Quantitative and Qualitative Disclosures
About Market Risk.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Not applicable because
we are a smaller reporting company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8. Financial Statements and Supplementary Data.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC. AND SUBSIDIARIES</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><b>INDEX TO FINANCIAL STATEMENTS</b></div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt; width: 92%">&#160;</td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">Report of Independent Registered Public Accounting Firm (PCAOB ID #100)</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Balance Sheet at December 31, 2022</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">Statement of Operations and Comprehensive Loss for the period from January 25, 2022 (inception) through December 31, 2022</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">Statement of Changes in Stockholders&#8217; Deficit for the period from January 25, 2022 (inception) through December 31, 2022</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">Statement of Cash Flows for the period from January 25, 2022 (inception) through December 31, 2022</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">Notes to Financial Statements</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Stockholders and Board of Directors of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cadrenal Therapeutics, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheet of Cadrenal Therapeutics,
Inc. as of December 31, 2022, and the related statements of operations and comprehensive loss, changes in stockholders&#8217; deficit
and cash flows for the period from January 25, 2022 (inception) to December 31, 2022, and the related notes (collectively referred to
as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company at December 31, 2022, and the results of its operations and its cash flows for the period from January 25, 2022
(inception) to December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion </i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements are the responsibility of the entity&#8217;s
management. Our responsibility is to express an opinion on the entity&#8217;s financial statements based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control
over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">WithumSmith+Brown, PC</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">East Brunswick, New Jersey</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 29, 2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">100</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC.<br/>
BALANCE SHEET</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">32,586</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">22,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">672,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">727,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,013</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">43,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">5,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">778,174</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">404,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">863,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">22,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Promissory note payable, net of debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd">43,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,334,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Convertible note payable, net of debt discount - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" scale="0" unitRef="usd">442,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible note payable, net of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="0" unitRef="usd">110,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent" scale="0" unitRef="usd">40,213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability, noncurrent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">21,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">6,329,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stockholders&#8217; deficit:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">75,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">8,193,875</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">8,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">1,154,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">5,551,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">778,174</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC.<br/>
STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January 25, 2022<br/>
 (inception) through<br/>
 December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">2,307,503</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" unitRef="usd">392,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">1,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">2,701,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,701,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">40,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense, amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd">66,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">3,905,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">4,012,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-0">Net loss per common share, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.85</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-1">Weighted average number of common shares used in computing net loss per common share, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">7,890,507</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC.<br/>
STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Additional<br/>
 Paid-In<br/>
 </td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Accumulated <br/>
</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Total<br/>
 Stockholders&#8217; </td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Capital</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Deficit</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Deficit</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%">Balance, January 25, 2022 (inception)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Issuance of founder shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">7,950,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">7,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">7,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Equity-based compensation - options, restricted stock and RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">243,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd">244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd">927,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd">928,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of placement agent warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd">51,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd">51,621</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of investor warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">175,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">175,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">8,193,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,194</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,154,985</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">5,551,150</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC.<br/>
STATEMENT OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January 25, 2022<br/>
 (inception) through<br/>
 December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">1,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">928,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">66,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">3,905,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">22,715</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="0" unitRef="usd">672,295</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" unitRef="usd">5,987</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">404,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" unitRef="usd">863,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">40,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,204,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Investment in property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">2,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">2,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from issuance of convertible notes, net of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd">1,011,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Proceeds from issuance of promissory notes, net of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd">219,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Proceeds from sale of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">7,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">1,239,635</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">32,586</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cash &#8211; beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Cash &#8211; end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">32,586</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Non-cash right of use assets and operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left"><b>$</b></td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" scale="0" unitRef="usd">47,090</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of non-cash financing activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Non-cash debt issuance costs - placement agent warrants</td><td>&#160;</td>
    <td style="text-align: left"><b>$</b></td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" unitRef="usd">51,621</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Fair value of financial instruments at issuance</td><td>&#160;</td>
    <td style="text-align: left"><b>$</b></td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd">474,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Issuance of investor warrants</td><td>&#160;</td>
    <td style="text-align: left"><b>$</b></td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">175,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CADRENAL THERAPEUTICS, INC.<br/>
Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;1. Description of Business and Summary
of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cadrenal Therapeutics, Inc. (the &#8220;Company&#8221;
or &#8220;Cadrenal&#8221;) was incorporated on January&#160;25, 2022 (inception) in the State of Delaware and is headquartered in Ponte
Vedra, Florida. Cadrenal is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular
heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process which targets a different pathway than most commonly
prescribed drugs for the treatment of thrombosis and AFib.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP) and applicable rules
and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) for the fair presentation of the Company&#8217;s
financial statements for the period from January&#160;25, 2022 (inception) through December 31, 2022. The Company&#8217;s date of inception
was January&#160;25, 2022 and the fiscal year-end is December&#160;31.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxUncertaintiesPolicy-c0_cont_1" escape="true" name="us-gaap:IncomeTaxUncertaintiesPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_IncomeTaxUncertaintiesPolicy-c0_cont_2" id="_IncomeTaxUncertaintiesPolicy-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation
initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented
as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether
the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating
effect of the Company plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within
one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate
the relevant conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after
the date that the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_IncomeTaxUncertaintiesPolicy-c0_cont_3" id="_IncomeTaxUncertaintiesPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability
and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since
inception, the Company has incurred operating losses, and negative cash flows from operations. For the period from January&#160;25, 2022
(inception) to December 31, 2022, the Company had a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAllocatedToGeneralPartners" scale="0" unitRef="usd">6,714,329</ix:nonFraction> which included $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCash" scale="0" unitRef="usd">4,901,824</ix:nonFraction> of non-cash expenses. Cash used in
operations for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" unitRef="usd">1,204,770</ix:nonFraction>. As of December 31, 2022, the Company
had cash of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">32,586</ix:nonFraction>, negative working capital of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:WorkingsCapital" scale="0" unitRef="usd">606,881</ix:nonFraction>, and an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction>. On January 24, 2023, the Company
consummated its initial public offering (the &#8220;IPO&#8221;) of <ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">1,400,000</ix:nonFraction> shares of its common stock at a public offering price of
$<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share, generating gross proceeds of $<ix:nonFraction contextRef="c14" decimals="1" format="ixt:num-dot-decimal" name="cvkd:GeneratingGrossProceeds" scale="0" unitRef="usd">7.0</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c15" decimals="-5" format="ixt:num-dot-decimal" name="cvkd:NetProceeds" scale="6" unitRef="usd">5.4</ix:nonFraction> million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_IncomeTaxUncertaintiesPolicy-c0_cont_4" id="_IncomeTaxUncertaintiesPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is projecting that its existing cash
balances as of March 2023 is sufficient to fund its operations for at least the next twelve&#160;months from the date of the filing of
its Annual Report on Form 10-K, however, the Company will require additional funding to commence and complete its planned Phase&#160;3
clinical trial and submit its NDA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_9" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_IncomeTaxUncertaintiesPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management intends to raise additional funds through
equity and debt financings. However, there can be no assurance that the Company will be able to complete any additional equity or debt
financings on terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital
needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_10" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock-c0_cont_1" escape="true" name="cvkd:EmergingGrowthCompanyStatusPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Emerging Growth Company Status</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_11" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;)
under the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), the Company may elect to take advantage of certain forms of relief
from various reporting requirements that are applicable to public companies. The relief afforded under the JOBS Act includes an extended
transition period for the implementation of new or revised accounting standards. The Company has elected to take advantage of this extended
transition period and, as a result, the Company&#8217;s financial statements may not be comparable to those of companies that implement
accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the
JOBS Act up until the last&#160;day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is
no longer an EGC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_12" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_13" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and
certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors
and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_14" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and other Risks
and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_15" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to significant concentrations of credit risk, consist primarily of cash. Cash is maintained at high credit quality financial
institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances
are insured up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" scale="0" unitRef="usd">250,000</ix:nonFraction> per depositor at each financial institution. The Company has never experienced any losses related to these
balances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_16" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common
for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product
candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_17" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_18" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are defined as components
of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker
(CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief
Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_19" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_20" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
purchased with original maturities of three&#160;months or less from the purchase date to be cash equivalents. The Company did not have
any cash equivalents at December&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_21" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_22" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all of its agreements to
determine if such instruments have derivatives or contain features that qualify as embedded derivatives. The Company accounts for certain
redemption features that are associated with convertible notes as liabilities at fair value and adjusts the instruments to their fair
value at the end of each reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses
arising from changes in the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive
loss for each reporting period while such instruments are outstanding. The embedded derivative liabilities are valued using a probability-weighted
expected return model. If the Company repays the noteholders or if, during the next round of financing, the note holders convert the debt
into equity, the derivative financial liabilities will be de-recognized and reclassified to stockholders&#8217; equity (deficit) on that
date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within 12&#160;months of the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_23" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_24" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_25" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_1" escape="true" name="cvkd:DeterminationOfTheFairValueOfCommonStockPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determination of the Fair Value of Common
Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_26" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_2" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s common
stock for purposes of stock-based awards has been determined by its board of directors. Because there has been no public market for the
Company&#8217;s common stock, and in the absence of arm&#8217;s-length transactions in the Company&#8217;s common stock with independent
third parties, the board of directors has determined the fair value of its common stock with the assistance of an independent third-party
valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of the Company&#8217;s common
stock on each grant date, the Company considered numerous objective and subjective factors, including, but not limited to, the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_27" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_3" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">independent third-party valuation as of May&#160;31, 2022;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_28" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_4" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Company&#8217;s current and expected operating and financial
performance, including our level of available capital resources;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_29" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_5" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the value of the Company&#8217;s tangible and intangible
assets;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_30" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_6" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">market conditions affecting comparable public companies,
as reflected in comparable companies&#8217; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_31" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_7" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the illiquidity of the Company&#8217;s common stock by virtue
of being a private company, and the resulting discount for lack of marketability;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_32" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_8" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the business risks we face;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_33" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_9" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_34" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the experience of management and the board of directors</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_35" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" continuedAt="_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy-c0_cont_1" escape="true" name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_36" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation id="_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, professional,
and other third-party costs that are directly associated with in-process equity financings until such financings are consummated at which
time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
As of December 31, 2022, deferred offering costs were $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">672,295</ix:nonFraction> and are included on the accompanying balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_37" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionCustomerAcquisitions-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionCustomerAcquisitions"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_38" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_RevenueRecognitionCustomerAcquisitions-c0_cont_2" id="_RevenueRecognitionCustomerAcquisitions-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates acquisitions of assets
and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition
by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated
in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition.
If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to
create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test
to determine whether an acquisition is a business combination or an acquisition of assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_39" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionCustomerAcquisitions-c0_cont_3" id="_RevenueRecognitionCustomerAcquisitions-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_40" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_RevenueRecognitionCustomerAcquisitions-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should
be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired
and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between
the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based
on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development
(&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular
research and development project. For an IPR&amp;D asset to have an alternative future use: (a)&#160;the Company must reasonably expect
that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;the
Company&#8217;s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that
is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts
allocated to IPR&amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent
consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial
targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of
payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_41" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_42" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the asset
and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected
to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_43" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes uncertain income tax positions
at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">50</ix:nonFraction>% likelihood of being sustained. Changes in recognition or measurement are reflected
in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment
of income taxes as a component of the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_44" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_43"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_45" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for
potential dilutive shares of common stock. Diluted net loss per common share is computed by dividing net loss by the weighted average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock or if-converted methods. Since the Company was in a loss position for all periods presented, basic net loss
per common share is the same as diluted net loss per common share since the effects of potentially dilutive securities are anti-dilutive.
Shares of common stock subject to repurchase are excluded from the weighted-average shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_46" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_45"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Loss</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_47" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is defined as the change in
equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were
the same for the period presented in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_48" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_47"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_49" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_50" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period from January&#160;25, 2022 (inception)
through December&#160;31, 2022, the Company&#8217;s research and development expenses were comprised primarily of the cost of the acquired
tecarfarin asset and related transaction costs, as well as stock-based compensation and consulting services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_51" id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="cvkd_PatentPolicyTextBlock-c0_cont_1" escape="true" name="cvkd:PatentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation id="cvkd_PatentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent costs are comprised primarily of external
legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force and are expensed
as incurred as a component of general and administrative expense.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;2. Recent Accounting Guidance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August&#160;2020, the FASB issued ASU No.&#160;2020-06,
Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#8212;&#160;Contracts
in Entity&#8217;s Own Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity, which simplifies
the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and
contracts on an entity&#8217;s own equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASU&#160;2020-06 is effective on a prospective
basis for annual reporting periods beginning after December&#160;15, 2023 and for interim periods within those periods. Early adoption
is permitted. The Company adopted ASU&#160;2020-06 on January 25, 2022 (inception). The adoption of ASU&#160;2020-06 did not have a material
impact on the Company&#8217;s financial position and results of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;3. Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities recorded at fair value
on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure
their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid
to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy
for disclosure of fair value measurements as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 1 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 2 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These
include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities
in markets that are not active.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 3 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies its embedded derivative
liability as a Level 3 financial instrument and measures and reports its embedded derivatives at fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial liabilities subject to fair value measurements
on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2022 are presented
in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Financial Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Derivative liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsAndHedgesLiabilities" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsAndHedgesLiabilities" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total Financial Liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_9" id="_FairValueDisclosuresTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative<br/>
 liabilities</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 25, 2022 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Fair value of financial instruments at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" unitRef="usd">474,348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value &#160; </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">3,905,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="0" unitRef="usd">4,379,944</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash, prepaid expenses,
deferred offering costs, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. There
were no transfers of liabilities among the fair value measurement categories during any of the periods presented.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;4. Accrued Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued liabilities consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:AccruedConsultingFees" scale="0" unitRef="usd">165,192</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CompensatedAbsencesLiability" scale="0" unitRef="usd">605,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">93,082</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">863,564</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AssetAcquisitionTextBlock-c0_cont_1" escape="true" name="us-gaap:AssetAcquisitionTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;5. Asset Purchase Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_2" id="_AssetAcquisitionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&#160;1, 2022, the Company completed
an asset purchase agreement with HESP LLC, the assignee of tecarfarin and related assets (the &#8220;Asset Purchase Agreement&#8221;).
Pursuant to the terms of the Asset Purchase Agreement, the Company acquired all of the assets of HESP LLC, including all intellectual
property and other rights related to tecarfarin, the tecarfarin IND&#160;77041, all rights under the license, development and commercialization
agreement dated as of September&#160;16, 2015 by and between Armetheon, Inc. (&#8220;Armetheon&#8221;) (which was later assigned by Armetheon
to Espero BioPharma, Inc. (&#8220;Espero&#8221;), and China Cardiovascular Focus Ltd, an affiliate of Lee&#8217;s Pharmaceutical Holdings
Limited (&#8220;Lee&#8217;s Pharmaceutical&#8221;), relating to tecarfarin and related trademarks. In consideration of the purchase of
the assets, the Company paid HESP LLC $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPurchaseOfOtherAssets1" scale="0" unitRef="usd">100,000</ix:nonFraction> on the closing date and paid an additional $<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd">100,000</ix:nonFraction> on June&#160;1, 2022. As additional
consideration, the Company agreed to pay HESP LLC the following development milestone payments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_3" id="_AssetAcquisitionTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Development Milestones</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone <br/> Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Completion of enrollment of Lee&#8217;s Pharmaceutical Phase&#160;3 clinical trial</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First MAA submitted in the People&#8217;s Republic of China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:FirstMAASubmittedInThePeoplesRepublicOfChina1" scale="0" unitRef="usd">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First Commercial Sale to a Third Party</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:FirstCommercialSaleToAThirdParty1" scale="0" unitRef="usd">1,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_4" id="_AssetAcquisitionTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Financing Milestones</span></i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_5" id="_AssetAcquisitionTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As additional consideration, the Company agreed
to pay the following amounts, up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd">2,000,000</ix:nonFraction>, upon each financing milestone as follows (i)&#160;<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure">35</ix:nonFraction>% of any proceeds received from any
licensing or partnering revenue; and (ii)&#160;IPO proceeds. The aggregate payments under the development milestone payments and financing
milestone payments shall not exceed $<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">2,000,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_6" id="_AssetAcquisitionTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for the transaction as
an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified
in-process research and development asset, the tecarfarin asset, thus satisfying the requirements of the screen test in accordance with
the criteria under ASC&#160;805-10-55-5C.&#160;The assets acquired in the transaction were measured based on the fair value of the consideration
paid including the direct transaction costs of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">20,095</ix:nonFraction>, as the fair value of the consideration paid was more readily determinable than
the fair value of the assets acquired. The following table summarizes the purchase price of the assets acquired:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_7" id="_AssetAcquisitionTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRegulatoryAssetsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">In process research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" unitRef="usd">200,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Transaction costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">20,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">220,095</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_8" id="_AssetAcquisitionTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs the Company incurred in connection
with this Asset Purchase Agreement were recognized as research and development expenses in the Company&#8217;s statement of operations
and comprehensive loss as these assets had no alternative future use at the time of the acquisition transaction. Due to the nature of
the regulatory, sales and financing-based milestones, the contingent consideration was not included in the initial cost of assets purchased
as they are contingent upon events that are outside the Company&#8217;s control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_9" id="_AssetAcquisitionTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, upon achievement or anticipated achievement
of each milestone, the Company will recognize the related appropriate payment as additional research and development expense. Contingent
consideration will not be recorded until it is probable the milestone events occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AssetAcquisitionTextBlock-c0_cont_10" id="_AssetAcquisitionTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company entered
into an Amendment to Asset Purchase Agreement, whereby in lieu of the $<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForOtherOperatingActivities" scale="0" unitRef="usd">1,800,000</ix:nonFraction> cash payment that would have been due to HESP LLC pursuant
to the Asset Purchase Agreement as a result of an initial public offering, HESP LLC agreed to accept shares of the Company&#8217;s common
stock, such number of shares to be calculated based upon a <ix:nonFraction contextRef="c23" decimals="2" format="ixt:num-dot-decimal" name="cvkd:DiscountPercentage" scale="-2" unitRef="pure">40</ix:nonFraction>% discount to the price of the Company&#8217;s common stock sold in the
initial public offering. If and when it is determined that it is probable this financing-based milestone (initial public offering) will
be achieved, the Company will recognize the payment of $<ix:nonFraction contextRef="c22" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" unitRef="usd">3.0</ix:nonFraction>&#160;million as research and development expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AssetAcquisitionTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, none of the contingent
events have occurred.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;6. Debt</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt outstanding is presented on the balance
sheet as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Convertible notes payable - related parties</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:ConvertibleNotesPayableRelatedParties" scale="0" unitRef="usd">550,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd">107,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd">442,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">575,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:DebtIssuanceCosts1" scale="0" unitRef="usd">464,620</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:ConvertibleDebt1" scale="0" unitRef="usd">110,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:DebtIssuanceCosts2" scale="0" unitRef="usd">206,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:ConvertibleDebt2" scale="0" unitRef="usd">43,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total debt, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="0" unitRef="usd">597,068</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>March&#160;2022 Convertible Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&#160;2022, the Company entered into
a convertible promissory note agreement (the &#8220;March&#160;2022 Note&#8221;) and received cash proceeds of $<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCashReceivedOnHedge" scale="0" unitRef="usd">500,000</ix:nonFraction>. The March&#160;2022
Note bears interest at a rate equal to simple interest of <ix:nonFraction contextRef="c26" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure">5.0</ix:nonFraction>% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The March&#160;2022 Note is due and payable on March&#160;1, 2025, unless earlier converted or repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the March&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $<ix:nonFraction contextRef="c25" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">3.0</ix:nonFraction>&#160;million is raised.
The principal and unpaid and accrued interest of the March&#160;2022 Note at the date of conversion will be converted into shares at
a conversion price equal to <ix:nonFraction contextRef="c25" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">80</ix:nonFraction>% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the
Company consummates a Change of Control prior to repayment in full of the March&#160;2022 Note, immediately prior to the Change of Control,
the outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly
into proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is <ix:nonFraction contextRef="c25" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure">80</ix:nonFraction>% of the
price per share of common equity paid at the Change of Control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the March&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the March&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityFairValueOfCollateral" scale="0" unitRef="usd">104,883</ix:nonFraction>, with the offsetting amount being recorded as a debt discount. Debt issuance costs totaled $<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" unitRef="usd">1,460</ix:nonFraction>. The debt discount
and debt issuance costs are being amortized to interest expense using the effective interest method over the expected term of the March&#160;2022
Note. The effective interest rate of the March&#160;2022 Note is <ix:nonFraction contextRef="c26" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">12.1</ix:nonFraction>% compared to a stated interest rate of <ix:nonFraction contextRef="c25" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure">5.0</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>June&#160;2022 Convertible Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&#160;2022, the Company entered into a
convertible promissory note agreement (the &#8220;June&#160;2022 Note&#8221;) and received cash proceeds of $<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCashReceivedOnHedge" scale="0" unitRef="usd">50,000</ix:nonFraction>. The June&#160;2022
Note bears interest at a rate equal to simple interest of <ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure">6.0</ix:nonFraction>% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The June&#160;2022 Note is due and payable on June&#160;13, 2025, unless earlier converted or repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the June&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $<ix:nonFraction contextRef="c27" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">3.0</ix:nonFraction>&#160;million is raised.
The principal and unpaid and accrued interest of the June&#160;2022 Note at the date of conversion will be converted into shares at a
conversion price equal to <ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">60</ix:nonFraction>% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the Company
consummates a Change of Control prior to repayment in full of the June&#160;2022 Note, immediately prior to the Change of Control, the
outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly into
proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is <ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="cvkd:PercentageOfPriceShare" scale="-2" unitRef="pure">60</ix:nonFraction>% of the price
per share of common equity paid at the Change of Control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the June&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the June&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityFairValueOfCollateral" scale="0" unitRef="usd">29,532</ix:nonFraction>, with the offsetting amount being recorded as a debt discount. The debt discount is amortized to interest expense
using the effective interest method over the expected term of the June&#160;2022 Note. The effective interest rate of the June&#160;2022
Note is <ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">25.7</ix:nonFraction>% compared to a stated interest rate of <ix:nonFraction contextRef="c27" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure">6.0</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Boustead Private Placement Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&#160;2022, the Company issued convertible
promissory notes in the aggregate amount of $<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="0" unitRef="usd">450,000</ix:nonFraction> (the &#8220;July&#160;2022&#160;Notes&#8221;), in August&#160;2022, the Company
issued a convertible promissory note in the amount of $<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredDividendsNetOfTax" scale="0" unitRef="usd">50,000</ix:nonFraction> (the &#8220;August&#160;2022 Note&#8221;) and in September&#160;2022, the
Company issued convertible promissory notes in the aggregate amount of $<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="0" unitRef="usd">75,000</ix:nonFraction> (the &#8220;September&#160;2022 Notes&#8221;). The July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Note bear interest at <ix:nonFraction contextRef="c32" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure">6</ix:nonFraction>% and mature on <ix:nonNumeric contextRef="c32" format="ixt:date-monthname-day-year-en" name="us-gaap:InvestmentMaturityDate">September&#160;13, 2025</ix:nonNumeric> (&#8220;Maturity
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal amount due under the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes (and, at the Company&#8217;s option, any accrued but unpaid interest
under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes) will be automatically converted, on or before
the Maturity Date, into Next Equity Securities in the Next Equity Financing. The July&#160;2022 Notes, the August&#160;2022 Note and
September&#160;2022 Notes are convertible into shares of common stock at a conversion price equal to the quotient obtained by dividing
(i)&#160;the entire principal amount of the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes, plus (if
applicable) any accrued but unpaid interest under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes
by (ii)&#160;sixty percent (<ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure">60</ix:nonFraction>%) of the price per share of the Next Equity Securities sold in the Next Equity Financing. In the event
of a Change of Control which occurs prior to repayment in full of the July&#160;2022 Notes, the August&#160;2022 Note or the September&#160;2022
Notes, immediately prior to the Change of Control, the outstanding principal and any accrued but unpaid interest on the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes will convert directly into our common equity (or directly into proceeds
paid to the holders of our common equity in connection with the Change of Control) at a price per share that is <ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="cvkd:CommonEquity" scale="-2" unitRef="pure">60</ix:nonFraction>% of the price per
share of common equity paid at the Change of Control. Boustead Securities, LLC acted as the placement agent for the private placement
and received as part of its compensation and five-year warrants to purchase shares of our common stock at a price equal to the conversion
price of the Private Placement Notes in an amount equal to <ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="cvkd:CommonStock" scale="-2" unitRef="pure">6</ix:nonFraction>% of the shares of common stock underlying the Private Placement Notes. The
Company has determined that the warrants issued to the placement agent receive equity treatment. The warrants were recorded at fair value
at issuance and recorded as debt issuance costs associated with the Boustead Private Placement Notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined the redemption features
in the July&#160;2022 Notes, August&#160;2022 Note and September&#160;2022 Notes contain rights and obligations for conversion contingent
upon a potential future financing event or a change in control, and that such features are required to be bifurcated from the host debt
instrument and accounted for as a derivative liability to be remeasured at the end of each reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_16" id="_DebtDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the July, August,
and September&#160;2022 Notes contain embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives
and Hedging. The Company determined that these redemption features contained rights and obligations for conversion contingent upon a
potential future financing event or a change in control. Thus, the embedded put options were bifurcated from the face value of the July,
August and September Notes and accounted for as a derivative liabilities to be remeasured at the end of each reporting period with the
change in the fair value included in other expense, in the accompanying statements of operations and comprehensive loss. The fair value
of the put option derivative liabilities at issuance was $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityFairValueOfCollateral" scale="0" unitRef="usd">339,934</ix:nonFraction>, with the offsetting amount being recorded as a debt discount. The
debt discount is being amortized to interest expense using the effective interest method over the expected term of the July, August and
September&#160;2022 Notes. The effective interest rates of the July, August and September&#160;2022 Notes were <ix:nonFraction contextRef="c35" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">36.3</ix:nonFraction>%, <ix:nonFraction contextRef="c36" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">26.1</ix:nonFraction>%, and <ix:nonFraction contextRef="c32" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">28.8</ix:nonFraction>%,
respectively, compared to a stated interest rate of <ix:nonFraction contextRef="c34" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">6.0</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_17" id="_DebtDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Convertible Promissory Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_18" id="_DebtDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2022, the Company closed a $<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">250,000</ix:nonFraction>
note offering (the &#8220;November Private Placement&#8221;) pursuant to which the Company sold to two accredited investors units consisting
of (i) notes in the aggregate principal amount of $<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="cvkd:AggregatePrincipalsAmount" scale="0" unitRef="usd">250,000</ix:nonFraction>, which bear interest at the rate of <ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">10</ix:nonFraction>%, repayable at the earlier of the time
of the completion of the IPO or November 30, 2023 (the &#8220;November Notes&#8221;) and (ii) warrants to purchase up to an aggregate
of <ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="cvkd:AggregateShares" scale="0" unitRef="shares">250,000</ix:nonFraction> shares of common stock exercisable at $<ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per common share, which are exercisable at any time and are automatically exercised
into shares of the Company&#8217;s common stock upon the consummation of the IPO (the &#8220;November Warrants&#8221;). At the time the
November Notes and November Warrants were sold, it was intended that the principal amount of the November Notes would be repaid upon
the consummation of the IPO out of the proceeds of the November Warrants exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_19" id="_DebtDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of the November Warrants triggered
an adjustment to the conversion price of the Private Placement Notes (the July 2022, August 2022 and September 2022 Notes) to $<ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per
share, pursuant to down-round protection included in those notes. As a result of the adjustment of the conversion price of the Private
Placement Notes, the five-year warrants issued to Boustead Securities, LLC in connection with the Private Placement, were amended to
provide for the purchase of an aggregate of <ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="cvkd:AggregateShares" scale="0" unitRef="shares">11,500</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price equal to <ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="cvkd:PercentageOfExercisePrice" scale="-2" unitRef="pure">60</ix:nonFraction>% of the
initial public offering price per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_20" id="_DebtDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also issued <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">15,000</ix:nonFraction> warrants to Boustead
for the placement of the November financing. The November placement agent warrants have an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per common share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_21" id="_DebtDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022, the Company entered into amendments
to the March 2022 Note and the June 2022 Note to adjust the conversion price of the March 2022 Note and the June 2022 Note to $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per
common share. The March 2022 Note and June 2022 Note originally had a conversion price equal to <ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure">80</ix:nonFraction>% and <ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure">60</ix:nonFraction>%, respectively, of the IPO
price. While this amendment was not required, as the March 2022 Note and June 2022 did not have down-round protection like the Private
Placement Notes, the amendment was entered into to provide the investors in the March and June Notes with the same conversion price as
the Private Placement notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company incurred debt issuance costs attributed to the November
Notes, which were recorded as a debt discount.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;7. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;25, 2022, the Company into an
agreement with Phamace, LLC, a consulting firm of which Quang Pham, the Company&#8217;s Chief Executive Officer, is the sole member,
for an initial term of January&#160;25, 2022 through February&#160;28, 2022. Pursuant to the agreement, the Company shall pay the sum
of $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdministrativeFeesExpense" scale="0" unitRef="usd">115,000</ix:nonFraction> to Phamace, LLC for advisory and administrative services rendered relating to preparing the Company to launch as an operating
company, which is due and payable on September&#160;30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;25, 2022, the Company issued <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">7,500,000</ix:nonFraction>
shares of common stock, pursuant to a subscription agreement, to Quang Pham, our Chief Executive Officer, of which <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">3,000,000</ix:nonFraction> were subsequently
transferred to a related trust, of which Mr.&#160;Pham&#8217;s child is a beneficiary and Mr.&#160;Pham is the trustee with sole voting
and disposition power with respect to the shares owned by the trust, <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">1,100,000</ix:nonFraction> were subsequently transferred to friends, family and a
trust of which Mr. Pham&#8217;s child is a beneficiary, but of which Mr. Pham has no voting or disposition power, and <ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">125,000</ix:nonFraction> were transferred
to non-profit organizations. Mr.&#160;Pham paid a total of $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="0" unitRef="usd">7,500</ix:nonFraction> for such founders shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&#160;1, 2022, the Company issued a convertible
promissory note in the amount of $<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" unitRef="usd">500,000</ix:nonFraction> to John Murphy, a member of the Company&#8217;s board of directors, which bears interest at
<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="cvkd:ConcentrationRiskPercentage01" scale="-2" unitRef="pure">5</ix:nonFraction>% and matures on March&#160;1, 2025. The note is convertible into shares of Common Stock at a conversion price equal to the quotient
obtained by dividing (i)&#160;the entire principal amount of the note plus (if applicable) any accrued but unpaid interest under the
Note by (ii)&#160;eighty percent (<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="cvkd:EquityMethodInvestmentOwnershipPercentage1" scale="-2" unitRef="pure">80</ix:nonFraction>%) of the price per share of the equity securities issued and sold at the initial closing of our
next equity financing. See Note&#160;6 for further discussion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&#160;17, 2022, the Company issued <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">450,000</ix:nonFraction>
shares of restricted common stock, pursuant to a restricted stock purchase agreement, to Matthew Szot its Chief Financial Officer, which
shares shall vest quarterly over a period of two&#160;years, subject to certain adjustments, as provided in the Restricted Stock Purchase
Agreement dated May&#160;17, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2022, the Company issued a convertible
promissory note in the amount of $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" unitRef="usd">50,000</ix:nonFraction> to Glynn Wilson, a member of the Company&#8217;s board of directors, which bears interest at
<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="cvkd:ConcentrationRiskPercentage01" scale="-2" unitRef="pure">6</ix:nonFraction>% and matures on September 13, 2025. <span style="font-family: Times New Roman, Times, Serif">See Note&#160;6 for further discussion.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;8. Leases, Commitments, and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At lease inception, the Company determines if
an arrangement is an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalation,
on a straight-line basis over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 842, Leases, the Company
determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease
commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all
leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the
balance sheet, but payments are recognized as expenses on a straight-line basis over the lease term. The Company has elected not to recognize
leases with terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease qualifies as a finance lease if any of
the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company
by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise,
(iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease
payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized
to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded
as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into contracts that contain
both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company
combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such
as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed
when the event determining the amount of variable consideration to be paid occurs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance and operating lease assets and liabilities
are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount
rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing
rate based upon the available information at the lease commencement date. Operating lease assets are further adjusted for prepaid or
accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating lease ROU assets
and liabilities as of December 31, 2022 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: 10pt">Operating lease ROU assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">43,578</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">22,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Noncurrent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">21,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">43,638</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating lease expense was $<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">4,394</ix:nonFraction> for the year ended December 31,
2022. Cash paid for amounts included in the measurement of operating lease liabilities included in operating cash flows was $<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLiabilities" scale="0" unitRef="usd">4,334</ix:nonFraction> for
the year ended December 31, 2022. The remaining operating lease term was 22 months, and the operating lease discount rate was <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure">12</ix:nonFraction>% as
of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future annual lease payments under non-cancellable
operating leases as of December 31, 2022 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">26,068</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd">22,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">48,387</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd">4,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">43,638</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the
future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will
be made and such expenditures can be reasonably estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the Company&#8217;s certificate
of incorporation and bylaws, the Company indemnifies its officers and directors for certain events or occurrences, subject to certain
limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability
insurance policy that may enable it to recover a portion of any amounts paid for future claims.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;9. Stockholders&#8217; Equity and
Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Certificate of Incorporation
filed on January&#160;25, 2022, the Company was authorized to issue a total of <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction> shares of common stock with a par value of
$<ix:nonFraction contextRef="c53" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share. On December 5, 2022, the Company filed an Amended and Restated Certificate of Incorporation to increase the authorized
capital stock of the Company to <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">82,500,000</ix:nonFraction> shares, consisting of <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">75,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction contextRef="c54" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, and <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">7,500,000</ix:nonFraction>
shares of preferred stock, par value $<ix:nonFraction contextRef="c55" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, which was approved by the Company&#8217;s Board of Directors, as well as a majority
of the Company&#8217;s shareholders, on December 5, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of common stock are entitled to one vote
for each share of common stock held of record for the election of the Company&#8217;s directors and all other matters requiring stockholder
action. Holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s
Board in its discretion out of funds legally available therefor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">8,193,875</ix:nonFraction></ix:nonFraction> shares
of common stock were issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total warrants
outstanding at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Issue
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise<br/>
    Price<br/>
    Per&#160;Share </b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expiration<br/>
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    January 25, 2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>New<br/>
    Issuance</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expired</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    December&#160;31,<br/>
    2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 24%; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; width: 12%; text-align: center; text-indent: 0pt"><ix:nonNumeric contextRef="c56" name="cvkd:PlacementAgentWarrant"><span style="font-family: Times New Roman, Times, Serif">July - Sept 2022</span></ix:nonNumeric></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">3.00</ix:nonFraction></span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 14.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c57" name="cvkd:WarrantsAndRightOutstandingMaturityDate">July - Sept 2027</ix:nonNumeric> &#160;</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">11,500</ix:nonFraction></span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">11,500</ix:nonFraction></span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"><ix:nonNumeric contextRef="c59" name="cvkd:PlacementAgentWarrant"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></ix:nonNumeric></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.00</ix:nonFraction></span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c60" name="cvkd:WarrantsAndRightOutstandingMaturityDate">Nov 2027</ix:nonNumeric> &#160;</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">15,000</ix:nonFraction></span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">15,000</ix:nonFraction></span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; white-space: nowrap; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Investor
    warrants</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; white-space: nowrap; text-align: center; text-indent: 0pt"><ix:nonNumeric contextRef="c62" name="cvkd:PlacementAgentWarrant"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></ix:nonNumeric></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="white-space: nowrap; padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.00</ix:nonFraction></span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c63" name="cvkd:WarrantsAndRightOutstandingMaturityDate">Earlier of IPO or Nov 2027</ix:nonNumeric> &#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">250,000</ix:nonFraction></span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">250,000</ix:nonFraction></span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-size: 11pt; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">276,500</ix:nonFraction></span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">276,500</ix:nonFraction></span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;10. Equity-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted the Cadrenal Therapeutics,
Inc. 2022 Equity Incentive Plan, or the Initial Plan, on July&#160;11, 2022, which was later amended and restated on October&#160;16,
2022, for purposes of clarifying the application of certain of the rules of the Initial Plan to awards approved before such amendment
and restatement of the Initial Plan and to facilitate the transition to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan (the &#8220;Successor Plan&#8221;) for the issuance and approval of awards after consummation of this offering. On October&#160;16,
2022, the Board adopted and the Company&#8217;s stockholders approved the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan, or the 2022 Plan, which will be a successor to and continuation of the Initial Plan and became effective on January 19, 2023. Upon
the effectiveness of the 2022 Plan, it replaced the Initial Plan, except with respect to awards outstanding under the Initial Plan, and
no further awards will be available for grant under the Initial Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain adjustments, the maximum number
of shares of common stock that could have been issued under the Plans in connection with awards was <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">2,000,000</ix:nonFraction> shares, of which <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">810,000</ix:nonFraction>
remained available for issuance as December 31, 2022. The maximum number of shares of common stock that may be issued under the 2022
Plan will automatically increase on January&#160;1 of each calendar year for a period of <ix:nonNumeric contextRef="c0" continuedAt="cvkd_stockOptionsGrantedSharesTerm-c0_cont_1" format="ixt-sec:durwordsen" name="cvkd:stockOptionsGrantedSharesTerm">ten</ix:nonNumeric>&#160;years commencing on January&#160;1,
2023 and ending on (and including) January&#160;1, 2032, to a number of shares of common stock equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure">20</ix:nonFraction>% of the total number of shares
of common stock outstanding on December&#160;31 of the preceding calendar<ix:continuation id="cvkd_stockOptionsGrantedSharesTerm-c0_cont_1"> year</ix:continuation>; provided, however that the board of directors, or the
compensation committee, may act prior to January&#160;1 of a given calendar year to provide that the increase for such year will be a
lesser number of shares of common stock. All available shares may be utilized toward the grant of any type of award under the 2022 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Weighted average assumptions used in the Black-Scholes
model are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 87%; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
    <br/>
    2022</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.98</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c82" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">4.10</ix:nonFraction>%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">&#8212;</span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term (years)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.27</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c82" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.81</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">62.4</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c82" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">62.5</ix:nonFraction>%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;11, 2022, the Company granted stock
options to purchase <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">650,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">0.64</ix:nonFraction> per common share. The stock option grants were issued
to directors, members of the Scientific Advisory Board, and other consultants to the Company and vest in periods ranging from <span style="-sec-ix-hidden: hidden-fact-46">one</span> to
<span style="-sec-ix-hidden: hidden-fact-47">three</span>&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued stock
options to purchase <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">300,000</ix:nonFraction> shares of common stock to our Chief Medical Officer. The options have an exercise price of $<ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">0.64</ix:nonFraction> per common
share and will vest quarterly over a period of <span style="-sec-ix-hidden: hidden-fact-48">three</span>&#160;years, subject to certain adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company granted
stock options to purchase <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">100,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">0.64</ix:nonFraction> per common share. The stock option grants were
issued to members of the Scientific Advisory Board and vest over <span style="-sec-ix-hidden: hidden-fact-49">three</span>&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Activity under the Plans for the period from
January&#160;25, 2022 (inception) to December&#160;31, 2022 is set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average <br/> Exercise Price <br/> Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Outstanding at January&#160;25, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -10pt; padding-left: 20pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">1,100,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.84</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="cvkd:WeightedAverageRemainingContractualLifeYearsGranted">9.57</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares">4,578,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Canceled/forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding at December&#160;31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,100,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.84</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.57</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">4,578,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable at December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" unitRef="shares">108,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">9.55</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">427,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and expected to vest as of December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">1,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">9.57</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" unitRef="usd">4,578,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted to date was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">1.11</ix:nonFraction>. At December&#160;31, 2022, the Company had $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">1,048,151</ix:nonFraction> of unrecognized stock-based compensation expense
related to stock options which will be recognized over the weighted average remaining requisite service period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">2.2</ix:nonNumeric>&#160;years. The
Company settles employee stock option exercises with newly issued shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;11, 2022, the Company issued restricted
stock of <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">46,875</ix:nonFraction> shares of common stock to a consultant. These shares fully vested on October&#160;1, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">40,000</ix:nonFraction>
shares of common stock to a consultant. These shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">40,000</ix:nonFraction>
shares of common stock to Steven Zelenkofske, a director, for recruiting services performed. These shares were fully vested upon the
date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;16, 2022, the Company issued
<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of common stock to John Murphy, a director. These shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;3, 2022, the Company issued <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">137,000</ix:nonFraction>
shares of common stock to various consultants for services rendered. <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares">70,000</ix:nonFraction> of the shares were subsequently returned and canceled. These
shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;3, 2022, the Company issued stock
options to purchase <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of common stock to a director. The options have an exercise price of $<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per common share and vest
over a three-year period, with <ix:nonFraction contextRef="c78" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure">33.33</ix:nonFraction>% vesting on the first anniversary of the effective date, and thereafter 1/36 on a monthly basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total stock compensation expense for the period
from January&#160;25, 2022 (inception) to December&#160;31, 2022 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:StockCompensationExpense" scale="0" unitRef="usd">928,049</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The allocation of stock-based compensation for
the period presented below was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">791,247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">136,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:EmployeeBenefitAndShareBasedCompensation" scale="0" unitRef="usd">928,049</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;11. Net Loss Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of the basic and diluted net loss per common share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Weighted average common shares outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">7,890,507</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><div style="-sec-ix-hidden: hidden-fact-50">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.85</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company was in a loss position for
the period presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities
would have been anti-dilutive. For the period from inception to December&#160;31, 2022, there were no potential dilutive securities other
than the convertible notes, stock options, and warrants.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 12. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s income (loss) before provision
(benefit) for income taxes for the period ended December 31, 2022 was generated in the following jurisdictions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" sign="-" unitRef="usd">6,714,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s provision is $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" unitRef="usd">0</ix:nonFraction>, which is
primarily driven by the federal and state statutory income tax rates on current year losses, offset by the Company&#8217;s full valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of income tax expense (benefit)
were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 20pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total current provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of income tax expense to the
amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the period ended December
31, 2022, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax benefit at statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">1,410,009</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State benefit, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd">263,978</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:IncometaxPermanentDifferences" scale="0" unitRef="usd">8,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">125,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="0" unitRef="usd">1,003,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Increase in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">536,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the net tax effects
of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December 31, 2022 are shown
below. The Company has established a full valuation allowance against net deferred tax assets due to the uncertainty that such assets
will be realized. The Company periodically evaluates the recoverability of its deferred tax assets. At such time as it is determined
that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The increase in
the valuation allowances of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" unitRef="usd">479,000</ix:nonFraction> for the period from January&#160;25, 2022 (inception) to December 31, 2022 was primarily due to
the Company&#8217;s net operating losses and basis differences in intangible assets generated during the current year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of deferred tax assets and liabilities
consisted of the following at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">298,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd">44,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Capitalized research costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="0" unitRef="usd">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Accruals and other temporary differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" unitRef="usd">135,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">532,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd">53,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">479,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company has net
operating loss carryforwards of approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">1.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" unitRef="usd">1.2</ix:nonFraction> million available to reduce future taxable income, if any, for federal
and state income tax purposes, respectively. The Company&#8217;s US federal and state net operating loss carryovers can be carried forward
indefinitely, but the deduction related to these net operating losses is limited to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">80</ix:nonFraction>% of taxable income when utilized in future&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The utilization of net operating loss carryforwards
and tax credit carryovers could be subject to annual limitations under Section&#160;382 and 383 of the Internal Revenue Code of 1986,
and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future.
These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset
future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382 and 383, results from transactions
increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over
a three-year period. The Company has not conducted an analysis of an ownership change under section 382. To the extent that a study is
completed and an ownership change is deemed to occur, the Company&#8217;s net operating losses and tax credits could be limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the two-step approach to
recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the
weight of available evidence indicates it is more likely than not that the position will be sustained upon audit, including resolution
of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more
than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" unitRef="pure">50</ix:nonFraction>% likely of being realized upon ultimate settlement. Income tax positions must meet a more likely than not recognition threshold
to be recognized under ASC&#160;740 upon initial measurement and in subsequent periods. ASC&#160;740-10 also provides guidance on measurement,
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2022, the Company did not have
any significant uncertain tax positions. The Company will recognize interest and penalties related to uncertain tax positions in income
tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts
have been recognized in the Company&#8217;s statement of operations and comprehensive loss. The Company does not anticipate a material
change to unrecognized tax benefits in the next twelve&#160;months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the Company&#8217;s tax&#160;years will
remain open for examination by the federal and state taxing authorities to the extent that the Company&#8217;s tax attributes are utilized
in future&#160;years to offset income or income taxes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"><b>Note&#160;13.
Subsequent Events</b></p></ix:nonNumeric><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">The Company
has evaluated events that occurred through March 29, 2023, the date that the financial statements were issued and determined that there
have been no events that have occurred that would require adjustments to our disclosures in the financial statements except for the transactions
described below:</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, the Company consummated its initial public offering (the &#8220;IPO&#8221;) of <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,400,000</ix:nonFraction> shares of its common stock at a public
offering price of $<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share, generating gross proceeds of $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="cvkd:GeneratingGrossProceed" scale="0" unitRef="usd">7,000,000</ix:nonFraction>. The Company&#8217;s shares of common stock commenced trading
on the Nasdaq Capital Market on January 20, 2023, under the symbol &#8220;CVKD.&#8221;</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">In connection
with the IPO, on January 19, 2023, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
Boustead Securities, LLC, as representative of the underwriters (the &#8220;Representative&#8221;).&#160;Pursuant to the Underwriting
Agreement, the Company agreed to issue to the underwriters a five-year warrant (the &#8220;Representative&#8217;s Warrant&#8221;) to
purchase an aggregate of <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cvkd:PurchaseAggregateShares" scale="0" unitRef="shares">84,000</ix:nonFraction> shares of the Company&#8217;s&#160;common stock, which is equal to six percent (<ix:nonFraction contextRef="c21" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" unitRef="pure">6</ix:nonFraction>%) of the shares of
common stock sold in the IPO. Such Representative&#8217;s Warrant has an exercise price of $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">6.00</ix:nonFraction>, which is equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cvkd:PublicOfferingPricePercentage" scale="-2" unitRef="pure">120</ix:nonFraction>% of the public
offering price of the common stock in the IPO.</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_5" id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
19, 2023, the Company issued <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">600,000</ix:nonFraction> shares of common stock to HESP LLC, pursuant to the terms of an Amendment to the Asset Purchase
Agreement, dated August 18, 2022, between the Company and HESP LLC. The Company recognized the payment of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd">3.0</ix:nonFraction>&#160;million as research
and development expense in January 2023. See Note 5 for further discussion.</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_6" id="_SubsequentEventsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, concurrent with the consummation of the IPO, the Company issued <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">1,140,700</ix:nonFraction> shares of common stock upon conversion of the convertible
promissory notes. See Note 6 for further discussion.</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_7" id="_SubsequentEventsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, the Company issued <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">250,000</ix:nonFraction> shares of common stock upon the exercise of the November Warrants. The $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">250,000</ix:nonFraction> of proceeds of the
warrant exercise were used to pay off the $<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd">250,000</ix:nonFraction> November Notes. See Note 6 for further discussion.</p></ix:continuation><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">After the closing of the IPO, the Company granted
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cvkd:SharesOfCommonStock" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of the Company&#8217;s common stock to the Company&#8217;s Chief Financial Officer.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure.</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9A. Controls and Procedures.</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our
Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December
31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act,
means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in
the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing
similar functions, as appropriate to allow timely decisions regarding required disclosure. We have adopted and maintain disclosure controls
and procedures (as defined Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that
information required to be disclosed in the reports filed under the Exchange Act, such as this Annual Report, is collected, recorded,
processed, summarized, and reported within the time periods specified in the rules of the SEC. Our disclosure controls and procedures
are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required
disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief
Executive Officer and Chief Financial Officer concluded that, as of such a date, our disclosure controls and procedures were effective
at the reasonable assurance level.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Report on Internal Control over Financial Reporting</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by SEC rules and regulations implementing
Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control over financial
reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. GAAP. Our
internal control over financial reporting includes those policies and procedures that:</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of our company,</td>
</tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being
made only in accordance with authorizations of our management and directors, and</td>
</tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">provide reasonable assurance regarding the prevention or timely detection of unauthorized
                                                                                  acquisition, use or disposition of our assets that could have a material effect on the financial statements.</td>
</tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect errors or misstatements in our financial statements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of
our internal control over financial reporting as of December 31, 2022. In making these assessments, management used the criteria set forth
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based
on our assessments and those criteria, management determined that our internal controls over financial reporting were effective as of
December 31, 2022.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">This Annual Report does not include an attestation report of internal
controls from our independent registered public accounting firm due to our status as an emerging growth company under the JOBS Act.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended December 31, 2022, there were no changes in
our internal control over financial reporting (as defined in Rules 13a 15(f) and 15d 15(f) of the Exchange Act) that occurred that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Report of Independent Registered Public Accounting Firm</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report does not include an attestation
report by WithumSmith+Brown, PC, our independent registered public accounting firm, regarding internal control over financial reporting.
As a smaller reporting company, our internal control over financial reporting was not subject to audit by our independent registered public
accounting firm pursuant to rules of the SEC that permit us to provide only management&#8217;s report.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9B. Other Information.</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Item 9C. Disclosure
Regarding Foreign Jurisdictions that Prevent Inspections.</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Not Applicable.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 99; Options: NewSection; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="c_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. Directors, Executive Officers and
Corporate Governance.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information About our Executive Officers and Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information concerning our directors
and executive officers, including their ages, as of March 14, 2023. There are no family relationships among any of our directors or executive
officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 33%; padding-right: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 5%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 60%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive Officers and Directors</i></b></span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Szot</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas Losordo</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee Directors</i></b></span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John R. Murphy</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Zelenkofske</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glynn Wilson</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 170.8pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 170.8pt 0pt 0; text-align: justify"><b><i>Quang Pham, Chairman and Chief
Executive Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quang Pham has served as our Chief Executive Officer
since he formed the Company on January 25, 2022. He previously served as Chief Executive Officer, Chairman of the Board of Directors and
founder of Espero BioPharma, Inc. (&#8220;Espero&#8221;), the previous sponsor of the tecarfarin IND, since its formation in March 2015
until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking
an assignment of Espero&#8217;s assets. He then served as a consultant to HESP LLC, the assignee of Espero, from July 2020 until December
2021. From February 2012 to August 2015, Mr. Pham was a partner with D+R LATHIAN, LLC, a life sciences multichannel marketing agency.
Prior to joining D+R LATHIAN, he founded and served as Chairman and Chief Executive Officer of Lathian Systems, Inc., a digital and database
marketing company serving the pharmaceutical industry from 2000 until 2003 and from 2008 until 2012 when the company was acquired by D&amp;R
Communications, LLC in February 2012. He has a Bachelor of Arts in Economics from UCLA, and served as a U.S. Marine Corps Officer. We
believe Mr. Pham is qualified to serve on our Board of Directors because of his significant business, mergers and acquisitions, and fundraising
experience, numerous interactions with the FDA, continuous five-year history with tecarfarin development, and his extensive knowledge
of the pharmaceutical industry and our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Matthew Szot, Chief Financial Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Matthew Szot has served as our Chief Financial
Officer since May 2022. From March 2010 to November 2021, Mr. Szot served as Executive Vice President and Chief Financial Officer of S&amp;W
Seed Company, a Nasdaq-listed agricultural seed biotechnology company. Since September 2020, Mr. Szot has served on the Board of Directors
and as Chairman of the Audit and Compensation Committees of INVO Bioscience, Inc., a Nasdaq-listed commercial-stage fertility company.
He also serves on the Board of Directors and serves as Vice-Chairman of the Board and as Chairman of the Audit Committee of SenesTech,
Inc., a Nasdaq-listed life science company with next-generation technologies for managing animal pest populations through fertility control.
From June 2018 to August 2019, Mr. Szot served on the Board of Directors and as Chairman of the Audit Committee of Eastside Distilling,
a Nasdaq-listed craft spirits company. From 2007 until 2011, Mr. Szot served as the Chief Financial Officer for Cardiff Partners, LLC,
a strategic consulting company that provided executive financial services to various publicly traded and privately held companies. From
2003 to 2006, he served as Chief Financial Officer of Rip Curl, Inc., a market leader in wetsuit and action sports apparel products. From
1996 to 2003, Mr. Szot was a Certified Public Accountant with KPMG in the San Diego and Chicago offices and served as an Audit Manager
for various publicly traded companies. Mr. Szot graduated from the University of Illinois, Champaign-Urbana with a BS in Agricultural
Economics/Accountancy. He is a Certified Public Accountant in the State of California. Mr. Szot brings a wealth of knowledge in mergers
and acquisitions, corporate strategy, equity and debt financings, corporate governance, SEC reporting and compliance, and developing and
implementing financial and operational workflows and process improvements. He also has extensive experience in international operations,
joint ventures, and technology license agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Douglas Losordo, M.D., Chief Medical Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Douglas Losordo has served as our Chief Medical
Officer since August 8, 2022. Dr. Losordo has worked in the biotech industry developing cell-based therapies for over twenty years. Since
February 2021, he has served on the Board of Directors of Longeveron Inc., a clinical-stage biotechnology company developing cellular
therapies for aging-related and life-threatening conditions. Dr. Losordo also served as Global Head Clinical Development and Operations
of American Regent, Inc., a clinical development pharmaceutical company from June 2021 until August 2022. Prior thereto he served as Chief
Medical Officer of KBP Biosciences Co., Ltd., a biotechnology research and development company, from November 2020 until June 2021 and
as Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences, a clinical-stage
biopharmaceutical company dedicated to the development of cellular therapies designed to reverse chronic disease, from August 2013 until
November 2020. Dr. Losordo has extensive knowledge of clinical, regulatory, manufacturing, supply chain and commercial factors unique
to cellular therapy technologies as a result of his prior industry experience. Dr. Losordo also previously served as a Professor of Medicine
at NYU Langone Medical Center and Northwestern University&#8217;s Feinberg School of Medicine. He received his MD from the University
of Vermont College of Medicine, and his B.A. in Zoology from the University of Vermont.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Steven Zelenkofske, D.O.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Steven Zelenkofske has served on our Board
of Directors since January 19, 2023, upon the effectiveness of the Registration Statement. Dr. Zelenkofske has served on the Board of
Directors of Dinaqor AG since May 2020. He has served as Chief Medical Officer of SwanBio Therapeutics since June 1, 2020. Dr. Zelenkofske
is also an advisor to Veralox Therapeutics, Inc., as Chair of the Scientific Advisory Board, a position he has held since March 2020.
Previously, he served as Executive Vice President and Chief Medical Officer of Achillion Pharmaceuticals, Inc. from August 2018 until
April 2020. Dr. Zelenkofske also served as Chief Medical Officer of uniQure N.V., from June 2017 to August 2018. Prior to joining uniQure,
N.V., Dr. Zelenkofske was Vice President and Therapeutic Head of Cardiovascular/Metabolism for AstraZeneca, a biopharmaceutical company,
from November 2014 to June 2017. From January 2009 to November 2014, Dr. Zelenkofske was Senior Vice President Clinical and Medical Affairs
and Chief Medical Officer of Regado Biosciences, Inc., a biotechnology company. Dr. Zelenkofske has held leadership positions at Sanofi-Aventis,
Boston Scientific, a medical device company, and Novartis Pharmaceuticals, a global healthcare company. Dr. Zelenkofske holds Bachelor
of Science and Master of Science degrees from Emory University and a Doctor of Osteopathic Medicine degree from the Philadelphia College
of Osteopathic Medicine. He conducted his graduate medical education at the Philadelphia College of Osteopathic Medicine and is board-certified
in internal medicine, cardiology and cardiac electrophysiology. We believe that Dr. Zelenkofske&#8217;s knowledge and experience working
in the biotech and pharmaceutical space will assist us as we work to complete our drug development and commercialization activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>John R. Murphy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">John R. Murphy has served on our Board of Directors
since January 19, 2023, upon the effectiveness of the Registration Statement. Since 2003, John R. Murphy has served on the Board of Directors
of O&#8217;Reilly Automotive, Inc., where he served as Chairman of the Audit Committee from 2003 until 2019. Currently, he serves on the
Audit Committee and Human Capital and Compensation Committee (Chair). Mr. Murphy has also served on the Board of Directors of Summit Materials,
Inc. since 2012, where he is currently the Chair of the Audit Committee. Previously he served as a Director, Audit Committee Chairman,
and Member of the Nominating and Governance Committee of Apria, Inc. (&#8220;Apria&#8221;) from August 2019 until April 2022. He also
served on the Board of Directors of Alight Solutions LLC and Audit Committee Chairman from February 2020 until May 2022 and DJO Global,
Inc. from 2012 until March 2019. Mr. Murphy also previously served on the Board of Directors of Graham Packaging, Inc. and Accuride Corporation,
Inc. He previously served as Interim Chief Financial Officer of Summit Materials, Inc. in 2013, Senior Vice President and Chief Financial
Officer of Smurfit-Stone Container Corporation from 2009 to 2010, and Chief Financial Officer, then President and Chief Operating Officer,
then President and Chief Executive Officer with Accuride Corporation, Inc. from 1998 to 2008. Mr. Murphy holds a Bachelor of Science in
Accounting from Pennsylvania State University and a Master of Business Administration from the University of Colorado, and is a Certified
Public Accountant. We believe Mr. Murphy&#8217;s substantial experience guiding public company boards and knowledge and experience as
chief financial officer will assist us in navigating the public reporting process when we become a public reporting company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Glynn Wilson, Ph.D.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Glynn Wilson has served on our Board of Directors
since January 19, 2023, upon the effectiveness of the Registration Statement. He has served on the Board of Directors of Jupiter Wellness,
Inc. (&#8220;Jupiter&#8221;) since November 2018, serving as Chairman since October 2019. Dr. Wilson also serves as Jupiter&#8217;s Chief
Scientific Officer since April 2021 and served as its Head of Research and Development from October 2019 to July 2021. Dr. Wilson previously
served as a Director of TapImmune, Inc. from February 2005 until October, 2018 and as Chief Executive Officer from July 2009 through September
2017. Dr. Wilson also served as President of Auriga Laboratories, Inc. from June 1, 2005 through March 13, 2006, and as Chief Scientific
Officer from March 13, 2016 through August 25, 2006. He was the Chief Scientific Officer at Tacora Corporation from 1994 to 1997 and was
the Vice-President, R&amp;D, at Access Pharmaceuticals from 1997 to 1998. Dr. Wilson was Research Area Head, Cell and Molecular Biology
in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals from 1984 &#8211; 1989 and Worldwide Head of Drug Delivery at SmithKline Beecham
from 1989 to 1994. He was a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Sanford Moore
and William Stein, from 1974 to 1979. Dr. Wilson is a recognized leader in the development of drug delivery systems and has been involved
in taking lead products &amp; technologies from concept to commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Wilson has a Ph. D. in Biochemistry and conducted
medical research at The Rockefeller University, New York. We believe that Dr. Wilson&#8217;s extensive background of success in corporate
management and product development, with tenures in both multinational and start-up biotech organizations, will assist us as we work to
complete our drug development and commercialization activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Selection of Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers serve at the discretion
of our Board of Directors. There are no familial relationships among our directors and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Composition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our amended and restated certificate
of incorporation, our Board of Directors is divided into three classes &#8212; Class I, Class II, and Class III &#8212; with each class
serving staggered three-year terms and subject to the terms of our amended and restated certificate of incorporation and amended and restated
bylaws, our Board of Directors consists of four members, as a classified board of directors. As a result, only one class of directors
will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year
terms. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders
to be held during 2023 for the Class I directors, 2024 for the Class II directors and 2025 for the Class III directors. Our directors
are divided among the three classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Class I directors are Quang Pham and Glynn Wilson and
their terms will expire at the annual meeting of stockholders to be held in 2023;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Class II director is John Murphy and his term will expire
at the annual meeting of stockholders to be held in 2024; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Class III director is Steven Zelenkofske and his term
will expire at the annual meeting of stockholders to be held in 2025.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon expiration of the term of a class of directors,
new directors for that class will be elected for three-year terms at the annual meeting of stockholders during the year in which that
term expires. Each director&#8217;s term shall continue until the election and qualification of his or her successor, or the director&#8217;s
earlier death, resignation or removal. Any additional directorships resulting from an increase in the number of authorized directors will
be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The classification of our Board of Directors may
have the effect of delaying or preventing a change of our management, a change of control or other corporate actions. Under Delaware law,
our amended and restated certificate of incorporation our directors may be removed only for cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principal Investigator</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sean Pokorney, M.D.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sean Pokorney has been designated as our Principal
Investigator. Dr. Pokorney is a cardiologist, electrophysiologist and researcher specializing in patients with ESRD and AFib. He is an
Assistant Professor of Medicine at Duke University and is a member of the Duke Clinical Research Institute. We entered into a Scientific
Advisory Board and Consulting Agreement with Dr. Pokorney (&#8220;Pokorney Agreement&#8221;), dated June 15, 2022, which provides that
he shall be granted stock options, pursuant to the Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan, to purchase 100,000 shares
of our Common Stock at an exercise price per share equal to the fair market value per share of the Company&#8217;s Common Stock on the
date of the grant, which stock options will vest over a three-year vesting schedule. The Pokorney Agreement further provides that we shall
pay Dr. Pokorney at the rate of $650 per hour for services that exceed the scope of work of general members of the Scientific Advisory
Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board (SAB)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend that our Scientific Advisory Board will
work with our management team in planning, developing and executing further scientific, clinical, and research and development initiatives
and strategies. Our scientific advisory board is comprised of the following individuals, who have significant experience in the field
of cardiovascular medicine:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Christopher Granger, MD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Professor of Medicine in the Division of Cardiology at Duke
University</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Director of Cardiac Care Unit for Duke University Medical
Center</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Member, Duke Clinical Research Institute (DCRI)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. Michael Gibson, MS, MD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">CEO of not-for profit Baim/PERFUSE Research Institutes</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Harvard University Professor</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Cardiologist at Beth Israel Deaconess Medical Center of Boston</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Founder and Chairman WikiDoc.org</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Richard Whitlock, MD, PhD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Cardiac Surgeon and Associate Professor at Population Health
Research Institute, McMaster University Medical Center</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Investigator, Population Health Research Institute</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. Michael Lincoff, MD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Vice Chairman, Department of Cardiovascular Medicine, Cleveland
Clinic</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Director of Clinical Research, Lerner Research Institute</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wolfgang C. Winkelmayer, MD, MPH, ScD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Chief, Section of Nephrology and Professor of Medicine, Baylor
College of Medicine</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Director, Selzman Institute for Kidney Health at Baylor College
of Medicine</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Elaine Hylek, MD, MPH</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Professor of Medicine at the Boston University School of
Medicine</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Director, Thrombosis and Anticoagulation Service at Boston
Medical Center</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Researcher focused on anticoagulation and stroke prevention
in AFib</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the rules of the Nasdaq Stock Market, independent
directors must comprise a majority of our Board of Directors. The rules of the Nasdaq Stock Market, as well as those of the SEC, impose
several requirements with respect to the independence of our directors. Our Board of Directors has conducted a review of its proposed
composition, the composition of its proposed committees and the independence of each director in accordance with these rules. Based upon
information requested from and provided by each director concerning his or her background, employment and affiliations, including family
relationships, our Board of Directors has determined that John R. Murphy, Dr. Steven Zelenkofske, and Dr. Glynn Wilson do not have relationships
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these
directors is &#8220;independent&#8221; as that term is defined under the rules of the Nasdaq Stock Market and the SEC. In making this
determination, our Board of Directors considered relationships that each director has with the Company, including the transactions described
under the section entitled &#8220;Certain Relationships and Related Party Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Controlled Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quang Pham, our Chief Executive Officer, beneficially
owns shares representing more than 50% of the voting power of our shares eligible to vote in the election of directors. As a result, we
are a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of the Nasdaq. Under these corporate governance
standards, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled
company&#8221; and may elect not to comply with certain corporate governance standards, including the requirements (1) that a majority
of our board of directors consist of independent directors, (2) that our board of directors have a compensation committee that is comprised
entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (3) that our
board of directors have a nominating and governance committee that is comprised entirely of independent directors with a written charter
addressing the committee&#8217;s purpose and responsibilities. At this time we do not intend to utilize any of these exemptions; however
they will be available to us should we choose to avail ourselves of any of the exemptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors has established an audit
committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and responsibilities
described below. Each committee operates under a written charter, that satisfies the applicable rules of the SEC and the listing standards
of the Nasdaq Stock Market. Members will serve on these committees until their resignation or until otherwise determined by our Board
of Directors. From time to time, our Board of Directors may establish other committees to facilitate the management of our business as
it sees fit and in accordance with applicable law and our corporate governance documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors has a standing Audit Committee,
Compensation Committee, and Nominating&#160;and Governance Committee. The following table shows the directors who are currently members
or Chairman of each of these committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-right: 0.75pt; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Members</b></span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; width: 3%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit<br/>
Committee</b></span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center; width: 3%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation<br/>
Committee</b></span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center; width: 3%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating<br/>
and<br/>
Governance<br/>
Committee</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</span></td>
    <td style="vertical-align: bottom; padding-right: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Murphy</span></td>
    <td style="vertical-align: bottom; padding-right: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Zelenkofske</span></td>
    <td style="vertical-align: bottom; padding-right: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glynn Wilson</span></td>
    <td style="vertical-align: bottom; padding-right: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 402pt 0pt 59.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee. </i></b>Our Audit Committee
consists of John Murphy, Dr. Steven Zelenkofske and Dr. Glynn Wilson, with John Murphy serving as the Chair of the Audit Committee. Our
Board of Directors has determined that all of the directors who will serve on our Audit Committee are independent within the meaning of
the rules and regulations of the Nasdaq Stock Market and Rule 10A-3 under the Exchange Act. In addition, our Board of Directors has determined
that John Murphy qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication
requirements of the Nasdaq Stock Market. The primary purpose of the audit committee is to oversee the quality and integrity of our accounting
and financial reporting processes and the audit of our financial statements. Specifically, the audit committee will:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">select and hire the independent registered public accounting
firm to audit our financial statements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">help to ensure the independence and performance of the independent
registered public accounting firm;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">approve audit and non-audit services and fees;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review financial statements and discuss with management and
the independent registered public accounting firm our annual audited and quarterly financial statements, the results of the independent
audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure
controls;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">prepare the audit committee report that the SEC requires
to be included in our annual proxy statement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review reports and communications from the independent registered
public accounting firm;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review the adequacy and effectiveness of our internal controls
and disclosure controls and procedure;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review our policies on risk assessment and risk management;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review and approve related party transactions; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">establish and oversee procedures for the receipt, retention
and treatment of accounting related complaints and the confidential submission by our employees of concerns regarding questionable accounting
or auditing matters.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee. </i></b>Our Compensation
Committee consists of Dr. Steven Zelenkofske and John Murphy, with Dr. Steven Zelenkofske serving as the Chair of the Compensation Committee.
Our Board of Directors has determined that all of the directors who will serve on our compensation committee are independent under the
listing standards, are &#8220;non-employee directors&#8221; as defined in rule 16b-3 promulgated under the Exchange Act and are &#8220;outside
directors&#8221; as that term is defined in Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Our compensation
committee oversees our compensation policies, plans and benefits programs. The compensation committee will also:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">oversee our overall compensation philosophy and compensation
policies, plans and benefit programs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review and recommend to our board of directors for approval
compensation for our executive officers and directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">prepare the compensation committee report that the SEC would
require to be included in our annual proxy statement if we were no longer deemed to be an emerging growth company or a smaller reporting
company; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">administer our equity compensation plans.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee.
</i></b>Our Nominating and Corporate Governance Committee consists of Dr. Glynn Wilson and Dr. Steven Zelenkofske, with Dr. Glynn Wilson
serving as the Chair of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee will oversee
and assist our Board of Directors in reviewing and recommending nominees for election as directors. All members who will serve on the
Nominating and Corporate Governance Committee are independent directors as defined under the listing standards of the Nasdaq Stock Market.
Specifically, the corporate governance and nominating committee will:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">identify, evaluate and make recommendations to our board
of directors regarding nominees for election to our board of directors and its committees, including consideration of recommendations
for election to the Board of Directors by stockholders if submitted in a timely manner in accordance with the procedures set forth in
our bylaws;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">consider and make recommendations to our board of directors
regarding the composition of our board of directors and its committees;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review developments in corporate governance practices;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">evaluate the adequacy of our corporate governance practices
and reporting; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">evaluate the performance of our board of directors and of
individual directors.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee Interlocks and Insider
Participation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No member of our Compensation Committee will be
serving, or will have ever served, as an officer or employee of ours. None of our executive officers currently serves, or has served during
the last completed year, as a member of the Board of Directors, Compensation Committee or other board committee performing equivalent
functions of any entity that has one or more executive officers who served as a member of our Board of Directors during the last completed
year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a code of business conduct and
ethics that is applicable to all of our employees, officers and directors. The full text of our code of business conduct and ethics will
be available on our website at <i>www.cadrenal.com</i>. If we amend or grant any waiver from a provision of our code of ethics that applies
to our directors or executive officers, we will publicly disclose such amendment or waiver on our website and as required by applicable
law, including by filing a Current Report on Form 8-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitation of Liability and Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws provide indemnification
for our directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law. The indemnification
agreements that we have entered into with each of our current executive officers and directors may, in some cases, be broader than the
specific indemnification provisions contained under Delaware law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as permitted by Delaware law, our
amended and restated certificate of incorporation includes provisions that eliminate the personal liability of our directors and officers
for monetary damages resulting from breaches of certain fiduciary duties as a director or officer, as applicable, except to the extent
such an exemption from liability thereof is not permitted under the Delaware General Corporation Law. The effect of these provisions is
to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director or officer
for breach of fiduciary duties as a director or officer, subject to certain exceptions in which case the director or officer would be
personally liable. An officer may not be exculpated for any action brought by or in the right of the corporation. A director may not be
exculpated for improper distributions to stockholders. Further, pursuant to Delaware law a director or officer may not be exculpated for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any breach of his or her duty of loyalty to us or to our
stockholders;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">acts or omissions not in good faith or that involve intentional
misconduct or a knowing violation of law; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any transaction from which the director or officer derived
an improper personal benefit.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Delaware law is amended to authorize corporate
action further eliminating or limiting the personal liability of directors and officers, then the liability of our directors and officers
will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our certificate of incorporation does not
eliminate the duty of care owed by our directors and officers and, in appropriate circumstances, equitable remedies, such as injunctive
or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect the responsibilities of
directors and officers under any other laws, such as the federal securities laws or other state or federal laws. Under our amended and
restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of an action or proceeding by or in
the right of our company or any of our subsidiaries, no indemnification will be provided for any claim where a court determines that the
indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions are necessary to attract
and retain qualified persons as directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing
a lawsuit against directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation
against directors and officers, even though an action, if successful, might benefit us and our stockholders. Moreover, a stockholder&#8217;s
investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these
indemnification provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or
otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which
indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification
by any director or officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with each of our current executive officers and intend to enter, into separate indemnification agreements with each of our
directors and executive officers, in addition to the indemnification that will be provided for in our amended and restated bylaws. The
indemnification agreements and our amended and restated bylaws require us to indemnify our directors and executive officers to the fullest
extent permitted by Delaware law. See the section titled &#8220;Description of Securities &#8212; Limitations on Liability and Indemnification
of Officers and Directors&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="c_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. Executive Compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our named executive officers for the year ended
December 31, 2022, which consist of our principal executive officer and the next most highly compensated executive officers, are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Quang Pham, Chairman and Chief Executive Officer</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Matthew Szot, Chief Financial Officer</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Douglas Losordo, Chief Medical Officer</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows compensation awarded
to or earned by our named executive officers, for the period from January 25, 2022 (inception) to December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Award<br/> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<br/> Incentive<br/> Plan<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33.5%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham<br/> <i>Chief Executive Officer</i><sup>(6)</sup></span></td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">350,000</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">337,500</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">128,723</td><td style="width: 0.5%; text-align: left"><sup>(3)</sup></td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 8%; text-align: right">816,223</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Szot<br/> <i>Chief Financial Officer</i><sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">187,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">172,105</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">359,605</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas Losordo<br/> <i>Chief Medical Officer</i><sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">625,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23,360</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">648,560</td><td style="text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Bonuses were accrued as of December 31, 2022, but such bonuses
were paid in February 2023.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">In accordance with SEC rules, this column reflects the aggregate
fair value of the stock and option awards granted as of their respective grant dates in accordance with Financial Accounting Standard
Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (ASC 718). The valuation assumptions used
in determining such amounts are described in Note 1 and Note 10 to our audited financial statements included elsewhere in this Annual
Report. These amounts do not correspond to the actual value that may be realized by the Named Executive Officers upon vesting or exercise
of such awards.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">All other compensation for Mr. Pham includes $115,000 of
accrued but unpaid consulting fees due to Phamace, LLC, a consulting firm of which Quang Pham, our Chief Executive Officer, is the sole
member. Other compensation also includes $13,723 for the cost of his monthly premiums for health insurance.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Amount represents Mr. Szot&#8217;s monthly consulting fee
of $22,500 from May 17, 2022 through December 31, 2022 plus $2,836 of premiums for health insurance.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Amount represents Mr. Losordo&#8217;s consulting fees from
August 8, 2022 through December 31, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Mr. Pham became our Chief Executive Officer on January 25,
2022 (inception).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(7)</td><td style="text-align: justify">Mr. Szot became our Chief Financial Officer on May 17, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(8)</td><td style="text-align: justify">Mr. Losordo became our Chief Medical Officer on August 8,
2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreements with Our Named Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Quang Pham Employment Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into an employment agreement with Quang
Pham, our Chief Executive Officer, on March 1, 2022. Mr. Pham&#8217;s employment is at-will. Mr. Pham&#8217;s annual base salary pursuant
to the employment agreement was initially $420,000, which increased to $675,000 upon the completion of our initial public offering. Mr.
Pham is eligible for an annual target bonus of up to 50% of his base salary, with the actual amount of the bonus, if any, based upon the
achievement by Mr. Pham and us of the applicable performance targets and goals as set by our board of directors or our compensation committee,
with individual performance targets determined in consultation with Mr. Pham. A bonus of $337,500 was paid to Mr. Pham in February 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Mr. Pham&#8217;s employment agreement,
we will need to provide 90 days&#8217; written notice to terminate his employment without cause. If Mr. Pham resigns for Good Reason,
as such term is defined in the employment agreement, or is terminated without cause (as such terms are defined below), he is entitled
to (i) a lump sum payment equal to 24 months of his base salary, (ii) a lump sum payment equal to his target bonus for the calendar year
in which his termination date occurs, (iii) full acceleration of any outstanding equity or equity-based awards that he has with respect
to us or any of our affiliates as of his termination date, (iv) extension of exercisability for the full term of any stock option, and
(v) payment of his full COBRA premiums for 24 months following his termination date, if applicable conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Pham is required to provide us 90 days&#8217;
written notice of the condition that qualifies as a Good Reason for his resignation and we will have 30 days from receipt of such notice
to remedy such condition. If Mr. Pham fails to provide the required notice such that we have the opportunity to cure the condition prior
to his resignation, or if he resigns more than nine months after the initial existence of the condition, his resignation shall not be
deemed for Good Reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we terminate Mr. Pham&#8217;s employment for
Cause, as such term is defined in the employment agreement, or if Mr. Pham voluntarily terminates his employment without Good Reason upon
30 days written notice to us, Mr. Pham shall be entitled to receive Accrued Obligations, as such term is defined in the employment agreement
and which includes earned, but unpaid, base salary, accrued, but unused, vacation, and vested benefits, as of the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Mr. Pham&#8217;s employment agreement,
if his employment is terminated due to his death or disability (as defined in the employment agreement), he is entitled to (i) a lump
sum payment equal to twelve months of his base salary, (ii) full acceleration of any outstanding equity or equity-based awards that he
has with respect to us or any of our affiliates as of his termination date, and (iii) Accrued Obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Matthew Szot Employment Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the initial public offering,
we entered into an employment agreement with Matthew Szot, our Chief Financial Officer, dated January 24, 2023. He will receive an annual
salary of $375,000 and is eligible for an annual target bonus of up to 50% of his base salary, with the actual amount of the bonus, if
any, based upon the achievement of Mr. Szot and us of the applicable performance targets and goals as set by our board of directors. A
cash bonus of $187,500 was paid to Mr. Szot in February 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Mr. Szot&#8217;s employment agreement,
we will need to provide 90 days&#8217; written notice to terminate his employment without Cause, as such term is defined in the employment
agreement. If Mr. Szot resigns for Good Reason, as such term is defined in the employment agreement, or is terminated without Cause, unrelated
to a Change of Control, as such term is defined in the employment agreement, he is entitled to (i) continuation of his base salary in
effect immediately prior to termination for a period of 12 months, (ii) a lump sum payment equal to his target bonus for the calendar
year in which his termination date occurs, (iii) full acceleration of any outstanding equity or equity-based awards as of his termination
date, (iv) extension of exercisability for the full term of any stock option, and (v) payment of his full COBRA premiums for 12 months
following his termination date, if applicable conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Szot will be required to provide us 90 days&#8217;
written notice of the condition that qualifies as a Good Reason for his resignation and we will have 30 days from receipt of such notice
to remedy such condition. If Mr. Szot fails to provide the required notice such that we do not have the opportunity to cure the condition
prior to his resignation, or if he resigns more than nine months after the initial existence of the condition, his resignation shall not
be deemed for Good Reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If at any time during a Change of Control Period,
as such term is defined in the employment agreement, Mr. Szot&#8217;s employment is terminated without Cause or Mr. Szot resigns for Good
Reason, he is entitled to: (i) a lump sum payment equal to 12 months of his base salary in effect immediately prior to termination plus
his target bonus for the fiscal year in which his termination date occurs; (ii) full acceleration of any outstanding equity or equity-based
awards as of his termination date; (iii) extension of exercisability for the full term of any stock option; and payment of his full COBRA
premiums for 12 months following his termination date, if applicable conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we terminate Mr. Szot&#8217;s employment for
Cause, or if Mr. Szot voluntarily terminates his employment without Good Reason upon 30 days written notice to us, Mr. Szot shall be entitled
to receive Accrued Obligations, as such term is defined in the employment agreement, as of the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Mr. Szot&#8217;s employment agreement,
if his employment is terminated due to his death or Disability (as defined in the employment agreement), he is entitled to (i) a lump
sum payment equal to twelve months of his base salary, (ii) full acceleration of any outstanding equity or equity-based awards that he
has with respect to us or any of our affiliates as of his termination date; and (iii) Accrued Obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Douglas Losordo Employment Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the initial public offering,
the Company entered into an employment agreement with Douglas Losordo, effective January 24, 2023. Under the employment agreement, Dr.
Losordo will continue to serve as our Chief Medical Officer. He will receive an annual base salary of $425,000, with an annual targeted
cash bonus of 40% of his base salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Dr. Losordo&#8217;s employment agreement,
we need to provide 90 days&#8217; written notice to terminate his employment without Cause, as such term is defined in the employment
agreement. If Dr. Losordo resigns for Good Reason, as such term is defined in the employment agreement, or is terminated without Cause,
unrelated to a Change of Control, as such term is defined in the employment agreement, he is entitled to (i) continuation of his base
salary in effect immediately prior to termination for a period of 6 months, (ii) a lump sum payment equal to 50% of his target bonus for
the calendar year in which his termination date occurs, (iii) full acceleration of any outstanding equity or equity-based awards as of
his termination date, (iv) extension of exercisability for the full term of any stock option, and (v) payment of his full COBRA premiums
for 6 months following his termination date, if applicable conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Losordo will be required to provide us 90
days&#8217; written notice of the condition that qualifies as a Good Reason for his resignation and we will have 30 days from receipt
of such notice to remedy such condition. If Dr. Losordo fails to provide the required notice such that we do not have the opportunity
to cure the condition prior to his resignation, or if he resigns more than nine months after the initial existence of the condition, his
resignation shall not be deemed for Good Reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If at any time during a Change of Control Period,
as such term is defined in the employment agreement, Dr. Losordo&#8217;s employment is terminated without Cause or Dr. Losordo resigns
for Good Reason, he is entitled to: (i) a lump sum payment equal to 12 months of his base salary in effect immediately prior to termination
plus his target bonus for the fiscal year in which his termination date occurs; (ii) full acceleration of any outstanding equity or equity-based
awards as of his termination date, (iii) extension of exercisability for the full term of any stock option; and (iv) payment of his full
COBRA premiums for 12 months following his termination date, if applicable conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we terminate Dr. Losordo&#8217;s employment
for Cause, or if Dr. Losordo voluntarily terminates his employment without Good Reason upon 30 days written notice to us, Dr. Losordo
shall be entitled to receive Accrued Obligations, as such term is defined in the employment agreement, as of the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information concerning
the number of shares of common stock underlying outstanding equity incentive awards for each of our executive officers as of December
31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="16" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-bottom: 1.5pt">Option Awards</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant<br/> Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> Exercisable (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> Unexercisable<br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/> Exercise<br/> Price<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/> Expiration<br/> Date</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares or<br/> Units of<br/> Stock<br/> not yet<br/> Vested<br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/> Value of<br/> Shares or<br/> Units <br/> not yet<br/> Vested<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left; text-indent: -9pt; padding-left: 9pt">Douglas Losordo</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/18/2022<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/17/2032</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">These options vest quarterly over a period of three years
commencing October 1, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2022 Initial Equity Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted the Cadrenal Therapeutics, Inc. 2022
Equity Incentive Plan, or the Initial Plan, on July 11, 2022, which was later amended and restated on October 16, 2022, for purposes of
clarifying the application of certain of the rules of the Initial Plan to awards approved before such amendment and restatement of the
Initial Plan and to facilitate the transition to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (the &#8220;Successor
Plan&#8221;) for the issuance and approval of awards. The principal provisions of the Initial Plan are summarized below. On October 16,
2022, the Board adopted, and our stockholders approved, the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan, (the &#8220;2022
Plan&#8221;), which will be a successor to and continuation of the Initial Plan and became effective upon the effective date of the Registration
Statement. The 2022 Plan replaced the Initial Plan, except with respect to awards outstanding under the Initial Plan, and no further awards
will be available for grant under the Initial Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Administration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Initial Plan vested broad powers in a committee
to administer and interpret the Initial Plan. Our board of directors has initially been designated to administer the Initial Plan. Except
when limited by the terms of the Initial Plan, our board of directors has the authority to, among other things, accelerate the vesting
or exercisability of an award. In its discretion, board of directors may delegate all or part of its authority and duties with respect
to granting awards to one or more of our officers, subject to certain limitations and provided applicable law so permits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may amend any outstanding
award at any time; provided, however, that no such amendment or termination may adversely affect awards then outstanding without the holder&#8217;s
permission. Additionally, as described more fully below, neither the board of directors nor any committee designated to administer the
Initial Plan, or the Administrator, is permitted to reprice outstanding options or stock appreciation rights without shareholder consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Eligibility</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of our employees, directors, consultants,
and other service providers, or those of our affiliates, were eligible to participate in the Initial Plan and could have been selected
by the Administrator to receive an award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vesting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Administrator determines the vesting conditions
for awards. These conditions may include the continued employment or service of the participant, the attainment of specific individual
or corporate performance goals, or other factors as determined in the Administrator&#8217;s discretion (collectively, &#8220;Vesting Conditions&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares of Stock Available for Issuance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain adjustments, the maximum number
of shares of common stock that could have been issued under the Initial Plan in connection with awards was 2,000,000 shares, of which
810,000 remained available for issuance as of the date the 2022 Plan became effective. All outstanding awards under the Initial Plan remain
outstanding but no further grants will be made under the Initial Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of any merger, consolidation, reorganization,
recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend
in kind, or other like change in capital structure (other than ordinary cash dividends), or other similar corporate event or transaction
that affects our common stock, the Administrator shall make adjustments to the number and kind of shares covered under outstanding Initial
Plan awards as it determines appropriate and equitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to Initial Plan awards that expire
without being fully exercised or that are otherwise forfeited, cancelled or terminated may be made available for issuance under the 2022
Plan. In addition, shares withheld in settlement of a tax withholding obligation, or in satisfaction of the exercise price payable upon
exercise of an option, will become available for issuance under the 2022 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Change of Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change of control, unless otherwise
provided in a grant agreement, employment agreement or other agreement between the Company and the participant, and unless otherwise determined
by an affirmative vote of a majority of the board of directors prior to the occurrence of such change of control: (i) all outstanding
stock options and stock appreciation rights which have been outstanding for at least six months shall become exercisable in full, whether
or not otherwise exercisable at such time, and any such stock option and stock appreciation right shall remain exercisable in full thereafter
until it expires pursuant to its terms; and (ii) all restrictions and deferral limitations contained in restricted stock and restricted
stock unit awards granted under the Initial Plan shall lapse and the shares of stock subject to such awards shall be distributed to the
participant within thirty (30) days of the change of control to the extent permitted under Section 409A of the Code. In addition, in the
event of a change of control, unless otherwise specifically prohibited under applicable laws or by the rules and regulations of any governing
governmental agencies or national securities exchanges, or unless the board of directors or the Administrator shall specify otherwise
in the applicable award agreement, the Administrator is authorized (but not obligated) to make any of the following adjustments (or any
combination thereof) in the terms and conditions of outstanding awards: (a) continuation or assumption of such outstanding awards under
the Initial Plan by the Company (if it is the surviving company or corporation) or by the surviving company or corporation or its parent;
(b) substitution by the surviving company or corporation or its parent of equity, equity-based and/or cash awards with substantially the
same terms for outstanding awards (to the extent permitted under Section 409A of the Code), including, in the case of options, substitution
by the surviving company or corporation or its parent of restricted stock or other equity in an amount equal to the intrinsic value of
such options; (c) accelerated exercisability, vesting and/or lapse of restrictions under outstanding awards immediately prior to the occurrence
of such event; (d) upon written notice, provide that any outstanding awards must be exercised, to the extent then exercisable, during
a reasonable period of time immediately prior to the scheduled consummation of the event or such other period as determined by the Administrator
(contingent upon the consummation of the event), and at the end of such period, such awards shall terminate to the extent not so exercised
within the relevant period; and (e) cancellation of all or any portion of outstanding awards for fair value (in the form of cash, stock,
other property or any combination thereof) as determined in the sole discretion of the Administrator and which value (for example, in
the case of options that are not in the money) may be zero.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Repricing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Administrator cannot without obtaining prior
approval of our stockholders, reduce the exercise price in effect for outstanding options under the Initial Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Miscellaneous</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, awards granted under the Initial Plan
shall be nontransferable except by will or by the laws of descent and distribution. No participant shall have any rights as a stockholder
with respect to shares covered by options or restricted stock units, unless and until such awards are settled in shares of common stock.
The Company&#8217;s obligation to issue shares or to otherwise make payments in respect of Initial Plan awards will be conditioned on
the Company&#8217;s ability to do so in compliance with all applicable laws and exchange listing requirements. The awards will be subject
to our recoupment and stock ownership policies, as may be in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2022 Successor Equity Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, the Board adopted, and our stockholders
approved, the 2022 Successor Equity Incentive Plan, as a successor to and continuation of the Initial Plan, which became effective on
January 19, 2023, upon the effectiveness of the Registration Statement. All outstanding awards under the Initial Plan remain outstanding
but no further grants will be made under the Initial Plan. The shares of common stock underlying any awards under the 2022 Plan and the
Initial Plan that are forfeited, canceled or otherwise terminated, other than by exercise, will be added back to the shares of common
stock available for issuance under the 2022 Plan. In addition, if any shares subject to an award under the 2022 Plan and the Initial Plan
are tendered or withheld by the Company to satisfy any exercise price or tax withholding obligation, such tendered or withheld shares
will be added back to the shares of common stock available for issuance under the 2022 Plan. Shares of common stock repurchased on the
open market will not be added back to the shares of Common Stock available for issuance under the 2022 Plan. The principal purpose of
the 2022 Plan is to attract, retain and incentivize the Company&#8217;s employees and other service providers through the granting of
certain stock-based awards, including performance-based awards. The material terms of the 2022 Plan are summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Administration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2022 Plan vests broad powers in a committee
to administer and interpret the 2022 Plan. Our board of directors has initially designated the compensation committee to administer the
2022 Plan. Except when limited by the terms of the 2022 Plan, the compensation committee has the authority to, among other things: select
the persons to be granted awards; determine the type, size and term of awards; establish performance objectives and conditions for earning
awards; determine whether such performance objectives and conditions have been met; and accelerate the vesting or exercisability of an
award. In its discretion, the compensation committee may delegate all or part of its authority and duties with respect to granting awards
to one or more of our officers, subject to certain limitations and provided applicable law so permits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may amend, alter or discontinue
the 2022 Plan and the compensation committee is able to amend any outstanding award at any time; provided, however, that no such amendment
or termination may adversely affect awards then outstanding without the holder&#8217;s permission. In addition, any amendments seeking
to increase the total number of shares reserved for issuance under the 2022 Plan or modifying the classes of participants eligible to
receive awards under the 2022 Plan requires ratification by our stockholders in accordance with applicable law. Additionally, as described
more fully below, neither the compensation committee nor the board of directors is permitted to reprice outstanding options or stock appreciation
rights without shareholder consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Eligibility</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of our employees, directors, and consultants,
or those of our affiliates, are eligible to participate in the 2022 Plan and may be selected by the compensation committee to receive
an award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vesting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The compensation committee determines the vesting
conditions for awards. These conditions may include the continued employment or service of the participant, the attainment of specific
individual or corporate performance goals, or other factors as determined in the compensation committee&#8217;s discretion (collectively,
&#8220;Vesting Conditions&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares of Stock Available for Issuance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain adjustments, as of the date
of this prospectus, the maximum number of shares of common stock that may be issued under the 2022 Plan in connection with awards is 1,910,000
shares, consisting of (i) the 760,000 shares of common stock reserved and available for issuance pursuant to the grant of new awards under
our Initial Plan, and (ii) the 1,150,000 shares subject to outstanding stock options or other awards granted under our Initial Plan or
the 2022 Plan that terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited
because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase
or exercise price, if any, as such shares become available from time to time. In addition, the maximum number of shares of common stock
that may be issued under the 2022 Plan will automatically increase on January 1 of each calendar year for a period of ten years commencing
on January 1, 2024 and ending on (and including) January 1, 2033, to a number of shares of common stock equal to 20% of the total number
of shares of common stock outstanding on December 31 of the preceding calendar year; provided, however that the board of directors, or
the compensation committee, may act prior to January 1 of a given calendar year to provide that the increase for such year will be a lesser
number of shares of common stock. All available shares may be utilized toward the grant of any type of award under the 2022 Plan. The
2022 Plan imposes a $100,000 limitation on the total grant date fair value with respect to which incentive stock options are exercisable
for the first time by an individual optionee during any single calendar year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of any merger, consolidation, sale
or disposition of all or substantially all our assets, sale or disposition of at least 50% of our outstanding securities, or other similar
corporate transaction that affects our common stock, the board of directors or compensation committee shall make adjustments to the number
and kind of shares authorized by the 2022 Plan and covered under outstanding 2022 Plan awards as it determines appropriate and equitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to 2022 Plan awards that expire
without being fully exercised or that are otherwise forfeited, cancelled or terminated may again be made available for issuance under
the 2022 Plan. In addition, shares withheld in settlement of a tax withholding obligation, or in satisfaction of the exercise price payable
upon exercise of an option, will again become available for issuance under the 2022 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Types of Awards</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following types of awards may be granted to
participants under the 2022 Plan: (i) incentive stock options, or ISOs; (ii) nonqualified stock options, or NQOs and together with ISOs,
options, (iii) stock appreciation rights, (iv) restricted stock, or (v) restricted stock units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Options. </i>An option entitles the holder
to purchase from us a stated number of shares of common stock. An ISO may only be granted to an employee of ours or our eligible affiliates.
The compensation committee will specify the number of shares of common stock subject to each option and the exercise price for such option,
provided that the exercise price may not be less than the fair market value of a share of common stock on the date the option is granted.
Notwithstanding the foregoing, if ISOs are granted to any 10% stockholder, the exercise price shall not be less than 110% of the fair
market value of common stock on the date the option is granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, options may be exercised in whole or
in part through a cash payment. The compensation committee may, in its sole discretion, permit payment of the exercise price of an option
pursuant to a &#8220;cashless exercise,&#8221; in the form of previously owned shares of common stock based on the fair market value of
the shares on the date the option is exercised, or through means of &#8220;net settlement,&#8221; which involves the cancellation of a
portion of the option to cover the cost of exercising the balance of the option or by such other means as it deems acceptable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All options shall be or become exercisable in
accordance with the terms of the applicable award agreement. The maximum term of an option shall be determined by the compensation committee
on the date of grant but shall not exceed 10 years (5 years in the case of ISOs granted to any 10% stockholder). In the case of ISOs,
the aggregate fair market value (determined as of the date of grant) of common stock with respect to which such ISOs become exercisable
for the first time during any calendar year cannot exceed $100,000. ISOs granted in excess of this limitation will be treated as non-qualified
stock options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Appreciation Rights. </i>A stock appreciation
right represents the right to receive, upon exercise, any appreciation in a share of common stock over a particular time period. The base
price of a stock appreciation right shall not be less than the fair market value of a share of common stock on the date the stock appreciation
right is granted. This award is intended to mirror the benefit the participant would have received if the compensation committee had granted
the participant an option. The maximum term of a stock appreciation right shall be determined by the compensation committee on the date
of grant but shall not exceed 10 years. Distributions with respect to stock appreciation rights may be made in cash, shares of common
stock, or a combination of both, at the board of director&#8217;s discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise provided in an award agreement
or determined by the compensation committee, if a participant terminates employment with us (or our affiliates) for any reason other than
cause, the participant may exercise his or her unexercised options and stock appreciation rights, to the extent they were exercisable
on the termination date, within the following period of time, provided however that in no event may any award be exercised after termination
of its maximum term: (i) three months following the date of such termination if such termination is a termination without cause (other
than any termination due to the participant&#8217;s disability or death); (ii) 12 months following the date of such termination if such
termination is due to the participant&#8217;s disability; (iii) 18 months following the date of such termination if such termination is
due to the participant&#8217;s death; or (iv) 18 months following the date of the participant&#8217;s death if such death occurs following
the date of such termination but during the period such Award is otherwise exercisable. If the participant terminates employment with
us (or our affiliates) for cause, all unexercised options and stock appreciation rights (whether vested or unvested) shall terminate and
be forfeited on the termination date. Unless otherwise provided by the compensation committee, any options and stock appreciation rights
that are not exercisable at the time of termination of employment shall terminate and be forfeited on the termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock. </i>A restricted stock award
is a grant of shares of common stock, which are subject to forfeiture restrictions during a restriction period. The compensation committee
will determine the price, if any, to be paid by the participant for each share of common stock subject to a restricted stock award. The
restricted stock may be subject to Vesting Conditions. If the specified Vesting Conditions are not attained, the participant will forfeit
the portion of the restricted stock award with respect to which those conditions are not attained, and the underlying common stock will
be forfeited to us. At the end of the restriction period, if the Vesting Conditions have been satisfied, the restrictions imposed will
lapse with respect to the applicable number of shares. Unless otherwise provided in an award agreement or determined by the compensation
committee, upon termination a participant will forfeit all restricted stock that then remains subject to forfeiture restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units. </i>Restricted stock
units are granted in reference to a specified number of shares of common stock and entitle the holder to receive, on the achievement of
applicable Vesting Conditions, shares of common stock. Unless otherwise provided in an award agreement or determined by the compensation
committee, upon termination a participant will forfeit all restricted stock units that then remain subject to forfeiture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Change of Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change of control, unless otherwise
provided in a grant agreement, employment agreement or other agreement between the Company and the participant, and unless otherwise determined
by an affirmative vote of a majority of the board of directors prior to the occurrence of such change of control: (i) the vesting and
settlement of all outstanding awards to non-employee directors will be automatically accelerated and the shares immediately issued to
the participant (or the Board may direct the payment of a cash settlement equal to the fair market value of the shares that would otherwise
be issued to the participant); (ii) the settlement of vested awards to employees and consultants will automatically be accelerated and
the shares immediately issued to the participant; and (iii) unvested awards to employees and consultants shall be terminated and forfeited
unless the acquiring entity assumes, continues or substitutes any such awards. Notwithstanding the foregoing, to the extent permitted
and in compliance with the requirements of Section 409A of the Code, the Board may in its discretion determine to elect to accelerate
the vesting and settlement of the unvested awards to employees and consultants upon a Change of Control, or direct the payment of a cash
settlement equal to the fair market value of the shares that would otherwise be issued to the participant).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Repricing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither our board of directors nor the compensation
committee may reduce the exercise price in effect for outstanding options under the 2022 Plan without obtaining the consent of any participant
whose award would be materially impaired by such action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Miscellaneous</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, awards granted under the 2022 Plan
shall be nontransferable except by will or by the laws of descent and distribution. No participant shall have any rights as a stockholder
with respect to shares covered by options or restricted stock units, unless and until such awards are settled in shares of common stock.
Our obligation to issue shares or to otherwise make payments in respect of 2022 Plan awards will be conditioned on our ability to do so
in compliance with all applicable laws and exchange listing requirements. The awards will be subject to our recoupment and stock ownership
policies, as may be in effect from time to time. The 2022 Plan expires 10 years after it becomes effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows certain information
with respect to the compensation of all of our non-employee directors for the fiscal year ended December&#160;31, 2022, all of whom were
director nominees at the time of grant, in anticipation of director services to be provided:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees Earned or <br/> Paid in Cash <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock <br/> Awards <br/> ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">John R. Murphy</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">187,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">225,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Steven Zelenkofske, D.O.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">118,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Glynn Wilson, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">149,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">149,650</td><td style="text-align: left">&#160;</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">In accordance with SEC rules, this column reflects the aggregate
fair value of the stock and option awards granted as of their respective grant dates in accordance with Financial Accounting Standard
Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (ASC 718). The valuation assumptions used
in determining such amounts are described in Note 1 and Note 10 to our audited financial statements included elsewhere in this Annual
Report. These amounts do not correspond to the actual value that may be realized by the Directors upon vesting or exercise of such awards.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended December 31, 2023, our
directors will each receive annual cash compensation in the amount of $35,000 and the Chair of the Audit Committee will receive additional
annual cash compensation of $15,000 per year. From time to time, we may grant additional stock options to certain of our non-employee
directors as compensation for their services as directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the aggregate number of
option awards outstanding at fiscal year-end of our non-employee directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares Subject to Outstanding Options as of December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">John R. Murphy</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Steven Zelenkofske, D.O.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Glynn Wilson, Ph.D.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the beneficial
ownership of our common stock as of March 28, 2023, by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each person, or group of affiliated persons, who is known
by us to beneficially own more than 5% of our common stock;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each of the named executive officers;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each of our directors and director; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">all of our current executive officers and directors as a
group</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 28, 2023, we had 11,634,575 shares of
common stock outstanding, held by approximately twenty-four (24) stockholders of record. This number does not include stockholders for
whom shares are held in a &#8220;nominee&#8221; or &#8220;street&#8221; name.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have determined beneficial ownership in accordance
with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise
indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect
to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily
indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based our calculation of the percentage of
beneficial ownership on 11,634,575 shares of our common stock outstanding as of March 28, 2023. We have deemed shares of our common stock
subject to securities that are currently convertible or exercisable into shares of common stock, or convertible or exercisable into shares
of our common stock within 60 days of March 28, 2023, to be outstanding and to be beneficially owned by the person holding the stock option
for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose
of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in
the table below is c/o Cadrenal Therapeutics, Inc., 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Named Executive Officers and Directors</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td><sup>&#160;</sup></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Quang Pham</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,300,000</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54.15</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Matthew Szot</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Douglas Losordo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">John Murphy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">594,792</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.11</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Steven Zelenkofske</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Glynn Wilson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All executive officers and directors as a group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,559,792</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64.98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">5% Stockholders other than executive officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">The PVBQ Living Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000,000</td><td style="text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.79</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">HESP LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.16</td><td style="text-align: left">%</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Represents beneficial ownership of less than one percent.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Includes (i) 3,300,000 shares of common stock owned by Quang
Pham; and (ii) 3,000,000 shares of common stock owned by The PVBQ Living Trust. The beneficiary of The PVBQ Living Trust (the &#8220;Trust&#8221;)
is Mr. Pham&#8217;s child and Mr. Pham is the trustee of the Trust and has sole voting and disposition power with respect to the shares
owned by the Trust. The address for the Trust is 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Consists of 450,000 shares of restricted common stock, which
shares shall vest quarterly over a period of two (2) years, subject to certain adjustments, and 50,000 shares of common stock.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 75,000 shares of common stock issuable upon the exercise of options held by Dr. Losordo that are exercisable within the 60-day period following March 28, 2023. Does not include 225,000 shares of common stock issuable upon the exercise of options held by Dr. Losordo that are not exercisable within the 60-day period following March 28, 2023.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Does not include 100,000 shares of common stock issuable upon the exercise
of options held by Mr. Murphy that are not exercisable within the 60-day period following March 28, 2023.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Does not include 50,000 shares of common stock issuable upon the exercise
of options held by Dr. Zelenkofske that are not exercisable within the 60-day period following March 28, 2023.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Does not include 50,000 shares of common stock issuable upon the exercise
of options held by Dr. Wilson that are not exercisable within the 60-day period following March 28, 2023.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(7)</td><td style="text-align: justify">Daniel Devorsetz, Chief Operating Officer of Horizon Technology
Finance Corporation (&#8220;Horizon&#8221;), the sole member of HESP LLC, has voting power over the shares that will be issued to HESP
LLC and an Investment Committee of Horizon, of which Daniel Devorsetz is one of several members, has investment power over such shares.
The address for HESP, LLC is 312 Farmington Avenue, Farmington, CT 06032.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes In Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Part II, Item 5&#8212; &#8220;Equity Compensation
Plan Information&#8221; for certain information regarding our equity compensation plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 13. Certain Relationships and Related
Transactions, and Director Independence.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the related party transactions described
below was negotiated on an arm&#8217;s length basis. We believe that the terms of such agreements are as favorable as those we could have
obtained from parties not related to us. The following are summaries of certain provisions of our related party agreements and are qualified
in their entirety by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable
agreements, they do not necessarily contain all of the information that you may find useful. We therefore urge you to review the agreements
in their entirety. Copies of the forms of the agreements have been filed as exhibits to the Registration Statement and are available electronically
on the website of the SEC at <i>www.sec.gov</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the compensation arrangements,
including employment, termination of employment and change in control arrangements, with our directors and executive officers, including
those discussed in the sections titled &#8220;Management&#8221; and &#8220;Executive Compensation,&#8221; the following is a description
of each transaction since January 25, 2022 or any currently proposed transaction in which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we have been or are to be a party to;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the amount involved exceeded or exceeds $120,000 or 1% of
the average of our total assets as of the end of the last two completed fiscal years; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any of our directors, executive officers or holders of more
than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals
or entities, had or will have a direct or indirect material interest.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For information on our compensation arrangements,
including employment, termination of employment and change in control arrangements, with our directors and executive officers, see the
sections titled &#8220;Management&#8221; and &#8220;Executive Compensation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 25, 2022, we entered into an agreement
with Phamace, LLC, a consulting firm of which Quang Pham, our Chief Executive Officer, is the sole member, for an initial term of January
25, 2022 through February 28, 2022 to provide advisory and administrative services relating to preparing the Company to launch as an operating
company. Pursuant to the agreement, the Company shall pay the sum of $115,000 to Phamace, LLC for services rendered, which was paid in
January 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 25, 2022, we issued 7,500,000 shares
of common stock, pursuant to a subscription agreement, to Quang Pham, our Chief Executive Officer. Mr. Pham paid a total of $7,500 for
such founders shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2022, we issued a convertible promissory
note in the amount of $500,000 to John Murphy, a director, which bears interest at 5% and matures on March 1, 2025. The note, as amended
in December 2022, converted into 514,792 shares of Common Stock at a conversion price equal to $1.00 upon consummation of the initial
public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 17, 2022, we issued 450,000 shares of restricted
common stock, pursuant to a restricted stock purchase agreement, to Matthew Szot, our Chief Financial Officer, which shares shall vest
quarterly over a period of two (2) years, subject to certain adjustments, as provided in the Restricted Stock Purchase Agreement dated
May 17, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, we issued stock options to purchase
an aggregate of 150,000 shares of common stock to two (2) directors. The options have an at an exercise price of $0.64 per common share
and will vest over a period of three (3) years, with 33.33% vesting on the first anniversary of the effective date, and thereafter 1/36
on a monthly basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued stock options to
purchase 300,000 shares of common stock to Douglas Losordo, our Chief Medical Officer. The options have an at an exercise price of $0.64
per common share and will vest quarterly over a period of three (3) years, subject to certain adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, we issued 40,000 shares of
common stock to Steven Zelenkofske, a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2022, we issued a convertible promissory
note in the amount of $50,000 to Glynn Wilson, a director, which bears interest at 6% and matures on September 13, 2025. The note was
converted into 50,000 shares of Common Stock at a conversion price equal to $1.00 upon consummation of the initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2022, we issued 50,000 shares
of common stock to John Murphy, a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2022, the Company issued stock options
to purchase 50,000 shares of common stock to Glynn Wilson, a director. The options have an exercise price of $5.00 per common share and
will vest over a three-year period, with 33.33% vesting on the first anniversary of the effective date, and thereafter 1/36 on a monthly
basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 24, 2023, we issued 50,000 shares of
common stock to Matthew Szot, our Chief Financial Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with each of our current executive officers and intend to enter into separate indemnification agreements with each of our directors
and executive officers, in addition to the indemnification that will be provided for in our amended and restated bylaws. The indemnification
agreements and our amended restated bylaws require us to indemnify our directors and executive officers to the fullest extent permitted
by Delaware law. See the section titled &#8220;Description of Securities &#8212; Limitations on Liability and Indemnification of Officers
and Directors&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Policy Regarding Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors recognizes the fact that
transactions with related persons present a heightened risk of conflicts of interest and/or improper valuation (or the perception thereof).
Our board of directors adopted a written policy on transactions with related persons that is in conformity with the requirements for issuers
having publicly held common stock that is listed on the Nasdaq Stock Market. Under the new policy:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any related person transaction, and any material amendment
or modification to a related person transaction, must be reviewed and approved or ratified by the Audit Committee; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any employment relationship or transaction involving an executive
officer and any related compensation must be approved by the compensation committee of the board of directors or recommended by the compensation
committee to the board of directors for its approval.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the review and approval or
ratification of a related person transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">management must disclose to the committee or disinterested
directors, as applicable, the name of the related person and the basis on which the person is a related person, the material terms of
the related person transaction, including the approximate dollar value of the amount involved in the transaction, and all the material
facts as to the related person&#8217;s direct or indirect interest in, or relationship to, the related person transaction;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">management must advise the committee or disinterested directors,
as applicable, as to whether the related person transaction complies with the terms of our agreements governing our material outstanding
indebtedness that limit or restrict our ability to enter into a related person transaction;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">management must advise the committee or disinterested directors,
as applicable, as to whether the related person transaction will be required to be disclosed in our applicable filings under the Securities
Act or the Exchange Act, and related rules, and, to the extent required to be disclosed, management must ensure that the related person
transaction is disclosed in accordance with the Securities Act and the Exchange Act and related rules; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">management must advise the committee or disinterested directors,
as applicable, as to whether the related person transaction constitutes a &#8220;personal loan&#8221; for purposes of Section 402 of
the Sarbanes-Oxley Act.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the related person transaction policy
provides that the committee or disinterested directors, as applicable, in connection with any approval or ratification of a related person
transaction involving a non-employee director, should consider whether such transaction would compromise the director&#8217;s status as
an &#8220;independent,&#8221; &#8220;outside,&#8221; or &#8220;non-employee&#8221; director, as applicable, under the rules and regulations
of the SEC, the Nasdaq Stock Market, and the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included under the heading &#8220;Directors,
Executive Officers and Corporate Governance&#8212;Director Independence&#8221; in Part III, Item 10 is hereby incorporated by reference
into this Item 13.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="c_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Principal Accounting Fees and Services.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WithumSmith+Brown, P.C. serves as our independent registered public
accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Independent Registered Public Accounting Firm Fees and Services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the aggregate fees
including expenses billed to us for the years ended December 31, 2022 and 2021 by our auditors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Period ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,130</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,522</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169,652</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee has adopted procedures for
pre-approving all audit and non-audit services provided by the independent registered public accounting firm, including the fees and terms
of such services. These procedures include reviewing detailed back-up documentation for audit and permitted non-audit services. The documentation
includes a description of, and a budgeted amount for, particular categories of non-audit services that are recurring in nature and therefore
anticipated at the time that the budget is submitted. Audit Committee approval is required to exceed the pre-approved amount for a particular
category of non-audit services and to engage the independent registered public accounting firm for any non-audit services not included
in those pre-approved amounts. For both types of pre-approval, the Audit Committee considers whether such services are consistent with
the rules on auditor independence promulgated by the SEC and the PCAOB. The Audit Committee also considers whether the independent registered
public accounting firm is best positioned to provide the most effective and efficient service, based on such reasons as the auditor&#8217;s
familiarity with our business, people, culture, accounting systems, risk profile, and whether the services enhance our ability to manage
or control risks, and improve audit quality. The Audit Committee may form and delegate pre-approval authority to subcommittees consisting
of one or more members of the Audit Committee, and such subcommittees must report any pre-approval decisions to the Audit Committee at
its next scheduled meeting. All of the services provided by the independent registered public accounting firm were pre-approved by the
Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 118; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="c_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. Exhibits and Financial Statement Schedules.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements. The financial statements required to be filed in this Annual Report are included in Part II, Item 8 hereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(2)</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All financial statement schedules have been omitted as the required information is either inapplicable or included in the Financial Statements or related notes included in Part II, Item 8 hereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(3)</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits. The exhibits listed below are required by Item 601 of Regulation S-K. Each management contract or compensatory plan or arrangement required to be filed as an exhibit to this Annual Report has been identified</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="c_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Form 10-K Summary.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex3-1_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Certificate of Incorporation (Incorporated by reference as Exhibit 3.1 to the Registration Statement on Form S-1
    (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex3-2_cadrenal.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws (Incorporated by reference as Exhibit 3.2 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022062909/fs12022a1ex4-1_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock
    Certificate (Incorporated by reference as Exhibit 4.1 to the Registration Statement on Form S-1 (333-267562) filed on September 22,
    2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex4-3_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory
    Note dated March 1, 2022 issued to John Murphy (Incorporated by reference as Exhibit 4.3 to the Registration Statement on Form S-1
    (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex4-4_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Note
    dated June 13, 2022 (Incorporated by reference as Exhibit 4.4 to the Registration Statement on Form S-1 (333-267562) filed on
    September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex4-5_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Private Placement
    Convertible Note (Incorporated by reference as Exhibit 4.5 to the Registration Statement on Form S-1 (333-267562) filed on September
    22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4.5</td>
    <td style="white-space: nowrap"><span style="color: #000000">&#160;</span></td>
    <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif; color: blue"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex4-6_cadrenal.htm" style="-sec-extract: exhibit">Form of November Private Placement Promissory Note (Incorporated by reference as Exhibit 4.6 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex4-7_cadrenal.htm">Form of Amended and Restated November Warrant (Incorporated by reference as Exhibit 4.7 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex4-8_cadrenal.htm">Form of Amended and Restated Placement Agent Warrant from Private Placement (Incorporated by reference as Exhibit 4.8 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex4-9_cadrenal.htm">Form of Placement Agent Warrant from November Private Placement (Incorporated by reference as Exhibit 4.9 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex4-10_cadrenal.htm">Form of Amendment to Convertible Promissory Note (Incorporated by reference as Exhibit 4.10 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140ex4-1_cadrenal.htm">Representative&#8217;s Warrant issued to Boustead Securities, LLC dated January 19, 2023 (Incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11*</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex4-11_cadrenal.htm">Description of Securities</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-1_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics,
    Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and
    Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted
    Stock Unit Agreement (Incorporated by reference as Exhibit 10.1 to the Registration Statement on Form S-1 (333-267562) filed on
    September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-2_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement,
    dated January 25, 2022, with Phamace LLC (Quang Pham) from company formation until initiation of payroll (Incorporated by reference
    as Exhibit 10.2 to the Registration Statement on Form S-1 (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-3_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement,
    dated March 1, 2022 with Quang Pham (Incorporated by reference as Exhibit 10.3 to the Registration Statement on Form S-1
    (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-5_cadrenal.htm" style="-sec-extract: exhibit">Restricted Stock Purchase Agreement with Matthew Szot (Incorporated by reference as Exhibit 10.5 to the Registration Statement on Form S-1 (333-267562) filed on September 22, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-7_cadrenal.htm" style="-sec-extract: exhibit">Asset Purchase Agreement dated as of April 1, 2022, between Cadrenal Therapeutics, Inc. and HESP LLC (Incorporated by reference as Exhibit 10.7 to the Registration Statement on Form S-1 (333-267562) filed on September 22, 2022)</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-8_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Assignment
    Agreement dated as of April 1, 2022, between Cadrenal Therapeutics, Inc. and HESP LLC (Incorporated by reference as Exhibit 10.8 to
    the Registration Statement on Form S-1 (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-9_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement
    with Quang Pham, dated January 25, 2022 (Incorporated by reference as Exhibit 10.9 to the Registration Statement on Form S-1
    (333-267562) filed on September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-10_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Investor Rights
    and Lockup Agreement (Incorporated by reference as Exhibit 10.10 to the Registration Statement on Form S-1 (333-267562) filed on
    September 22, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+&#160;</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1937993/000121390022062909/fs12022a1ex10-13_cadrenal.htm">License, Development and Commercialization Agreement Effective as of September 16, 2015 by and between Armetheon, Inc. and China Cardiovascular Focus Ltd. (Incorporated by reference as Exhibit 10.13 to the Registration Statement on Form S-1 (333-267562) filed on October 11, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-14_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics,
Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference as Exhibit 10.14 to the Registration Statement on Form
S-1 (333-267562) filed on October 17, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-15_cadrenal.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant
Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference
as Exhibit 10.15 to the Registration Statement on Form S-1 (333-267562) filed on October 17, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140ex10-1_cadrenal.htm">Form of Indemnification Agreement (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140ex10-2_cadrenal.htm">Amendment to Asset Purchase Agreement, dated as of August 18, 2022, between Cadrenal Therapeutics, Inc. and HESP LLC (Incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140ex10-3_cadrenal.htm">Employment Agreement with Matthew Szot (Incorporated by reference as Exhibit 10.3 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140ex10-4_cadrenal.htm">Employment Agreement with Douglas Losordo (Incorporated by reference as Exhibit 10.4 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-16_cadrenal.htm">Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Exhibit 10.5 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-17_cadrenal.htm">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference as Exhibit 10.6 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-18_cadrenal.htm">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference as Exhibit 10.7 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex21-1_cadrenal.htm">Subsidiaries of Registrant</a> &#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex23-1_cadrenal.htm">Consent of Independent Registered Public Accounting Firm</a>&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex31-1_cadrenal.htm">Certification of the Principal Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex31-2_cadrenal.htm">Certification of the Principal Financial Officer and Principal Accounting Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex32-1_cadrenal.htm">Certification by the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex32-2_cadrenal.htm">Certification by the Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 9%; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="width: 90%; padding-right: 0pt; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Labeled*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</span></td></tr>
</table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"># </span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this Annual Report.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+ </span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain portions of this exhibit indicated therein by [***] have been omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 40%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cadrenal Therapeutics, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March
    29, 2023</span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Quang Pham </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive&#160;Officer </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant, Cadrenal Therapeutics,
Inc., in the capacities and on the date indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 2%; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 50%; border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Quang Pham&#160;&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Chief Executive Officer</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang
    Pham</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew Szot</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Szot</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">and
    Principal Accounting Officer)</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    John R. Murphy</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    R. Murphy</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt"></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glynn
    Wilson</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Steven Zelenkofske</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Zelenkofske</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">98</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-0" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.85</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">7890507</ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-5" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-6" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-9" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-10" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-11" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-12" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-13" name="cvkd:IssuanceOfInvestorWarrantsinShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-18" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-19" name="us-gaap:DerivativeInstrumentsAndHedgesLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-20" name="us-gaap:DerivativeInstrumentsAndHedgesLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-21" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-23" name="us-gaap:DeferredTaxLiabilitiesDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-24" name="us-gaap:CommonStockOtherSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c57" id="hidden-fact-25" name="us-gaap:WarrantsAndRightsOutstandingTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c61" id="hidden-fact-26" name="us-gaap:CommonStockOtherSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c60" id="hidden-fact-27" name="us-gaap:WarrantsAndRightsOutstandingTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c64" id="hidden-fact-28" name="us-gaap:CommonStockOtherSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c63" id="hidden-fact-29" name="us-gaap:WarrantsAndRightsOutstandingTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c7" id="hidden-fact-30" name="us-gaap:CommonStockOtherSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c3" id="hidden-fact-31" name="us-gaap:WarrantsAndRightsOutstandingTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c81" id="hidden-fact-32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-36" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c7" id="hidden-fact-37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-40" name="cvkd:WeightedAverageRemainingContractualLifeYearsExercised" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="cvkd:WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c67" id="hidden-fact-46" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P1Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c68" id="hidden-fact-47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c71" id="hidden-fact-48" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c73" id="hidden-fact-49" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P3Y</ix:nonNumeric>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-50" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.85</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-53" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-55" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-57" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-59" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-60" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-61" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-62" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001937993</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="cvkd-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-24</xbrli:startDate>
    <xbrli:endDate>2023-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:HESPLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-10</xbrli:startDate>
    <xbrli:endDate>2022-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:HESPLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2007-04-01</xbrli:startDate>
    <xbrli:endDate>2008-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:March2022ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:March2022ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:June2022ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:June2022ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2022-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte736TxGWJtCVQIJrRbpO1oo2I=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:MrPhamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:JohnMurphyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-17</xbrli:startDate>
    <xbrli:endDate>2022-05-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:GlynnWilsonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-22</xbrli:startDate>
    <xbrli:endDate>2022-08-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-11</xbrli:startDate>
    <xbrli:endDate>2022-07-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:ChiefMedicalOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-18</xbrli:startDate>
    <xbrli:endDate>2022-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvkd:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-18</xbrli:startDate>
    <xbrli:endDate>2022-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:StevenZelenkofskemMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:JohnMurphyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-03</xbrli:startDate>
    <xbrli:endDate>2022-10-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937993</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>f10k2022ex4-11_cadrenal.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTERED PURSUANT TO SECTION 12 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cadrenal Therapeutics, Inc. (the &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo;) has one class of securities registered under Section&nbsp;12 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which is our common stock, par value $0.001 per share (the &ldquo;common
stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a description of the material
terms of our common stock. This is a summary only and does not purport to be complete. It is subject to and qualified in its entirety
by reference to our Certificate of Incorporation (the &ldquo;Certificate of Incorporation&rdquo;), and our Bylaws (the &ldquo;Bylaws&rdquo;),
each of which are incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K. We encourage you to read our
Certificate of Incorporation, our Bylaws and the applicable provisions of&nbsp;the Delaware General Corporation Law, for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are authorized to issue 75,000,000 shares of
common stock. Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of our
directors and all other matters requiring stockholder action, except with respect to amendments to our certificate of incorporation that
alter or change the powers, preferences, rights or other terms of any outstanding preferred stock if the holders of such affected series
of preferred stock are entitled to vote on such an amendment. Our directors are elected by a plurality of the votes cast by the stockholders
entitled to vote at our annual meeting of stockholders, and are not entitled to cumulative voting rights. Holders of common stock are
entitled to receive such dividends, if any, as may be declared from time to time by our Board of Directors in its discretion out of funds
legally available therefor. The payment of dividends, if any, on shares of our common stock are subject to the prior payment of dividends
on any outstanding preferred stock, of which there is none. Upon our liquidation or dissolution, the holders of our common stock are entitled
to receive a pro rata portion of all assets remaining available for distribution to stockholders after payment of all liabilities and
provision for the liquidation of any shares of preferred stock outstanding at that time. The holders of our common stock have no preemptive,
subscription or redemption rights, and have no rights to convert their common stock into any other securities. The absence of preemptive
rights could result in a dilution of the interest of the existing stockholders should additional shares of our common stock be issued.
In addition, the rights of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares
of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forum Selection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District
of Delaware or other state courts of the State of Delaware) is the exclusive forum for (i)&nbsp;any derivative action or proceeding brought
on our behalf; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee or agent of
the Company to the Company or our stockholders; (iii)&nbsp;any action asserting a claim arising pursuant to the provisions of the Delaware
General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv)&nbsp;any action
asserting a claim against us that is governed by the internal affairs doctrine of the State of Delaware; provided that, if and only if
the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, or the Company consents
in writing to the selection of an alternative forum, such action may be brought in another state or federal court sitting in the State
of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district
courts of the United&nbsp;States of America is the exclusive forum for the resolution of any complaint asserting a cause of action against
under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision does not apply to suits brought to enforce any
liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Nothing in
our amended and restated certificate of incorporation or amended and restated bylaws preclude stockholders that assert claims under the
Exchange&nbsp;Act from bringing such claims in state or federal court, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and amended and restated bylaws contain provisions that may delay, defer, or discourage another party from acquiring control of us. We
expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which
we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our
board of directors the power to discourage acquisitions that some stockholders may favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Section&nbsp;203 of the Delaware General
Corporation Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to Section&nbsp;203 of the Delaware
General Corporation Law. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in
a &ldquo;business combination&rdquo; with any &ldquo;interested stockholder&rdquo; for three&nbsp;years following the date that the person
became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or
unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo; includes, among other things,
a merger or consolidation involving us and the &ldquo;interested stockholder&rdquo; and the sale of more than 10% of our assets. In general,
an &ldquo;interested stockholder&rdquo; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any
entity or person affiliated with or controlling or controlled by such entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Classified Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors is divided into three classes
serving three-year terms, with one class being elected each year by a plurality of the votes cast by the stockholders entitled to vote
on the election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Proposals of Business and Nominations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws generally regulates
proposals of business and nominations for election of directors by stockholders. In general, Section 5 requires stockholders intending
to submit proposals or nominations at a stockholders&rsquo; meeting to provide the Company with advance notice thereof, including information
regarding the stockholder proposing the business or nomination as well as information regarding the proposed business or nominee. Section
5 also provides a time period during which business or nominations must be provided to the Company that creates a predictable window for
the submission of such notices, eliminating the risk that the Company finds a meeting will be contested after printing its proxy materials
for an uncontested election and providing the Company with a reasonable opportunity to respond to nominations and proposals by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Blank Check Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has the right to issue
preferred stock in one or more series and to determine the designations, rights, preferences of such preferred stock without stockholder
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Board Vacancies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws generally provide
that only our board of directors (and not the stockholders) may fill vacancies and newly created directorships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stockholder Action by Written Consent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and our amended and restated bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting
or special meeting of stockholders may only be taken if it is properly brought before such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Meetings of Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders may only
be called by our board of directors, Chairman of the board of directors, or our Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment of Certificate of Incorporation
or Bylaws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Delaware General Corporation Law provides
generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&rsquo;s
certificate of incorporation or bylaws, unless a corporation&rsquo;s certificate of incorporation or bylaws, as the case may be, requires
a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of
the holders of at least 66 2/3% of the votes which all our stockholders would be eligible to cast in an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Liability and Indemnification
of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws provide indemnification
for our directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law. The indemnification
agreements that we have entered into with each of our current executive officers and that we intend to enter into with each of our directors
and executive officers may, in some cases, be broader than the specific indemnification provisions contained under Delaware law. In addition,
as permitted by Delaware law, our amended and restated certificate of incorporation includes provisions that eliminate the personal liability
of our directors and officers for monetary damages resulting from breaches of certain fiduciary duties as a director or officer, as applicable,
except to the extent such an exemption from liability thereof is not permitted under the Delaware General Corporation Law. The effect
of these provisions is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against
a director or officer for breach of fiduciary duties as a director or officer, subject to certain exceptions in which case the director
or officer would be personally liable. An officer may not be exculpated for any action brought by or in the right of the corporation.
A director may not be exculpated for improper distributions to stockholders. Further, pursuant to Delaware law a director or officer may
not be exculpated for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any breach of his or her duty of loyalty to us or our stockholders;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any transaction from which the director or officer derived
an improper personal benefit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These limitations of liability do not apply to
liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies such as injunctive
relief or rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws provide that we
will indemnify our directors and executive officers to the fullest extent permitted by law, and may indemnify other officers, employees
and other agents. Our amended and restated bylaws also provide that we are obligated to advance expenses incurred by a director or executive
officer in advance of the final disposition of any action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with each of our current executive officers and plan to enter into separate indemnification agreements with our directors and
executive officers. These agreements, among other things, require us to indemnify our directors and officers for any and all expenses
(including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses,
duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments, fines and amounts paid in
settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection with any action or proceeding
arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which
the person provides services at our request provided that such person follows the procedures for determining entitlement to indemnification
and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions and indemnification agreements
are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing
a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against
directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations
and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant
to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, there is no pending litigation or
proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any
threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dissenters&rsquo; Rights of Appraisal and Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Delaware General Corporation Law, with
certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of Cadrenal Therapeutics,
Inc. Pursuant to the Delaware General Corporation Law, stockholders who properly request and perfect appraisal rights in connection with
such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court
of Chancery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stockholders&rsquo; Derivative Actions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Delaware General Corporation Law, any
of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that
the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&rsquo;s
stock thereafter devolved by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock is Transfer Online, Inc., 512 SE Salmon Street, Portland, OR&nbsp;97214.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trading Symbol and Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &ldquo;CVKD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>f10k2022ex21-1_cadrenal.htm
<DESCRIPTION>SUBSIDIARIES OF REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>f10k2022ex23-1_cadrenal.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
in the Registration Statement on Form S-8 (No.&nbsp;333-268372) of Cadrenal Therapeutics, Inc. of our report dated March 29, 2023, relating
to the consolidated financial statements, which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ WithumSmith+Brown, P.C.</FONT></TD>
    <TD STYLE="width: 60%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East Brunswick, New Jersey</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;29, 2023</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>f10k2022ex31-1_cadrenal.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">I, Quang Pham, certify
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of Cadrenal Therapeutics, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financing reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 29,
    2023</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Quang Pham</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>f10k2022ex31-2_cadrenal.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE
SECURITIES EXCHANGE ACT OF 1934,</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Matthew Szot, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of Cadrenal Therapeutics, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Szot</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Szot</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 31%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>f10k2022ex32-1_cadrenal.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION PURSUANT
TO</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>18 U.S.C. SECTION 1350,</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>AS ADOPTED PURSUANT
TO</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
Annual Report of Cadrenal Therapeutics, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Quang Pham, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Registrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2023</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Quang Pham </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 31%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>f10k2022ex32-2_cadrenal.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION PURSUANT
TO</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>18 U.S.C. SECTION 1350,</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>AS ADOPTED PURSUANT
TO</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
Annual Report of Cadrenal Therapeutics, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed
with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Matthew Szot, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Registrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 29, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew Szot</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Szot</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $4 3\# 2(  A$! Q$!_\0
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M222">VM&NYY/+/EQHI4$9[M\P.!G^5 %#_A67@C_ *%C3?\ OR*/^%9>"/\
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MQ2YNK:.W,@#(J2[\J0""3@8ZTKZV-/9RY.?IL7J***9F%%%% !1110 4444
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M8<C,R;&88;K\W]T&MGQ#/KDOQE\&IJ=E:06,=S>"REAF+O*OE<EP1\IZ?F:
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M\CK:***D@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXW?\
M).9O^OF+^9KT:O.?C=_R3F;_ *^8OYF@#;^&7_),O#O_ %XQ_P JS+_2+C6O
M%NH0N;*"R50S.DBN6<!=OFQEN3RW\*D ##<UI_#+_DF7AW_KQC_E47C0^&+%
MX;_Q)H$=S:@$/J#6R2"''0/_ !8/L"* .ETV6"2QC2":VE$0$3&VQY:L!@@
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M!Q%(&*YZ9QTH L5YS\;O^2<S?]?,7\S7HU><_&[_ ))S-_U\Q?S- &W\,O\
MDF7AW_KQC_E7/>-+ZZC\50SK;Z?+#:Q-'"]SHUU=/#*=I+*8U*]",$>X[5T/
MPR_Y)EX=_P"O&/\ E6)X^U"U?4[2./6'TF> LCWL4-R\L9PK;52,;&!!&=Y(
M]CS@ [?2+:*WTZ-D5/,G FGD6+RO-D8#<Y7L3Z'I5'QFNI-X,U==(\TZ@;9O
M)\K[^?\ 9]\9QCFM>S;?96["5I@8U/F.NTOQU(P,$]<8J:@#Q"YBU9M/A2UM
M=3%O&+A=)DMTN$#W1DB,<A1B6C&/,'SG;@,>];'B)]>;XR^#1JD6GI8"YO/L
M+6S.9&7RN?,!X!Z=/>O5Z\]\:_\ )4OAY_UVO?\ T2* /0J*** "BBB@ HHH
MH **** "BBB@ HHHH *BN(([JVEMY5W1RH48>H(P:EHH&G9W1Q&@3R6&K6HF
M)_TE6T^X)_Y^(,[#_P "CS^0KMZXW6K&0ZEJ-M;@":XB34+0^EQ"0"/Q&W\S
M74:;?1:GIMM?0G]W/&KCVR.GX=*:UBGVT_KY%UE:HVMI:_?O^-RU1112,PHH
MHH **** "N0U+0;^WU=-0MKC4;Q&B,;".X198_FR-I88V^W7ZUU]5KC4+*T<
M)<WEO"Y&0LDJJ2/Q-)QYM#:C7E1;:ZF/X:T*YTR$RW-U<>9([R&V\P-&FXYY
MXY;U(XR370U#;W=M=H7MKB*90<%HW# '\*D9U0 NP4$@ DXY/04*/*K$U:LJ
MLG.6[//IO >HG2]+MO/CE:#3WL9D%PT2?,P.\$*21Q@CY3TY%:TGAW4DN]1%
MO'IKK<O)-'=W*F21&:$1A-N.F1US]W(QWKJ?/B&[]ZGR,%;YA\I/0'WY'YU)
M3,SA])\'7D5\ES?BV=!>17'E,_FD;()(^NQ1G+*1@  #VIFK>#]4NM/DM+5K
M-4F:]+?-Y9!F<LAW;"2H'#*,9XYXKMQ/"T[0+*AF0!FC##< >A(]*>[K&A=V
M"JHR23@ 4 <E!X3GB0L3;>>^IV]X\@!RR1I&I!..N4./K4_AWPQ)HES9R8MU
M6+3A:R"(8WN'W;NG(Z]>>:Z>B@ KSGXW?\DYF_Z^8OYFO1J\Y^-W_).9O^OF
M+^9H V_AE_R3+P[_ ->,?\JP_'BZ?9:^MW>:MJEF9-.G*!-5-I [(5Q&O!^=
ML]NPS@UN?#+_ ))EX=_Z\8_Y5@^.SXS:]D$$4W]@K)"5;2HTDN-FX>:7W?,I
M"[MOE@GI0!WND%&T6P,44L49MXRL<Q)=!M& Q/.1WINLZG%HNBWNISHSQVD#
MS,B=6VC.![GI4]F8S8VYB:1H_+7:9<[R,<;L\Y]<\T7MJ+VRFMC--!YJ%?-@
M?8Z>ZGL: .(;XFQ)80W1TLR#RY)[E8;I'^SPQNB,Q/=LN/DX/!]LT_%U]:77
MQ9\!06]U!+-!/>B6..0,T9\D?> Y'0]:V)OAMI5QN>>]U!YYV<WDWF*&NU<H
M61\+@+^[0?* <#KR:P?%&C:9IWQ?\#WEE8P07-[<7K7,L: -*1$.6/?J?SH
M]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_$?^C+8ZJ.ME<*7/_3-_
MD;^8/X5'H/\ Q+]3U/1CPD<GVJV&?^64A)('T<,/Q%;%]:)?6%Q:2?<FC:,_
MB,5YU+J&HS:A8W<=Z+5K"WCM;MQ$'*[Y&C=CGJ R(?;)-725Y./=?D:5'>BI
M?RNWR>OYW/3:*Q_#=W=7FENU[,)IH[B:$R! NX(Y4' XZ"MBI:L[&2=U<***
M*0PHHHH *\[U@W%MXME?4[S3!NM%\IY]/:5=N]L*!G[P[GOQQ7HE%7"?*R)1
MYCBO!BW3ZEJDT-Q9M8&<;A!:-$';RUY7)X [\')!KH/$EG)?>'KR*%<SJ@EA
M&,_O$(=?_'E%:M%$Y<SN.,>56/-[/3[UM4L;A]-N5BUAAJMX"IS')$6=$;/1
MB&A4 _\ /,^E+I]YX@O8KJ-9]1B29+,B1E9GB9I]LH!9% 8)U !5>HKT>BH*
M//[FVNM*N]6>(ZB3=:C%&;@NP^1;9<$LJ,VTMQ\HZX&1S387\0WFAR7-S-?B
M>+10RP&$ 27!,JG<I7EL!/E_3FO0J* .2L?[7'B 3RW%ZT#ZC/ 864")8!&2
MAQC^\!AL]\5UM%% !7G/QN_Y)S-_U\Q?S->C5YS\;O\ DG,W_7S%_,T ;?PR
M_P"29>'?^O&/^5<[XA^(E_IGBJ[TJ"[T&%%F%I&E].8GB8PK+Y[G.#'R5"@
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M@ HHHH **** "O.?C=_R3F;_ *^8OYFO1J\Y^-W_ "3F;_KYB_F: -OX9?\
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MP9 4]\=ZU_LGQ:_Z"GA3_OQ-0!Z#17GWV3XM?]!3PI_WXFH^R?%K_H*>%/\
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M;9M*LS 8O(\OR5QY>[=MQCINYQZ\T^70=)F@>"73;5XGF$[*8A@R  !_][
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M_P#Q=%% !_PT/XS_ .??2/\ P'?_ .+H_P"&A_&?_/OI'_@._P#\7110 ?\
M#0_C/_GWTC_P'?\ ^+H_X:'\9_\ /OI'_@.__P 7110 ?\-#^,_^??2/_ =_
M_BZ/^&A_&?\ S[Z1_P" [_\ Q=%% !_PT/XS_P"??2/_  '?_P"+H_X:'\9_
M\^^D?^ [_P#Q=%% !_PT/XS_ .??2/\ P'?_ .+H_P"&A_&?_/OI'_@._P#\
M7110 ?\ #0_C/_GWTC_P'?\ ^+H_X:'\9_\ /OI'_@.__P 7110 ?\-#^,_^
M??2/_ =__BZ/^&A_&?\ S[Z1_P" [_\ Q=%% !_PT/XS_P"??2/_  '?_P"+
MH_X:'\9_\^^D?^ [_P#Q=%% !_PT/XS_ .??2/\ P'?_ .+H_P"&A_&?_/OI
M'_@._P#\7110 ?\ #0_C/_GWTC_P'?\ ^+H_X:'\9_\ /OI'_@.__P 7110
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) M # 2(  A$! Q$!_\0
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MU% &S_PEGB'_ *#%U^8_PH_X2SQ#_P!!BZ_,?X5C44 ;/_"6>(?^@Q=?F/\
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MB'_H,77YC_"C_A+/$/\ T&+K\Q_A6-10!L_\)9XA_P"@Q=?F/\*/^$L\0_\
M08NOS'^%8U% &S_PEGB'_H,77YC_  KK_AWK6IZGJ]W%?7TUQ&D 95<C .X<
MUYO7=?"W_D.7W_7L/_0A0!8^*G_'UI?^Y)_-:\]KT+XJ?\?6E_[DG\UKSV@
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M4_,/QZ__ *ZEE!BU"6^@B66_M-"A>V4KNP3NRP'<C^M 'G=QI][9QK)=6=Q
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MGG\/ZQ;6SW,^F7,<"+N:1DP /6NFUVYN=>T&]O(Y[JUN+98_[1TZ4D)@?==
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M  N#QG_S_6O_ ("K0!V7_"M_$'I:?]_C_A1_PK?Q!Z6G_?X_X5QO_"X/&?\
MS_6O_@*M'_"X/&?_ #_6O_@*M '9?\*W\0>EI_W^/^%'_"M_$'I:?]_C_A7&
M_P#"X/&?_/\ 6O\ X"K1_P +@\9_\_UK_P" JT =E_PK?Q!Z6G_?X_X4?\*W
M\0>EI_W^/^%;OPH\6:OXKL-3EU>:.5X)D2,I$$P"N3TK;USQ%>:;J;6T*0E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %;7A3_D/Q?[C_ ,JQ:VO"G_(?B_W'
M_E0!R7QY_P"/[0_^N<W\TKR"O7_CS_Q_:'_USF_FE>04""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /;_ (#?\@K6_P#KXC_]!K>\6?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *#6]XL_Y#S_ /7-: -7PYK&GV6D+#<W*QR!V.T@]"?I6M_PD>D?\_J?D?\
M"O.:*!GH_P#PD6D?\_T?Y'_"C_A(M(_Y_H_R/^%><9%&10!Z/_PD6D?\_P!'
M^1_PH_X2+2/^?Z/\C_A7G&11D4 >C_\ "1:1_P _T?Y'_"C_ (2+2/\ G^C_
M "/^%><9%&10!Z/_ ,)%I'_/]'^1_P */^$BTC_G^C_(_P"%><9%&10!Z/\
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M.O-Z* /2/[?TG_G_ (?SH_M_2?\ G_A_.O-Z* /2/[?TG_G_ (?SH_M_2?\
MG_A_.O-Z* /2?[?TH_\ +_#_ -]4?V]I7_/_  ?]]5YM10!Z3_;VE?\ /_!_
MWU1_;VE?\_\ !_WU7FU% 'I/]O:5_P _\'_?5']O:5_S_P '_?5>;44 >D_V
M]I7_ #_P?]]4C^(-*1&;[;$<#.%.2:\WHH T=8U>;5KG>V4A4_NX_3W/O6=1
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %;7A3_D/Q?[C_P JQ:VO"G_(?B_W'_E0!R7QY_X_M#_ZYS?S
M2O(*]?\ CS_Q_:'_ -<YOYI7D% @HHHH ]%\#?\ )-?'?_7"/_T%Z75&8? '
M1T!.U]28,.Q&9#S^(%>=!F (#, >H!X-&YMNW<VWTSQ^5 'T-X>);4/ 18DG
M^Q)^3_NPUPG@(KJOAWQ=X:MKJ.WU>_8R0,[;?. )RN?S!]FS7FHDD&,2.,<#
M#'BD#%6#*Q# Y# X(/UH ]5MM&NO ?PR\1P>(6ABEU3$5I8B4.2V,;N..X/'
M9:G\?2./BMX1&\_)':E.?NDRG./K@5Y+-/-</OGFEF?&-TCECCZFFEV)!+L2
M.A).10!["9';]I($L25.P<]%^SYQ]*N1Z+>^(/A]XITW3Y42YEU^X*H[[!+B
M13LS[XKQ+>^[=O;=_>W'/YTX32A=HFD W;L!SC/K]?>@#U273Y_ WPFOM.U\
MQ_:]0O$>WL!('*A60D\<=%)...GK5SQGX0U?QWXAT[Q!X>N8+C39H(Q',9@O
MV4@Y)QU[YXYSQ7C\LTMQ)YD\TDKXQND<L<?4TL=Q<0QM'%<31H_WE20J&^H!
MYH ]NO-3U/4?B/J,GA:.QU-+/3X[;4()Y%"WAW-E5]QD\].H/6K>DZ)IFB_$
ME_[/MQ9R7.AO-<V*N'%N^].!CH.O XXXX->"1220.)(9'B=>C1L5(_$4&61I
M&D,LAD;[SECD_4]Z /;?"^B7^M^%=/T[Q3IEE=:*;1I+75([A1+9KCA6/TQT
MX['.#7B4BJDLBH^]%8A7_O '@_C3A/.L!@6>40MR8PY"GZCI4= !1110![?\
M!O\ D%:W_P!?$?\ Z#6]XL_Y#S_]<UK!^ W_ ""M;_Z^(_\ T&M[Q9_R'G_Z
MYK0!N^#T5M'<E03YS=1["N@\J/\ N+^58'@[_D#/_P!=V_D*Z&@!GDQ?\\T_
M[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_OD4^B@!GDQ?\ /-/^^11Y
M,7_/-/\ OD4^B@!GDQ?\\T_[Y%'DQ?\ /-/^^13Z* (S!">L2?\ ?(H^SP_\
M\8_^^14E% $?V>'_ )XQ_P#?(H^SP_\ /&/_ +Y%244 1_9X?^>,?_?(H^SP
M_P#/&/\ [Y%244 1_9X?^>,?_?(H^SP_\\8_^^14E% $?V> _P#+&/\ [Y%)
M]EM_^>$7_? J6B@"+[+;_P#/"+_O@4?9;?\ YX1?]\"I:* *MQIUI=6[PR6\
M>UA@X4 CZ&O/]7TF;2;KRY/FB;F.3'##_&O2JKWME!?VKV]PFY&_,'U'O0!Y
M;15[5=+GTJZ,,OS(>8Y .&'^-4:!A1110 4444 %%%% !1110 4444 %%%%
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M_P"N<W\TKR"O7_CS_P ?VA_]<YOYI7D% @HHHH **** "BBB@ HHHH ****
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M6NHQW,<?D,XD1HU<AL^^T].1ZU8TK7-7O+6TL],BM&DM]/M[BXDOIG)<R+D
M$<]CEC71+H&EK;VT"V:"*VWF%<GY-X(;OW#'\ZAN?"VAWD5M'/IT3K;1B*+.
M<A!T4G/(]CFCDGW!XG"O10MOT^[2^NGGYF/J_B76+>35VL+>P\O2;=9+@7#M
MF1F3=A<8X ]>I]*N^&+R>[O]<::5W"W,>Q2Q(0&%&(7T&2:N:AX7T35)1)>:
M?%(PC\KJ5R@Z @$9QVSTJ]::?:6+S/;0B-IV#2$$_,0H4'\@!^%4HRYKMZ&4
MZ]#V/)"-I.W3TZW?GV['G]OK>K/9V4!AO1$VN>6;XSC:R^>1LQG=C'&,8XK7
ML?&&H7NIIY>F.^GR736X*P2;T )7>7QL(R.0.0*Z)=$TU;:.W%JHACN/M2KD
M\2[MV[KZG--CT#2HM3.HI91K=EBWF#/WCP6QTR?7&:E0FNIM/%8::=Z?>WS_
M *^71:G.VOBK6)VTN[:WL%T_4KEXHE#,98U <@GL2=G;I5:VUC6]3NO"=[))
M;01WLLC-#%OP5\LG#<\]"1Z''I72Q^%=#BU 7T>GQK<B0RAPS85CG) S@9R<
MX'-68=%TZ!+%(K556PS]F )_=Y&TXY]"1S0H3ZL4L3AE\$._3R?F^ZUZVOH8
MWB+57\.ZS:ZI/-)_9TL$D$L98[5D4;T('J<,OXBLBTUGQ!9:=<0QBVEN+&R%
M]>M>N^YGD#/L3'0*!C\,5VNH:;9ZK;"VOK=)X0ZOL;IN!R#574_#FD:Q.LU_
M8I-($\O<21E?0X(R/K3E"5[IDT<304(QJ1N^NBZ;=NC:>O9ZV.8A\17T%YJ&
MI-A[=(;"6>$EBL4<BMYC(,\$9!^@J>;QC?-!:O:VB/\ ;[B86C"*23]Q'@;R
MJ\DL>0!C@YKI8]%TZ%9U2U0+<0K!*,D[XU!55/T!(I+C0M,NK""QFLXVM[<
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MO]X_WC61110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^/[0_\ KG-_-*\@KU_X\_\ ']H?_7.;^:5Y!0(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ]O^ W_(*UO_KXC_\ 0:WO%G_(>?\ ZYK6
M#\!O^05K?_7Q'_Z#6]XL_P"0\_\ US6@#$HHHH&%%%% !1110 4444 %%%%
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M+=+&"H7:4ST_&NBHH X__A"9?^?Y/^_1_P :/^$)E_Y_D_[]'_&NPHH X_\
MX0F7_G^3_OT?\:/^$)E_Y_D_[]'_ !KL** ./_X0F7_G^3_OT?\ &C_A"9?^
M?Y/^_1_QKL** ./_ .$)E_Y_D_[]'_&C_A"9?^?Y/^_1_P :["B@#C_^$)E_
MY_D_[]'_ !H_X0F7_G^3_OT?\:["B@#C_P#A"9?^?Y/^_1_QH_X0F7_G^3_O
MT?\ &NPHH X__A"9?^?Y/^_1_P :/^$)E_Y_D_[]'_&NPHH X_\ X0F7_G^3
M_OT?\:/^$)E_Y_D_[]'_ !KL** ./_X0F7_G^3_OT?\ &C_A"9?^?Y/^_1_Q
MKL** ./_ .$)E_Y_D_[]'_&C_A"9?^?Y/^_1_P :["B@#C_^$)E_Y_D_[]'_
M !H_X0F7_G^3_OT?\:["B@#C_P#A"9?^?Y/^_1_QH_X0F7_G^3_OT?\ &NPH
MH X__A"9?^?Y/^_1_P :/^$)E_Y_D_[]'_&NPHH X_\ X0F7_G^3_OT?\:/^
M$)E_Y_D_[]'_ !KL** ./_X0F7_G^3_OT?\ &C_A"9?^?Y/^_1_QKL** ./_
M .$)E_Y_D_[]'_&C_A"9?^?Y/^_1_P :["B@#C_^$)E_Y_D_[]'_ !H_X0F7
M_G^3_OT?\:["B@#C_P#A"9?^?Y/^_1_QH_X0F7_G^3_OT?\ &NPHH X__A"9
M?^?Y/^_1_P :/^$)E_Y_D_[]'_&NPHH X_\ X0F7_G^3_OT?\:/^$)E_Y_D_
M[]'_ !KL** ./_X0F7_G^3_OT?\ &C_A"9?^?Y/^_1_QKL** ./_ .$)E_Y_
MD_[]'_&C_A"9?^?Y/^_1_P :["B@#C_^$)E_Y_D_[]'_ !H_X0F7_G^3_OT?
M\:["B@#C_P#A"9?^?Y/^_1_QH_X0F7_G^3_OT?\ &NPHH X__A"9?^?Y/^_1
M_P :/^$)E_Y_D_[]'_&NPHH X_\ X0F7_G^3_OT?\:/^$)E_Y_D_[]'_ !KL
M** ./_X0F7_G^3_OT?\ &C_A"9?^?Y/^_1_QKL** ./_ .$)E_Y_D_[]'_&C
M_A"9?^?Y/^_1_P :["B@#C_^$)E_Y_D_[]'_ !H_X0F7_G^3_OT?\:["B@#C
M_P#A"9?^?Y/^_1_QH_X0F7_G^3_OT?\ &NPHH X__A"9?^?Y/^_1_P :/^$)
ME_Y_D_[]'_&NPHH X_\ X0F7_G^3_OT?\:/^$)E_Y_D_[]'_ !KL** ./_X0
MF7_G^3_OT?\ &C_A"9?^?Y/^_1_QKL** ./_ .$)E_Y_D_[]'_&KVD>&9-,U
2%+IKI9 JD;0F.OXUT5% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K 9H# 2(  A$! Q$!_\0
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M.,C?@H?FPQ'7I44_@#2KCQ VJO<7P5[J.]ELA,!;R7" !9&7&<C XS@D#(H
MYWP_XRUVZU/P_?7]Q:MIFORW<:6JP[3:"+<4._/S9"'=D=^*ZK_A8'@X]/%.
MC_\ @;'_ (U7TCP!I.CZO%?PSWLB6[3-9VDLH:&U,IS)Y:XSSD]2<9.*XWQS
MINFM\2=.BN;&!K1M-VOA,;"9>&&/I2;LKC2N=S_PL'P:/^9IT?\ \#8_\:/^
M%@^#?^AJT;_P-C_QKG8_ PMY]EA?R1OC*P3N=K#U1QV^H-3&PO;%=MX=1MP.
MLJVMO=Q_F$##\10F(W/^%@^#?^AJT;_P-C_QH_X6#X-_Z&K1O_ V/_&LZRLY
M;X$Z?KVCW9_N2Z<FX?4*P(_*KW]DZXO_ "Q\.R>YM'7^IHN _P#X6#X-_P"A
MJT;_ ,#8_P#&C_A8/@W_ *&K1O\ P-C_ ,:9_9FN?\^7AW_OR_\ A33H>MR'
M>9=#B(Z1IIY96^I+9_*BX$O_  L'P;_T-6C?^!L?^-'_  L'P;_T-6C?^!L?
M^-1_9-:M^9-$T.\7OY+&)OR92/UH^WI <7OA"ZB_VH8(IU_\=.?THN!)_P +
M!\&_]#5HW_@;'_C1_P +!\&_]#5HW_@;'_C3%U[PIN"3K!:N?X;JT,)_\>4"
MM.U&A7RYM!ITX_Z9!&_E1<#/_P"%@^#?^AJT;_P-C_QH_P"%@^#?^AJT;_P-
MC_QK:_LVP_Y\K;_OTO\ A1_9MA_SY6W_ 'Z7_"F!B_\ "P?!O_0U:-_X&Q_X
MT?\ "P?!O_0U:-_X&Q_XUM?V98?\^5M_WZ7_  H_LRP_Y\K;_OTO^% &+_PL
M'P;_ -#5HW_@;'_C1_PL'P;_ -#5HW_@;'_C6U_9EA_SY6W_ 'Z7_"C^S+#_
M )\K;_OTO^% &+_PL'P;_P!#5HW_ (&Q_P"-'_"P?!O_ $-6C?\ @;'_ (UM
M?V98?\^5M_WZ7_"C^S+#_GRMO^_2_P"% &+_ ,+!\&_]#5HW_@;'_C1_PL'P
M;_T-6C?^!L?^-;7]F6'_ #Y6W_?I?\*/[,L/^?*V_P"_2_X4 8O_  L'P;_T
M-6C?^!L?^-'_  L'P;_T-6C?^!L?^-;7]F6'_/E;?]^E_P */[,L/^?*V_[]
M+_A0!B_\+!\&_P#0U:-_X&Q_XT?\+!\&_P#0U:-_X&Q_XUM?V98?\^5M_P!^
ME_PH_LRP_P"?*V_[]+_A0!B_\+!\&_\ 0U:-_P"!L?\ C1_PL'P;_P!#5HW_
M (&Q_P"-;7]F6'_/E;?]^E_PH_LRP_Y\K;_OTO\ A0!B_P#"P?!O_0U:-_X&
MQ_XT?\+!\&_]#5HW_@;'_C6U_9EA_P ^5M_WZ7_"C^S+#_GRMO\ OTO^% &+
M_P +!\&_]#5HW_@;'_C1_P +!\&_]#5HW_@;'_C6U_9EA_SY6W_?I?\ "C^S
M+#_GRMO^_2_X4 8O_"P?!O\ T-6C?^!L?^-'_"P?!O\ T-6C?^!L?^-;7]F6
M'_/E;?\ ?I?\*/[,L/\ GRMO^_2_X4 8O_"P?!O_ $-6C?\ @;'_ (T?\+!\
M&_\ 0U:-_P"!L?\ C6U_9EA_SY6W_?I?\*/[,L/^?*V_[]+_ (4 8O\ PL'P
M;_T-6C?^!L?^-'_"P?!O_0U:-_X&Q_XUM?V98?\ /E;?]^E_PH_LRP_Y\K;_
M +]+_A0!EVOC?PK?745K:>(]*GN)6"1Q1W:,SL>@ !Y-;U<3XZL[6!?#;PVT
M,;?V_9C<D8!^\?2NVH **** "BBB@ HHHH **** "BBB@ HHHH *\X\80F;Q
ME=NJ;VM]"6Y4?]<[D,?T!'XUZ/7(3Q)/\4WAD&4DT!E8>H,^#0!K:5Y5Y8-9
MRG?]G("/GDH1E&!_W2/RJVL\MFP2[.Z(\+/C]&]/K7/>'YGMM.TRXD;)BW:9
M=?5&*H3^(_\ 'JZY@&4JP!!X(-2ET*EW*-[HVF:EAKNRAE;LY7##Z,.:I_V%
M=6O_ "#=9NX0.D5QB=/_ ![YA^=7A:SVQ(M)4$7:.4$A?H>PI?.OD^_:QR>\
M<G]"*=R2A]K\06G_ !\:=;7J#J]I+L;_ +X?C_QZE'BG3XSMO5N;!^F+N%D'
M_?7*_K5[^T%7_703Q>[1Y'YC-21W5K< JLT;YX*Y_I1= .M[NVNTWVUQ%,G]
MZ-PP_2IJRKCPWH]S)YC6$22_\](<QM^:X-0_V#=0?\>.N7\6.BS%9U_\>&?U
MI@;3*KKM90P/8C-9=SX:T2\;=/I5HS_WQ$ WYCFH=OB6WZ/IMXH_O*\+'_T(
M4O\ :^JP_P#'SX?G(_O6TZ2?H2IHL!&/"=E%_P >5YJ5D/[L%X^W\F)%(=+U
M^U&;/7Q<8Z1WULK ^Q9-I_G4I\2PI_K].U2$>K6;$?FN:='XIT=Y$0W31,Y"
MCSH7C&?3+ "BPBO_ &[J-CQJVB3J@ZW%B?/C^I PX_(UHZ?K>F:KG[%>PS,.
MJ!L.OU4\C\15^L_4-"TO5<&]LH97'23;AU^C#D?G2U&:%%<__8>IV/.E:W-L
M'2WOU\]/H&X<?F:4:KK]J,7>@>?CK)8W*L#[A7VFBX&_16#_ ,)9:1'_ $RQ
MU.S']Z:S<K^:Y%3V_BC0KIMD6K6F_P#N/($;\C@T70&O13(Y8Y5W1NKKZJ<B
MGTP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y#Q_\ ZKPW_P!C
M!9_^A&NOKD/'_P#JO#?_ &,%G_Z$:Z^@ HHHH **** "BBB@ HHHH **** "
MBBN3M?B'HEUJHLMMW%$[3I#>RP[;>9H03($;/.,-U !VG&: .LKE/^:M#_L!
M'_T?4WA[QOIGB2]^R6T%[;RM;"[@%W#Y?VB G D3DY7..N#R.*A_YJT/^P$?
M_1] $ME:HVJ^(M(D^5)V2[C_ .VBX)'T9":V=*NGNK!#+Q/&3%,/1UX/^/XU
MFWW^B>,]+N<X6\@EM'],KB1?Y/5O_CQU[TAOE_ 2J/ZK_P"@TI;IE;HU****
M9(5%+;03_P"MA1_]Y<U+10!3_L]4_P"/>::'V#;A^1S1NOH/O)'<+ZK\C?D>
M*N44K 5X;V&9_+R8Y?\ GG(-K?\ UZL5%/;Q7";)4##MZCZ'M5;=<6/W]T]N
M/XQRZ?7U'OUHVW O5'/!%<P/#/&DL3C#(XR&'N*6.5)HP\;AD/0@T^F!S_V+
M4-!.[3=][IXZV3M^\B'_ $R8]1_LG\#6IIVJ6FJ0&6UEW;3M=&&UXV]&4\@U
M<K+U'1(KN<7EM*UGJ"C"W,0Y(_NN.CK['\,4 :E%8EMK<MK<)9:W$MK<,=L<
MZG]Q.?\ 9)^Z?]D_AFMN@ JO<V-I>+MN;6"<>DL8;^=6** ,.3PAH+OO33D@
M?^];,T)_\<(IO_"-/"<V>N:M;^BM.)E_)P?YUO44K(#!^Q>);<_N=9L[H?W;
MJTVG\T8?RIC:UJFE'=K>FH;7O=V#-*J?[Z$;@/<9KH:*+ 06EY;7ULES:3QS
MPN,J\;!@?QJ>L.[\-1?:7O=)G?3+UN6>$ QRG_;CZ-]>#[U"OB&YTQA#XBM1
M;#.%OH,O;M]3UC/^]Q[T7[@=%138Y$EC62-U=&&593D$>QIU, HHHH ****
M"BBB@ HHHH **** .0\?_P"J\-_]C!9_^A&NOKD/'_\ JO#?_8P6?_H1KKZ
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M9PW*?=D4-CT]14]9=C_H6J7-B>(Y?](A_$_./P//_ JU*2>@-!1113$%%%%
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MM9N?E_X ?X3[=/I5NRU&"]#*FY)D_P!9#(,.GU']>E"?1A;L6Z***H04444
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M!-16!97=QHUY'I>I2M)!(=MG>/\ Q_\ 3-S_ '_0_P 7UK?H **** .0\?\
M^J\-_P#8P6?_ *$:Z^N0\?\ ^J\-_P#8P6?_ *$:Z^@ HHHH **** "BBB@
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M4<#CZGO6;:^!X;7X;-X,%](T)M9+;[28QNPQ)SMSCO0!RFL?$7Q'H4\%M?\
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M74+"VU2PEL[N/?#*,,,X(]"#V(/(-9>BW]S;W;:'JLF^]B7=!<'C[5$/XO\
M>'1A^/0UO5FZUI":M:*JR&"[A;S;:X4?-%(.A]QV([@TP-*BLG1-7;4(I;>[
MC$&I6I"74 / /9E]5;J#^':M:D 4444 %5;^R6^MC&6*2*0T<@ZHXZ$5:HI-
M7 I:;>M=1/'.H2ZA.R9!V/J/8]15VLS4K>6&5=2M4+3Q#$D8_P"6L?<?4=1_
M]>KUO/%=6\<\+!HW&Y2/2DGT8WW):***H04444 %%%% !1110 4444 %%%%
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M]C!9_P#H1KKZ "BBB@ HHHH **** "BBB@ HHHH **** "N4_P":M#_L!?\
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M42^B[O,OY%=E_?@8!51Q0!WU%%% !1110 4444 %%%% !1110 4444 %%%%
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M'"L"5/H?2N7_ .:M#_L!?^UZ .KHHHH **** "BBHI;F"W>))IHXVF?9$KL
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M50MM#'' SV^M>=1^/-;B\+ZW=7=I8?VK::R-*@CB+^3N8QJ"Q/) +G/3..U
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M&&R!@ YSG-==X3\/KX8\.6VE^>;B1"\DLVW;YDCL78X[#+' ]*VJ* "BBB@
MJ.>)9X)(7SLD4JV/0C%244 >5P?"*9].>POM4MA%!ISZ?926MIY;X+JXDE.[
MYF!1>!@=3U-=;X9\.:AIVJZGK.LWUO=ZGJ"Q1N;:$QQ1QQ@A0 23DDDDY[^U
M=/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 8_BVVGO/!NMVMK$TMQ-83QQQIU=C&P 'U)KSW7M#\02>']
M#M[2SO-\/A:YMI4C)&V<Q1!5.#][(8#Z5ZU10!XGJG@&\@@UUM/T_4C+'8V5
MQ8;;F0DWF3YKC+<O@+DG^M:>FZ#K/_"PY;K41J4=RNJO/%>0VV^.6U*X6)I2
M^%3'&S;D$9]Z]9HH \D\9VM_/XA\:65C'-)J%]H=J]BL1P[!)7#[3[%A^=4]
M4\"W=K/XCETS3]1W6\NGSZ5MN)&Q(6'VATRW+8'S$U[$UM URERT,9G12B2E
M1N53C(!Z@' X]A4M 'D-MH6M?\)?#+_9>HQZRFN27%QJ[2?N'L"6(C!W8(*E
M5"8X(SQ65;>!M8_L?2HQIEZ;F]T?4(=3\Z9CNDQFW5\M@8;&,5[G10!XE_PA
MDNJ6]N3X?U"WAMO"LL444A:-EO1(2!PW))RRYXZ&M/0;35=-\56FJ:E87<BM
MIRMJ=W?Q;?L92V /E2AL,I8'*%>#DYKUJHYH8KB%X)XTEBD4JZ.H96!Z@@]1
M0!RWPPAE@^&F@I*I1C;!PIZA6)9?_'2*ZVFHBQH$10J*,*H& !Z4Z@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #3 3$# 2(  A$! Q$!_\0
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MH/SHRW]T?G3)'44W+?W1^=&6_NC\Z '44W+?W1^=&6_NC\Z '44W+>@_.G4
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M_,;?0KN4/*A51\T0Y'('M@>IR,#)R*S/#E\I2:U6$/<0Q*[&"X65),Y ^88
M;CH>V.3UK5UJQGU+2I;2WN&@D=D_>*Q4A0X+8(Y&0"/QI=-L9[#S(VN5F@)S
M&/)5'7UR5P&_(?C0!6\/2.]I=N\+1L;V?*,02OSGT.*U\G^Z:R]"_P!3>_\
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M>WGBV,/M+.JD0\N"#AN3F-N1D5);>,[*YGMXA;7"&:01EFVA$)QM!;."3N'
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B @@# 2(  A$! Q$!_\0
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M ^BF>='_ ,]%_.CSH_\ GHOYT /HIGG1_P#/1?SH\Z/_ )Z+^= #Z*9YT?\
MST7\Z/.C_P">B_G0 ^BF>='_ ,]%_.CSH_\ GHOYT /HIGG1_P#/1?SH\Z/_
M )Z+^= #Z*9YT?\ ST7\Z/.C_P">B_G0 ^BF>='_ ,]%_.CSH_\ GHOYT /H
MIGG1_P#/1?SH\Z/_ )Z+^= #Z*9YT?\ ST7\Z/.C_P">B_G0 ^BF>='_ ,]%
M_.CSH_\ GHOYT /HIGG1_P#/1?SH\Z/_ )Z+^= #Z*9YT?\ ST7\Z/.C_P">
MB_G0 ^BF>='_ ,]%_.CSH_\ GHOYT /HIGG1_P#/1?SH\Z/_ )Z+^= #Z*9Y
MT?\ ST7\Z/.C_P">B_G0 ^BF>='_ ,]%_.CSH_\ GHOYT /HIGG1_P#/1?SH
M\Z/_ )Z+^= #Z*9YT?\ ST7\Z/.C_P">B_G0 ^BF>='_ ,]%_.CSH_\ GHOY
MT /HIGG1_P#/1?SH\Z/_ )Z+^= #Z*9YT?\ ST7\Z/.C_P">B_G0 ^BF>;'_
M ,]%_.B@#SC4(E+:H_V99=,?41)+JX3,MN0PW*HZD*5V[AP 3P<5Z2"" 1R#
M6'+X4L)7F4RW:VLTAEEM%F(A=B<G(ZX)Y(!Q6Z!@8'2@ J/RBW^L<M[#@5)1
M0 @4*,  #V%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<_KGC30?#^5O;U#./^6$/SR?D.GXXKH*^<=0 _M2\X'_'Q
M)_Z$: /3/^%P^'_^?34?^_2__%4?\+A\/?\ /IJ/_?I?_BJ\KP/2C ]* /5/
M^%P^'O\ GTU'_OTO_P 51_PN'P]_SZ:C_P!^E_\ BJ\KP/2C ]* /5/^%P^'
MO^?34?\ OTO_ ,51_P +A\/?\^FH_P#?I?\ XJO*\#THP/2@#U3_ (7#X>_Y
M]-1_[]+_ /%4?\+A\/?\^FH_]^E_^*KRO ]*,#TH ]3/QB\/#K:Z@/K$O_Q5
M='X6\7Z=XN@N9M/CG1;=PC^<H&21GC!-?.>L?ZR'_=/\Z]6^!W_(*UC_ *^$
M_P#0: /5J*** "BBB@#/N]=TNQNUM;F]C2=L?N^21GIG'3/O6A7 VU]J>F:?
MKVL1/9%8=1F,\,D;>9(%8*!OSQ\NW P>WK7>J=R@X(R,X- "T=**C\D$Y<ES
M[]/RH //C[,3] 31Y\?JW_?)J2B@"/SX_5O^^31Y\?JW_?)J2B@"/SX_5O\
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M.3_OFCS?^F<G_?- $E%1^;_TSD_[YH\W_IG)_P!\T 245'YO_3.3_OFCS?\
MIG)_WS0!)14?F_\ 3.3_ +YH\W_IG)_WS0!)7SEJ/_(4O/\ KO)_Z$:^B?-_
MV'_[YKYUU#_D)WG_ %WD_P#0C0!7HHHH **** "BBB@ HHHH R=8_P!9#_NG
M^=>K? [_ )!6L?\ 7PG_ *#7E.L?ZR'_ '3_ #KU3X(OMTK6/E8_Z0G0?[-
M'K%%1^;_ -,Y/^^:/-_Z9R?]\T 245'YO^P__?-% ' :K+J$5[!>7FD7?VB7
M5H=C!XROEH6V1K\V<GEN<<DUZ$I)4$@@GL>U-DBCEV^9&K[6#+N&<$="/>GT
M %,6)0=QRS>K<T^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#SR;\Q3Z* &;W_ .>3?F*-[_\ /)OS%/HH 9O?_GDWYBC>_P#SR;\Q3Z*
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M^@FIG\+ \.'04M(.@I:^:,PHHHH **** "BBB@ KG-4_Y",OX?RKHZYS5/\
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MJ@'''M7B8MK1'921H45'NE_YYK_WU_\ 6HW2_P#/-?\ OK_ZU<)N250US_D
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M0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0!E:Q_K(?]T_SKU;X'?\@K6/\
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M/_GU@_[]BC[#9_\ /K!_W[%6*ANKNWL8#/=3)#$"!N<X&3T'UHN%D-^PV?\
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M)K&GN(3]JC7SY6AAWG;YCJ2"%SUZ&B["P_\ LO3_ /GQMO\ ORO^%']EZ?\
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MYHLNP$O]GV7_ #YV_P#WZ'^%310Q0+MBC2-<YPB@#/X55;5]/2_6Q:\A%TQ
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M22611MW$:3!N ?[R@?K6S8Z=9Z9"T-E;I!&\C2%4&!N8Y)JU0 4444 %%%%
M!7'V-[?QQ6MI9RQ(UWJ-XC22J7V!6=L@9'/%=A52/2[*)XG2W56BD>5#S\KO
MG<?QR?SH Y?[5J&I:AHX$L$=Y%->6[S>62IV?+N"YZG XSZT\:E+?16CW,,!
MG>SO4>15.08V"G;SP#C./I72QZ790S)-';JLB/)(K#/#/RY_&FKI%@@0+;*
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MA$$N23O0 @ G/H3^=6D18T5$&%4  >@H =1110 4444 %%%% !1110 4444
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M%#*S8.!V0D\ 9-=A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "W ?8# 2(  A$! Q$!_\0
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MNKRP/.EK'O,:$ MR!@$_6M2N2^)__)-M<_ZX#_T(5YIWF+_PM*\_Z%*\_P#
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MO]1+_N-_*O3/AY_R3GPY_P!@^'_T 5YG-_J)?]QOY5Z9\//^2<^'/^P?#_Z
M*\W'?9._!]3I:I:IJ^G:+:"ZU2^M[.W+!/-GD"+N/09/?@U=K@?BP VAZ,"
M0=8@X(S_  O7GQ5VD=LG9-FS_P +#\&_]#1I'_@6G^-'_"P_!O\ T-&D?^!:
M?XUYGY,/_/&+_O@4>3#_ ,\8O^^!7H?4?[QQ?7%V.QT7QUX3AUOQ%+)XDTM$
MFO(WB9KI ' MX@2.>1D$?A6W_P +#\&_]#1I'_@6G^->9^3%_P \8O\ O@4>
M3#_SQB_[X%'U'^\'UQ=CTP?$+P:3@>*-(R?^GM/\:Z0$$ @Y!Z&OGSQ%%$/#
MFHD11@^0W(05] 0?\>\7^X/Y5R5Z/LFE>YT4JOM$W8DHHHK V"BBB@ HHHH
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MKIP]:<Y-2/"SS*\-A*$9T4TV[;M]&>H4445W'R04444 %%%% !1110 4444
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M(D$;,9-PRN% R<@$]* .6\5^'-&TO_A&I[/3;6*YBU>Q@6X$0\W8IV@%^IX
M'6N[N/\ CVE_W#_*N4\:3)<67AN:(DQR:W9.I((R"V1P>175W'_'M+_N'^5
M'@'AC_D5M+_Z]UK5K*\,?\BMI?\ U[K6K7T-/X5Z'B3^)A1115DA78?"?_D!
MZS_V&)__ $%*X^NP^$__ " ]9_[#$_\ Z"E<&.^!>IV83XF=]7)?$_\ Y)KK
MG_7 ?^A"NMKDOB?_ ,DUUS_K@/\ T(5Y:W/09Y^>II*4]325]&>&%%%% #)O
M]1+_ +C?RKTSX>?\DY\.?]@^'_T 5YG-_J)?]QOY5Z9\//\ DG/AS_L'P_\
MH KS<=]D[\'U.EK@OBO_ ,@31O\ L,0?^@O7>UP7Q7_Y FC?]AB#_P!!>N"G
M\:]3KG\+..HHHKZ$\4**** ,SQ'_ ,BWJ/\ UP:O?8/^/>+_ '!_*O O$?\
MR+>H_P#7!J]]@_X]XO\ <'\J\K'?$CT<)\+)****X#L"BBB@ HHHH @OKDV6
MGW-T(GF,,32>7&,L^ 3@>YQ7&>"O'S^*=2:R=+!V6!YG>QG,BQ890%;(')#]
M?5&XXKLM0^U?V;=?8=OVOR7\C=TWX.W/MG%<#\/[KQ!>:W=SWTRFU>-A- &@
M/D2*55-WE9(D8"5F!XY7% '3>,-(U'7=#ETVPDLU2X5HYUN@^"I'!4J<@@X.
M.AZ<5C:_X0UO6+:%%U"R\V*UGT_S)(VR\$T:*SD#CS 5) 'R\T_XE:LNE:/:
M[=9FT^ZGE,=LD4B1>=*5.TN[#"QJ?F;UQCG.#G>-==N(-'T^2V\16J-;+(UZ
M(+GR7NI$B#>7&P5@&.[<%/7*T 3WOAZPT?X@^%+BU%QYLTMT',EQ)(#B ]%9
MB%_ "NQUS_D :E_UZR_^@&N,N;_5;SQ[X2^VZ1]BM@]RT,K7(=Y,VY^\@4;3
MCKR:[/7/^0!J7_7K+_Z : /F+3?^07:?]<4_]!%6JJZ;_P @NT_ZXI_Z"*M5
MX,MV?L5'^%'T7Y(****DU"O5_@M_R -9_P"PH_\ Z+CKRBO5_@M_R -9_P"P
MH_\ Z+CKLP?QOT/E^)_]UA_B_1GI=8WB[_D2]=_[!\__ *+:MFL;Q=_R)>N_
M]@^?_P!%M7J'P!\XVO\ QYP?]<U_D*EJ*U_X\X/^N:_R%2UX#W/V2G\"]%^2
M"BBBD6%>I?!3_D%:]_V$O_:25Y;7J7P4_P"05KW_ &$O_:25V8/XWZ'R_$_^
MZQ_Q?HSU"BB@G R:]0^ "BF>=%_ST3_OH5C7_AW1=2O'NKKSC,X )COI8QP,
M?=5P/TH W**X/4O#.C0^(-$MXGNUAN'F$RC4I_F"QDC^/UK8_P"$.\.^ES_X
M,KC_ ..4 =)148EB4 "1,#C[U/5U<95@1['- "T444 ><_$*XO!K=E MS?M:
MO;,(K;3-1CMIOM!;Y6<.REDQP.H!SD'-=QHR7\>B6*:HZ2:@MN@N73HTFT;B
M/QS7G-[X5UIKWQ#YW@[1=8_M&ZEDBO;J[59%C*A47!C8C:!V(KT+P]:W=CX:
MTNTU!]]Y!:11SONW;G50"<]^1UH C\2Z;=:QH<VGVLJQ&X>-)69B,P[QY@!'
M<IN'XUD^*=!U#6[7[-%8:9+#;S!K19;B6(J#$5W90?*RLW Y!'H:ZRB@#S;Q
M#X>N=._X1>ZN]=U.]N$U2PAECEF'D.PPI<)C()(SUZFO1;C_ (]I?]P_RKF/
M'?\ J?#_ /V';/\ ]#KI[C_CVE_W#_*@#P#PQ_R*VE_]>ZUJUE>&/^16TO\
MZ]UK5KZ&G\*]#Q)_$PHHHJR0KL/A/_R ]9_[#$__ *"E<?78?"?_ ) >L_\
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MM55TW_D%VG_7%/\ T$5:KP9;L_8J/\*/HOR04445)J%>K_!;_D :S_V%'_\
M1<=>45ZO\%O^0!K/_84?_P!%QUV8/XWZ'R_$_P#NL/\ %^C/2ZQO%W_(EZ[_
M -@^?_T6U;-8WB[_ )$O7?\ L'S_ /HMJ]0^ /G&U_X\X/\ KFO\A4M16O\
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M=M([.77(].-LS.VD6,<[>;NXWEP<#'0#\:Z_3&=]*M'D:=G,*EFN$"R$X_B
MX#>H%>=?$S3--O\ 6['[9=127'V?%O9S0S2(&#Y+,8_NJPRN3R2%QT-=SX8C
MCB\*:1'%<QW,:V<06>-=JR#8,,!V!H R?B%:F\T"&)KJ[MH?M2-*]M:R3DJ
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M$_\ Z"E<.-=X*QUX3XV=]7)?$_\ Y)KKG_7 ?^A"NMKDOB?_ ,DUUS_K@/\
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M?CWPE!8ZC:W,T4]R9(HIE9XQ]G;[P!R/QKJ]<_Y &I?]>LO_ * : /F+3?\
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M"7_M)*[<'\;]#PN(J:IX*$%TE^C/4*R/%?\ R)^M_P#7A/\ ^BVK7K(\5_\
M(GZW_P!>$_\ Z+:O4/A#YNL_^/&W_P"N2?R%:VEW4-HE](XB,WV?%OYL8<>9
MN7H",9QFLFS_ ./&W_ZY)_(5-7@/<_8>15*2B^R_0WI=5LK;4=0-O$S03.&C
M\D(JCY>>&4XYSTQ4R7UOJ4VFB^U4P(EF\5RPRI8;R1'D#@$8[<"N;HI6,'@H
M6T;OW^5NI=U>X:ZU:XG:2&3<1AH<[,   #(!X  Y]*]'^"G_ "!==_["A_\
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M'V63@X_W:D^T#_GA=_\ @))_\37T$/'WA[[;>6S7I7[,L+>9Y;,LOFKO7R\
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MR3$UTV%"(F9XQ&VU%4*H 4$  #.3WHHH U]#\+6F@W1N+>:>1C8VUCB0@C9
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CI2]V8S)O;(&R-8UQQZ*/QK2HHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "T @$# 2(  A$! Q$!_\0
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M?]\"C[-!_P \(O\ O@5)17I61R$?V:#_ )X1?]\"C[-!_P \(O\ O@5)119
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MPB_[X%'V:#_GA%_WP*DHHL@(_LT'_/"+_O@4?9H/^>$7_? J2BBR C^S0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCFN#=61TE^BJ*:E&K".[1K60\#S/NL?9NA_G[5>S2:L,****0!1110 4444
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M26Z_Y\8O^_Y_^)K)HH]E#L'M)&M_PDMU_P ^,7_?\_\ Q-'_  DMU_SXQ?\
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M#VDC6_X26Z_Y\8O^_P"?_B:/^$ENO^?&+_O^?_B:R:*/90[![21K?\)+=?\
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MH_L35?\ GC;_ /?X_P#Q-=;16GMYD>SB<E_8FJ_\\;?_ +_G_P")H_L35?\
MGC;_ /?\_P#Q-=6LB.2%=6(Z@'.*=1[>8>SB<E_8FJ_\\;?_ +_G_P")H_L3
M5?\ GC;_ /?\_P#Q-=5)-%%CS)$3()^9@.!U_*G A@"""#R"*/;S#V<3D_[$
MU7_GC;_]_P __$T?V)JO_/&W_P"_Y_\ B:ZVBCV\P]G$Y+^Q-5_YXV__ '_/
M_P 31_8FJ_\ /&W_ ._Y_P#B:ZPNH8*6&X]!GDTM'MYA[.)R7]B:K_SQM_\
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M_&LC_A7/AK_GSD_[_-_C1_PKGPU_SYR?]_F_QIVH]W]R_P P]_LC7_M/2/\
MH+V__@6/\:/[3TC_ *"]O_X%C_&LC_A7/AK_ )\Y/^_S?XT?\*Y\-?\ /G)_
MW^;_ !I6H]W]R_S#W^R-?^T](_Z"]O\ ^!8_QH_M/2/^@O;_ /@6/\:R/^%<
M^&O^?.3_ +_-_C1_PKGPU_SYR?\ ?YO\:+4>[^Y?YA[_ &1K_P!IZ1_T%[?_
M ,"Q_C1_:>D?]!>W_P# L?XUD?\ "N?#7_/G)_W^;_&C_A7/AK_GSD_[_-_C
M1:CW?W+_ ##W^R-?^T](_P"@O;_^!8_QH_M/2/\ H+V__@6/\:R/^%<^&O\
MGSD_[_-_C1_PKGPU_P ^<G_?YO\ &BU'N_N7^8>_V1K_ -IZ1_T%[?\ \"Q_
MC1_:>D?]!>W_ / L?XUD?\*Y\-?\^<G_ '^;_&C_ (5SX:_Y\Y/^_P W^-%J
M/=_<O\P]_LC9CU;28RW_ !-K5@>S7*G'ZU']OT0DLVIVI)).?M8_QKF+SPMX
M+L-7L-+N+>=;N_+"!0TA#%5+'+=!P#U/:FZ'X8\'>(;4W5C87OV?C9+,)(UD
M!SRI/WAQVHM1[O[E_F%Y]D=3]OT/_H)6G_@6/_BJ/M^A_P#02M/_  +'_P 5
M65_PKGPU_P ^<G_?YO\ &C_A7/AK_GSD_P"_S?XT[4>[^Y?YA[_9&K]OT/\
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M*MNVR,!DJ<*,=@H P*[:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"\/?@<T44 ,TW3;72K5K>T0JC2O*V6)+.[%F))ZDDFK=%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>cvkd-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:07 UTC 2023 -->
<xs:schema xmlns:cvkd="http://www.cadrenal.com/20221231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.cadrenal.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvkd-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvkd-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvkd-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvkd-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet" id="cvkd_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals" id="cvkd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheet (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement" id="cvkd_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statement of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals" id="cvkd_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statement of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ShareholdersEquityType2or3" id="cvkd_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statement of Changes in Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ConsolidatedCashFlow" id="cvkd_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/RecentAccountingGuidance" id="cvkd_r_RecentAccountingGuidance">
        <link:definition>008 - Disclosure - Recent Accounting Guidance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/FairValueMeasurements" id="cvkd_r_FairValueMeasurements">
        <link:definition>009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AccruedLiabilities" id="cvkd_r_AccruedLiabilities">
        <link:definition>010 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreement" id="cvkd_r_AssetPurchaseAgreement">
        <link:definition>011 - Disclosure - Asset Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/Debt" id="cvkd_r_Debt">
        <link:definition>012 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/RelatedPartyTransactions" id="cvkd_r_RelatedPartyTransactions">
        <link:definition>013 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingencies" id="cvkd_r_LeasesCommitmentsandContingencies">
        <link:definition>014 - Disclosure - Leases, Commitments, and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrants" id="cvkd_r_StockholdersEquityandWarrants">
        <link:definition>015 - Disclosure - Stockholders' Equity and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/EquityBasedCompensation" id="cvkd_r_EquityBasedCompensation">
        <link:definition>016 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/NetLossPerShare" id="cvkd_r_NetLossPerShare">
        <link:definition>017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/IncomeTaxes" id="cvkd_r_IncomeTaxes">
        <link:definition>018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/SubsequentEvents" id="cvkd_r_SubsequentEvents">
        <link:definition>019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AccountingPoliciesByPolicy" id="cvkd_r_AccountingPoliciesByPolicy">
        <link:definition>020 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/FairValueMeasurementsTables" id="cvkd_r_FairValueMeasurementsTables">
        <link:definition>021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AccruedLiabilitiesTables" id="cvkd_r_AccruedLiabilitiesTables">
        <link:definition>022 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementTables" id="cvkd_r_AssetPurchaseAgreementTables">
        <link:definition>023 - Disclosure - Asset Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/DebtTables" id="cvkd_r_DebtTables">
        <link:definition>024 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables" id="cvkd_r_LeasesCommitmentsandContingenciesTables">
        <link:definition>025 - Disclosure - Leases, Commitments, and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables" id="cvkd_r_StockholdersEquityandWarrantsTables">
        <link:definition>026 - Disclosure - Stockholders' Equity and Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/EquityBasedCompensationTables" id="cvkd_r_EquityBasedCompensationTables">
        <link:definition>027 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/NetLossPerShareTables" id="cvkd_r_NetLossPerShareTables">
        <link:definition>028 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/IncomeTaxesTables" id="cvkd_r_IncomeTaxesTables">
        <link:definition>029 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>030 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" id="cvkd_r_ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable">
        <link:definition>031 - Disclosure - Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable" id="cvkd_r_ScheduleofderivativeliabilityTable">
        <link:definition>032 - Disclosure - Fair Value Measurements (Details) - Schedule of derivative liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable" id="cvkd_r_ScheduleofAccruedLiabilitiesConsistTable">
        <link:definition>033 - Disclosure - Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementDetails" id="cvkd_r_AssetPurchaseAgreementDetails">
        <link:definition>034 - Disclosure - Asset Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable" id="cvkd_r_ScheduleofdevelopmentmilestonepaymentsTable">
        <link:definition>035 - Disclosure - Asset Purchase Agreement (Details) - Schedule of development milestone payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable" id="cvkd_r_ScheduleofpurchasepriceoftheassetsTable">
        <link:definition>036 - Disclosure - Asset Purchase Agreement (Details) - Schedule of purchase price of the assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/DebtDetails" id="cvkd_r_DebtDetails">
        <link:definition>037 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte73/PQJDQgE06rdKfUc42n2kE=] CSR-->
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable" id="cvkd_r_ScheduleofdebtoutstandingTable">
        <link:definition>038 - Disclosure - Debt (Details) - Schedule of debt outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/RelatedPartyTransactionsDetails" id="cvkd_r_RelatedPartyTransactionsDetails">
        <link:definition>039 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails" id="cvkd_r_LeasesCommitmentsandContingenciesDetails">
        <link:definition>040 - Disclosure - Leases, Commitments, and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable" id="cvkd_r_ScheduleofoperatingleaseROUassetsandliabilitiesTable">
        <link:definition>041 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable" id="cvkd_r_ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable">
        <link:definition>042 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails" id="cvkd_r_StockholdersEquityandWarrantsDetails">
        <link:definition>043 - Disclosure - Stockholders' Equity and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable" id="cvkd_r_ScheduleofSummarizestheTotalWarrantsOutstandingTable">
        <link:definition>044 - Disclosure - Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/EquityBasedCompensationDetails" id="cvkd_r_EquityBasedCompensationDetails">
        <link:definition>045 - Disclosure - Equity-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable" id="cvkd_r_ScheduleofoptionandwarrantTable">
        <link:definition>046 - Disclosure - Equity-Based Compensation (Details) - Schedule of option and warrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable" id="cvkd_r_ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable">
        <link:definition>047 - Disclosure - Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable" id="cvkd_r_ScheduleofallocationsharebasedcompensationperiodsTable">
        <link:definition>048 - Disclosure - Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable" id="cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable">
        <link:definition>049 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals" id="cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals">
        <link:definition>050 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/IncomeTaxesDetails" id="cvkd_r_IncomeTaxesDetails">
        <link:definition>051 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable" id="cvkd_r_ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable">
        <link:definition>052 - Disclosure - Income Taxes (Details) - Schedule of company&#8217;s income (loss) before provision (benefit) for income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable" id="cvkd_r_ScheduleofcomponentsofincometaxexpensebenefitTable">
        <link:definition>053 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable" id="cvkd_r_ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable">
        <link:definition>054 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable" id="cvkd_r_ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable">
        <link:definition>055 - Disclosure - Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/SubsequentEventsDetails" id="cvkd_r_SubsequentEventsDetails">
        <link:definition>056 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cadrenal.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfDerivativeLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfDerivativeLiabilityAbstract"/>
  <xs:element name="ScheduleOfAccruedLiabilitiesConsistAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract"/>
  <xs:element name="ScheduleOfDevelopmentMilestonePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract"/>
  <xs:element name="ScheduleOfPurchasePriceOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfDebtOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfDebtOutstandingAbstract"/>
  <xs:element name="ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfOptionAndWarrantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfOptionAndWarrantAbstract"/>
  <xs:element name="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract"/>
  <xs:element name="ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
  <xs:element name="ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract"/>
  <xs:element name="ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="StockholdersDeficitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_StockholdersDeficitAbstract"/>
  <xs:element name="OtherExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_OtherExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_UnlabeledAbstract0"/>
  <xs:element name="FinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_FinancialLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_UnlabeledAbstract3"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_AssetsAbstract0"/>
  <xs:element name="LiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_LiabilitiesAbstract0"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_CurrentAbstract"/>
  <xs:element name="NoncurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_NoncurrentAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DenominatorAbstract"/>
  <xs:element name="CurrentAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_CurrentAbstract0"/>
  <xs:element name="DeferredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DeferredAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DeferredTaxAssetsAbstract"/>
  <xs:element name="IssuanceOfInvestorWarrantsinShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_IssuanceOfInvestorWarrantsinShares"/>
  <xs:element name="NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities"/>
  <xs:element name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock"/>
  <xs:element name="DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock"/>
  <xs:element name="PatentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PatentPolicyTextBlock"/>
  <xs:element name="ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems"/>
  <xs:element name="AccruedConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_AccruedConsultingFees"/>
  <xs:element name="CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial"/>
  <xs:element name="FirstMAASubmittedInThePeoplesRepublicOfChina1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1"/>
  <xs:element name="FirstCommercialSaleToAThirdParty1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_FirstCommercialSaleToAThirdParty1"/>
  <xs:element name="DebtDetailsScheduleofdebtoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_DebtDetailsScheduleofdebtoutstandingTable"/>
  <xs:element name="DebtDetailsScheduleofdebtoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems"/>
  <xs:element name="ConvertibleNotesPayableRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ConvertibleNotesPayableRelatedParties"/>
  <xs:element name="DebtIssuanceCosts1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DebtIssuanceCosts1"/>
  <xs:element name="ConvertibleDebt1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ConvertibleDebt1"/>
  <xs:element name="DebtIssuanceCosts2" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DebtIssuanceCosts2"/>
  <xs:element name="ConvertibleDebt2" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ConvertibleDebt2"/>
  <xs:element name="PlacementAgentWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PlacementAgentWarrant"/>
  <xs:element name="WarrantsAndRightOutstandingMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_WarrantsAndRightOutstandingMaturityDate"/>
  <xs:element name="EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable"/>
  <xs:element name="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems"/>
  <xs:element name="WeightedAverageRemainingContractualLifeYearsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_WeightedAverageRemainingContractualLifeYearsGranted"/>
  <xs:element name="WeightedAverageRemainingContractualLifeYearsExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_WeightedAverageRemainingContractualLifeYearsExercised"/>
  <xs:element name="WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired"/>
  <xs:element name="EmployeeBenefitAndShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_EmployeeBenefitAndShareBasedCompensation"/>
  <xs:element name="IncometaxPermanentDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_IncometaxPermanentDifferences"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="WorkingsCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_WorkingsCapital"/>
  <xs:element name="GeneratingGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_GeneratingGrossProceeds"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_NetProceeds"/>
  <xs:element name="AssetPurchaseAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_AssetPurchaseAgreementDetailsTable"/>
  <xs:element name="AssetPurchaseAgreementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_AssetPurchaseAgreementDetailsLineItems"/>
  <xs:element name="DiscountPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DiscountPercentage"/>
  <xs:element name="DebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_DebtDetailsTable"/>
  <xs:element name="DebtDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DebtDetailsLineItems"/>
  <xs:element name="PercentageOfPriceShare" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PercentageOfPriceShare"/>
  <xs:element name="CommonEquity" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_CommonEquity"/>
  <xs:element name="CommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_CommonStock"/>
  <xs:element name="AggregatePrincipalsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_AggregatePrincipalsAmount"/>
  <xs:element name="AggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_AggregateShares"/>
  <xs:element name="PercentageOfExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PercentageOfExercisePrice"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="ConcentrationRiskPercentage01" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ConcentrationRiskPercentage01"/>
  <xs:element name="EquityMethodInvestmentOwnershipPercentage1" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_EquityMethodInvestmentOwnershipPercentage1"/>
  <xs:element name="StockholdersEquityandWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_StockholdersEquityandWarrantsDetailsTable"/>
  <xs:element name="StockholdersEquityandWarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_StockholdersEquityandWarrantsDetailsLineItems"/>
  <xs:element name="EquityBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_EquityBasedCompensationDetailsTable"/>
  <xs:element name="EquityBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_EquityBasedCompensationDetailsLineItems"/>
  <xs:element name="stockOptionsGrantedSharesTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_stockOptionsGrantedSharesTerm"/>
  <xs:element name="StockCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_StockCompensationExpense"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cvkd_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_SubsequentEventsDetailsLineItems"/>
  <xs:element name="GeneratingGrossProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cvkd_GeneratingGrossProceed"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PurchaseAggregateShares"/>
  <xs:element name="PublicOfferingPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PublicOfferingPricePercentage"/>
  <xs:element name="SharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_SharesOfCommonStock"/>
  <xs:element name="BousteadPrivatePlacementNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_BousteadPrivatePlacementNotesMember"/>
  <xs:element name="ChiefMedicalOfficerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ChiefMedicalOfficerMember"/>
  <xs:element name="GlynnWilsonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_GlynnWilsonMember"/>
  <xs:element name="HESPLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_HESPLLCMember"/>
  <xs:element name="InvestorWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_InvestorWarrantsMember"/>
  <xs:element name="JohnMurphyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_JohnMurphyMember"/>
  <xs:element name="June2022ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_June2022ConvertibleNoteMember"/>
  <xs:element name="March2022ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_March2022ConvertibleNoteMember"/>
  <xs:element name="MrPhamMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_MrPhamMember"/>
  <xs:element name="NonConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_NonConvertiblePromissoryNoteMember"/>
  <xs:element name="PlacementAgentWarrantOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PlacementAgentWarrantOneMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_PlacementAgentWarrantsMember"/>
  <xs:element name="ScientificAdvisoryBoardMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_ScientificAdvisoryBoardMember"/>
  <xs:element name="StevenZelenkofskemMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_StevenZelenkofskemMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cvkd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>cvkd-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:07 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedBalanceSheet" roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedIncomeStatement" roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedCashFlow" roleURI="http://www.cadrenal.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofAccruedLiabilitiesConsistTable" roleURI="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofpurchasepriceoftheassetsTable" roleURI="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofdebtoutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofallocationsharebasedcompensationperiodsTable" roleURI="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_Depreciation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_InterestExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherExpenses" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte73+46BaRwcD/6PMN5suUqAWk=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="cvkd_AccruedConsultingFees" xlink:href="cvkd-20221231.xsd#cvkd_AccruedConsultingFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="cvkd_AccruedConsultingFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_CompensatedAbsencesLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleNotesPayableRelatedParties" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleNotesPayableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="cvkd_ConvertibleNotesPayableRelatedParties" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DeferredFinanceCostsNet" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt1" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_ConvertibleDebt1" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts1" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_ConvertibleDebt1" xlink:to="cvkd_DebtIssuanceCosts1" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt2" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_ConvertibleDebt2" xlink:to="us-gaap_NotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts2" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_ConvertibleDebt2" xlink:to="cvkd_DebtIssuanceCosts2" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_ConvertibleDebt" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="cvkd_ConvertibleDebt1" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent" xlink:to="cvkd_ConvertibleDebt2" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable">
    <loc xlink:type="locator" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:href="cvkd-20221231.xsd#cvkd_EmployeeBenefitAndShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>cvkd-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:07 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedBalanceSheet" roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedIncomeStatement" roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ShareholdersEquityType2or3" roleURI="http://www.cadrenal.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedCashFlow" roleURI="http://www.cadrenal.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RecentAccountingGuidance" roleURI="http://www.cadrenal.com/role/RecentAccountingGuidance"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_FairValueMeasurements" roleURI="http://www.cadrenal.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccruedLiabilities" roleURI="http://www.cadrenal.com/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreement" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_Debt" roleURI="http://www.cadrenal.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RelatedPartyTransactions" roleURI="http://www.cadrenal.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingencies" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrants" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensation" roleURI="http://www.cadrenal.com/role/EquityBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_NetLossPerShare" roleURI="http://www.cadrenal.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxes" roleURI="http://www.cadrenal.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_SubsequentEvents" roleURI="http://www.cadrenal.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccountingPoliciesByPolicy" roleURI="http://www.cadrenal.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_FairValueMeasurementsTables" roleURI="http://www.cadrenal.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccruedLiabilitiesTables" roleURI="http://www.cadrenal.com/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreementTables" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DebtTables" roleURI="http://www.cadrenal.com/role/DebtTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingenciesTables" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrantsTables" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensationTables" roleURI="http://www.cadrenal.com/role/EquityBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_NetLossPerShareTables" roleURI="http://www.cadrenal.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxesTables" roleURI="http://www.cadrenal.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" roleURI="http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofderivativeliabilityTable" roleURI="http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofAccruedLiabilitiesConsistTable" roleURI="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofdevelopmentmilestonepaymentsTable" roleURI="http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofpurchasepriceoftheassetsTable" roleURI="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofdebtoutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoperatingleaseROUassetsandliabilitiesTable" roleURI="http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable" roleURI="http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofSummarizestheTotalWarrantsOutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoptionandwarrantTable" roleURI="http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofallocationsharebasedcompensationperiodsTable" roleURI="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable" roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals" roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable" roleURI="http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcomponentsofincometaxexpensebenefitTable" roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable" roleURI="http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreementDetails" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DebtDetails" roleURI="http://www.cadrenal.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RelatedPartyTransactionsDetails" roleURI="http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingenciesDetails" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrantsDetails" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensationDetails" roleURI="http://www.cadrenal.com/role/EquityBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxesDetails" roleURI="http://www.cadrenal.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_SubsequentEventsDetails" roleURI="http://www.cadrenal.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.cadrenal.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersDeficitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersDeficitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Liabilities" xlink:to="cvkd_StockholdersDeficitAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_OtherExpenseAbstract" xlink:href="cvkd-20221231.xsd#cvkd_OtherExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="cvkd_OtherExpenseAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="us-gaap_OtherExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_IssuanceOfInvestorWarrantsinShares" xlink:href="cvkd-20221231.xsd#cvkd_IssuanceOfInvestorWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cvkd_IssuanceOfInvestorWarrantsinShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:href="cvkd-20221231.xsd#cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RecentAccountingGuidance">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreement">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/Debt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrants">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionCustomerAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionCustomerAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionCustomerAcquisitions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PatentPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_PatentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cvkd_PatentPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreementTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRegulatoryAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:to="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_FinancialLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_FinancialLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:to="cvkd_FinancialLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_FinancialLiabilitiesAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_FinancialLiabilitiesAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDerivativeLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_AccruedConsultingFees" xlink:href="cvkd-20221231.xsd#cvkd_AccruedConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="cvkd_AccruedConsultingFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="us-gaap_CompensatedAbsencesLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:href="cvkd-20221231.xsd#cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:href="cvkd-20221231.xsd#cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_FirstCommercialSaleToAThirdParty1" xlink:href="cvkd-20221231.xsd#cvkd_FirstCommercialSaleToAThirdParty1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="cvkd_FirstCommercialSaleToAThirdParty1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable">
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_DebtDetailsScheduleofdebtoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleNotesPayableRelatedParties" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleNotesPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_ConvertibleNotesPayableRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_ConvertibleDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts1" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_DebtIssuanceCosts1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt1" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_ConvertibleDebt1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_NotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts2" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_DebtIssuanceCosts2" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt2" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_ConvertibleDebt2" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_DebtCurrent" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_AssetsAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_AssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:to="cvkd_AssetsAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetsAbstract0" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_LiabilitiesAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_LiabilitiesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:to="cvkd_LiabilitiesAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_CurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_LiabilitiesAbstract0" xlink:to="cvkd_CurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_CurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_NoncurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_LiabilitiesAbstract0" xlink:to="cvkd_NoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_NoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_LiabilitiesAbstract0" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cvkd_PlacementAgentWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrantOneMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cvkd_PlacementAgentWarrantOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_InvestorWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_InvestorWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cvkd_InvestorWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrant" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="cvkd_PlacementAgentWarrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_WarrantsAndRightOutstandingMaturityDate" xlink:href="cvkd-20221231.xsd#cvkd_WarrantsAndRightOutstandingMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="cvkd_WarrantsAndRightOutstandingMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable">
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte7330b0LPMAT6ovxxk5991fok=] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:href="cvkd-20221231.xsd#cvkd_EmployeeBenefitAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="cvkd_EmployeeBenefitAndShareBasedCompensation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_NumeratorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="cvkd_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DenominatorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DenominatorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="cvkd_DenominatorAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_CurrentAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="cvkd_CurrentAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_CurrentAbstract0" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_CurrentAbstract0" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_CurrentAbstract0" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_CurrentAbstract0" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeferredAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="cvkd_DeferredAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_IncometaxPermanentDifferences" xlink:href="cvkd-20221231.xsd#cvkd_IncometaxPermanentDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="cvkd_IncometaxPermanentDifferences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeferredTaxAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="cvkd_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_WorkingsCapital" xlink:href="cvkd-20221231.xsd#cvkd_WorkingsCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="cvkd_WorkingsCapital" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_GeneratingGrossProceeds" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="cvkd_GeneratingGrossProceeds" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_NetProceeds" xlink:href="cvkd-20221231.xsd#cvkd_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="cvkd_NetProceeds" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreementDetails">
    <loc xlink:type="locator" xlink:label="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_AssetPurchaseAgreementDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="cvkd_AssetPurchaseAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_AssetPurchaseAgreementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_AssetPurchaseAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_HESPLLCMember" xlink:href="cvkd-20221231.xsd#cvkd_HESPLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_HESPLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsForOtherOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_DiscountPercentage" xlink:href="cvkd-20221231.xsd#cvkd_DiscountPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="cvkd_DiscountPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_DebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_DebtDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_March2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_March2022ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cvkd_March2022ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_June2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_June2022ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cvkd_June2022ConvertibleNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_BousteadPrivatePlacementNotesMember" xlink:href="cvkd-20221231.xsd#cvkd_BousteadPrivatePlacementNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cvkd_BousteadPrivatePlacementNotesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_NonConvertiblePromissoryNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_NonConvertiblePromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cvkd_NonConvertiblePromissoryNoteMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCashReceivedOnHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DerivativeCashReceivedOnHedge" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityFairValueOfCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOfCollateral"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilityFairValueOfCollateral" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PercentageOfPriceShare" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfPriceShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_PercentageOfPriceShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredDividendsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredDividendsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredDividendsNetOfTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_InvestmentMaturityDate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_CommonEquity" xlink:href="cvkd-20221231.xsd#cvkd_CommonEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_CommonEquity" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_CommonStock" xlink:href="cvkd-20221231.xsd#cvkd_CommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_CommonStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_AggregatePrincipalsAmount" xlink:href="cvkd-20221231.xsd#cvkd_AggregatePrincipalsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_AggregatePrincipalsAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_AggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_AggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_AggregateShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PercentageOfExercisePrice" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_PercentageOfExercisePrice" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_RelatedPartyTransactionsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="cvkd_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_MrPhamMember" xlink:href="cvkd-20221231.xsd#cvkd_MrPhamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_MrPhamMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_JohnMurphyMember" xlink:href="cvkd-20221231.xsd#cvkd_JohnMurphyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_JohnMurphyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_GlynnWilsonMember" xlink:href="cvkd-20221231.xsd#cvkd_GlynnWilsonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_GlynnWilsonMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConcentrationRiskPercentage01" xlink:href="cvkd-20221231.xsd#cvkd_ConcentrationRiskPercentage01"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="cvkd_ConcentrationRiskPercentage01" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityMethodInvestmentOwnershipPercentage1" xlink:href="cvkd-20221231.xsd#cvkd_EquityMethodInvestmentOwnershipPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="cvkd_EquityMethodInvestmentOwnershipPercentage1" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails">
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="cvkd_StockholdersEquityandWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="cvkd_EquityBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ChiefMedicalOfficerMember" xlink:href="cvkd-20221231.xsd#cvkd_ChiefMedicalOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_ChiefMedicalOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScientificAdvisoryBoardMember" xlink:href="cvkd-20221231.xsd#cvkd_ScientificAdvisoryBoardMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_ScientificAdvisoryBoardMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_StevenZelenkofskemMember" xlink:href="cvkd-20221231.xsd#cvkd_StevenZelenkofskemMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_StevenZelenkofskemMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_JohnMurphyMember" xlink:href="cvkd-20221231.xsd#cvkd_JohnMurphyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cvkd_JohnMurphyMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cvkd_ScientificAdvisoryBoardMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_stockOptionsGrantedSharesTerm" xlink:href="cvkd-20221231.xsd#cvkd_stockOptionsGrantedSharesTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="cvkd_stockOptionsGrantedSharesTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockCompensationExpense" xlink:href="cvkd-20221231.xsd#cvkd_StockCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="cvkd_StockCompensationExpense" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="cvkd_SubsequentEventsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cvkd_SubsequentEventsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cvkd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_GeneratingGrossProceed" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_GeneratingGrossProceed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PurchaseAggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_PurchaseAggregateShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_PublicOfferingPricePercentage" xlink:href="cvkd-20221231.xsd#cvkd_PublicOfferingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_PublicOfferingPricePercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cvkd_SharesOfCommonStock" xlink:href="cvkd-20221231.xsd#cvkd_SharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_SharesOfCommonStock" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>cvkd-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:07 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Total other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash &#8211; end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US">Recent Accounting Guidance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US">Balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl0" xml:lang="en-US">Balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract_lbl" xml:lang="en-US">Schedule of Development Milestone Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule of Purchase Price of the Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:to="cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Total convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt1" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvkd_ConvertibleDebt1_lbl" xml:lang="en-US">Total convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt1" xlink:to="cvkd_ConvertibleDebt1_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleDebt2" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvkd_ConvertibleDebt2_lbl" xml:lang="en-US">Total convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt2" xlink:to="cvkd_ConvertibleDebt2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Total debt, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of Future Annual Lease Payments Under Non Cancellable Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:to="cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Outstanding, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract_lbl" xml:lang="en-US">Schedule of Options and Warrants Granted Exercised Forfeited and Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number Outstanding Beginning (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number Outstanding Ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted- Average Exercise Price Per Share Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Beginning (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Ending (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract_lbl" xml:lang="en-US">Schedule of Allocation Share Based Compensation Periods [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:href="cvkd-20221231.xsd#cvkd_EmployeeBenefitAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:to="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of Company SIncome Loss Before Provision Benefit for Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense to the Amount Computed by Applying the Statutory Federal Income Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Note offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Promissory note payable, net of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US">Convertible note payable, net of debt discount - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible note payable, net of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersDeficitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersDeficitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_StockholdersDeficitAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="cvkd_StockholdersDeficitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized, 8,193,875 issued and outstanding as of December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Company authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">In process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_OtherExpenseAbstract" xlink:href="cvkd-20221231.xsd#cvkd_OtherExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_OtherExpenseAbstract_lbl" xml:lang="en-US">Other expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="cvkd_OtherExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Interest expense, amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_UnlabeledAbstract" xlink:href="cvkd-20221231.xsd#cvkd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract" xlink:to="cvkd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Net loss per share, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Net loss per share, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares used in computing net loss per common share, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common share, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of founder shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of founder shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">New shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Equity-based compensation - options, restricted stock and RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Equity-based compensation - options, restricted stock and RSUs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Restricted stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of placement agent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of placement agent warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of investor warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_IssuanceOfInvestorWarrantsinShares" xlink:href="cvkd-20221231.xsd#cvkd_IssuanceOfInvestorWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_IssuanceOfInvestorWarrantsinShares_lbl" xml:lang="en-US">Issuance of investor warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IssuanceOfInvestorWarrantsinShares" xlink:to="cvkd_IssuanceOfInvestorWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes, net of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of promissory notes, net of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_UnlabeledAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract0" xlink:to="cvkd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:href="cvkd-20221231.xsd#cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US">Non-cash right of use assets and operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash financing activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Non-cash debt issuance costs - placement agent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair value of financial instruments at issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of investor warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Investment in property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Guidance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial liabilities subject to fair value measurements on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_FinancialLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_FinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_FinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FinancialLiabilitiesAbstract" xlink:to="cvkd_FinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xml:lang="en-US">Derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Fair value of financial instruments at issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities consist</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AccruedConsultingFees" xlink:href="cvkd-20221231.xsd#cvkd_AccruedConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_AccruedConsultingFees_lbl" xml:lang="en-US">Accrued consulting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AccruedConsultingFees" xlink:to="cvkd_AccruedConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensatedAbsencesLiability_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatedAbsencesLiability" xlink:to="us-gaap_CompensatedAbsencesLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Asset Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of development milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:to="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:href="cvkd-20221231.xsd#cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl" xml:lang="en-US">Completion of enrollment of Lee&#8217;s Pharmaceutical Phase 3 clinical trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:to="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:href="cvkd-20221231.xsd#cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl" xml:lang="en-US">First MAA submitted in the People&#8217;s Republic of China</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:to="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_FirstCommercialSaleToAThirdParty1" xlink:href="cvkd-20221231.xsd#cvkd_FirstCommercialSaleToAThirdParty1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_FirstCommercialSaleToAThirdParty1_lbl" xml:lang="en-US">First Commercial Sale to a Third Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstCommercialSaleToAThirdParty1" xlink:to="cvkd_FirstCommercialSaleToAThirdParty1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRegulatoryAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRegulatoryAssetsTextBlock_lbl" xml:lang="en-US">Schedule of purchase price of the assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:to="us-gaap_ScheduleOfRegulatoryAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConvertibleNotesPayableRelatedParties" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleNotesPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_ConvertibleNotesPayableRelatedParties_lbl" xml:lang="en-US">Convertible notes payable - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleNotesPayableRelatedParties" xlink:to="cvkd_ConvertibleNotesPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_UnlabeledAbstract1" xlink:href="cvkd-20221231.xsd#cvkd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract1" xlink:to="cvkd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_UnlabeledAbstract2" xlink:href="cvkd-20221231.xsd#cvkd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract2" xlink:to="cvkd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Promissory note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_UnlabeledAbstract3" xlink:href="cvkd-20221231.xsd#cvkd_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract3" xlink:to="cvkd_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Leases, Commitments, and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease ROU assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AssetsAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_AssetsAbstract0_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AssetsAbstract0" xlink:to="cvkd_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_LiabilitiesAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_LiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_LiabilitiesAbstract0_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_LiabilitiesAbstract0" xlink:to="cvkd_LiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_CurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_CurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CurrentAbstract" xlink:to="cvkd_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_NoncurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_NoncurrentAbstract_lbl" xml:lang="en-US">Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NoncurrentAbstract" xlink:to="cvkd_NoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of future annual lease payments under non-cancellable operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of summarizes the total warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrant" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PlacementAgentWarrant_lbl" xml:lang="en-US">Issue Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrant" xlink:to="cvkd_PlacementAgentWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_WarrantsAndRightOutstandingMaturityDate" xlink:href="cvkd-20221231.xsd#cvkd_WarrantsAndRightOutstandingMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WarrantsAndRightOutstandingMaturityDate" xlink:to="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">New Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Stock options shares issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of option and warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of options and warrants granted, exercised, forfeited and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number Outstanding Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number Outstanding Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number Outstanding Canceled/forfeited/expired (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Canceled/forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate Intrinsic Value Canceled/forfeited/expired (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number Outstanding Options vested and exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Options vested and exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number Outstanding Options vested and expected to vest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share Options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Options vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of allocation share based compensation periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_NumeratorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NumeratorAbstract" xlink:to="cvkd_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DenominatorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DenominatorAbstract" xlink:to="cvkd_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of company&#8217;s income (loss) before provision (benefit) for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_CurrentAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_CurrentAbstract0_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CurrentAbstract0" xlink:to="cvkd_CurrentAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeferredAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DeferredAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeferredAbstract" xlink:to="cvkd_DeferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit at statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_IncometaxPermanentDifferences" xlink:href="cvkd-20221231.xsd#cvkd_IncometaxPermanentDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_IncometaxPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IncometaxPermanentDifferences" xlink:to="cvkd_IncometaxPermanentDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Equity-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xml:lang="en-US">Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net of allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeferredTaxAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="cvkd_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Equity-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Capitalized research costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals and other temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts1" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvkd_DebtIssuanceCosts1_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts1" xlink:to="cvkd_DebtIssuanceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtIssuanceCosts2" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvkd_DebtIssuanceCosts2_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts2" xlink:to="cvkd_DebtIssuanceCosts2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrantsMember" xlink:to="cvkd_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PlacementAgentWarrantOneMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PlacementAgentWarrantOneMember_lbl" xml:lang="en-US">Placement Agent Warrant one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrantOneMember" xlink:to="cvkd_PlacementAgentWarrantOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_InvestorWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_InvestorWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_InvestorWarrantsMember" xlink:to="cvkd_InvestorWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl" xml:lang="en-US">Net Income (Loss) Allocated to General Partners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_lbl" xml:lang="en-US">Cash provided in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Cash used in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_WorkingsCapital" xlink:href="cvkd-20221231.xsd#cvkd_WorkingsCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_WorkingsCapital_lbl" xml:lang="en-US">Workings Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WorkingsCapital" xlink:to="cvkd_WorkingsCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Shares amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Per share amount (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_GeneratingGrossProceeds" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_GeneratingGrossProceeds_lbl" xml:lang="en-US">Generating gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceeds" xlink:to="cvkd_GeneratingGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_NetProceeds" xlink:href="cvkd-20221231.xsd#cvkd_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_NetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NetProceeds" xlink:to="cvkd_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl" xml:lang="en-US">Financial institution depositor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xml:lang="en-US">Purchase of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Paid an additional</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Agreed to pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Received from proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Financing payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Direct transaction cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForOtherOperatingActivities_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherOperatingActivities" xlink:to="us-gaap_PaymentsForOtherOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DiscountPercentage" xlink:href="cvkd-20221231.xsd#cvkd_DiscountPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DiscountPercentage_lbl" xml:lang="en-US">Discount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DiscountPercentage" xlink:to="cvkd_DiscountPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCashReceivedOnHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeCashReceivedOnHedge_lbl" xml:lang="en-US">Cash proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCashReceivedOnHedge" xlink:to="us-gaap_DerivativeCashReceivedOnHedge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Simple interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Total proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Conversion price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Price per share percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityFairValueOfCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOfCollateral"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityFairValueOfCollateral_lbl" xml:lang="en-US">Derivative liability at issuance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityFairValueOfCollateral" xlink:to="us-gaap_DerivativeLiabilityFairValueOfCollateral_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xml:lang="en-US">Debt issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PercentageOfPriceShare" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfPriceShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PercentageOfPriceShare_lbl" xml:lang="en-US">Percentage of Price Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfPriceShare" xlink:to="cvkd_PercentageOfPriceShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl" xml:lang="en-US">Aggregate amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredDividendsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredDividendsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredDividendsNetOfTax_lbl" xml:lang="en-US">Convertible promissory note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredDividendsNetOfTax" xlink:to="us-gaap_ConvertiblePreferredDividendsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bear interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentMaturityDate" xlink:to="us-gaap_InvestmentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_CommonEquity" xlink:href="cvkd-20221231.xsd#cvkd_CommonEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_CommonEquity_lbl" xml:lang="en-US">Common equity percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CommonEquity" xlink:to="cvkd_CommonEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_CommonStock" xlink:href="cvkd-20221231.xsd#cvkd_CommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_CommonStock_lbl" xml:lang="en-US">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CommonStock" xlink:to="cvkd_CommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AggregatePrincipalsAmount" xlink:href="cvkd-20221231.xsd#cvkd_AggregatePrincipalsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_AggregatePrincipalsAmount_lbl" xml:lang="en-US">Aggregate principal amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AggregatePrincipalsAmount" xlink:to="cvkd_AggregatePrincipalsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_AggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_AggregateShares_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AggregateShares" xlink:to="cvkd_AggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Exercisable per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_PercentageOfExercisePrice" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PercentageOfExercisePrice_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfExercisePrice" xlink:to="cvkd_PercentageOfExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax_lbl" xml:lang="en-US">Exercise price per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Percentage of conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0" xml:lang="en-US">Conversion secured percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Administrative services (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Common stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl0" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Founder shares paid (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible promissory note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ConcentrationRiskPercentage01" xlink:href="cvkd-20221231.xsd#cvkd_ConcentrationRiskPercentage01"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_ConcentrationRiskPercentage01_lbl" xml:lang="en-US">Bears interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConcentrationRiskPercentage01" xlink:to="cvkd_ConcentrationRiskPercentage01_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityMethodInvestmentOwnershipPercentage1" xlink:href="cvkd-20221231.xsd#cvkd_EquityMethodInvestmentOwnershipPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl" xml:lang="en-US">Equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityMethodInvestmentOwnershipPercentage1" xlink:to="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common stock for gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_stockOptionsGrantedSharesTerm" xlink:href="cvkd-20221231.xsd#cvkd_stockOptionsGrantedSharesTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_stockOptionsGrantedSharesTerm_lbl" xml:lang="en-US">Stock options granted shares term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_stockOptionsGrantedSharesTerm" xlink:to="cvkd_stockOptionsGrantedSharesTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Shares amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Percentage of amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockCompensationExpense" xlink:href="cvkd-20221231.xsd#cvkd_StockCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_StockCompensationExpense_lbl" xml:lang="en-US">Total stock compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockCompensationExpense" xlink:to="cvkd_StockCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Federal and state statutory income tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Valuation allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte73zgPaA9zVm+B9SW46OaRQko=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Operating loss future taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xml:lang="en-US">Settlement percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_GeneratingGrossProceed" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_GeneratingGrossProceed_lbl" xml:lang="en-US">Generating gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceed" xlink:to="cvkd_GeneratingGrossProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PurchaseAggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PurchaseAggregateShares" xlink:to="cvkd_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xml:lang="en-US">Initial public offering price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Exercisable price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PublicOfferingPricePercentage" xlink:href="cvkd-20221231.xsd#cvkd_PublicOfferingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PublicOfferingPricePercentage_lbl" xml:lang="en-US">Public offering price, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PublicOfferingPricePercentage" xlink:to="cvkd_PublicOfferingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Authorized capital stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds of warrant exercise (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Pay off (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_SharesOfCommonStock" xlink:href="cvkd-20221231.xsd#cvkd_SharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_SharesOfCommonStock_lbl" xml:lang="en-US">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_SharesOfCommonStock" xlink:to="cvkd_SharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy_lbl" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit and other Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock_lbl" xml:lang="en-US">Determination of the Fair Value of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" xlink:to="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionCustomerAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionCustomerAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionCustomerAcquisitions_lbl" xml:lang="en-US">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionCustomerAcquisitions" xlink:to="us-gaap_RevenueRecognitionCustomerAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_PatentPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_PatentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_PatentPolicyTextBlock_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PatentPolicyTextBlock" xlink:to="cvkd_PatentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member[</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_HESPLLCMember" xlink:href="cvkd-20221231.xsd#cvkd_HESPLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_HESPLLCMember_lbl" xml:lang="en-US">HESP LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_HESPLLCMember" xlink:to="cvkd_HESPLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_March2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_March2022ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_March2022ConvertibleNoteMember_lbl" xml:lang="en-US">March 2022 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_March2022ConvertibleNoteMember" xlink:to="cvkd_March2022ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_June2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_June2022ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_June2022ConvertibleNoteMember_lbl" xml:lang="en-US">June 2022 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_June2022ConvertibleNoteMember" xlink:to="cvkd_June2022ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_BousteadPrivatePlacementNotesMember" xlink:href="cvkd-20221231.xsd#cvkd_BousteadPrivatePlacementNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_BousteadPrivatePlacementNotesMember_lbl" xml:lang="en-US">Boustead Private Placement Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_BousteadPrivatePlacementNotesMember" xlink:to="cvkd_BousteadPrivatePlacementNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_NonConvertiblePromissoryNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_NonConvertiblePromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_NonConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Non-Convertible Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NonConvertiblePromissoryNoteMember" xlink:to="cvkd_NonConvertiblePromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_MrPhamMember" xlink:href="cvkd-20221231.xsd#cvkd_MrPhamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_MrPhamMember_lbl" xml:lang="en-US">Mr.Pham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_MrPhamMember" xlink:to="cvkd_MrPhamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_JohnMurphyMember" xlink:href="cvkd-20221231.xsd#cvkd_JohnMurphyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_JohnMurphyMember_lbl" xml:lang="en-US">John Murphy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_JohnMurphyMember" xlink:to="cvkd_JohnMurphyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_GlynnWilsonMember" xlink:href="cvkd-20221231.xsd#cvkd_GlynnWilsonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_GlynnWilsonMember_lbl" xml:lang="en-US">Glynn Wilson [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GlynnWilsonMember" xlink:to="cvkd_GlynnWilsonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ChiefMedicalOfficerMember" xlink:href="cvkd-20221231.xsd#cvkd_ChiefMedicalOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_ChiefMedicalOfficerMember_lbl" xml:lang="en-US">Chief Medical Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ChiefMedicalOfficerMember" xlink:to="cvkd_ChiefMedicalOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScientificAdvisoryBoardMember" xlink:href="cvkd-20221231.xsd#cvkd_ScientificAdvisoryBoardMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_ScientificAdvisoryBoardMember_lbl" xml:lang="en-US">Scientific Advisory Board [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScientificAdvisoryBoardMember" xlink:to="cvkd_ScientificAdvisoryBoardMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_StevenZelenkofskemMember" xlink:href="cvkd-20221231.xsd#cvkd_StevenZelenkofskemMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_StevenZelenkofskemMember_lbl" xml:lang="en-US">Steven Zelenkofske [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StevenZelenkofskemMember" xlink:to="cvkd_StevenZelenkofskemMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:to="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:to="cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingTable_lbl" xml:lang="en-US">Schedule Of Debt Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingTable" xlink:to="cvkd_DebtDetailsScheduleofdebtoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems_lbl" xml:lang="en-US">Schedule Of Debt Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable_lbl" xml:lang="en-US">Equity-Based Compensation (Details) - Schedule of option and warrant [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:to="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems_lbl" xml:lang="en-US">Equity-Based Compensation (Details) - Schedule of option and warrant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AssetPurchaseAgreementDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AssetPurchaseAgreementDetailsTable_lbl" xml:lang="en-US">Asset Purchase Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AssetPurchaseAgreementDetailsTable" xlink:to="cvkd_AssetPurchaseAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AssetPurchaseAgreementDetailsLineItems_lbl" xml:lang="en-US">Asset Purchase Agreement (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AssetPurchaseAgreementDetailsLineItems" xlink:to="cvkd_AssetPurchaseAgreementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtDetailsTable_lbl" xml:lang="en-US">Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtDetailsTable" xlink:to="cvkd_DebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_DebtDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtDetailsLineItems_lbl" xml:lang="en-US">Debt (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtDetailsLineItems" xlink:to="cvkd_DebtDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_RelatedPartyTransactionsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_RelatedPartyTransactionsDetailsTable" xlink:to="cvkd_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_RelatedPartyTransactionsDetailsLineItems" xlink:to="cvkd_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Equity and Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsTable" xlink:to="cvkd_StockholdersEquityandWarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_StockholdersEquityandWarrantsDetailsLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity and Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockholdersEquityandWarrantsDetailsLineItems" xlink:to="cvkd_StockholdersEquityandWarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EquityBasedCompensationDetailsTable_lbl" xml:lang="en-US">Equity-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityBasedCompensationDetailsTable" xlink:to="cvkd_EquityBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_EquityBasedCompensationDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EquityBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Equity-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityBasedCompensationDetailsLineItems" xlink:to="cvkd_EquityBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_SubsequentEventsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_SubsequentEventsDetailsTable" xlink:to="cvkd_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cvkd_SubsequentEventsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_SubsequentEventsDetailsLineItems" xlink:to="cvkd_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_AccruedConsultingFees_lbl0" xml:lang="en-US">Accrued consulting fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AccruedConsultingFees" xlink:to="cvkd_AccruedConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_AggregatePrincipalsAmount_lbl0" xml:lang="en-US">The amount of aggregate principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AggregatePrincipalsAmount" xlink:to="cvkd_AggregatePrincipalsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl0" xml:lang="en-US">Amount expenses on completion of enrollment of Lee&#8217;s pharmaceutical phase 3 clinical trial.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:to="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_ConcentrationRiskPercentage01_lbl0" xml:lang="en-US">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the &quot;benchmark&quot; (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConcentrationRiskPercentage01" xlink:to="cvkd_ConcentrationRiskPercentage01_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_ConvertibleDebt1_lbl0" xml:lang="en-US">The amount of total convertible debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt1" xlink:to="cvkd_ConvertibleDebt1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_ConvertibleDebt2_lbl0" xml:lang="en-US">The amount of total convertible debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt2" xlink:to="cvkd_ConvertibleDebt2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_DebtIssuanceCosts1_lbl0" xml:lang="en-US">The amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts1" xlink:to="cvkd_DebtIssuanceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_DebtIssuanceCosts2_lbl0" xml:lang="en-US">The amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts2" xlink:to="cvkd_DebtIssuanceCosts2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_DiscountPercentage_lbl0" xml:lang="en-US">The percentage of discount price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DiscountPercentage" xlink:to="cvkd_DiscountPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl0" xml:lang="en-US">Amount of expense for employee benefit and equity-based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:to="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl0" xml:lang="en-US">The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityMethodInvestmentOwnershipPercentage1" xlink:to="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_FirstCommercialSaleToAThirdParty1_lbl0" xml:lang="en-US">First Commercial Sale to a Third Party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstCommercialSaleToAThirdParty1" xlink:to="cvkd_FirstCommercialSaleToAThirdParty1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl0" xml:lang="en-US">First MAA submitted in the People&#8217;s Republic of China</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:to="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_GeneratingGrossProceed_lbl0" xml:lang="en-US">Amount of generating gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceed" xlink:to="cvkd_GeneratingGrossProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_GeneratingGrossProceeds_lbl0" xml:lang="en-US">The amount of generating gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceeds" xlink:to="cvkd_GeneratingGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_IncometaxPermanentDifferences_lbl0" xml:lang="en-US">Income tax Permanent Differences,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IncometaxPermanentDifferences" xlink:to="cvkd_IncometaxPermanentDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_IssuanceOfInvestorWarrantsinShares_lbl0" xml:lang="en-US">The amount of issuance of investor warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IssuanceOfInvestorWarrantsinShares" xlink:to="cvkd_IssuanceOfInvestorWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_NetProceeds_lbl0" xml:lang="en-US">The amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NetProceeds" xlink:to="cvkd_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl0" xml:lang="en-US">The amount of non-cash right of use assets and operating lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_PercentageOfExercisePrice_lbl0" xml:lang="en-US">Percentage of exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfExercisePrice" xlink:to="cvkd_PercentageOfExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_PercentageOfPriceShare_lbl0" xml:lang="en-US">Percentage of price share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfPriceShare" xlink:to="cvkd_PercentageOfPriceShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_PlacementAgentWarrant_lbl0" xml:lang="en-US">Description of placement agent warrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrant" xlink:to="cvkd_PlacementAgentWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_PublicOfferingPricePercentage_lbl0" xml:lang="en-US">The amount of public offering price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PublicOfferingPricePercentage" xlink:to="cvkd_PublicOfferingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_PurchaseAggregateShares_lbl0" xml:lang="en-US">Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common share authorized, Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PurchaseAggregateShares" xlink:to="cvkd_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl0" xml:lang="en-US">Disclosure of development milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:to="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_StockCompensationExpense_lbl0" xml:lang="en-US">The amount of stock compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockCompensationExpense" xlink:to="cvkd_StockCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl0" xml:lang="en-US">Warrants And Rights outstanding Maturity Date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WarrantsAndRightOutstandingMaturityDate" xlink:to="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl0" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl0" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl0" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years) Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_stockOptionsGrantedSharesTerm_lbl0" xml:lang="en-US">Stock options granted shares term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_stockOptionsGrantedSharesTerm" xlink:to="cvkd_stockOptionsGrantedSharesTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_JohnMurphyMember_lbl0" xml:lang="en-US">John Murphy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_JohnMurphyMember" xlink:to="cvkd_JohnMurphyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_ScientificAdvisoryBoardMember_lbl0" xml:lang="en-US">ScientificAdvisoryBoard[Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScientificAdvisoryBoardMember" xlink:to="cvkd_ScientificAdvisoryBoardMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvkd_StevenZelenkofskemMember_lbl0" xml:lang="en-US">Steven Zelenkofske.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StevenZelenkofskemMember" xlink:to="cvkd_StevenZelenkofskemMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_CommonEquity_lbl0" xml:lang="en-US">Common Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CommonEquity" xlink:to="cvkd_CommonEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl1" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl0" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Life Years Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsExercised" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PatentPolicyTextBlock_lbl0" xml:lang="en-US">Patent Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PatentPolicyTextBlock" xlink:to="cvkd_PatentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl0" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl0" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRegulatoryAssetsTextBlock_lbl0" xml:lang="en-US">Schedule of Regulatory Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:to="us-gaap_ScheduleOfRegulatoryAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Payments to Acquire in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_March2022ConvertibleNoteMember_lbl0" xml:lang="en-US">March2022 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_March2022ConvertibleNoteMember" xlink:to="cvkd_March2022ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentMaturityDate_lbl0" xml:lang="en-US">Investment Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentMaturityDate" xlink:to="us-gaap_InvestmentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl0" xml:lang="en-US">Subordinated Borrowing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DenominatorAbstract_lbl0" xml:lang="en-US">Denominator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DenominatorAbstract" xlink:to="cvkd_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_NonConvertiblePromissoryNoteMember_lbl0" xml:lang="en-US">Non Convertible Promissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NonConvertiblePromissoryNoteMember" xlink:to="cvkd_NonConvertiblePromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl0" xml:lang="en-US">Interest Income, Deposit with Financial Institution, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_CurrentAbstract0_lbl0" xml:lang="en-US">Current Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CurrentAbstract0" xlink:to="cvkd_CurrentAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AggregatePrincipalsAmount_lbl1" xml:lang="en-US">Aggregate Principals Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AggregatePrincipalsAmount" xlink:to="cvkd_AggregatePrincipalsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_FinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FinancialLiabilitiesAbstract" xlink:to="cvkd_FinancialLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_GeneratingGrossProceeds_lbl1" xml:lang="en-US">Generating Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceeds" xlink:to="cvkd_GeneratingGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredDividendsNetOfTax_lbl0" xml:lang="en-US">Convertible Preferred Dividends, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredDividendsNetOfTax" xlink:to="us-gaap_ConvertiblePreferredDividendsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionCustomerAcquisitions_lbl0" xml:lang="en-US">Revenue Recognition, Customer Acquisitions [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionCustomerAcquisitions" xlink:to="us-gaap_RevenueRecognitionCustomerAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtIssuanceCosts2_lbl1" xml:lang="en-US">Debt Issuance Costs2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts2" xlink:to="cvkd_DebtIssuanceCosts2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtIssuanceCosts1_lbl1" xml:lang="en-US">Debt Issuance Costs1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtIssuanceCosts1" xlink:to="cvkd_DebtIssuanceCosts1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1" xml:lang="en-US">Noncash Right Of Use Assets And Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeCashReceivedOnHedge_lbl0" xml:lang="en-US">Derivative, Cash Received on Hedge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCashReceivedOnHedge" xlink:to="us-gaap_DerivativeCashReceivedOnHedge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax_lbl0" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Per Share, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PlacementAgentWarrantOneMember_lbl0" xml:lang="en-US">Placement Agent Warrant One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrantOneMember" xlink:to="cvkd_PlacementAgentWarrantOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract_lbl" xml:lang="en-US">Schedule Of Accrued Liabilities Consist Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PlacementAgentWarrant_lbl1" xml:lang="en-US">Placement Agent Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrant" xlink:to="cvkd_PlacementAgentWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PercentageOfPriceShare_lbl1" xml:lang="en-US">Percentage Of Price Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfPriceShare" xlink:to="cvkd_PercentageOfPriceShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl0" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_StevenZelenkofskemMember_lbl1" xml:lang="en-US">Steven Zelenkofskem Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StevenZelenkofskemMember" xlink:to="cvkd_StevenZelenkofskemMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl0" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_June2022ConvertibleNoteMember_lbl0" xml:lang="en-US">June2022 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_June2022ConvertibleNoteMember" xlink:to="cvkd_June2022ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScientificAdvisoryBoardMember_lbl1" xml:lang="en-US">Scientific Advisory Board Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScientificAdvisoryBoardMember" xlink:to="cvkd_ScientificAdvisoryBoardMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_FirstCommercialSaleToAThirdParty1_lbl1" xml:lang="en-US">First Commercial Sale To AThird Party1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstCommercialSaleToAThirdParty1" xlink:to="cvkd_FirstCommercialSaleToAThirdParty1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract2" xlink:to="cvkd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract1" xlink:to="cvkd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract3" xlink:to="cvkd_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract0" xlink:to="cvkd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_IssuanceOfInvestorWarrantsinShares_lbl1" xml:lang="en-US">Issuance Of Investor Warrantsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IssuanceOfInvestorWarrantsinShares" xlink:to="cvkd_IssuanceOfInvestorWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ChiefMedicalOfficerMember_lbl0" xml:lang="en-US">Chief Medical Officer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ChiefMedicalOfficerMember" xlink:to="cvkd_ChiefMedicalOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl1" xml:lang="en-US">Employee Benefit And Share Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EmployeeBenefitAndShareBasedCompensation" xlink:to="cvkd_EmployeeBenefitAndShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DeferredAbstract_lbl0" xml:lang="en-US">Deferred Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeferredAbstract" xlink:to="cvkd_DeferredAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems_lbl0" xml:lang="en-US">Debt Details Scheduleofdebtoutstanding Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="cvkd_DebtDetailsScheduleofdebtoutstandingLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DiscountPercentage_lbl1" xml:lang="en-US">Discount Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DiscountPercentage" xlink:to="cvkd_DiscountPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl0" xml:lang="en-US">Deferred Policy Acquisition Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_UnlabeledAbstract" xlink:to="cvkd_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_stockOptionsGrantedSharesTerm_lbl1" xml:lang="en-US">stock Options Granted Shares Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_stockOptionsGrantedSharesTerm" xlink:to="cvkd_stockOptionsGrantedSharesTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl0" xml:lang="en-US">Asset Acquisition [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl0" xml:lang="en-US">Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensatedAbsencesLiability_lbl0" xml:lang="en-US">Compensated Absences Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatedAbsencesLiability" xlink:to="us-gaap_CompensatedAbsencesLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeferredTaxAssetsAbstract" xlink:to="cvkd_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOtherOperatingActivities_lbl0" xml:lang="en-US">Payments for Other Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherOperatingActivities" xlink:to="us-gaap_PaymentsForOtherOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl0" xml:lang="en-US">Net Income (Loss) Allocated to General Partners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Life Years Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsGranted" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ConcentrationRiskPercentage01_lbl1" xml:lang="en-US">Concentration Risk Percentage01</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConcentrationRiskPercentage01" xlink:to="cvkd_ConcentrationRiskPercentage01_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_NumeratorAbstract_lbl0" xml:lang="en-US">Numerator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NumeratorAbstract" xlink:to="cvkd_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_InvestorWarrantsMember_lbl0" xml:lang="en-US">Investor Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_InvestorWarrantsMember" xlink:to="cvkd_InvestorWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_IncometaxPermanentDifferences_lbl1" xml:lang="en-US">Incometax Permanent Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_IncometaxPermanentDifferences" xlink:to="cvkd_IncometaxPermanentDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_GlynnWilsonMember_lbl0" xml:lang="en-US">Glynn Wilson Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GlynnWilsonMember" xlink:to="cvkd_GlynnWilsonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfOptionAndWarrantAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOptionAndWarrantAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfOptionAndWarrantAbstract_lbl" xml:lang="en-US">Schedule Of Option And Warrant Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfOptionAndWarrantAbstract" xlink:to="cvkd_ScheduleOfOptionAndWarrantAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_HESPLLCMember_lbl0" xml:lang="en-US">HESPLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_HESPLLCMember" xlink:to="cvkd_HESPLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AggregateShares_lbl0" xml:lang="en-US">Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AggregateShares" xlink:to="cvkd_AggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl0" xml:lang="en-US">Derivative Instruments and Hedges, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_LiabilitiesAbstract0_lbl0" xml:lang="en-US">Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_LiabilitiesAbstract0" xlink:to="cvkd_LiabilitiesAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_StockholdersDeficitAbstract_lbl0" xml:lang="en-US">Stockholders Deficit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockholdersDeficitAbstract" xlink:to="cvkd_StockholdersDeficitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_JohnMurphyMember_lbl1" xml:lang="en-US">John Murphy Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_JohnMurphyMember" xlink:to="cvkd_JohnMurphyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_WorkingsCapital_lbl0" xml:lang="en-US">Workings Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WorkingsCapital" xlink:to="cvkd_WorkingsCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PercentageOfExercisePrice_lbl1" xml:lang="en-US">Percentage Of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PercentageOfExercisePrice" xlink:to="cvkd_PercentageOfExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Summarizes The Total Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract" xlink:to="cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0" xml:lang="en-US">Payments for Purchase of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl1" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0" xml:lang="en-US">Payments for Repurchase of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl0" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ConvertibleDebt2_lbl1" xml:lang="en-US">Convertible Debt2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt2" xlink:to="cvkd_ConvertibleDebt2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ConvertibleDebt1_lbl1" xml:lang="en-US">Convertible Debt1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleDebt1" xlink:to="cvkd_ConvertibleDebt1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl1" xml:lang="en-US">First MAASubmitted In The Peoples Republic Of China1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:to="cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Income Tax Expense Benefit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PublicOfferingPricePercentage_lbl1" xml:lang="en-US">Public Offering Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PublicOfferingPricePercentage" xlink:to="cvkd_PublicOfferingPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDerivativeLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfDerivativeLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Derivative Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDerivativeLiabilityAbstract" xlink:to="cvkd_ScheduleOfDerivativeLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Asset Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CurrentAbstract" xlink:to="cvkd_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ConvertibleNotesPayableRelatedParties_lbl0" xml:lang="en-US">Convertible Notes Payable Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ConvertibleNotesPayableRelatedParties" xlink:to="cvkd_ConvertibleNotesPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_StockCompensationExpense_lbl1" xml:lang="en-US">Stock Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_StockCompensationExpense" xlink:to="cvkd_StockCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfDebtOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDebtOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfDebtOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Debt Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDebtOutstandingAbstract" xlink:to="cvkd_ScheduleOfDebtOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityFairValueOfCollateral_lbl0" xml:lang="en-US">Derivative Liability, Fair Value of Collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityFairValueOfCollateral" xlink:to="us-gaap_DerivativeLiabilityFairValueOfCollateral_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_OtherExpenseAbstract_lbl0" xml:lang="en-US">Other Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_OtherExpenseAbstract" xlink:to="cvkd_OtherExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_NoncurrentAbstract_lbl0" xml:lang="en-US">Noncurrent Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NoncurrentAbstract" xlink:to="cvkd_NoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl0" xml:lang="en-US">Accrued Environmental Loss Contingencies, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl0" xml:lang="en-US">Administrative Fees Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_MrPhamMember_lbl0" xml:lang="en-US">Mr Pham Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_MrPhamMember" xlink:to="cvkd_MrPhamMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl1" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_SharesOfCommonStock_lbl0" xml:lang="en-US">Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_SharesOfCommonStock" xlink:to="cvkd_SharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AssetsAbstract0" xlink:to="cvkd_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl1" xml:lang="en-US">Warrants And Right Outstanding Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WarrantsAndRightOutstandingMaturityDate" xlink:to="cvkd_WarrantsAndRightOutstandingMaturityDate_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PlacementAgentWarrantsMember" xlink:to="cvkd_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_GeneratingGrossProceed_lbl1" xml:lang="en-US">Generating Gross Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_GeneratingGrossProceed" xlink:to="cvkd_GeneratingGrossProceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_PurchaseAggregateShares_lbl1" xml:lang="en-US">Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_PurchaseAggregateShares" xlink:to="cvkd_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl0" xml:lang="en-US">Convertible Subordinated Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Derivative Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock_lbl0" xml:lang="en-US">Determination Of The Fair Value Of Common Stock Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" xlink:to="cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock_lbl0" xml:lang="en-US">Emerging Growth Company Status Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="cvkd_EmergingGrowthCompanyStatusPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0" xml:lang="en-US">Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Life Years Canceledforfeitedexpired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:to="cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Financial Liabilities Subject To Fair Value Measurements On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract" xlink:to="cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Development Milestone Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:to="cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_BousteadPrivatePlacementNotesMember_lbl0" xml:lang="en-US">Boustead Private Placement Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_BousteadPrivatePlacementNotesMember" xlink:to="cvkd_BousteadPrivatePlacementNotesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Operating Lease Rou Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:to="cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy_lbl0" xml:lang="en-US">Income Tax Uncertainties, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_AccruedConsultingFees_lbl1" xml:lang="en-US">Accrued Consulting Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_AccruedConsultingFees" xlink:to="cvkd_AccruedConsultingFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl1" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl1" xml:lang="en-US">Completion Of Enrollment Of Lees Pharmaceutical Phase3 Clinical Trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:to="cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_NetProceeds_lbl1" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_NetProceeds" xlink:to="cvkd_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_CommonStock_lbl0" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_CommonStock" xlink:to="cvkd_CommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl1" xml:lang="en-US">Equity Method Investment Ownership Percentage1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvkd_EquityMethodInvestmentOwnershipPercentage1" xlink:to="cvkd_EquityMethodInvestmentOwnershipPercentage1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>cvkd-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 01:44:07 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedBalanceSheet" roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedIncomeStatement" roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ShareholdersEquityType2or3" roleURI="http://www.cadrenal.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ConsolidatedCashFlow" roleURI="http://www.cadrenal.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RecentAccountingGuidance" roleURI="http://www.cadrenal.com/role/RecentAccountingGuidance"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_FairValueMeasurements" roleURI="http://www.cadrenal.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccruedLiabilities" roleURI="http://www.cadrenal.com/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreement" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_Debt" roleURI="http://www.cadrenal.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RelatedPartyTransactions" roleURI="http://www.cadrenal.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingencies" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrants" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensation" roleURI="http://www.cadrenal.com/role/EquityBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_NetLossPerShare" roleURI="http://www.cadrenal.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxes" roleURI="http://www.cadrenal.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_SubsequentEvents" roleURI="http://www.cadrenal.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccountingPoliciesByPolicy" roleURI="http://www.cadrenal.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_FairValueMeasurementsTables" roleURI="http://www.cadrenal.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AccruedLiabilitiesTables" roleURI="http://www.cadrenal.com/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreementTables" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DebtTables" roleURI="http://www.cadrenal.com/role/DebtTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingenciesTables" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrantsTables" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensationTables" roleURI="http://www.cadrenal.com/role/EquityBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_NetLossPerShareTables" roleURI="http://www.cadrenal.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxesTables" roleURI="http://www.cadrenal.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" roleURI="http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofderivativeliabilityTable" roleURI="http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofAccruedLiabilitiesConsistTable" roleURI="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofdevelopmentmilestonepaymentsTable" roleURI="http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofpurchasepriceoftheassetsTable" roleURI="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofdebtoutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoperatingleaseROUassetsandliabilitiesTable" roleURI="http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable" roleURI="http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofSummarizestheTotalWarrantsOutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoptionandwarrantTable" roleURI="http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable" roleURI="http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofallocationsharebasedcompensationperiodsTable" roleURI="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable" roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals" roleURI="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable" roleURI="http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcomponentsofincometaxexpensebenefitTable" roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable" roleURI="http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_AssetPurchaseAgreementDetails" roleURI="http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_DebtDetails" roleURI="http://www.cadrenal.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_RelatedPartyTransactionsDetails" roleURI="http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_LeasesCommitmentsandContingenciesDetails" roleURI="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_StockholdersEquityandWarrantsDetails" roleURI="http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_EquityBasedCompensationDetails" roleURI="http://www.cadrenal.com/role/EquityBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_IncomeTaxesDetails" roleURI="http://www.cadrenal.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#cvkd_r_SubsequentEventsDetails" roleURI="http://www.cadrenal.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cvkd-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.cadrenal.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="StockholdersDeficitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersDeficitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Liabilities" xlink:to="StockholdersDeficitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpenseAbstract" xlink:href="cvkd-20221231.xsd#cvkd_OtherExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfInvestorWarrantsinShares" xlink:href="cvkd-20221231.xsd#cvkd_IssuanceOfInvestorWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfInvestorWarrantsinShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:href="cvkd-20221231.xsd#cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="NoncashRightOfUseAssetsAndOperatingLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RecentAccountingGuidance">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreement">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/Debt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrants">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EmergingGrowthCompanyStatusPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeterminationOfTheFairValueOfCommonStockPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionCustomerAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionCustomerAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionCustomerAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentPolicyTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_PatentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreementTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="ScheduleOfDevelopmentMilestonePaymentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRegulatoryAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRegulatoryAssetsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:href="cvkd-20221231.xsd#cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_FinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems" xlink:to="FinancialLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDerivativeLiabilityAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDerivativeLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedConsultingFees" xlink:href="cvkd-20221231.xsd#cvkd_AccruedConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="AccruedConsultingFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="us-gaap_CompensatedAbsencesLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesConsistAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" xlink:href="cvkd-20221231.xsd#cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstMAASubmittedInThePeoplesRepublicOfChina1" xlink:href="cvkd-20221231.xsd#cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="FirstMAASubmittedInThePeoplesRepublicOfChina1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstCommercialSaleToAThirdParty1" xlink:href="cvkd-20221231.xsd#cvkd_FirstCommercialSaleToAThirdParty1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDevelopmentMilestonePaymentsAbstract" xlink:to="FirstCommercialSaleToAThirdParty1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPurchasePriceOfTheAssetsAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDebtOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfDebtOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="DebtDetailsScheduleofdebtoutstandingTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsScheduleofdebtoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtOutstandingAbstract" xlink:to="DebtDetailsScheduleofdebtoutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingTable" xlink:to="DebtDetailsScheduleofdebtoutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableRelatedParties" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleNotesPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="ConvertibleNotesPayableRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_ConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts1" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="DebtIssuanceCosts1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebt1" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="ConvertibleDebt1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_NotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2" xlink:href="cvkd-20221231.xsd#cvkd_DebtIssuanceCosts2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="DebtIssuanceCosts2" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebt2" xlink:href="cvkd-20221231.xsd#cvkd_ConvertibleDebt2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="ConvertibleDebt2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsScheduleofdebtoutstandingLineItems" xlink:to="us-gaap_DebtCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AssetsAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_AssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:to="AssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_LiabilitiesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract" xlink:to="LiabilitiesAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract0" xlink:to="CurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncurrentAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract0" xlink:to="NoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract0" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PlacementAgentWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantOneMember" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrantOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PlacementAgentWarrantOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorWarrantsMember" xlink:href="cvkd-20221231.xsd#cvkd_InvestorWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="InvestorWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrant" xlink:href="cvkd-20221231.xsd#cvkd_PlacementAgentWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="PlacementAgentWarrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndRightOutstandingMaturityDate" xlink:href="cvkd-20221231.xsd#cvkd_WarrantsAndRightOutstandingMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightOutstandingMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionAndWarrantAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOptionAndWarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable"/>
    <loc xlink:type="locator" xlink:label="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionAndWarrantAbstract" xlink:to="EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantTable" xlink:to="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraIG1dA7PQftV8Yi+f831JHe3PXT8UDpsQsKyFcMFK1H5ILk1x9N0bcdS9vK1xgaHSM5sKJdMri5O2rsqMSAeeEJbf2iPbmIoup/CB46paZYdknM3syo67521oJsGX3iwa6LyVtWTQ4i6CJolivHzEF8Pd5s8rdQSLvY9orTT3U3NtWNc/AJlh+WDV83jc11f1Q3NSMTte738VmgWgxBkZM4/n8WJb16b0=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeYearsGranted" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="WeightedAverageRemainingContractualLifeYearsGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeYearsExercised" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="WeightedAverageRemainingContractualLifeYearsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" xlink:href="cvkd-20221231.xsd#cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitAndShareBasedCompensation" xlink:href="cvkd-20221231.xsd#cvkd_EmployeeBenefitAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllocationShareBasedCompensationPeriodsAbstract" xlink:to="EmployeeBenefitAndShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DenominatorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="DenominatorAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract0" xlink:href="cvkd-20221231.xsd#cvkd_CurrentAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="CurrentAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract0" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract0" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract0" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract0" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="DeferredAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncometaxPermanentDifferences" xlink:href="cvkd-20221231.xsd#cvkd_IncometaxPermanentDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="IncometaxPermanentDifferences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="cvkd-20221231.xsd#cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingsCapital" xlink:href="cvkd-20221231.xsd#cvkd_WorkingsCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="WorkingsCapital" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneratingGrossProceeds" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="GeneratingGrossProceeds" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="cvkd-20221231.xsd#cvkd_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="NetProceeds" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/AssetPurchaseAgreementDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="AssetPurchaseAgreementDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AssetPurchaseAgreementDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_AssetPurchaseAgreementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="AssetPurchaseAgreementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HESPLLCMember" xlink:href="cvkd-20221231.xsd#cvkd_HESPLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HESPLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsTable" xlink:to="AssetPurchaseAgreementDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsForOtherOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DiscountPercentage" xlink:href="cvkd-20221231.xsd#cvkd_DiscountPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="DiscountPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetPurchaseAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DebtDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DebtDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_DebtDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="DebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_March2022ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="March2022ConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2022ConvertibleNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_June2022ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="June2022ConvertibleNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BousteadPrivatePlacementNotesMember" xlink:href="cvkd-20221231.xsd#cvkd_BousteadPrivatePlacementNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="BousteadPrivatePlacementNotesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonConvertiblePromissoryNoteMember" xlink:href="cvkd-20221231.xsd#cvkd_NonConvertiblePromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="NonConvertiblePromissoryNoteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsTable" xlink:to="DebtDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCashReceivedOnHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DerivativeCashReceivedOnHedge" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityFairValueOfCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOfCollateral"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilityFairValueOfCollateral" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPriceShare" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfPriceShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="PercentageOfPriceShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredDividendsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredDividendsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredDividendsNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_InvestmentMaturityDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonEquity" xlink:href="cvkd-20221231.xsd#cvkd_CommonEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="CommonEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStock" xlink:href="cvkd-20221231.xsd#cvkd_CommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="CommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePrincipalsAmount" xlink:href="cvkd-20221231.xsd#cvkd_AggregatePrincipalsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="AggregatePrincipalsAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_AggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="AggregateShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfExercisePrice" xlink:href="cvkd-20221231.xsd#cvkd_PercentageOfExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="PercentageOfExercisePrice" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrPhamMember" xlink:href="cvkd-20221231.xsd#cvkd_MrPhamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrPhamMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JohnMurphyMember" xlink:href="cvkd-20221231.xsd#cvkd_JohnMurphyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JohnMurphyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GlynnWilsonMember" xlink:href="cvkd-20221231.xsd#cvkd_GlynnWilsonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GlynnWilsonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskPercentage01" xlink:href="cvkd-20221231.xsd#cvkd_ConcentrationRiskPercentage01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ConcentrationRiskPercentage01" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentOwnershipPercentage1" xlink:href="cvkd-20221231.xsd#cvkd_EquityMethodInvestmentOwnershipPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityandWarrantsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityandWarrantsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_StockholdersEquityandWarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityandWarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsTable" xlink:to="StockholdersEquityandWarrantsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityandWarrantsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/EquityBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityBasedCompensationDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityBasedCompensationDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_EquityBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="EquityBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChiefMedicalOfficerMember" xlink:href="cvkd-20221231.xsd#cvkd_ChiefMedicalOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChiefMedicalOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScientificAdvisoryBoardMember" xlink:href="cvkd-20221231.xsd#cvkd_ScientificAdvisoryBoardMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ScientificAdvisoryBoardMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StevenZelenkofskemMember" xlink:href="cvkd-20221231.xsd#cvkd_StevenZelenkofskemMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="StevenZelenkofskemMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JohnMurphyMember" xlink:href="cvkd-20221231.xsd#cvkd_JohnMurphyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JohnMurphyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScientificAdvisoryBoardMember_0" xlink:href="cvkd-20221231.xsd#cvkd_ScientificAdvisoryBoardMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ScientificAdvisoryBoardMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsTable" xlink:to="EquityBasedCompensationDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="stockOptionsGrantedSharesTerm" xlink:href="cvkd-20221231.xsd#cvkd_stockOptionsGrantedSharesTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="stockOptionsGrantedSharesTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockCompensationExpense" xlink:href="cvkd-20221231.xsd#cvkd_StockCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityBasedCompensationDetailsLineItems" xlink:to="StockCompensationExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="cvkd-20221231.xsd#cvkd_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneratingGrossProceed" xlink:href="cvkd-20221231.xsd#cvkd_GeneratingGrossProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="GeneratingGrossProceed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="cvkd-20221231.xsd#cvkd_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PurchaseAggregateShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPricePercentage" xlink:href="cvkd-20221231.xsd#cvkd_PublicOfferingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PublicOfferingPricePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStock" xlink:href="cvkd-20221231.xsd#cvkd_SharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SharesOfCommonStock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cadrenal.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="cvkd-20221231.xsd#cvkd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016657712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CADRENAL THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVKD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,634,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,279,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0860746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">822 A1A North<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ponte Vedra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-0701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759018435728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 32,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">22,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">672,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">727,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">43,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">778,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">404,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">863,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">22,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Promissory note payable, net of debt discount</a></td>
<td class="nump">43,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,334,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent', window );">Convertible note payable, net of debt discount - related party</a></td>
<td class="nump">442,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible note payable, net of debt discount</a></td>
<td class="nump">110,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">4,379,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent', window );">Accrued interest</a></td>
<td class="nump">40,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">21,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,329,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_StockholdersDeficitAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized, 8,193,875 issued and outstanding as of December 31, 2022</a></td>
<td class="nump">8,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,154,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,714,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(5,551,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 778,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_StockholdersDeficitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_StockholdersDeficitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759014061440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet (Parentheticals)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,193,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,193,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013974400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Operations and Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 2,307,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">392,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,701,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,701,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_OtherExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">40,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Interest expense, amortization of debt discount</a></td>
<td class="nump">66,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">3,905,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total other expenses</a></td>
<td class="nump">4,012,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic and diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares used in computing net loss per common share, basic and diluted (in Shares) | shares</a></td>
<td class="nump">7,890,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_OtherExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_OtherExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759018420544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Operations and Comprehensive Loss (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted | $ / shares</a></td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common share, diluted | shares</a></td>
<td class="nump">7,890,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013921472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Stockholders&#8217; Deficit - 11 months ended Dec. 31, 2022 - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 24, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 24, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of founder shares</a></td>
<td class="nump">$ 7,950<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of founder shares (in Shares)</a></td>
<td class="nump">7,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Equity-based compensation - options, restricted stock and RSUs</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">927,805<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">928,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Equity-based compensation - options, restricted stock and RSUs (in Shares)</a></td>
<td class="nump">243,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of placement agent warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">51,621<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">51,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of placement agent warrants (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of investor warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">175,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_IssuanceOfInvestorWarrantsinShares', window );">Issuance of investor warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,714,329)<span></span>
</td>
<td class="num">(6,714,329)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,194<span></span>
</td>
<td class="nump">$ 1,154,985<span></span>
</td>
<td class="num">$ (6,714,329)<span></span>
</td>
<td class="num">$ (5,551,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">8,193,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_IssuanceOfInvestorWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of investor warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_IssuanceOfInvestorWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759018476336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">928,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">66,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">3,905,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(22,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred offering costs</a></td>
<td class="num">(672,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(5,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">404,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">863,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued interest</a></td>
<td class="nump">40,213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,204,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Investment in property and equipment</a></td>
<td class="num">(2,279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of debt issuance costs</a></td>
<td class="nump">1,011,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory notes, net of debt issuance costs</a></td>
<td class="nump">219,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">7,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,239,635<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">32,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of the period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of the period</a></td>
<td class="nump">32,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Non-cash right of use assets and operating lease liabilities</a></td>
<td class="nump">47,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash debt issuance costs - placement agent warrants</a></td>
<td class="nump">51,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of financial instruments at issuance</a></td>
<td class="nump">474,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of investor warrants</a></td>
<td class="nump">$ 175,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash right of use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;1. Description of Business and Summary
of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cadrenal Therapeutics, Inc. (the &#8220;Company&#8221;
or &#8220;Cadrenal&#8221;) was incorporated on January&#160;25, 2022 (inception) in the State of Delaware and is headquartered in Ponte
Vedra, Florida. Cadrenal is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular
heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process which targets a different pathway than most commonly
prescribed drugs for the treatment of thrombosis and AFib.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP) and applicable rules
and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) for the fair presentation of the Company&#8217;s
financial statements for the period from January&#160;25, 2022 (inception) through December 31, 2022. The Company&#8217;s date of inception
was January&#160;25, 2022 and the fiscal year-end is December&#160;31.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation
initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented
as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether
the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating
effect of the Company plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within
one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate
the relevant conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after
the date that the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability
and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since
inception, the Company has incurred operating losses, and negative cash flows from operations. For the period from January&#160;25, 2022
(inception) to December 31, 2022, the Company had a net loss of $6,714,329 which included $4,901,824 of non-cash expenses. Cash used in
operations for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $1,204,770. As of December 31, 2022, the Company
had cash of $32,586, negative working capital of $606,881, and an accumulated deficit of $6,714,329. On January 24, 2023, the Company
consummated its initial public offering (the &#8220;IPO&#8221;) of 1,400,000 shares of its common stock at a public offering price of
$5.00 per share, generating gross proceeds of $7.0 million and net proceeds of $5.4 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is projecting that its existing cash
balances as of March 2023 is sufficient to fund its operations for at least the next twelve&#160;months from the date of the filing of
its Annual Report on Form 10-K, however, the Company will require additional funding to commence and complete its planned Phase&#160;3
clinical trial and submit its NDA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management intends to raise additional funds through
equity and debt financings. However, there can be no assurance that the Company will be able to complete any additional equity or debt
financings on terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital
needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Emerging Growth Company Status</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;)
under the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), the Company may elect to take advantage of certain forms of relief
from various reporting requirements that are applicable to public companies. The relief afforded under the JOBS Act includes an extended
transition period for the implementation of new or revised accounting standards. The Company has elected to take advantage of this extended
transition period and, as a result, the Company&#8217;s financial statements may not be comparable to those of companies that implement
accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the
JOBS Act up until the last&#160;day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is
no longer an EGC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and
certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors
and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and other Risks
and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to significant concentrations of credit risk, consist primarily of cash. Cash is maintained at high credit quality financial
institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances
are insured up to $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these
balances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common
for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product
candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are defined as components
of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker
(CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief
Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
purchased with original maturities of three&#160;months or less from the purchase date to be cash equivalents. The Company did not have
any cash equivalents at December&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all of its agreements to
determine if such instruments have derivatives or contain features that qualify as embedded derivatives. The Company accounts for certain
redemption features that are associated with convertible notes as liabilities at fair value and adjusts the instruments to their fair
value at the end of each reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses
arising from changes in the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive
loss for each reporting period while such instruments are outstanding. The embedded derivative liabilities are valued using a probability-weighted
expected return model. If the Company repays the noteholders or if, during the next round of financing, the note holders convert the debt
into equity, the derivative financial liabilities will be de-recognized and reclassified to stockholders&#8217; equity (deficit) on that
date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within 12&#160;months of the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determination of the Fair Value of Common
Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s common
stock for purposes of stock-based awards has been determined by its board of directors. Because there has been no public market for the
Company&#8217;s common stock, and in the absence of arm&#8217;s-length transactions in the Company&#8217;s common stock with independent
third parties, the board of directors has determined the fair value of its common stock with the assistance of an independent third-party
valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of the Company&#8217;s common
stock on each grant date, the Company considered numerous objective and subjective factors, including, but not limited to, the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">independent third-party valuation as of May&#160;31, 2022;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Company&#8217;s current and expected operating and financial
performance, including our level of available capital resources;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the value of the Company&#8217;s tangible and intangible
assets;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">market conditions affecting comparable public companies,
as reflected in comparable companies&#8217; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the illiquidity of the Company&#8217;s common stock by virtue
of being a private company, and the resulting discount for lack of marketability;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the business risks we face;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the experience of management and the board of directors</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, professional,
and other third-party costs that are directly associated with in-process equity financings until such financings are consummated at which
time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
As of December 31, 2022, deferred offering costs were $672,295 and are included on the accompanying balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates acquisitions of assets
and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition
by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated
in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition.
If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to
create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test
to determine whether an acquisition is a business combination or an acquisition of assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should
be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired
and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between
the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based
on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development
(&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular
research and development project. For an IPR&amp;D asset to have an alternative future use: (a)&#160;the Company must reasonably expect
that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;the
Company&#8217;s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that
is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts
allocated to IPR&amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent
consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial
targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of
payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the asset
and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected
to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes uncertain income tax positions
at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected
in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment
of income taxes as a component of the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for
potential dilutive shares of common stock. Diluted net loss per common share is computed by dividing net loss by the weighted average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock or if-converted methods. Since the Company was in a loss position for all periods presented, basic net loss
per common share is the same as diluted net loss per common share since the effects of potentially dilutive securities are anti-dilutive.
Shares of common stock subject to repurchase are excluded from the weighted-average shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Loss</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is defined as the change in
equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were
the same for the period presented in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period from January&#160;25, 2022 (inception)
through December&#160;31, 2022, the Company&#8217;s research and development expenses were comprised primarily of the cost of the acquired
tecarfarin asset and related transaction costs, as well as stock-based compensation and consulting services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent costs are comprised primarily of external
legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force and are expensed
as incurred as a component of general and administrative expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021669056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Guidance<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Recent Accounting Guidance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;2. Recent Accounting Guidance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August&#160;2020, the FASB issued ASU No.&#160;2020-06,
Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#8212;&#160;Contracts
in Entity&#8217;s Own Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity, which simplifies
the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and
contracts on an entity&#8217;s own equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASU&#160;2020-06 is effective on a prospective
basis for annual reporting periods beginning after December&#160;15, 2023 and for interim periods within those periods. Early adoption
is permitted. The Company adopted ASU&#160;2020-06 on January 25, 2022 (inception). The adoption of ASU&#160;2020-06 did not have a material
impact on the Company&#8217;s financial position and results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759101871136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;3. Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities recorded at fair value
on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure
their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid
to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy
for disclosure of fair value measurements as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 1 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 2 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These
include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities
in markets that are not active.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify; width: 0.75in">Level 3 &#8212;&#160;</td>
                                                                                       <td style="text-align: justify">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies its embedded derivative
liability as a Level 3 financial instrument and measures and reports its embedded derivatives at fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial liabilities subject to fair value measurements
on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2022 are presented
in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Financial Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Derivative liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,379,944</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,379,944</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total Financial Liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative<br/>
 liabilities</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 25, 2022 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Fair value of financial instruments at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,348</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value &#160; </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,905,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash, prepaid expenses,
deferred offering costs, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. There
were no transfers of liabilities among the fair value measurement categories during any of the periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020450336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;4. Accrued Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued liabilities consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">165,192</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">605,290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,082</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">863,564</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020644080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Purchase Agreement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;5. Asset Purchase Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&#160;1, 2022, the Company completed
an asset purchase agreement with HESP LLC, the assignee of tecarfarin and related assets (the &#8220;Asset Purchase Agreement&#8221;).
Pursuant to the terms of the Asset Purchase Agreement, the Company acquired all of the assets of HESP LLC, including all intellectual
property and other rights related to tecarfarin, the tecarfarin IND&#160;77041, all rights under the license, development and commercialization
agreement dated as of September&#160;16, 2015 by and between Armetheon, Inc. (&#8220;Armetheon&#8221;) (which was later assigned by Armetheon
to Espero BioPharma, Inc. (&#8220;Espero&#8221;), and China Cardiovascular Focus Ltd, an affiliate of Lee&#8217;s Pharmaceutical Holdings
Limited (&#8220;Lee&#8217;s Pharmaceutical&#8221;), relating to tecarfarin and related trademarks. In consideration of the purchase of
the assets, the Company paid HESP LLC $100,000 on the closing date and paid an additional $100,000 on June&#160;1, 2022. As additional
consideration, the Company agreed to pay HESP LLC the following development milestone payments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Development Milestones</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone <br/> Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Completion of enrollment of Lee&#8217;s Pharmaceutical Phase&#160;3 clinical trial</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First MAA submitted in the People&#8217;s Republic of China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First Commercial Sale to a Third Party</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,200,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Financing Milestones</span></i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As additional consideration, the Company agreed
to pay the following amounts, up to $2,000,000, upon each financing milestone as follows (i)&#160;35% of any proceeds received from any
licensing or partnering revenue; and (ii)&#160;IPO proceeds. The aggregate payments under the development milestone payments and financing
milestone payments shall not exceed $2,000,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for the transaction as
an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified
in-process research and development asset, the tecarfarin asset, thus satisfying the requirements of the screen test in accordance with
the criteria under ASC&#160;805-10-55-5C.&#160;The assets acquired in the transaction were measured based on the fair value of the consideration
paid including the direct transaction costs of $20,095, as the fair value of the consideration paid was more readily determinable than
the fair value of the assets acquired. The following table summarizes the purchase price of the assets acquired:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">In process research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Transaction costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs the Company incurred in connection
with this Asset Purchase Agreement were recognized as research and development expenses in the Company&#8217;s statement of operations
and comprehensive loss as these assets had no alternative future use at the time of the acquisition transaction. Due to the nature of
the regulatory, sales and financing-based milestones, the contingent consideration was not included in the initial cost of assets purchased
as they are contingent upon events that are outside the Company&#8217;s control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, upon achievement or anticipated achievement
of each milestone, the Company will recognize the related appropriate payment as additional research and development expense. Contingent
consideration will not be recorded until it is probable the milestone events occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company entered
into an Amendment to Asset Purchase Agreement, whereby in lieu of the $1,800,000 cash payment that would have been due to HESP LLC pursuant
to the Asset Purchase Agreement as a result of an initial public offering, HESP LLC agreed to accept shares of the Company&#8217;s common
stock, such number of shares to be calculated based upon a 40% discount to the price of the Company&#8217;s common stock sold in the
initial public offering. If and when it is determined that it is probable this financing-based milestone (initial public offering) will
be achieved, the Company will recognize the payment of $3.0&#160;million as research and development expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, none of the contingent
events have occurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759109187936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;6. Debt</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt outstanding is presented on the balance
sheet as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Convertible notes payable - related parties</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">550,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,040</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(464,620</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,380</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(206,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,728</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total debt, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">597,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>March&#160;2022 Convertible Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&#160;2022, the Company entered into
a convertible promissory note agreement (the &#8220;March&#160;2022 Note&#8221;) and received cash proceeds of $500,000. The March&#160;2022
Note bears interest at a rate equal to simple interest of 5.0% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The March&#160;2022 Note is due and payable on March&#160;1, 2025, unless earlier converted or repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the March&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $3.0&#160;million is raised.
The principal and unpaid and accrued interest of the March&#160;2022 Note at the date of conversion will be converted into shares at
a conversion price equal to 80% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the
Company consummates a Change of Control prior to repayment in full of the March&#160;2022 Note, immediately prior to the Change of Control,
the outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly
into proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is 80% of the
price per share of common equity paid at the Change of Control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the March&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the March&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $104,883, with the offsetting amount being recorded as a debt discount. Debt issuance costs totaled $1,460. The debt discount
and debt issuance costs are being amortized to interest expense using the effective interest method over the expected term of the March&#160;2022
Note. The effective interest rate of the March&#160;2022 Note is 12.1% compared to a stated interest rate of 5.0%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>June&#160;2022 Convertible Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&#160;2022, the Company entered into a
convertible promissory note agreement (the &#8220;June&#160;2022 Note&#8221;) and received cash proceeds of $50,000. The June&#160;2022
Note bears interest at a rate equal to simple interest of 6.0% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The June&#160;2022 Note is due and payable on June&#160;13, 2025, unless earlier converted or repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the June&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $3.0&#160;million is raised.
The principal and unpaid and accrued interest of the June&#160;2022 Note at the date of conversion will be converted into shares at a
conversion price equal to 60% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the Company
consummates a Change of Control prior to repayment in full of the June&#160;2022 Note, immediately prior to the Change of Control, the
outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly into
proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is 60% of the price
per share of common equity paid at the Change of Control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the June&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the June&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $29,532, with the offsetting amount being recorded as a debt discount. The debt discount is amortized to interest expense
using the effective interest method over the expected term of the June&#160;2022 Note. The effective interest rate of the June&#160;2022
Note is 25.7% compared to a stated interest rate of 6.0%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Boustead Private Placement Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&#160;2022, the Company issued convertible
promissory notes in the aggregate amount of $450,000 (the &#8220;July&#160;2022&#160;Notes&#8221;), in August&#160;2022, the Company
issued a convertible promissory note in the amount of $50,000 (the &#8220;August&#160;2022 Note&#8221;) and in September&#160;2022, the
Company issued convertible promissory notes in the aggregate amount of $75,000 (the &#8220;September&#160;2022 Notes&#8221;). The July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Note bear interest at 6% and mature on September&#160;13, 2025 (&#8220;Maturity
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal amount due under the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes (and, at the Company&#8217;s option, any accrued but unpaid interest
under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes) will be automatically converted, on or before
the Maturity Date, into Next Equity Securities in the Next Equity Financing. The July&#160;2022 Notes, the August&#160;2022 Note and
September&#160;2022 Notes are convertible into shares of common stock at a conversion price equal to the quotient obtained by dividing
(i)&#160;the entire principal amount of the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes, plus (if
applicable) any accrued but unpaid interest under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes
by (ii)&#160;sixty percent (60%) of the price per share of the Next Equity Securities sold in the Next Equity Financing. In the event
of a Change of Control which occurs prior to repayment in full of the July&#160;2022 Notes, the August&#160;2022 Note or the September&#160;2022
Notes, immediately prior to the Change of Control, the outstanding principal and any accrued but unpaid interest on the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes will convert directly into our common equity (or directly into proceeds
paid to the holders of our common equity in connection with the Change of Control) at a price per share that is 60% of the price per
share of common equity paid at the Change of Control. Boustead Securities, LLC acted as the placement agent for the private placement
and received as part of its compensation and five-year warrants to purchase shares of our common stock at a price equal to the conversion
price of the Private Placement Notes in an amount equal to 6% of the shares of common stock underlying the Private Placement Notes. The
Company has determined that the warrants issued to the placement agent receive equity treatment. The warrants were recorded at fair value
at issuance and recorded as debt issuance costs associated with the Boustead Private Placement Notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined the redemption features
in the July&#160;2022 Notes, August&#160;2022 Note and September&#160;2022 Notes contain rights and obligations for conversion contingent
upon a potential future financing event or a change in control, and that such features are required to be bifurcated from the host debt
instrument and accounted for as a derivative liability to be remeasured at the end of each reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether the July, August,
and September&#160;2022 Notes contain embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives
and Hedging. The Company determined that these redemption features contained rights and obligations for conversion contingent upon a
potential future financing event or a change in control. Thus, the embedded put options were bifurcated from the face value of the July,
August and September Notes and accounted for as a derivative liabilities to be remeasured at the end of each reporting period with the
change in the fair value included in other expense, in the accompanying statements of operations and comprehensive loss. The fair value
of the put option derivative liabilities at issuance was $339,934, with the offsetting amount being recorded as a debt discount. The
debt discount is being amortized to interest expense using the effective interest method over the expected term of the July, August and
September&#160;2022 Notes. The effective interest rates of the July, August and September&#160;2022 Notes were 36.3%, 26.1%, and 28.8%,
respectively, compared to a stated interest rate of 6.0%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Convertible Promissory Note</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2022, the Company closed a $250,000
note offering (the &#8220;November Private Placement&#8221;) pursuant to which the Company sold to two accredited investors units consisting
of (i) notes in the aggregate principal amount of $250,000, which bear interest at the rate of 10%, repayable at the earlier of the time
of the completion of the IPO or November 30, 2023 (the &#8220;November Notes&#8221;) and (ii) warrants to purchase up to an aggregate
of 250,000 shares of common stock exercisable at $1.00 per common share, which are exercisable at any time and are automatically exercised
into shares of the Company&#8217;s common stock upon the consummation of the IPO (the &#8220;November Warrants&#8221;). At the time the
November Notes and November Warrants were sold, it was intended that the principal amount of the November Notes would be repaid upon
the consummation of the IPO out of the proceeds of the November Warrants exercise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of the November Warrants triggered
an adjustment to the conversion price of the Private Placement Notes (the July 2022, August 2022 and September 2022 Notes) to $1.00 per
share, pursuant to down-round protection included in those notes. As a result of the adjustment of the conversion price of the Private
Placement Notes, the five-year warrants issued to Boustead Securities, LLC in connection with the Private Placement, were amended to
provide for the purchase of an aggregate of 11,500 shares of the Company&#8217;s common stock at an exercise price equal to 60% of the
initial public offering price per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also issued 15,000 warrants to Boustead
for the placement of the November financing. The November placement agent warrants have an exercise price of $1.00 per common share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022, the Company entered into amendments
to the March 2022 Note and the June 2022 Note to adjust the conversion price of the March 2022 Note and the June 2022 Note to $1.00 per
common share. The March 2022 Note and June 2022 Note originally had a conversion price equal to 80% and 60%, respectively, of the IPO
price. While this amendment was not required, as the March 2022 Note and June 2022 did not have down-round protection like the Private
Placement Notes, the amendment was entered into to provide the investors in the March and June Notes with the same conversion price as
the Private Placement notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company incurred debt issuance costs attributed to the November
Notes, which were recorded as a debt discount.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020618144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;7. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;25, 2022, the Company into an
agreement with Phamace, LLC, a consulting firm of which Quang Pham, the Company&#8217;s Chief Executive Officer, is the sole member,
for an initial term of January&#160;25, 2022 through February&#160;28, 2022. Pursuant to the agreement, the Company shall pay the sum
of $115,000 to Phamace, LLC for advisory and administrative services rendered relating to preparing the Company to launch as an operating
company, which is due and payable on September&#160;30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;25, 2022, the Company issued 7,500,000
shares of common stock, pursuant to a subscription agreement, to Quang Pham, our Chief Executive Officer, of which 3,000,000 were subsequently
transferred to a related trust, of which Mr.&#160;Pham&#8217;s child is a beneficiary and Mr.&#160;Pham is the trustee with sole voting
and disposition power with respect to the shares owned by the trust, 1,100,000 were subsequently transferred to friends, family and a
trust of which Mr. Pham&#8217;s child is a beneficiary, but of which Mr. Pham has no voting or disposition power, and 125,000 were transferred
to non-profit organizations. Mr.&#160;Pham paid a total of $7,500 for such founders shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&#160;1, 2022, the Company issued a convertible
promissory note in the amount of $500,000 to John Murphy, a member of the Company&#8217;s board of directors, which bears interest at
5% and matures on March&#160;1, 2025. The note is convertible into shares of Common Stock at a conversion price equal to the quotient
obtained by dividing (i)&#160;the entire principal amount of the note plus (if applicable) any accrued but unpaid interest under the
Note by (ii)&#160;eighty percent (80%) of the price per share of the equity securities issued and sold at the initial closing of our
next equity financing. See Note&#160;6 for further discussion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&#160;17, 2022, the Company issued 450,000
shares of restricted common stock, pursuant to a restricted stock purchase agreement, to Matthew Szot its Chief Financial Officer, which
shares shall vest quarterly over a period of two&#160;years, subject to certain adjustments, as provided in the Restricted Stock Purchase
Agreement dated May&#160;17, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2022, the Company issued a convertible
promissory note in the amount of $50,000 to Glynn Wilson, a member of the Company&#8217;s board of directors, which bears interest at
6% and matures on September 13, 2025. <span style="font-family: Times New Roman, Times, Serif">See Note&#160;6 for further discussion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759101871136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments, and Contingencies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Leases, Commitments, and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;8. Leases, Commitments, and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At lease inception, the Company determines if
an arrangement is an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalation,
on a straight-line basis over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 842, Leases, the Company
determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease
commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all
leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the
balance sheet, but payments are recognized as expenses on a straight-line basis over the lease term. The Company has elected not to recognize
leases with terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease qualifies as a finance lease if any of
the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company
by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise,
(iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease
payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized
to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded
as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into contracts that contain
both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company
combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such
as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed
when the event determining the amount of variable consideration to be paid occurs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance and operating lease assets and liabilities
are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount
rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing
rate based upon the available information at the lease commencement date. Operating lease assets are further adjusted for prepaid or
accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating lease ROU assets
and liabilities as of December 31, 2022 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: 10pt">Operating lease ROU assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">43,578</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,288</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Noncurrent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating lease expense was $4,394 for the year ended December 31,
2022. Cash paid for amounts included in the measurement of operating lease liabilities included in operating cash flows was $4,334 for
the year ended December 31, 2022. The remaining operating lease term was 22 months, and the operating lease discount rate was 12% as
of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future annual lease payments under non-cancellable
operating leases as of December 31, 2022 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,068</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,319</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,387</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,749</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the
future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will
be made and such expenditures can be reasonably estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the Company&#8217;s certificate
of incorporation and bylaws, the Company indemnifies its officers and directors for certain events or occurrences, subject to certain
limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability
insurance policy that may enable it to recover a portion of any amounts paid for future claims.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759018464288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Warrants<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;9. Stockholders&#8217; Equity and
Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Certificate of Incorporation
filed on January&#160;25, 2022, the Company was authorized to issue a total of 10,000,000 shares of common stock with a par value of
$0.001 per share. On December 5, 2022, the Company filed an Amended and Restated Certificate of Incorporation to increase the authorized
capital stock of the Company to 82,500,000 shares, consisting of 75,000,000 shares of common stock, par value $0.001 per share, and 7,500,000
shares of preferred stock, par value $0.001 per share, which was approved by the Company&#8217;s Board of Directors, as well as a majority
of the Company&#8217;s shareholders, on December 5, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of common stock are entitled to one vote
for each share of common stock held of record for the election of the Company&#8217;s directors and all other matters requiring stockholder
action. Holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s
Board in its discretion out of funds legally available therefor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, 8,193,875 shares
of common stock were issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total warrants
outstanding at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Issue
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise<br/>
    Price<br/>
    Per&#160;Share </b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expiration<br/>
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    January 25, 2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>New<br/>
    Issuance</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expired</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    December&#160;31,<br/>
    2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 24%; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; width: 12%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">July - Sept 2022</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;3.00</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 14.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July - Sept 2027 &#160;</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">11,500</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">11,500</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">1.00</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 2027 &#160;</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; white-space: nowrap; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Investor
    warrants</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; white-space: nowrap; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="white-space: nowrap; padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">1.00</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earlier of IPO or Nov 2027 &#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-size: 11pt; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">276,500</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">276,500</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020426288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;10. Equity-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted the Cadrenal Therapeutics,
Inc. 2022 Equity Incentive Plan, or the Initial Plan, on July&#160;11, 2022, which was later amended and restated on October&#160;16,
2022, for purposes of clarifying the application of certain of the rules of the Initial Plan to awards approved before such amendment
and restatement of the Initial Plan and to facilitate the transition to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan (the &#8220;Successor Plan&#8221;) for the issuance and approval of awards after consummation of this offering. On October&#160;16,
2022, the Board adopted and the Company&#8217;s stockholders approved the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan, or the 2022 Plan, which will be a successor to and continuation of the Initial Plan and became effective on January 19, 2023. Upon
the effectiveness of the 2022 Plan, it replaced the Initial Plan, except with respect to awards outstanding under the Initial Plan, and
no further awards will be available for grant under the Initial Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain adjustments, the maximum number
of shares of common stock that could have been issued under the Plans in connection with awards was 2,000,000 shares, of which 810,000
remained available for issuance as December 31, 2022. The maximum number of shares of common stock that may be issued under the 2022
Plan will automatically increase on January&#160;1 of each calendar year for a period of ten&#160;years commencing on January&#160;1,
2023 and ending on (and including) January&#160;1, 2032, to a number of shares of common stock equal to 20% of the total number of shares
of common stock outstanding on December&#160;31 of the preceding calendar year; provided, however that the board of directors, or the
compensation committee, may act prior to January&#160;1 of a given calendar year to provide that the increase for such year will be a
lesser number of shares of common stock. All available shares may be utilized toward the grant of any type of award under the 2022 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Weighted average assumptions used in the Black-Scholes
model are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 87%; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
    <br/>
    2022</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.98%&#160;&#8211;&#160;4.10%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">&#8212;</span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term (years)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27&#160;&#8211;&#160;5.81</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.4%&#160;&#8211;&#160;62.5%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;11, 2022, the Company granted stock
options to purchase 650,000 shares of common stock at an exercise price of $0.64 per common share. The stock option grants were issued
to directors, members of the Scientific Advisory Board, and other consultants to the Company and vest in periods ranging from <span style="-sec-ix-hidden: hidden-fact-46">one</span> to
<span style="-sec-ix-hidden: hidden-fact-47">three</span>&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued stock
options to purchase 300,000 shares of common stock to our Chief Medical Officer. The options have an exercise price of $0.64 per common
share and will vest quarterly over a period of <span style="-sec-ix-hidden: hidden-fact-48">three</span>&#160;years, subject to certain adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company granted
stock options to purchase 100,000 shares of common stock at an exercise price of $0.64 per common share. The stock option grants were
issued to members of the Scientific Advisory Board and vest over <span style="-sec-ix-hidden: hidden-fact-49">three</span>&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Activity under the Plans for the period from
January&#160;25, 2022 (inception) to December&#160;31, 2022 is set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average <br/> Exercise Price <br/> Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Outstanding at January&#160;25, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -10pt; padding-left: 20pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,578,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Canceled/forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding at December&#160;31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,100,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,578,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable at December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">427,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and expected to vest as of December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,578,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted to date was $1.11. At December&#160;31, 2022, the Company had $1,048,151 of unrecognized stock-based compensation expense
related to stock options which will be recognized over the weighted average remaining requisite service period of 2.2&#160;years. The
Company settles employee stock option exercises with newly issued shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;11, 2022, the Company issued restricted
stock of 46,875 shares of common stock to a consultant. These shares fully vested on October&#160;1, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued 40,000
shares of common stock to a consultant. These shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;18, 2022, the Company issued 40,000
shares of common stock to Steven Zelenkofske, a director, for recruiting services performed. These shares were fully vested upon the
date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;16, 2022, the Company issued
50,000 shares of common stock to John Murphy, a director. These shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;3, 2022, the Company issued 137,000
shares of common stock to various consultants for services rendered. 70,000 of the shares were subsequently returned and canceled. These
shares were fully vested upon the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;3, 2022, the Company issued stock
options to purchase 50,000 shares of common stock to a director. The options have an exercise price of $5.00 per common share and vest
over a three-year period, with 33.33% vesting on the first anniversary of the effective date, and thereafter 1/36 on a monthly basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total stock compensation expense for the period
from January&#160;25, 2022 (inception) to December&#160;31, 2022 was $928,049.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The allocation of stock-based compensation for
the period presented below was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">791,247</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">928,049</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020514576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;11. Net Loss Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of the basic and diluted net loss per common share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(6,714,329</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Weighted average common shares outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,890,507</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><div style="-sec-ix-hidden: hidden-fact-50">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.85</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company was in a loss position for
the period presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities
would have been anti-dilutive. For the period from inception to December&#160;31, 2022, there were no potential dilutive securities other
than the convertible notes, stock options, and warrants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021678784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 12. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s income (loss) before provision
(benefit) for income taxes for the period ended December 31, 2022 was generated in the following jurisdictions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,714,329</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,714,329</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s provision is $0, which is
primarily driven by the federal and state statutory income tax rates on current year losses, offset by the Company&#8217;s full valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of income tax expense (benefit)
were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 20pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total current provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of income tax expense to the
amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the period ended December
31, 2022, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax benefit at statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,410,009</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State benefit, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(263,978</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,003,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Increase in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">536,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the net tax effects
of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December 31, 2022 are shown
below. The Company has established a full valuation allowance against net deferred tax assets due to the uncertainty that such assets
will be realized. The Company periodically evaluates the recoverability of its deferred tax assets. At such time as it is determined
that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The increase in
the valuation allowances of $479,000 for the period from January&#160;25, 2022 (inception) to December 31, 2022 was primarily due to
the Company&#8217;s net operating losses and basis differences in intangible assets generated during the current year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of deferred tax assets and liabilities
consisted of the following at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">298,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Capitalized research costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Accruals and other temporary differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">532,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(479,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company has net
operating loss carryforwards of approximately $1.2 million and $1.2 million available to reduce future taxable income, if any, for federal
and state income tax purposes, respectively. The Company&#8217;s US federal and state net operating loss carryovers can be carried forward
indefinitely, but the deduction related to these net operating losses is limited to 80% of taxable income when utilized in future&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The utilization of net operating loss carryforwards
and tax credit carryovers could be subject to annual limitations under Section&#160;382 and 383 of the Internal Revenue Code of 1986,
and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future.
These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset
future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382 and 383, results from transactions
increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over
a three-year period. The Company has not conducted an analysis of an ownership change under section 382. To the extent that a study is
completed and an ownership change is deemed to occur, the Company&#8217;s net operating losses and tax credits could be limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the two-step approach to
recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the
weight of available evidence indicates it is more likely than not that the position will be sustained upon audit, including resolution
of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more
than 50% likely of being realized upon ultimate settlement. Income tax positions must meet a more likely than not recognition threshold
to be recognized under ASC&#160;740 upon initial measurement and in subsequent periods. ASC&#160;740-10 also provides guidance on measurement,
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2022, the Company did not have
any significant uncertain tax positions. The Company will recognize interest and penalties related to uncertain tax positions in income
tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts
have been recognized in the Company&#8217;s statement of operations and comprehensive loss. The Company does not anticipate a material
change to unrecognized tax benefits in the next twelve&#160;months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the Company&#8217;s tax&#160;years will
remain open for examination by the federal and state taxing authorities to the extent that the Company&#8217;s tax attributes are utilized
in future&#160;years to offset income or income taxes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016637280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"><b>Note&#160;13.
Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">The Company
has evaluated events that occurred through March 29, 2023, the date that the financial statements were issued and determined that there
have been no events that have occurred that would require adjustments to our disclosures in the financial statements except for the transactions
described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, the Company consummated its initial public offering (the &#8220;IPO&#8221;) of 1,400,000 shares of its common stock at a public
offering price of $5.00 per share, generating gross proceeds of $7,000,000. The Company&#8217;s shares of common stock commenced trading
on the Nasdaq Capital Market on January 20, 2023, under the symbol &#8220;CVKD.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">In connection
with the IPO, on January 19, 2023, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
Boustead Securities, LLC, as representative of the underwriters (the &#8220;Representative&#8221;).&#160;Pursuant to the Underwriting
Agreement, the Company agreed to issue to the underwriters a five-year warrant (the &#8220;Representative&#8217;s Warrant&#8221;) to
purchase an aggregate of 84,000 shares of the Company&#8217;s&#160;common stock, which is equal to six percent (6%) of the shares of
common stock sold in the IPO. Such Representative&#8217;s Warrant has an exercise price of $6.00, which is equal to 120% of the public
offering price of the common stock in the IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
19, 2023, the Company issued 600,000 shares of common stock to HESP LLC, pursuant to the terms of an Amendment to the Asset Purchase
Agreement, dated August 18, 2022, between the Company and HESP LLC. The Company recognized the payment of $3.0&#160;million as research
and development expense in January 2023. See Note 5 for further discussion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, concurrent with the consummation of the IPO, the Company issued 1,140,700 shares of common stock upon conversion of the convertible
promissory notes. See Note 6 for further discussion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">On January
24, 2023, the Company issued 250,000 shares of common stock upon the exercise of the November Warrants. The $250,000 of proceeds of the
warrant exercise were used to pay off the $250,000 November Notes. See Note 6 for further discussion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify">After the closing of the IPO, the Company granted
50,000 shares of the Company&#8217;s common stock to the Company&#8217;s Chief Financial Officer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759017147008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP) and applicable rules
and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) for the fair presentation of the Company&#8217;s
financial statements for the period from January&#160;25, 2022 (inception) through December 31, 2022. The Company&#8217;s date of inception
was January&#160;25, 2022 and the fiscal year-end is December&#160;31.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesPolicy', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation
initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented
as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether
the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating
effect of the Company plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within
one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate
the relevant conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after
the date that the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability
and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since
inception, the Company has incurred operating losses, and negative cash flows from operations. For the period from January&#160;25, 2022
(inception) to December 31, 2022, the Company had a net loss of $6,714,329 which included $4,901,824 of non-cash expenses. Cash used in
operations for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $1,204,770. As of December 31, 2022, the Company
had cash of $32,586, negative working capital of $606,881, and an accumulated deficit of $6,714,329. On January 24, 2023, the Company
consummated its initial public offering (the &#8220;IPO&#8221;) of 1,400,000 shares of its common stock at a public offering price of
$5.00 per share, generating gross proceeds of $7.0 million and net proceeds of $5.4 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is projecting that its existing cash
balances as of March 2023 is sufficient to fund its operations for at least the next twelve&#160;months from the date of the filing of
its Annual Report on Form 10-K, however, the Company will require additional funding to commence and complete its planned Phase&#160;3
clinical trial and submit its NDA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management intends to raise additional funds through
equity and debt financings. However, there can be no assurance that the Company will be able to complete any additional equity or debt
financings on terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital
needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Emerging Growth Company Status</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;)
under the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), the Company may elect to take advantage of certain forms of relief
from various reporting requirements that are applicable to public companies. The relief afforded under the JOBS Act includes an extended
transition period for the implementation of new or revised accounting standards. The Company has elected to take advantage of this extended
transition period and, as a result, the Company&#8217;s financial statements may not be comparable to those of companies that implement
accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the
JOBS Act up until the last&#160;day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is
no longer an EGC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and
certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors
and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit and other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and other Risks
and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to significant concentrations of credit risk, consist primarily of cash. Cash is maintained at high credit quality financial
institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances
are insured up to $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these
balances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common
for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product
candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are defined as components
of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker
(CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief
Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
purchased with original maturities of three&#160;months or less from the purchase date to be cash equivalents. The Company did not have
any cash equivalents at December&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all of its agreements to
determine if such instruments have derivatives or contain features that qualify as embedded derivatives. The Company accounts for certain
redemption features that are associated with convertible notes as liabilities at fair value and adjusts the instruments to their fair
value at the end of each reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses
arising from changes in the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive
loss for each reporting period while such instruments are outstanding. The embedded derivative liabilities are valued using a probability-weighted
expected return model. If the Company repays the noteholders or if, during the next round of financing, the note holders convert the debt
into equity, the derivative financial liabilities will be de-recognized and reclassified to stockholders&#8217; equity (deficit) on that
date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within 12&#160;months of the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock', window );">Determination of the Fair Value of Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determination of the Fair Value of Common
Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s common
stock for purposes of stock-based awards has been determined by its board of directors. Because there has been no public market for the
Company&#8217;s common stock, and in the absence of arm&#8217;s-length transactions in the Company&#8217;s common stock with independent
third parties, the board of directors has determined the fair value of its common stock with the assistance of an independent third-party
valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of the Company&#8217;s common
stock on each grant date, the Company considered numerous objective and subjective factors, including, but not limited to, the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">independent third-party valuation as of May&#160;31, 2022;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the Company&#8217;s current and expected operating and financial
performance, including our level of available capital resources;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the value of the Company&#8217;s tangible and intangible
assets;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">market conditions affecting comparable public companies,
as reflected in comparable companies&#8217; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the illiquidity of the Company&#8217;s common stock by virtue
of being a private company, and the resulting discount for lack of marketability;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the business risks we face;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the experience of management and the board of directors</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, professional,
and other third-party costs that are directly associated with in-process equity financings until such financings are consummated at which
time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
As of December 31, 2022, deferred offering costs were $672,295 and are included on the accompanying balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionCustomerAcquisitions', window );">Acquisitions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates acquisitions of assets
and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition
by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated
in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition.
If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to
create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test
to determine whether an acquisition is a business combination or an acquisition of assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should
be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired
and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between
the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based
on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development
(&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular
research and development project. For an IPR&amp;D asset to have an alternative future use: (a)&#160;the Company must reasonably expect
that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;the
Company&#8217;s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that
is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts
allocated to IPR&amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent
consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial
targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of
payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the asset
and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected
to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Due to the Company&#8217;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes uncertain income tax positions
at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected
in the period in which judgment occurs. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment
of income taxes as a component of the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for
potential dilutive shares of common stock. Diluted net loss per common share is computed by dividing net loss by the weighted average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock or if-converted methods. Since the Company was in a loss position for all periods presented, basic net loss
per common share is the same as diluted net loss per common share since the effects of potentially dilutive securities are anti-dilutive.
Shares of common stock subject to repurchase are excluded from the weighted-average shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Loss</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is defined as the change in
equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were
the same for the period presented in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period from January&#160;25, 2022 (inception)
through December&#160;31, 2022, the Company&#8217;s research and development expenses were comprised primarily of the cost of the acquired
tecarfarin asset and related transaction costs, as well as stock-based compensation and consulting services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PatentPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent costs are comprised primarily of external
legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force and are expensed
as incurred as a component of general and administrative expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PatentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PatentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=35755530&amp;loc=d3e11264-158415<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionCustomerAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for incremental direct costs incurred related to the acquisition or origination of a customer contract in a transaction that results in revenue deferral (that is, whether such costs are expensed as incurred or deferred and charged to expense in proportion to the revenue recognized.) Also describes the entity's policy for determining which costs are capitalized as contract acquisition or origination costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionCustomerAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020492912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial liabilities subject to fair value measurements on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Financial Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Derivative liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,379,944</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4,379,944</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total Financial Liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative<br/>
 liabilities</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 25, 2022 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Fair value of financial instruments at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,348</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value &#160; </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,905,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,379,944</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020514576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities consist</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">165,192</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">605,290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,082</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">863,564</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020431856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock', window );">Schedule of development milestone payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Development Milestones</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone <br/> Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Completion of enrollment of Lee&#8217;s Pharmaceutical Phase&#160;3 clinical trial</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First MAA submitted in the People&#8217;s Republic of China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">First Commercial Sale to a Third Party</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,200,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRegulatoryAssetsTextBlock', window );">Schedule of purchase price of the assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">In process research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Transaction costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRegulatoryAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6499975&amp;loc=d3e44250-110382<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501251&amp;loc=d3e52485-110419<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 340<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6499975&amp;loc=d3e44264-110382<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRegulatoryAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020484688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of debt outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Convertible notes payable - related parties</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">550,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,040</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(464,620</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,380</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Promissory note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(206,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,728</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total debt, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">597,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013978880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments, and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of operating lease ROU assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: 10pt">Operating lease ROU assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">43,578</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,288</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Noncurrent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future annual lease payments under non-cancellable operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,068</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,319</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,387</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,749</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759022013168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of summarizes the total warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Issue
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise<br/>
    Price<br/>
    Per&#160;Share </b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expiration<br/>
    Date</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    January 25, 2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>New<br/>
    Issuance</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Expired</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding<br/>
    as of<br/>
    December&#160;31,<br/>
    2022</b></span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 24%; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; width: 12%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">July - Sept 2022</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;3.00</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 14.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July - Sept 2027 &#160;</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">11,500</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 0.5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">11,500</span></td><td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Placement
    agent warrants</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">1.00</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 2027 &#160;</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; white-space: nowrap; text-align: left; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Investor
    warrants</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; white-space: nowrap; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Nov 2022</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="white-space: nowrap; padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">1.00</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earlier of IPO or Nov 2027 &#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-size: 11pt; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">276,500</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">276,500</span></td><td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759018419824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option and warrant</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 87%; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,
    <br/>
    2022</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.98%&#160;&#8211;&#160;4.10%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">&#8212;</span></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term (years)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27&#160;&#8211;&#160;5.81</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.4%&#160;&#8211;&#160;62.5%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options and warrants granted, exercised, forfeited and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average <br/> Exercise Price <br/> Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Outstanding at January&#160;25, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -10pt; padding-left: 20pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,578,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Canceled/forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding at December&#160;31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,100,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,578,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable at December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">427,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Options vested and expected to vest as of December&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,578,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of allocation share based compensation periods</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">791,247</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">928,049</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020546960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per common share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25, <br/> 2022 <br/> (Inception) to <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(6,714,329</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Weighted average common shares outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,890,507</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><div style="-sec-ix-hidden: hidden-fact-50">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.85</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016573952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of company&#8217;s income (loss) before provision (benefit) for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,714,329</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,714,329</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 20pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total current provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;25,<br/> 2022<br/> (Inception)&#160;to<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax benefit at statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,410,009</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State benefit, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(263,978</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,003,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Increase in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">536,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">298,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Capitalized research costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Accruals and other temporary differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">532,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(479,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759017111648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAllocatedToGeneralPartners', window );">Net Income (Loss) Allocated to General Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,714,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash', window );">Cash provided in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,901,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WorkingsCapital', window );">Workings Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease', window );">Financial institution depositor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares amount (in Shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_GeneratingGrossProceeds', window );">Generating gross proceeds</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_NetProceeds', window );">Net proceeds</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_GeneratingGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of generating gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_GeneratingGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_WorkingsCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_WorkingsCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in interest income on deposit with financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(iii)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(i)<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(ii)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAllocatedToGeneralPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of net income allocated to general partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAllocatedToGeneralPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013928784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 4,379,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">4,379,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">4,379,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">$ 4,379,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_FinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_FinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016876336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of derivative liability<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfDerivativeLiabilityAbstract', window );"><strong>Schedule Of Derivative Liability Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Balance beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value of financial instruments at issuance</a></td>
<td class="nump">474,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="nump">3,905,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Balance ending</a></td>
<td class="nump">$ 4,379,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021937712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract', window );"><strong>Schedule Of Accrued Liabilities Consist Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AccruedConsultingFees', window );">Accrued consulting fees</a></td>
<td class="nump">$ 165,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensatedAbsencesLiability', window );">Accrued compensation</a></td>
<td class="nump">605,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">93,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 863,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_AccruedConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_AccruedConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatedAbsencesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19366-108361<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatedAbsencesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759014010928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AssetPurchaseAgreementDetailsLineItems', window );"><strong>Asset Purchase Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Paid an additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Received from proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Direct transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AssetPurchaseAgreementDetailsLineItems', window );"><strong>Asset Purchase Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_HESPLLCMember', window );">HESP LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AssetPurchaseAgreementDetailsLineItems', window );"><strong>Asset Purchase Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForOtherOperatingActivities', window );">Cash payment</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DiscountPercentage', window );">Discount percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_AssetPurchaseAgreementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_AssetPurchaseAgreementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of discount price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_HESPLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_HESPLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759017184992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreement (Details) - Schedule of development milestone payments<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract', window );"><strong>Schedule of Development Milestone Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial', window );">Completion of enrollment of Lee&#8217;s Pharmaceutical Phase 3 clinical trial</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1', window );">First MAA submitted in the People&#8217;s Republic of China</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_FirstCommercialSaleToAThirdParty1', window );">First Commercial Sale to a Third Party</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expenses on completion of enrollment of Lee&#8217;s pharmaceutical phase 3 clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_FirstCommercialSaleToAThirdParty1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First Commercial Sale to a Third Party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_FirstCommercialSaleToAThirdParty1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First MAA submitted in the People&#8217;s Republic of China</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759017093312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreement (Details) - Schedule of purchase price of the assets - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2008</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract', window );"><strong>Schedule of Purchase Price of the Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">In process research and development</a></td>
<td class="nump">$ 392,859<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012459744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsLineItems', window );"><strong>Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Note offering (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax', window );">Exercise price per common share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_March2022ConvertibleNoteMember', window );">March 2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsLineItems', window );"><strong>Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCashReceivedOnHedge', window );">Cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Simple interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price per share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOfCollateral', window );">Derivative liability at issuance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Debt issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_June2022ConvertibleNoteMember', window );">June 2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsLineItems', window );"><strong>Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCashReceivedOnHedge', window );">Cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Simple interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOfCollateral', window );">Derivative liability at issuance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PercentageOfPriceShare', window );">Percentage of Price Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_BousteadPrivatePlacementNotesMember', window );">Boustead Private Placement Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsLineItems', window );"><strong>Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price per share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOfCollateral', window );">Derivative liability at issuance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">28.80%<span></span>
</td>
<td class="nump">26.10%<span></span>
</td>
<td class="nump">36.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Aggregate amount (in Dollars)</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredDividendsNetOfTax', window );">Convertible promissory note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentMaturityDate', window );">Maturity date</a></td>
<td class="text">Sep. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_CommonEquity', window );">Common equity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_CommonStock', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_NonConvertiblePromissoryNoteMember', window );">Non-Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsLineItems', window );"><strong>Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Note offering (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AggregatePrincipalsAmount', window );">Aggregate principal amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AggregateShares', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercisable per common share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Per share amount (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PercentageOfExercisePrice', window );">Percentage of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_AggregatePrincipalsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_AggregatePrincipalsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_AggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_AggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_CommonEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_CommonEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_CommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_CommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DebtDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DebtDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PercentageOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PercentageOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PercentageOfPriceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of price share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PercentageOfPriceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredDividendsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The after-tax amount of any dividends on convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496177-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredDividendsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCashReceivedOnHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period on settlement of a hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCashReceivedOnHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOfCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of securities pledged as collateral against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226013-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOfCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share impact of the gain (loss) on the extinguishment of debt, net of applicable taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_March2022ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvkd_March2022ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_June2022ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvkd_June2022ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_BousteadPrivatePlacementNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvkd_BousteadPrivatePlacementNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvkd_NonConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvkd_NonConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759014009296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - Schedule of debt outstanding<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtDetailsScheduleofdebtoutstandingLineItems', window );"><strong>Schedule Of Debt Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ConvertibleNotesPayableRelatedParties', window );">Convertible notes payable - related parties</a></td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="num">(107,040)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt</a></td>
<td class="nump">442,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible note payable</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtIssuanceCosts1', window );">Debt issuance costs</a></td>
<td class="num">(464,620)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ConvertibleDebt1', window );">Total convertible debt</a></td>
<td class="nump">110,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note payable</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DebtIssuanceCosts2', window );">Debt issuance costs</a></td>
<td class="num">(206,272)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ConvertibleDebt2', window );">Total convertible debt</a></td>
<td class="nump">43,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total debt, net</a></td>
<td class="nump">$ 597,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ConvertibleDebt1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of total convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ConvertibleDebt1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ConvertibleDebt2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of total convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ConvertibleDebt2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ConvertibleNotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ConvertibleNotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DebtDetailsScheduleofdebtoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DebtDetailsScheduleofdebtoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DebtIssuanceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DebtIssuanceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DebtIssuanceCosts2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DebtIssuanceCosts2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012411072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative services (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Founder shares paid (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ConcentrationRiskPercentage01', window );">Bears interest percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityMethodInvestmentOwnershipPercentage1', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ConcentrationRiskPercentage01', window );">Bears interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_MrPhamMember', window );">Mr.Pham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember', window );">John Murphy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible promissory note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_GlynnWilsonMember', window );">Glynn Wilson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible promissory note (in Dollars)</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ConcentrationRiskPercentage01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ConcentrationRiskPercentage01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_EquityMethodInvestmentOwnershipPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_EquityMethodInvestmentOwnershipPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_MrPhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_MrPhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_GlynnWilsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_GlynnWilsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020384448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments, and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 4,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 4,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021343520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_AssetsAbstract0', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 43,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, Current</a></td>
<td class="nump">22,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_NoncurrentAbstract', window );"><strong>Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, Noncurrent</a></td>
<td class="nump">21,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 43,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_AssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_AssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_NoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_NoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759017217680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract', window );"><strong>Schedule of Future Annual Lease Payments Under Non Cancellable Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 26,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">22,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">48,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 43,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016874608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity and Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 05, 2022</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_StockholdersEquityandWarrantsDetailsLineItems', window );"><strong>Stockholders' Equity and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Company authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">8,193,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">8,193,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_StockholdersEquityandWarrantsDetailsLineItems', window );"><strong>Stockholders' Equity and Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Company authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_StockholdersEquityandWarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_StockholdersEquityandWarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013838816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">New Issuance</a></td>
<td class="nump">276,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Ending</a></td>
<td class="nump">276,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantsMember', window );">Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PlacementAgentWarrant', window );">Issue Date</a></td>
<td class="text">July - Sept 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WarrantsAndRightOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">July - Sept 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">New Issuance</a></td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Ending</a></td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantOneMember', window );">Placement Agent Warrant one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PlacementAgentWarrant', window );">Issue Date</a></td>
<td class="text">Nov 2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WarrantsAndRightOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Nov 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">New Issuance</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Ending</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=cvkd_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PlacementAgentWarrant', window );">Issue Date</a></td>
<td class="text">Nov 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WarrantsAndRightOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Earlier of IPO or Nov 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">New Issuance</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding, Ending</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PlacementAgentWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of placement agent warrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PlacementAgentWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_WarrantsAndRightOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights outstanding Maturity Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_WarrantsAndRightOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cvkd_PlacementAgentWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cvkd_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cvkd_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012817312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock for gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_stockOptionsGrantedSharesTerm', window );">Stock options granted shares term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Conversion secured percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock options shares issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,048,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,193,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares amount</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of amount</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_StockCompensationExpense', window );">Total stock compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 928,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cvkd_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ChiefMedicalOfficerMember', window );">Chief Medical Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock options shares issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock options shares issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_StevenZelenkofskemMember', window );">Steven Zelenkofske [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember', window );">John Murphy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsLineItems', window );"><strong>Equity-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_EquityBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_EquityBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_StockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of stock compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_StockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_stockOptionsGrantedSharesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options granted shares term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_stockOptionsGrantedSharesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cvkd_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cvkd_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_StevenZelenkofskemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_StevenZelenkofskemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvkd_JohnMurphyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013339328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Details) - Schedule of option and warrant<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems', window );"><strong>Equity-Based Compensation (Details) - Schedule of option and warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">62.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems', window );"><strong>Equity-Based Compensation (Details) - Schedule of option and warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">62.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013290288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract', window );"><strong>Schedule of Options and Warrants Granted Exercised Forfeited and Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding Beginning (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years) Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Beginning (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number Outstanding Granted (in Shares) | shares</a></td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Granted</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WeightedAverageRemainingContractualLifeYearsGranted', window );">Weighted- Average Remaining Contractual Life (Years) Granted</a></td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate Intrinsic Value Granted</a></td>
<td class="nump">$ 4,578,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number Outstanding Exercised (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WeightedAverageRemainingContractualLifeYearsExercised', window );">Weighted- Average Remaining Contractual Life (Years) Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value Exercised (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number Outstanding Canceled/forfeited/expired (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Canceled/forfeited/expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired', window );">Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic Value Canceled/forfeited/expired (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding Ending (in Shares) | shares</a></td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Ending</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (Years) Ending</a></td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Ending (in Dollars) | $</a></td>
<td class="nump">$ 4,578,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number Outstanding Options vested and exercisable (in Shares) | shares</a></td>
<td class="nump">108,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Options vested and exercisable</a></td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years) Options vested and exercisable</a></td>
<td class="text">9 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Options vested and exercisable (in Dollars) | $</a></td>
<td class="nump">$ 427,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number Outstanding Options vested and expected to vest (in Shares) | shares</a></td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share Options vested and expected to vest</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years) Options vested and expected to vest</a></td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options vested and expected to vest (in Dollars) | $</a></td>
<td class="nump">$ 4,578,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_WeightedAverageRemainingContractualLifeYearsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (Years) Exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_WeightedAverageRemainingContractualLifeYearsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_WeightedAverageRemainingContractualLifeYearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (Years) Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_WeightedAverageRemainingContractualLifeYearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020433440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract', window );"><strong>Schedule of Allocation Share Based Compensation Periods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 791,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">136,802<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_EmployeeBenefitAndShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 928,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_EmployeeBenefitAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_EmployeeBenefitAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021392320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net loss | $</a></td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding | shares</a></td>
<td class="nump">7,890,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic | $ / shares</a></td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759020629360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract', window );"><strong>Schedule of Basic and Diluted Net Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759021305584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal and state statutory income tax rates</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">479,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Operating loss future taxable income</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax rate</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Settlement percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759016892304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of company&#8217;s income (loss) before provision (benefit) for income taxes<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract', window );"><strong>Schedule of Company SIncome Loss Before Provision Benefit for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">$ (6,714,329)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012341728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of income tax expense (benefit)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_CurrentAbstract0', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DeferredAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_CurrentAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_CurrentAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DeferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DeferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012352224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract', window );"><strong>Schedule of Reconciliation of Income Tax Expense to the Amount Computed by Applying the Statutory Federal Income Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at statutory tax rate</a></td>
<td class="num">$ (1,410,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State benefit, net of federal benefit</a></td>
<td class="num">(263,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_IncometaxPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">125,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivatives</a></td>
<td class="nump">1,003,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">536,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net of allowance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_IncometaxPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax Permanent Differences,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_IncometaxPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759013903680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 298,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research costs</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and other temporary differences</a></td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">532,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Convertible debt</a></td>
<td class="num">(53,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(479,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139759012761296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Exercisable price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_PublicOfferingPricePercentage', window );">Public offering price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Shares of common stock</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_SharesOfCommonStock', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_GeneratingGrossProceed', window );">Generating gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Authorized capital stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds of warrant exercise (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Pay off (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Initial public offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvkd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,140,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_GeneratingGrossProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of generating gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_GeneratingGrossProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PublicOfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of public offering price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PublicOfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common share authorized, Purchase aggregate shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvkd_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvkd_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvkd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>f10k2022_cadrenalth_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvkd="http://www.cadrenal.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cvkd-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:HESPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:HESPLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2007-04-01</startDate>
            <endDate>2008-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:March2022ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:March2022ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:June2022ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:June2022ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:BousteadPrivatePlacementNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvkd:NonConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:MrPhamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:JohnMurphyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-05-17</startDate>
            <endDate>2022-05-17</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:GlynnWilsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:PlacementAgentWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cvkd:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:ChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-08-18</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cvkd:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-18</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:StevenZelenkofskemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvkd:JohnMurphyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937993</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-19</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-41596</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">CADRENAL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">88-0860746</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">822 A1A North</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Suite 306</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Ponte Vedra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">32082</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(904)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">300-0701</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">CVKD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">13279306</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">11634575</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">East Brunswick, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c0">100</dei:AuditorFirmId>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">32586</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">22715</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" unitRef="usd">672295</us-gaap:DeferredOfferingCosts>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">727596</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1013</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">43578</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">5987</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">778174</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">404897</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">863564</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">22288</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">43728</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1334477</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent contextRef="c3" decimals="0" unitRef="usd">442960</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c3" decimals="0" unitRef="usd">110380</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c3" decimals="0" unitRef="usd">4379944</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent contextRef="c3" decimals="0" unitRef="usd">40213</us-gaap:AccruedEnvironmentalLossContingenciesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">21350</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">6329324</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">8193875</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">8193875</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">8194</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">1154985</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-6714329</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">-5551150</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">778174</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">2307503</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c0" decimals="0" unitRef="usd">392859</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">1266</us-gaap:Depreciation>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">2701628</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-2701628</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">40192</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="0" unitRef="usd">66913</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" unitRef="usd">3905596</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherExpenses contextRef="c0" decimals="0" unitRef="usd">4012701</us-gaap:OtherExpenses>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">7890507</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c8" decimals="INF" unitRef="shares">7950000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c8" decimals="0" unitRef="usd">7950</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" unitRef="usd">7950</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c8" decimals="INF" unitRef="shares">243875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c8" decimals="0" unitRef="usd">244</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c9" decimals="0" unitRef="usd">927805</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c0" decimals="0" unitRef="usd">928049</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c9" decimals="0" unitRef="usd">51621</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c0" decimals="0" unitRef="usd">51621</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c9" decimals="0" unitRef="usd">175559</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="0" unitRef="usd">175559</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="0" unitRef="usd">-6714329</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c11" decimals="INF" unitRef="shares">8193875</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" unitRef="usd">8194</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" unitRef="usd">1154985</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" unitRef="usd">-6714329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">-5551150</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">1266</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">928049</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" unitRef="usd">66913</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" unitRef="usd">3905596</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">22715</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="c0" decimals="0" unitRef="usd">672295</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="0" unitRef="usd">5987</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">404897</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">863622</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">40213</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-1204770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">2279</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-2279</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c0" decimals="0" unitRef="usd">1011964</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c0" decimals="0" unitRef="usd">219721</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" unitRef="usd">7950</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">1239635</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">32586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">32586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvkd:NoncashRightOfUseAssetsAndOperatingLeaseLiabilities contextRef="c0" decimals="0" unitRef="usd">47090</cvkd:NoncashRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c0" decimals="0" unitRef="usd">51621</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c0" decimals="0" unitRef="usd">474349</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:StockIssued1 contextRef="c0" decimals="0" unitRef="usd">175559</us-gaap:StockIssued1>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;1. Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cadrenal Therapeutics, Inc. (the &#x201c;Company&#x201d;
or &#x201c;Cadrenal&#x201d;) was incorporated on January&#160;25, 2022 (inception) in the State of Delaware and is headquartered in Ponte
Vedra, Florida. Cadrenal is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular
heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process which targets a different pathway than most commonly
prescribed drugs for the treatment of thrombosis and AFib.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP) and applicable rules
and regulations of the U.S.&#160;Securities and Exchange Commission (&#x201c;SEC&#x201d;) for the fair presentation of the Company&#x2019;s
financial statements for the period from January&#160;25, 2022 (inception) through December 31, 2022. The Company&#x2019;s date of inception
was January&#160;25, 2022 and the fiscal year-end is December&#160;31.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;)
205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation
initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented
as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether
the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating
effect of the Company plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within
one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate
the relevant conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after
the date that the financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability
and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since
inception, the Company has incurred operating losses, and negative cash flows from operations. For the period from January&#160;25, 2022
(inception) to December 31, 2022, the Company had a net loss of $6,714,329 which included $4,901,824 of non-cash expenses. Cash used in
operations for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $1,204,770. As of December 31, 2022, the Company
had cash of $32,586, negative working capital of $606,881, and an accumulated deficit of $6,714,329. On January 24, 2023, the Company
consummated its initial public offering (the &#x201c;IPO&#x201d;) of 1,400,000 shares of its common stock at a public offering price of
$5.00 per share, generating gross proceeds of $7.0 million and net proceeds of $5.4 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is projecting that its existing cash
balances as of March 2023 is sufficient to fund its operations for at least the next twelve&#160;months from the date of the filing of
its Annual Report on Form 10-K, however, the Company will require additional funding to commence and complete its planned Phase&#160;3
clinical trial and submit its NDA.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management intends to raise additional funds through
equity and debt financings. However, there can be no assurance that the Company will be able to complete any additional equity or debt
financings on terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital
needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Emerging Growth Company Status&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;)
under the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), the Company may elect to take advantage of certain forms of relief
from various reporting requirements that are applicable to public companies. The relief afforded under the JOBS Act includes an extended
transition period for the implementation of new or revised accounting standards. The Company has elected to take advantage of this extended
transition period and, as a result, the Company&#x2019;s financial statements may not be comparable to those of companies that implement
accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the
JOBS Act up until the last&#160;day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is
no longer an EGC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and
certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors
and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit and other Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, which potentially subject
the Company to significant concentrations of credit risk, consist primarily of cash. Cash is maintained at high credit quality financial
institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances
are insured up to $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these
balances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to a number of risks common
for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product
candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested
manufacturing capabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are defined as components
of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker
(CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief
Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
purchased with original maturities of three&#160;months or less from the purchase date to be cash equivalents. The Company did not have
any cash equivalents at December&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Derivative Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates all of its agreements to
determine if such instruments have derivatives or contain features that qualify as embedded derivatives. The Company accounts for certain
redemption features that are associated with convertible notes as liabilities at fair value and adjusts the instruments to their fair
value at the end of each reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses
arising from changes in the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive
loss for each reporting period while such instruments are outstanding. The embedded derivative liabilities are valued using a probability-weighted
expected return model. If the Company repays the noteholders or if, during the next round of financing, the note holders convert the debt
into equity, the derivative financial liabilities will be de-recognized and reclassified to stockholders&#x2019; equity (deficit) on that
date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within 12&#160;months of the balance sheet date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Determination of the Fair Value of Common
Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Company&#x2019;s common
stock for purposes of stock-based awards has been determined by its board of directors. Because there has been no public market for the
Company&#x2019;s common stock, and in the absence of arm&#x2019;s-length transactions in the Company&#x2019;s common stock with independent
third parties, the board of directors has determined the fair value of its common stock with the assistance of an independent third-party
valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of the Company&#x2019;s common
stock on each grant date, the Company considered numerous objective and subjective factors, including, but not limited to, the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;independent third-party valuation as of May&#160;31, 2022;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the Company&#x2019;s current and expected operating and financial
performance, including our level of available capital resources;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the value of the Company&#x2019;s tangible and intangible
assets;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;market conditions affecting comparable public companies,
as reflected in comparable companies&#x2019; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the illiquidity of the Company&#x2019;s common stock by virtue
of being a private company, and the resulting discount for lack of marketability;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the business risks we face;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the experience of management and the board of directors&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes certain legal, professional,
and other third-party costs that are directly associated with in-process equity financings until such financings are consummated at which
time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
As of December 31, 2022, deferred offering costs were $672,295 and are included on the accompanying balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates acquisitions of assets
and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition
by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated
in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition.
If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to
create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test
to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should
be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired
and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between
the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based
on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development
(&#x201c;IPR&amp;amp;D&#x201d;) asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular
research and development project. For an IPR&amp;amp;D asset to have an alternative future use: (a)&#160;the Company must reasonably expect
that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;the
Company&#x2019;s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that
is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts
allocated to IPR&amp;amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent
consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial
targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of
payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income taxes are accounted for under the asset
and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected
to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Due to the Company&#x2019;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation
allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes uncertain income tax positions
at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected
in the period in which judgment occurs. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment
of income taxes as a component of the provision for income taxes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for
potential dilutive shares of common stock. Diluted net loss per common share is computed by dividing net loss by the weighted average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock or if-converted methods. Since the Company was in a loss position for all periods presented, basic net loss
per common share is the same as diluted net loss per common share since the effects of potentially dilutive securities are anti-dilutive.
Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive loss is defined as the change in
equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were
the same for the period presented in the accompanying financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the period from January&#160;25, 2022 (inception)
through December&#160;31, 2022, the Company&#x2019;s research and development expenses were comprised primarily of the cost of the acquired
tecarfarin asset and related transaction costs, as well as stock-based compensation and consulting services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patent costs are comprised primarily of external
legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force and are expensed
as incurred as a component of general and administrative expense.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP) and applicable rules
and regulations of the U.S.&#160;Securities and Exchange Commission (&#x201c;SEC&#x201d;) for the fair presentation of the Company&#x2019;s
financial statements for the period from January&#160;25, 2022 (inception) through December 31, 2022. The Company&#x2019;s date of inception
was January&#160;25, 2022 and the fiscal year-end is December&#160;31.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:IncomeTaxUncertaintiesPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;)
205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation
initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented
as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether
the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating
effect of the Company plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within
one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate
the relevant conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after
the date that the financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities
and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability
and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since
inception, the Company has incurred operating losses, and negative cash flows from operations. For the period from January&#160;25, 2022
(inception) to December 31, 2022, the Company had a net loss of $6,714,329 which included $4,901,824 of non-cash expenses. Cash used in
operations for the period January&#160;25, 2022 (inception) to December 31, 2022 totaled $1,204,770. As of December 31, 2022, the Company
had cash of $32,586, negative working capital of $606,881, and an accumulated deficit of $6,714,329. On January 24, 2023, the Company
consummated its initial public offering (the &#x201c;IPO&#x201d;) of 1,400,000 shares of its common stock at a public offering price of
$5.00 per share, generating gross proceeds of $7.0 million and net proceeds of $5.4 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is projecting that its existing cash
balances as of March 2023 is sufficient to fund its operations for at least the next twelve&#160;months from the date of the filing of
its Annual Report on Form 10-K, however, the Company will require additional funding to commence and complete its planned Phase&#160;3
clinical trial and submit its NDA.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management intends to raise additional funds through
equity and debt financings. However, there can be no assurance that the Company will be able to complete any additional equity or debt
financings on terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital
needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxUncertaintiesPolicy>
    <us-gaap:NetIncomeLossAllocatedToGeneralPartners contextRef="c0" decimals="0" unitRef="usd">6714329</us-gaap:NetIncomeLossAllocatedToGeneralPartners>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash contextRef="c3" decimals="0" unitRef="usd">4901824</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c0" decimals="0" unitRef="usd">1204770</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">32586</us-gaap:CashEquivalentsAtCarryingValue>
    <cvkd:WorkingsCapital contextRef="c3" decimals="0" unitRef="usd">606881</cvkd:WorkingsCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-6714329</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ExcessStockSharesIssued contextRef="c14" decimals="0" unitRef="shares">1400000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare contextRef="c14" decimals="2" unitRef="usdPershares">5</us-gaap:SaleOfStockPricePerShare>
    <cvkd:GeneratingGrossProceeds contextRef="c14" decimals="1" unitRef="usd">7</cvkd:GeneratingGrossProceeds>
    <cvkd:NetProceeds contextRef="c15" decimals="-5" unitRef="usd">5400000</cvkd:NetProceeds>
    <cvkd:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Emerging Growth Company Status&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;)
under the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), the Company may elect to take advantage of certain forms of relief
from various reporting requirements that are applicable to public companies. The relief afforded under the JOBS Act includes an extended
transition period for the implementation of new or revised accounting standards. The Company has elected to take advantage of this extended
transition period and, as a result, the Company&#x2019;s financial statements may not be comparable to those of companies that implement
accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the
JOBS Act up until the last&#160;day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is
no longer an EGC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</cvkd:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value
of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and
certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors
and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit and other Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, which potentially subject
the Company to significant concentrations of credit risk, consist primarily of cash. Cash is maintained at high credit quality financial
institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances
are insured up to $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these
balances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to a number of risks common
for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product
candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested
manufacturing capabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease contextRef="c0" decimals="0" unitRef="usd">250000</us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are defined as components
of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker
(CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief
Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
purchased with original maturities of three&#160;months or less from the purchase date to be cash equivalents. The Company did not have
any cash equivalents at December&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Derivative Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates all of its agreements to
determine if such instruments have derivatives or contain features that qualify as embedded derivatives. The Company accounts for certain
redemption features that are associated with convertible notes as liabilities at fair value and adjusts the instruments to their fair
value at the end of each reporting period. Derivative financial liabilities are initially recorded at fair value, with gains and losses
arising from changes in the fair value recognized in other income (expense) in the accompanying statements of operations and comprehensive
loss for each reporting period while such instruments are outstanding. The embedded derivative liabilities are valued using a probability-weighted
expected return model. If the Company repays the noteholders or if, during the next round of financing, the note holders convert the debt
into equity, the derivative financial liabilities will be de-recognized and reclassified to stockholders&#x2019; equity (deficit) on that
date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
settlement of the derivative instrument could be required within 12&#160;months of the balance sheet date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cvkd:DeterminationOfTheFairValueOfCommonStockPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Determination of the Fair Value of Common
Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Company&#x2019;s common
stock for purposes of stock-based awards has been determined by its board of directors. Because there has been no public market for the
Company&#x2019;s common stock, and in the absence of arm&#x2019;s-length transactions in the Company&#x2019;s common stock with independent
third parties, the board of directors has determined the fair value of its common stock with the assistance of an independent third-party
valuation prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. In assessing the fair value of the Company&#x2019;s common
stock on each grant date, the Company considered numerous objective and subjective factors, including, but not limited to, the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;independent third-party valuation as of May&#160;31, 2022;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the Company&#x2019;s current and expected operating and financial
performance, including our level of available capital resources;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the value of the Company&#x2019;s tangible and intangible
assets;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;market conditions affecting comparable public companies,
as reflected in comparable companies&#x2019; market trading multiples, initial public offering valuations, comparable sales or merger
transactions, and other metrics;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the illiquidity of the Company&#x2019;s common stock by virtue
of being a private company, and the resulting discount for lack of marketability;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the business risks we face;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the likelihood of achieving a particular liquidity event,
such as a sale, a merger, or an initial public offering, given prevailing pharmaceutical and biotechnology industry and capital markets
conditions; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the experience of management and the board of directors&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</cvkd:DeterminationOfTheFairValueOfCommonStockPolicyTextBlock>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes certain legal, professional,
and other third-party costs that are directly associated with in-process equity financings until such financings are consummated at which
time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
As of December 31, 2022, deferred offering costs were $672,295 and are included on the accompanying balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" unitRef="usd">672295</us-gaap:DeferredOfferingCosts>
    <us-gaap:RevenueRecognitionCustomerAcquisitions contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates acquisitions of assets
and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition
by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated
in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition.
If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to
create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test
to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Acquisitions meeting the definition of business
combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the
net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair
values of the net assets acquired is recorded as goodwill.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For asset acquisitions, a cost accumulation model
is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition.
The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should
be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired
and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between
the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based
on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development
(&#x201c;IPR&amp;amp;D&#x201d;) asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular
research and development project. For an IPR&amp;amp;D asset to have an alternative future use: (a)&#160;the Company must reasonably expect
that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b)&#160;the
Company&#x2019;s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that
is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts
allocated to IPR&amp;amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent
consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial
targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of
payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionCustomerAcquisitions>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income taxes are accounted for under the asset
and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected
to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Due to the Company&#x2019;s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation
allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes uncertain income tax positions
at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected
in the period in which judgment occurs. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment
of income taxes as a component of the provision for income taxes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for
potential dilutive shares of common stock. Diluted net loss per common share is computed by dividing net loss by the weighted average
number of shares of common stock and common stock equivalents of potentially dilutive securities outstanding for the period determined
using the treasury stock or if-converted methods. Since the Company was in a loss position for all periods presented, basic net loss
per common share is the same as diluted net loss per common share since the effects of potentially dilutive securities are anti-dilutive.
Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive loss is defined as the change in
equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were
the same for the period presented in the accompanying financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed as
incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf.
Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development;
is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable
alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are capitalized and then expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the period from January&#160;25, 2022 (inception)
through December&#160;31, 2022, the Company&#x2019;s research and development expenses were comprised primarily of the cost of the acquired
tecarfarin asset and related transaction costs, as well as stock-based compensation and consulting services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cvkd:PatentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patent costs are comprised primarily of external
legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force and are expensed
as incurred as a component of general and administrative expense.&lt;/p&gt;</cvkd:PatentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;2. Recent Accounting Guidance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August&#160;2020, the FASB issued ASU No.&#160;2020-06,
Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#x2014;&#160;Contracts
in Entity&#x2019;s Own Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity, which simplifies
the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and
contracts on an entity&#x2019;s own equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASU&#160;2020-06 is effective on a prospective
basis for annual reporting periods beginning after December&#160;15, 2023 and for interim periods within those periods. Early adoption
is permitted. The Company adopted ASU&#160;2020-06 on January 25, 2022 (inception). The adoption of ASU&#160;2020-06 did not have a material
impact on the Company&#x2019;s financial position and results of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;3. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities recorded at fair value
on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure
their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid
to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy
for disclosure of fair value measurements as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.75in"&gt;Level 1 &#x2014;&#160;&lt;/td&gt;
                                                                                       &lt;td style="text-align: justify"&gt;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.75in"&gt;Level 2 &#x2014;&#160;&lt;/td&gt;
                                                                                       &lt;td style="text-align: justify"&gt;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These
include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities
in markets that are not active.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.75in"&gt;Level 3 &#x2014;&#160;&lt;/td&gt;
                                                                                       &lt;td style="text-align: justify"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies its embedded derivative
liability as a Level 3 financial instrument and measures and reports its embedded derivatives at fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial liabilities subject to fair value measurements
on a recurring basis and the level of inputs used in such measurements by major security type as of December&#160;31, 2022 are presented
in the following table:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Financial Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-19"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-20"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-21"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-22"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 25, 2022 &lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-23"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Fair value of financial instruments at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value &#160; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,905,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of cash, prepaid expenses,
deferred offering costs, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. There
were no transfers of liabilities among the fair value measurement categories during any of the periods presented.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Financial Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-19"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-20"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-21"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-22"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="c18" decimals="0" unitRef="usd">4379944</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="c3" decimals="0" unitRef="usd">4379944</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c18" decimals="0" unitRef="usd">4379944</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c3" decimals="0" unitRef="usd">4379944</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 25, 2022 &lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-23"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Fair value of financial instruments at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value &#160; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,905,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,379,944&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c0" decimals="0" unitRef="usd">474348</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" unitRef="usd">3905596</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c3" decimals="0" unitRef="usd">4379944</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;4. Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Accrued consulting fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;165,192&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;605,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;863,564&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Accrued consulting fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;165,192&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;605,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;863,564&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cvkd:AccruedConsultingFees contextRef="c3" decimals="0" unitRef="usd">165192</cvkd:AccruedConsultingFees>
    <us-gaap:CompensatedAbsencesLiability contextRef="c3" decimals="0" unitRef="usd">605290</us-gaap:CompensatedAbsencesLiability>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">93082</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">863564</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;5. Asset Purchase Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April&#160;1, 2022, the Company completed
an asset purchase agreement with HESP LLC, the assignee of tecarfarin and related assets (the &#x201c;Asset Purchase Agreement&#x201d;).
Pursuant to the terms of the Asset Purchase Agreement, the Company acquired all of the assets of HESP LLC, including all intellectual
property and other rights related to tecarfarin, the tecarfarin IND&#160;77041, all rights under the license, development and commercialization
agreement dated as of September&#160;16, 2015 by and between Armetheon, Inc. (&#x201c;Armetheon&#x201d;) (which was later assigned by Armetheon
to Espero BioPharma, Inc. (&#x201c;Espero&#x201d;), and China Cardiovascular Focus Ltd, an affiliate of Lee&#x2019;s Pharmaceutical Holdings
Limited (&#x201c;Lee&#x2019;s Pharmaceutical&#x201d;), relating to tecarfarin and related trademarks. In consideration of the purchase of
the assets, the Company paid HESP LLC $100,000 on the closing date and paid an additional $100,000 on June&#160;1, 2022. As additional
consideration, the Company agreed to pay HESP LLC the following development milestone payments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Development Milestones&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Milestone &lt;br/&gt; Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Completion of enrollment of Lee&#x2019;s Pharmaceutical Phase&#160;3 clinical trial&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;First MAA submitted in the People&#x2019;s Republic of China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;First Commercial Sale to a Third Party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Financing Milestones&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As additional consideration, the Company agreed
to pay the following amounts, up to $2,000,000, upon each financing milestone as follows (i)&#160;35% of any proceeds received from any
licensing or partnering revenue; and (ii)&#160;IPO proceeds. The aggregate payments under the development milestone payments and financing
milestone payments shall not exceed $2,000,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for the transaction as
an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified
in-process research and development asset, the tecarfarin asset, thus satisfying the requirements of the screen test in accordance with
the criteria under ASC&#160;805-10-55-5C.&#160;The assets acquired in the transaction were measured based on the fair value of the consideration
paid including the direct transaction costs of $20,095, as the fair value of the consideration paid was more readily determinable than
the fair value of the assets acquired. The following table summarizes the purchase price of the assets acquired:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;In process research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220,095&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All costs the Company incurred in connection
with this Asset Purchase Agreement were recognized as research and development expenses in the Company&#x2019;s statement of operations
and comprehensive loss as these assets had no alternative future use at the time of the acquisition transaction. Due to the nature of
the regulatory, sales and financing-based milestones, the contingent consideration was not included in the initial cost of assets purchased
as they are contingent upon events that are outside the Company&#x2019;s control.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, upon achievement or anticipated achievement
of each milestone, the Company will recognize the related appropriate payment as additional research and development expense. Contingent
consideration will not be recorded until it is probable the milestone events occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August&#160;18, 2022, the Company entered
into an Amendment to Asset Purchase Agreement, whereby in lieu of the $1,800,000 cash payment that would have been due to HESP LLC pursuant
to the Asset Purchase Agreement as a result of an initial public offering, HESP LLC agreed to accept shares of the Company&#x2019;s common
stock, such number of shares to be calculated based upon a 40% discount to the price of the Company&#x2019;s common stock sold in the
initial public offering. If and when it is determined that it is probable this financing-based milestone (initial public offering) will
be achieved, the Company will recognize the payment of $3.0&#160;million as research and development expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December&#160;31, 2022, none of the contingent
events have occurred.&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="c19" decimals="0" unitRef="usd">100000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c20" decimals="0" unitRef="usd">100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Development Milestones&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Milestone &lt;br/&gt; Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Completion of enrollment of Lee&#x2019;s Pharmaceutical Phase&#160;3 clinical trial&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;First MAA submitted in the People&#x2019;s Republic of China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;First Commercial Sale to a Third Party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock>
    <cvkd:CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial contextRef="c0" decimals="0" unitRef="usd">250000</cvkd:CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial>
    <cvkd:FirstMAASubmittedInThePeoplesRepublicOfChina1 contextRef="c0" decimals="0" unitRef="usd">350000</cvkd:FirstMAASubmittedInThePeoplesRepublicOfChina1>
    <cvkd:FirstCommercialSaleToAThirdParty1 contextRef="c0" decimals="0" unitRef="usd">1200000</cvkd:FirstCommercialSaleToAThirdParty1>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c0" decimals="0" unitRef="usd">2000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c3" decimals="2" unitRef="pure">0.35</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c21" decimals="0" unitRef="usd">2000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c3" decimals="0" unitRef="usd">20095</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfRegulatoryAssetsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;In process research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220,095&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRegulatoryAssetsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c24" decimals="0" unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c24" decimals="0" unitRef="usd">20095</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c24" decimals="0" unitRef="usd">220095</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PaymentsForOtherOperatingActivities contextRef="c22" decimals="0" unitRef="usd">1800000</us-gaap:PaymentsForOtherOperatingActivities>
    <cvkd:DiscountPercentage contextRef="c23" decimals="2" unitRef="pure">0.40</cvkd:DiscountPercentage>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c22" decimals="-5" unitRef="usd">3000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;6. Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Debt outstanding is presented on the balance
sheet as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Convertible notes payable - related parties&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;550,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(464,620&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Promissory note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(206,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,728&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total debt, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;597,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;March&#160;2022 Convertible Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March&#160;2022, the Company entered into
a convertible promissory note agreement (the &#x201c;March&#160;2022 Note&#x201d;) and received cash proceeds of $500,000. The March&#160;2022
Note bears interest at a rate equal to simple interest of 5.0% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The March&#160;2022 Note is due and payable on March&#160;1, 2025, unless earlier converted or repaid.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the March&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $3.0&#160;million is raised.
The principal and unpaid and accrued interest of the March&#160;2022 Note at the date of conversion will be converted into shares at
a conversion price equal to 80% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the
Company consummates a Change of Control prior to repayment in full of the March&#160;2022 Note, immediately prior to the Change of Control,
the outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly
into proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is 80% of the
price per share of common equity paid at the Change of Control.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated whether the March&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the March&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $104,883, with the offsetting amount being recorded as a debt discount. Debt issuance costs totaled $1,460. The debt discount
and debt issuance costs are being amortized to interest expense using the effective interest method over the expected term of the March&#160;2022
Note. The effective interest rate of the March&#160;2022 Note is 12.1% compared to a stated interest rate of 5.0%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;June&#160;2022 Convertible Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June&#160;2022, the Company entered into a
convertible promissory note agreement (the &#x201c;June&#160;2022 Note&#x201d;) and received cash proceeds of $50,000. The June&#160;2022
Note bears interest at a rate equal to simple interest of 6.0% per annum computed on the basis of the 360-day year of twelve (12)&#160;30-day&#160;months.
The June&#160;2022 Note is due and payable on June&#160;13, 2025, unless earlier converted or repaid.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the June&#160;2022 Note, the principal
and accrued but unpaid interest will be automatically converted into equity securities sold in the Next Equity Financing of the Company
comprising a single transaction or a series of related transactions in which total proceeds of at least $3.0&#160;million is raised.
The principal and unpaid and accrued interest of the June&#160;2022 Note at the date of conversion will be converted into shares at a
conversion price equal to 60% of the price per share paid by investors purchasing such shares in the Next Equity Financing. If the Company
consummates a Change of Control prior to repayment in full of the June&#160;2022 Note, immediately prior to the Change of Control, the
outstanding principal and any unpaid and accrued interest will automatically convert into common equity of the Company (or directly into
proceeds paid to the holders of common equity in connection with the Change of Control) at a price per share that is 60% of the price
per share of common equity paid at the Change of Control.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated whether the June&#160;2022
Note contains embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives and Hedging. The Company
determined that these redemption features contained rights and obligations for conversion contingent upon a potential future financing
event or a change in control. Thus, the embedded put options were bifurcated from the face value of the June&#160;2022 Note and accounted
for as a derivative liability to be remeasured at the end of each reporting period with the change in the fair value included in other
expense, in the accompanying statement of operations and comprehensive loss. The fair value of the put option derivative liability at
issuance was $29,532, with the offsetting amount being recorded as a debt discount. The debt discount is amortized to interest expense
using the effective interest method over the expected term of the June&#160;2022 Note. The effective interest rate of the June&#160;2022
Note is 25.7% compared to a stated interest rate of 6.0%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Boustead Private Placement Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July&#160;2022, the Company issued convertible
promissory notes in the aggregate amount of $450,000 (the &#x201c;July&#160;2022&#160;Notes&#x201d;), in August&#160;2022, the Company
issued a convertible promissory note in the amount of $50,000 (the &#x201c;August&#160;2022 Note&#x201d;) and in September&#160;2022, the
Company issued convertible promissory notes in the aggregate amount of $75,000 (the &#x201c;September&#160;2022 Notes&#x201d;). The July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Note bear interest at 6% and mature on September&#160;13, 2025 (&#x201c;Maturity
Date&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The principal amount due under the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes (and, at the Company&#x2019;s option, any accrued but unpaid interest
under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes) will be automatically converted, on or before
the Maturity Date, into Next Equity Securities in the Next Equity Financing. The July&#160;2022 Notes, the August&#160;2022 Note and
September&#160;2022 Notes are convertible into shares of common stock at a conversion price equal to the quotient obtained by dividing
(i)&#160;the entire principal amount of the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes, plus (if
applicable) any accrued but unpaid interest under the July&#160;2022 Notes, the August&#160;2022 Note and the September&#160;2022 Notes
by (ii)&#160;sixty percent (60%) of the price per share of the Next Equity Securities sold in the Next Equity Financing. In the event
of a Change of Control which occurs prior to repayment in full of the July&#160;2022 Notes, the August&#160;2022 Note or the September&#160;2022
Notes, immediately prior to the Change of Control, the outstanding principal and any accrued but unpaid interest on the July&#160;2022
Notes, the August&#160;2022 Note and the September&#160;2022 Notes will convert directly into our common equity (or directly into proceeds
paid to the holders of our common equity in connection with the Change of Control) at a price per share that is 60% of the price per
share of common equity paid at the Change of Control. Boustead Securities, LLC acted as the placement agent for the private placement
and received as part of its compensation and five-year warrants to purchase shares of our common stock at a price equal to the conversion
price of the Private Placement Notes in an amount equal to 6% of the shares of common stock underlying the Private Placement Notes. The
Company has determined that the warrants issued to the placement agent receive equity treatment. The warrants were recorded at fair value
at issuance and recorded as debt issuance costs associated with the Boustead Private Placement Notes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has determined the redemption features
in the July&#160;2022 Notes, August&#160;2022 Note and September&#160;2022 Notes contain rights and obligations for conversion contingent
upon a potential future financing event or a change in control, and that such features are required to be bifurcated from the host debt
instrument and accounted for as a derivative liability to be remeasured at the end of each reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated whether the July, August,
and September&#160;2022 Notes contain embedded features that meet the definition of derivatives under FASB ASC&#160;815, Derivatives
and Hedging. The Company determined that these redemption features contained rights and obligations for conversion contingent upon a
potential future financing event or a change in control. Thus, the embedded put options were bifurcated from the face value of the July,
August and September Notes and accounted for as a derivative liabilities to be remeasured at the end of each reporting period with the
change in the fair value included in other expense, in the accompanying statements of operations and comprehensive loss. The fair value
of the put option derivative liabilities at issuance was $339,934, with the offsetting amount being recorded as a debt discount. The
debt discount is being amortized to interest expense using the effective interest method over the expected term of the July, August and
September&#160;2022 Notes. The effective interest rates of the July, August and September&#160;2022 Notes were 36.3%, 26.1%, and 28.8%,
respectively, compared to a stated interest rate of 6.0%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-Convertible Promissory Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 30, 2022, the Company closed a $250,000
note offering (the &#x201c;November Private Placement&#x201d;) pursuant to which the Company sold to two accredited investors units consisting
of (i) notes in the aggregate principal amount of $250,000, which bear interest at the rate of 10%, repayable at the earlier of the time
of the completion of the IPO or November 30, 2023 (the &#x201c;November Notes&#x201d;) and (ii) warrants to purchase up to an aggregate
of 250,000 shares of common stock exercisable at $1.00 per common share, which are exercisable at any time and are automatically exercised
into shares of the Company&#x2019;s common stock upon the consummation of the IPO (the &#x201c;November Warrants&#x201d;). At the time the
November Notes and November Warrants were sold, it was intended that the principal amount of the November Notes would be repaid upon
the consummation of the IPO out of the proceeds of the November Warrants exercise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The issuance of the November Warrants triggered
an adjustment to the conversion price of the Private Placement Notes (the July 2022, August 2022 and September 2022 Notes) to $1.00 per
share, pursuant to down-round protection included in those notes. As a result of the adjustment of the conversion price of the Private
Placement Notes, the five-year warrants issued to Boustead Securities, LLC in connection with the Private Placement, were amended to
provide for the purchase of an aggregate of 11,500 shares of the Company&#x2019;s common stock at an exercise price equal to 60% of the
initial public offering price per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also issued 15,000 warrants to Boustead
for the placement of the November financing. The November placement agent warrants have an exercise price of $1.00 per common share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2022, the Company entered into amendments
to the March 2022 Note and the June 2022 Note to adjust the conversion price of the March 2022 Note and the June 2022 Note to $1.00 per
common share. The March 2022 Note and June 2022 Note originally had a conversion price equal to 80% and 60%, respectively, of the IPO
price. While this amendment was not required, as the March 2022 Note and June 2022 did not have down-round protection like the Private
Placement Notes, the amendment was entered into to provide the investors in the March and June Notes with the same conversion price as
the Private Placement notes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company incurred debt issuance costs attributed to the November
Notes, which were recorded as a debt discount.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Convertible notes payable - related parties&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;550,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(464,620&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Promissory note payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(206,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,728&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total debt, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;597,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <cvkd:ConvertibleNotesPayableRelatedParties contextRef="c3" decimals="0" unitRef="usd">550000</cvkd:ConvertibleNotesPayableRelatedParties>
    <us-gaap:DeferredFinanceCostsNet contextRef="c3" decimals="0" unitRef="usd">107040</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebt contextRef="c3" decimals="0" unitRef="usd">442960</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleNotesPayable contextRef="c3" decimals="0" unitRef="usd">575000</us-gaap:ConvertibleNotesPayable>
    <cvkd:DebtIssuanceCosts1 contextRef="c3" decimals="0" unitRef="usd">464620</cvkd:DebtIssuanceCosts1>
    <cvkd:ConvertibleDebt1 contextRef="c3" decimals="0" unitRef="usd">110380</cvkd:ConvertibleDebt1>
    <us-gaap:NotesPayable contextRef="c3" decimals="0" unitRef="usd">250000</us-gaap:NotesPayable>
    <cvkd:DebtIssuanceCosts2 contextRef="c3" decimals="0" unitRef="usd">206272</cvkd:DebtIssuanceCosts2>
    <cvkd:ConvertibleDebt2 contextRef="c3" decimals="0" unitRef="usd">43728</cvkd:ConvertibleDebt2>
    <us-gaap:DebtCurrent contextRef="c3" decimals="0" unitRef="usd">597068</us-gaap:DebtCurrent>
    <us-gaap:DerivativeCashReceivedOnHedge contextRef="c25" decimals="0" unitRef="usd">500000</us-gaap:DerivativeCashReceivedOnHedge>
    <us-gaap:DerivativeFixedInterestRate contextRef="c26" decimals="3" unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c25" decimals="-5" unitRef="usd">3000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c25" decimals="2" unitRef="pure">0.80</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c25" decimals="2" unitRef="pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:DerivativeLiabilityFairValueOfCollateral contextRef="c26" decimals="0" unitRef="usd">104883</us-gaap:DerivativeLiabilityFairValueOfCollateral>
    <us-gaap:DeferredFinanceCostsCurrentGross contextRef="c26" decimals="0" unitRef="usd">1460</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c26" decimals="3" unitRef="pure">0.121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c25" decimals="3" unitRef="pure">0.05</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:DerivativeCashReceivedOnHedge contextRef="c27" decimals="0" unitRef="usd">50000</us-gaap:DerivativeCashReceivedOnHedge>
    <us-gaap:DerivativeFixedInterestRate contextRef="c28" decimals="3" unitRef="pure">0.06</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c27" decimals="-5" unitRef="usd">3000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c27" decimals="2" unitRef="pure">0.60</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <cvkd:PercentageOfPriceShare contextRef="c28" decimals="2" unitRef="pure">0.60</cvkd:PercentageOfPriceShare>
    <us-gaap:DerivativeLiabilityFairValueOfCollateral contextRef="c28" decimals="0" unitRef="usd">29532</us-gaap:DerivativeLiabilityFairValueOfCollateral>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c28" decimals="3" unitRef="pure">0.257</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c27" decimals="3" unitRef="pure">0.06</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c29" decimals="0" unitRef="usd">450000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:ConvertiblePreferredDividendsNetOfTax contextRef="c30" decimals="0" unitRef="usd">50000</us-gaap:ConvertiblePreferredDividendsNetOfTax>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c31" decimals="0" unitRef="usd">75000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c32" decimals="2" unitRef="pure">0.06</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InvestmentMaturityDate contextRef="c32">2025-09-13</us-gaap:InvestmentMaturityDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c33" decimals="2" unitRef="pure">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cvkd:CommonEquity contextRef="c33" decimals="2" unitRef="pure">0.60</cvkd:CommonEquity>
    <cvkd:CommonStock contextRef="c33" decimals="2" unitRef="pure">0.06</cvkd:CommonStock>
    <us-gaap:DerivativeLiabilityFairValueOfCollateral contextRef="c34" decimals="0" unitRef="usd">339934</us-gaap:DerivativeLiabilityFairValueOfCollateral>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c35" decimals="3" unitRef="pure">0.363</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c36" decimals="3" unitRef="pure">0.261</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c32" decimals="3" unitRef="pure">0.288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c34" decimals="3" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredOfferingCosts contextRef="c37" decimals="0" unitRef="usd">250000</us-gaap:DeferredOfferingCosts>
    <cvkd:AggregatePrincipalsAmount contextRef="c37" decimals="0" unitRef="usd">250000</cvkd:AggregatePrincipalsAmount>
    <us-gaap:InvestmentInterestRate contextRef="c37" decimals="2" unitRef="pure">0.10</us-gaap:InvestmentInterestRate>
    <cvkd:AggregateShares contextRef="c37" decimals="0" unitRef="shares">250000</cvkd:AggregateShares>
    <us-gaap:SharesIssuedPricePerShare contextRef="c37" decimals="2" unitRef="usdPershares">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="c38" decimals="2" unitRef="usdPershares">1</us-gaap:SaleOfStockPricePerShare>
    <cvkd:AggregateShares contextRef="c38" decimals="0" unitRef="shares">11500</cvkd:AggregateShares>
    <cvkd:PercentageOfExercisePrice contextRef="c39" decimals="2" unitRef="pure">0.60</cvkd:PercentageOfExercisePrice>
    <us-gaap:ExcessStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">15000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax contextRef="c0" decimals="2" unitRef="usdPershares">1</us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c3" decimals="2" unitRef="usdPershares">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c40" decimals="2" unitRef="pure">0.80</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c41" decimals="2" unitRef="pure">0.60</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;7. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January&#160;25, 2022, the Company into an
agreement with Phamace, LLC, a consulting firm of which Quang Pham, the Company&#x2019;s Chief Executive Officer, is the sole member,
for an initial term of January&#160;25, 2022 through February&#160;28, 2022. Pursuant to the agreement, the Company shall pay the sum
of $115,000 to Phamace, LLC for advisory and administrative services rendered relating to preparing the Company to launch as an operating
company, which is due and payable on September&#160;30, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January&#160;25, 2022, the Company issued 7,500,000
shares of common stock, pursuant to a subscription agreement, to Quang Pham, our Chief Executive Officer, of which 3,000,000 were subsequently
transferred to a related trust, of which Mr.&#160;Pham&#x2019;s child is a beneficiary and Mr.&#160;Pham is the trustee with sole voting
and disposition power with respect to the shares owned by the trust, 1,100,000 were subsequently transferred to friends, family and a
trust of which Mr. Pham&#x2019;s child is a beneficiary, but of which Mr. Pham has no voting or disposition power, and 125,000 were transferred
to non-profit organizations. Mr.&#160;Pham paid a total of $7,500 for such founders shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March&#160;1, 2022, the Company issued a convertible
promissory note in the amount of $500,000 to John Murphy, a member of the Company&#x2019;s board of directors, which bears interest at
5% and matures on March&#160;1, 2025. The note is convertible into shares of Common Stock at a conversion price equal to the quotient
obtained by dividing (i)&#160;the entire principal amount of the note plus (if applicable) any accrued but unpaid interest under the
Note by (ii)&#160;eighty percent (80%) of the price per share of the equity securities issued and sold at the initial closing of our
next equity financing. See Note&#160;6 for further discussion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May&#160;17, 2022, the Company issued 450,000
shares of restricted common stock, pursuant to a restricted stock purchase agreement, to Matthew Szot its Chief Financial Officer, which
shares shall vest quarterly over a period of two&#160;years, subject to certain adjustments, as provided in the Restricted Stock Purchase
Agreement dated May&#160;17, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 22, 2022, the Company issued a convertible
promissory note in the amount of $50,000 to Glynn Wilson, a member of the Company&#x2019;s board of directors, which bears interest at
6% and matures on September 13, 2025. &lt;span style="font-family: Times New Roman, Times, Serif"&gt;See Note&#160;6 for further discussion.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AdministrativeFeesExpense contextRef="c42" decimals="0" unitRef="usd">115000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:CommonStockDividendsShares contextRef="c43" decimals="0" unitRef="shares">7500000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="c44" decimals="0" unitRef="shares">3000000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="c45" decimals="0" unitRef="shares">1100000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="c42" decimals="0" unitRef="shares">125000</us-gaap:CommonStockDividendsShares>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c42" decimals="0" unitRef="usd">7500</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c46" decimals="0" unitRef="usd">500000</us-gaap:ConvertibleDebtNoncurrent>
    <cvkd:ConcentrationRiskPercentage01 contextRef="c47" decimals="2" unitRef="pure">0.05</cvkd:ConcentrationRiskPercentage01>
    <cvkd:EquityMethodInvestmentOwnershipPercentage1 contextRef="c48" decimals="2" unitRef="pure">0.80</cvkd:EquityMethodInvestmentOwnershipPercentage1>
    <us-gaap:CommonStockDividendsShares contextRef="c49" decimals="0" unitRef="shares">450000</us-gaap:CommonStockDividendsShares>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c50" decimals="0" unitRef="usd">50000</us-gaap:ConvertibleDebtNoncurrent>
    <cvkd:ConcentrationRiskPercentage01 contextRef="c51" decimals="2" unitRef="pure">0.06</cvkd:ConcentrationRiskPercentage01>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;8. Leases, Commitments, and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At lease inception, the Company determines if
an arrangement is an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalation,
on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 842, Leases, the Company
determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease
commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all
leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the
balance sheet, but payments are recognized as expenses on a straight-line basis over the lease term. The Company has elected not to recognize
leases with terms of 12 months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A lease qualifies as a finance lease if any of
the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company
by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise,
(iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease
payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized
to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded
as operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company enters into contracts that contain
both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company
combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such
as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed
when the event determining the amount of variable consideration to be paid occurs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finance and operating lease assets and liabilities
are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount
rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing
rate based upon the available information at the lease commencement date. Operating lease assets are further adjusted for prepaid or
accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating lease ROU assets
and liabilities as of December 31, 2022 are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: 10pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;43,578&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Noncurrent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Operating lease expense was $4,394 for the year ended December 31,
2022. Cash paid for amounts included in the measurement of operating lease liabilities included in operating cash flows was $4,334 for
the year ended December 31, 2022. The remaining operating lease term was 22 months, and the operating lease discount rate was 12% as
of December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Future annual lease payments under non-cancellable
operating leases as of December 31, 2022 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#x2019;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the
future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will
be made and such expenditures can be reasonably estimated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Indemnification&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the Company&#x2019;s certificate
of incorporation and bylaws, the Company indemnifies its officers and directors for certain events or occurrences, subject to certain
limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability
insurance policy that may enable it to recover a portion of any amounts paid for future claims.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: 10pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;43,578&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Noncurrent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">43578</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">22288</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">21350</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">43638</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense contextRef="c52" decimals="0" unitRef="usd">4394</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInOperatingLiabilities contextRef="c52" decimals="0" unitRef="usd">4334</us-gaap:IncreaseDecreaseInOperatingLiabilities>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c3" decimals="2" unitRef="pure">0.12</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" unitRef="usd">26068</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="0" unitRef="usd">22319</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" unitRef="usd">48387</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" unitRef="usd">4749</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">43638</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;9. Stockholders&#x2019; Equity and
Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Certificate of Incorporation
filed on January&#160;25, 2022, the Company was authorized to issue a total of 10,000,000 shares of common stock with a par value of
$0.001 per share. On December 5, 2022, the Company filed an Amended and Restated Certificate of Incorporation to increase the authorized
capital stock of the Company to 82,500,000 shares, consisting of 75,000,000 shares of common stock, par value $0.001 per share, and 7,500,000
shares of preferred stock, par value $0.001 per share, which was approved by the Company&#x2019;s Board of Directors, as well as a majority
of the Company&#x2019;s shareholders, on December 5, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Holders of common stock are entitled to one vote
for each share of common stock held of record for the election of the Company&#x2019;s directors and all other matters requiring stockholder
action. Holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#x2019;s
Board in its discretion out of funds legally available therefor.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December&#160;31, 2022, 8,193,875 shares
of common stock were issued and outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the total warrants
outstanding at December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Issue
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;br/&gt;
    Per&#160;Share &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Expiration&lt;br/&gt;
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;br/&gt;
    as of&lt;br/&gt;
    January 25, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;New&lt;br/&gt;
    Issuance&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Expired&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;br/&gt;
    as of&lt;br/&gt;
    December&#160;31,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 24%; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    agent warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; width: 12%; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July - Sept 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 14.5%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July - Sept 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    agent warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nov 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nov 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; white-space: nowrap; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; white-space: nowrap; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nov 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earlier of IPO or Nov 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; font-size: 11pt; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c53" decimals="0" unitRef="shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c53" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c54" decimals="0" unitRef="shares">82500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c54" decimals="0" unitRef="shares">75000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c54" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c55" decimals="0" unitRef="shares">7500000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c55" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">8193875</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">8193875</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Issue
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;br/&gt;
    Per&#160;Share &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Expiration&lt;br/&gt;
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;br/&gt;
    as of&lt;br/&gt;
    January 25, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;New&lt;br/&gt;
    Issuance&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Expired&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;br/&gt;
    as of&lt;br/&gt;
    December&#160;31,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt; vertical-align: bottom; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 24%; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    agent warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; width: 12%; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July - Sept 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 14.5%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July - Sept 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 8%; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; width: 0.5%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Placement
    agent warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nov 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nov 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; white-space: nowrap; text-align: left; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; white-space: nowrap; text-align: center; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nov 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earlier of IPO or Nov 2027 &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; font-size: 11pt; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; font-size: 11pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; border-bottom: Black 4pt double; text-align: right; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <cvkd:PlacementAgentWarrant contextRef="c56">July - Sept 2022</cvkd:PlacementAgentWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c57" decimals="2" unitRef="usdPershares">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvkd:WarrantsAndRightOutstandingMaturityDate contextRef="c57">July - Sept 2027</cvkd:WarrantsAndRightOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c57" decimals="INF" unitRef="shares">11500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c57" decimals="INF" unitRef="shares">11500</us-gaap:CommonStockOtherSharesOutstanding>
    <cvkd:PlacementAgentWarrant contextRef="c59">Nov 2022</cvkd:PlacementAgentWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c60" decimals="2" unitRef="usdPershares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvkd:WarrantsAndRightOutstandingMaturityDate contextRef="c60">Nov 2027</cvkd:WarrantsAndRightOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c60" decimals="INF" unitRef="shares">15000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c60" decimals="INF" unitRef="shares">15000</us-gaap:CommonStockOtherSharesOutstanding>
    <cvkd:PlacementAgentWarrant contextRef="c62">Nov 2022</cvkd:PlacementAgentWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c63" decimals="2" unitRef="usdPershares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvkd:WarrantsAndRightOutstandingMaturityDate contextRef="c63">Earlier of IPO or Nov 2027</cvkd:WarrantsAndRightOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c63" decimals="INF" unitRef="shares">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c63" decimals="INF" unitRef="shares">250000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c3" decimals="INF" unitRef="shares">276500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">276500</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;10. Equity-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company adopted the Cadrenal Therapeutics,
Inc. 2022 Equity Incentive Plan, or the Initial Plan, on July&#160;11, 2022, which was later amended and restated on October&#160;16,
2022, for purposes of clarifying the application of certain of the rules of the Initial Plan to awards approved before such amendment
and restatement of the Initial Plan and to facilitate the transition to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan (the &#x201c;Successor Plan&#x201d;) for the issuance and approval of awards after consummation of this offering. On October&#160;16,
2022, the Board adopted and the Company&#x2019;s stockholders approved the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive
Plan, or the 2022 Plan, which will be a successor to and continuation of the Initial Plan and became effective on January 19, 2023. Upon
the effectiveness of the 2022 Plan, it replaced the Initial Plan, except with respect to awards outstanding under the Initial Plan, and
no further awards will be available for grant under the Initial Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Subject to certain adjustments, the maximum number
of shares of common stock that could have been issued under the Plans in connection with awards was 2,000,000 shares, of which 810,000
remained available for issuance as December 31, 2022. The maximum number of shares of common stock that may be issued under the 2022
Plan will automatically increase on January&#160;1 of each calendar year for a period of ten&#160;years commencing on January&#160;1,
2023 and ending on (and including) January&#160;1, 2032, to a number of shares of common stock equal to 20% of the total number of shares
of common stock outstanding on December&#160;31 of the preceding calendar year; provided, however that the board of directors, or the
compensation committee, may act prior to January&#160;1 of a given calendar year to provide that the increase for such year will be a
lesser number of shares of common stock. All available shares may be utilized toward the grant of any type of award under the 2022 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures its stock-based awards granted
to employees, consultants and directors based on the estimated fair values of the awards and recognizes the compensation over the requisite
service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. Stock-based
compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to
vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Weighted average assumptions used in the Black-Scholes
model are set forth below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 87%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
    &lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.98%&#160;&#x2013;&#160;4.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27&#160;&#x2013;&#160;5.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62.4%&#160;&#x2013;&#160;62.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July&#160;11, 2022, the Company granted stock
options to purchase 650,000 shares of common stock at an exercise price of $0.64 per common share. The stock option grants were issued
to directors, members of the Scientific Advisory Board, and other consultants to the Company and vest in periods ranging from &lt;span style="-sec-ix-hidden: hidden-fact-46"&gt;one&lt;/span&gt; to
&lt;span style="-sec-ix-hidden: hidden-fact-47"&gt;three&lt;/span&gt;&#160;years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August&#160;18, 2022, the Company issued stock
options to purchase 300,000 shares of common stock to our Chief Medical Officer. The options have an exercise price of $0.64 per common
share and will vest quarterly over a period of &lt;span style="-sec-ix-hidden: hidden-fact-48"&gt;three&lt;/span&gt;&#160;years, subject to certain adjustments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August&#160;18, 2022, the Company granted
stock options to purchase 100,000 shares of common stock at an exercise price of $0.64 per common share. The stock option grants were
issued to members of the Scientific Advisory Board and vest over &lt;span style="-sec-ix-hidden: hidden-fact-49"&gt;three&lt;/span&gt;&#160;years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Activity under the Plans for the period from
January&#160;25, 2022 (inception) to December&#160;31, 2022 is set forth below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average &lt;br/&gt; Exercise Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted- &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Outstanding at January&#160;25, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 20pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Canceled/forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding at December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and exercisable at December&#160;31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;427,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and expected to vest as of December&#160;31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average grant date fair value of
options granted to date was $1.11. At December&#160;31, 2022, the Company had $1,048,151 of unrecognized stock-based compensation expense
related to stock options which will be recognized over the weighted average remaining requisite service period of 2.2&#160;years. The
Company settles employee stock option exercises with newly issued shares of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July&#160;11, 2022, the Company issued restricted
stock of 46,875 shares of common stock to a consultant. These shares fully vested on October&#160;1, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August&#160;18, 2022, the Company issued 40,000
shares of common stock to a consultant. These shares were fully vested upon the date of grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August&#160;18, 2022, the Company issued 40,000
shares of common stock to Steven Zelenkofske, a director, for recruiting services performed. These shares were fully vested upon the
date of grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September&#160;16, 2022, the Company issued
50,000 shares of common stock to John Murphy, a director. These shares were fully vested upon the date of grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October&#160;3, 2022, the Company issued 137,000
shares of common stock to various consultants for services rendered. 70,000 of the shares were subsequently returned and canceled. These
shares were fully vested upon the date of grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October&#160;3, 2022, the Company issued stock
options to purchase 50,000 shares of common stock to a director. The options have an exercise price of $5.00 per common share and vest
over a three-year period, with 33.33% vesting on the first anniversary of the effective date, and thereafter 1/36 on a monthly basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total stock compensation expense for the period
from January&#160;25, 2022 (inception) to December&#160;31, 2022 was $928,049.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The allocation of stock-based compensation for
the period presented below was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25, &lt;br/&gt; 2022 &lt;br/&gt; (Inception) to &lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;791,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;928,049&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c3" decimals="0" unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharesIssued contextRef="c3" decimals="0" unitRef="shares">810000</us-gaap:SharesIssued>
    <cvkd:stockOptionsGrantedSharesTerm contextRef="c0">P10Y</cvkd:stockOptionsGrantedSharesTerm>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c0" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 87%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,
    &lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.98%&#160;&#x2013;&#160;4.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27&#160;&#x2013;&#160;5.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62.4%&#160;&#x2013;&#160;62.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c81" decimals="4" unitRef="pure">0.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c82" decimals="4" unitRef="pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c81">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c82">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c81" decimals="3" unitRef="pure">0.624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c82" decimals="3" unitRef="pure">0.625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c65" decimals="0" unitRef="shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c66" decimals="2" unitRef="usdPershares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c69" decimals="0" unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c70" decimals="2" unitRef="usdPershares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c72" decimals="0" unitRef="shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c72" decimals="2" unitRef="usdPershares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average &lt;br/&gt; Exercise Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted- &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Outstanding at January&#160;25, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 20pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Canceled/forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding at December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and exercisable at December&#160;31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;427,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and expected to vest as of December&#160;31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,578,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c0" decimals="INF" unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">0.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cvkd:WeightedAverageRemainingContractualLifeYearsGranted contextRef="c0">P9Y6M25D</cvkd:WeightedAverageRemainingContractualLifeYearsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="c0" decimals="0" unitRef="usdPershares">4578000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P9Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" unitRef="usd">4578000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c3" decimals="INF" unitRef="shares">108330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P9Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c3" decimals="0" unitRef="usd">427629</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P9Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" unitRef="usd">4578000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c0" decimals="2" unitRef="usdPershares">1.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c3" decimals="0" unitRef="usd">1048151</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c0">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c65" decimals="0" unitRef="shares">46875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:CommonStockSharesIssued contextRef="c74" decimals="0" unitRef="shares">40000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c75" decimals="0" unitRef="shares">40000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c76" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c77" decimals="0" unitRef="shares">137000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="c78" decimals="0" unitRef="shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockSharesIssued contextRef="c79" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c80" decimals="2" unitRef="usdPershares">5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c78" decimals="4" unitRef="pure">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <cvkd:StockCompensationExpense contextRef="c0" decimals="0" unitRef="usd">928049</cvkd:StockCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25, &lt;br/&gt; 2022 &lt;br/&gt; (Inception) to &lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;791,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;928,049&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">791247</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">136802</us-gaap:ResearchAndDevelopmentExpense>
    <cvkd:EmployeeBenefitAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">928049</cvkd:EmployeeBenefitAndShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;11. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table sets forth the computation
of the basic and diluted net loss per common share:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25, &lt;br/&gt; 2022 &lt;br/&gt; (Inception) to &lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Weighted average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,890,507&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;Net loss per share, basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the Company was in a loss position for
the period presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities
would have been anti-dilutive. For the period from inception to December&#160;31, 2022, there were no potential dilutive securities other
than the convertible notes, stock options, and warrants.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25, &lt;br/&gt; 2022 &lt;br/&gt; (Inception) to &lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Weighted average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,890,507&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;Net loss per share, basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">7890507</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 12. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s income (loss) before provision
(benefit) for income taxes for the period ended December 31, 2022 was generated in the following jurisdictions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 10pt"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s provision is $0, which is
primarily driven by the federal and state statutory income tax rates on current year losses, offset by the Company&#x2019;s full valuation
allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of income tax expense (benefit)
were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total current provision&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total deferred provision&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of income tax expense to the
amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the period ended December
31, 2022, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax benefit at statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,410,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State benefit, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(263,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Equity-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,003,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Increase in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;536,226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income taxes reflect the net tax effects
of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities at December 31, 2022 are shown
below. The Company has established a full valuation allowance against net deferred tax assets due to the uncertainty that such assets
will be realized. The Company periodically evaluates the recoverability of its deferred tax assets. At such time as it is determined
that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The increase in
the valuation allowances of $479,000 for the period from January&#160;25, 2022 (inception) to December 31, 2022 was primarily due to
the Company&#x2019;s net operating losses and basis differences in intangible assets generated during the current year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of deferred tax assets and liabilities
consisted of the following at December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;298,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Equity-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Capitalized research costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Accruals and other temporary differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;532,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Convertible debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(479,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company has net
operating loss carryforwards of approximately $1.2 million and $1.2 million available to reduce future taxable income, if any, for federal
and state income tax purposes, respectively. The Company&#x2019;s US federal and state net operating loss carryovers can be carried forward
indefinitely, but the deduction related to these net operating losses is limited to 80% of taxable income when utilized in future&#160;years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The utilization of net operating loss carryforwards
and tax credit carryovers could be subject to annual limitations under Section&#160;382 and 383 of the Internal Revenue Code of 1986,
and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future.
These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset
future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382 and 383, results from transactions
increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over
a three-year period. The Company has not conducted an analysis of an ownership change under section 382. To the extent that a study is
completed and an ownership change is deemed to occur, the Company&#x2019;s net operating losses and tax credits could be limited.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the two-step approach to
recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the
weight of available evidence indicates it is more likely than not that the position will be sustained upon audit, including resolution
of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more
than 50% likely of being realized upon ultimate settlement. Income tax positions must meet a more likely than not recognition threshold
to be recognized under ASC&#160;740 upon initial measurement and in subsequent periods. ASC&#160;740-10 also provides guidance on measurement,
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2022, the Company did not have
any significant uncertain tax positions. The Company will recognize interest and penalties related to uncertain tax positions in income
tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts
have been recognized in the Company&#x2019;s statement of operations and comprehensive loss. The Company does not anticipate a material
change to unrecognized tax benefits in the next twelve&#160;months.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All of the Company&#x2019;s tax&#160;years will
remain open for examination by the federal and state taxing authorities to the extent that the Company&#x2019;s tax attributes are utilized
in future&#160;years to offset income or income taxes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 10pt"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(6,714,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossAttributableToParent contextRef="c0" decimals="0" unitRef="usd">-6714329</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total current provision&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total deferred provision&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;January&#160;25,&lt;br/&gt; 2022&lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax benefit at statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,410,009&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State benefit, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(263,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Equity-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,003,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Increase in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;536,226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" unitRef="usd">-1410009</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" unitRef="usd">-263978</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <cvkd:IncometaxPermanentDifferences contextRef="c0" decimals="0" unitRef="usd">8910</cvkd:IncometaxPermanentDifferences>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">125248</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c3" decimals="0" unitRef="usd">1003603</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="0" unitRef="usd">536226</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">479000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;298,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Equity-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Capitalized research costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Accruals and other temporary differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;532,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Convertible debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"&gt;Valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(479,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">298000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="0" unitRef="usd">44000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c3" decimals="0" unitRef="usd">55000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c3" decimals="0" unitRef="usd">135000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">532000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">53000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">479000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="-5" unitRef="usd">1200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c3" decimals="-5" unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements contextRef="c0" decimals="2" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;&lt;b&gt;Note&#160;13.
Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;The Company
has evaluated events that occurred through March 29, 2023, the date that the financial statements were issued and determined that there
have been no events that have occurred that would require adjustments to our disclosures in the financial statements except for the transactions
described below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;On January
24, 2023, the Company consummated its initial public offering (the &#x201c;IPO&#x201d;) of 1,400,000 shares of its common stock at a public
offering price of $5.00 per share, generating gross proceeds of $7,000,000. The Company&#x2019;s shares of common stock commenced trading
on the Nasdaq Capital Market on January 20, 2023, under the symbol &#x201c;CVKD.&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;In connection
with the IPO, on January 19, 2023, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with
Boustead Securities, LLC, as representative of the underwriters (the &#x201c;Representative&#x201d;).&#160;Pursuant to the Underwriting
Agreement, the Company agreed to issue to the underwriters a five-year warrant (the &#x201c;Representative&#x2019;s Warrant&#x201d;) to
purchase an aggregate of 84,000 shares of the Company&#x2019;s&#160;common stock, which is equal to six percent (6%) of the shares of
common stock sold in the IPO. Such Representative&#x2019;s Warrant has an exercise price of $6.00, which is equal to 120% of the public
offering price of the common stock in the IPO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;On January
19, 2023, the Company issued 600,000 shares of common stock to HESP LLC, pursuant to the terms of an Amendment to the Asset Purchase
Agreement, dated August 18, 2022, between the Company and HESP LLC. The Company recognized the payment of $3.0&#160;million as research
and development expense in January 2023. See Note 5 for further discussion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;On January
24, 2023, concurrent with the consummation of the IPO, the Company issued 1,140,700 shares of common stock upon conversion of the convertible
promissory notes. See Note 6 for further discussion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;On January
24, 2023, the Company issued 250,000 shares of common stock upon the exercise of the November Warrants. The $250,000 of proceeds of the
warrant exercise were used to pay off the $250,000 November Notes. See Note 6 for further discussion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-left: 0; text-align: justify"&gt;After the closing of the IPO, the Company granted
50,000 shares of the Company&#x2019;s common stock to the Company&#x2019;s Chief Financial Officer.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c83" decimals="0" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare contextRef="c84" decimals="2" unitRef="usdPershares">5</us-gaap:SharesIssuedPricePerShare>
    <cvkd:GeneratingGrossProceed contextRef="c85" decimals="0" unitRef="usd">7000000</cvkd:GeneratingGrossProceed>
    <cvkd:PurchaseAggregateShares contextRef="c3" decimals="0" unitRef="shares">84000</cvkd:PurchaseAggregateShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="c21" decimals="2" unitRef="pure">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:SharePrice contextRef="c3" decimals="2" unitRef="usdPershares">6</us-gaap:SharePrice>
    <cvkd:PublicOfferingPricePercentage contextRef="c0" decimals="2" unitRef="pure">1.20</cvkd:PublicOfferingPricePercentage>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c86" decimals="0" unitRef="shares">600000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-5" unitRef="usd">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:CommonStockDividendsShares contextRef="c83" decimals="0" unitRef="shares">1140700</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="c85" decimals="0" unitRef="shares">250000</us-gaap:CommonStockDividendsShares>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c85" decimals="0" unitRef="usd">250000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c14" decimals="0" unitRef="usd">250000</us-gaap:WarrantsAndRightsOutstanding>
    <cvkd:SharesOfCommonStock contextRef="c0" decimals="0" unitRef="shares">50000</cvkd:SharesOfCommonStock>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-0"
      unitRef="usdPershares">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-1"
      unitRef="shares">7890507</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c6"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c7"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c9"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c10"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c10"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c8"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c8"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c10"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <cvkd:IssuanceOfInvestorWarrantsinShares
      contextRef="c8"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c8"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c10"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c8"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c9"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c7"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities
      contextRef="c16"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities
      contextRef="c17"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c16"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="c7"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c58"
      id="hidden-fact-24"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c57" id="hidden-fact-25" xsi:nil="true"/>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c61"
      id="hidden-fact-26"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c60" id="hidden-fact-27" xsi:nil="true"/>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c64"
      id="hidden-fact-28"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c63" id="hidden-fact-29" xsi:nil="true"/>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c7"
      id="hidden-fact-30"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c3" id="hidden-fact-31" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c81"
      id="hidden-fact-32"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c82"
      id="hidden-fact-33"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c7"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-35"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-36" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c7"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cvkd:WeightedAverageRemainingContractualLifeYearsExercised contextRef="c0" id="hidden-fact-40" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cvkd:WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c67" id="hidden-fact-46">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c68" id="hidden-fact-47">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c71" id="hidden-fact-48">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c73" id="hidden-fact-49">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-50"
      unitRef="usdPershares">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001937993</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MA'56-.ECWR=21HH$A:"6GE'7;DI-I5?Y=ALVWD=ZWTD4]7\F]""=!,&<)A+
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M2/9K'DT3P;))[$ ;G1K49W,M0*/FWY2:"K R_TZK6?XM?D7+0%ZJX5/H%^,
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MMVK)UAJ57/5YL@J;XC(*4^(2-N(2OX>7K^5H2DT<AE&4NHIDY";V@_-&-#L
M)X<Q><, H3-8W5540U6U5#HR.45K%)$\"1Q21[IB/U[?)]4J;8I>C(,P<TD;
MX8O]]+V%*7='S9KUU4Q.00SEE.>1H]W(R&+B9_%+N_-&,V"9=0#(E,=10%SS
M'AEQ3+P<=;<ZY$8TQR*W"L+3ML=A[$@(.5F2^L%[Z*Y7<D&FY$U"DH?$E8L1
MO23T3D_W6A2/6U&53*I/'S*"TTNS_> %U_;UL9?D_W&:(B.IB9_4-Z*N8=>E
MC.HY^AB<!P$V#8YVM.K8)4KC>1 $Y@^I+04%B'9Z*R3_AY5SE,UQ'LZS-$8
M6E.!9O$%FTJEX<#4!%6F.V'[P>HU+%)>MB#6@9A. QG.7?D89P'BGP4^ER4W
M&TNH";,\/^,-*FC+H4:L(J;(QSB.\LRQ1"8C](D?^M"C7=T= 'JL!ZN *>[/
MDA1'4)P.!2/OB9_WA\90[OJTZIDB_2R.8Q@45Z..4"=^J$\:M:^>]^K+)GLY
MZS)S<;+W-M\Q_J#R@3<*H+4!P^ \A3>4AT\#AQ,MVGX[OA8:-O?]X9914&4>
M@/L; ?/0\<3L\(</-*M_ 5!+ P04    "  9KWU6K&8"(FD"  #F!0  &
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MW0JL6Q"OZVM:.EM$*=(C*3L;^N%[I&19F64!?;$WUH/)^__N>'>Z^5'I+Z8
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M=@OP_ZU2]O3@!-I)?OD-4$L#!!0    ( !FO?5;8QA4G<P(  ((%   8
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M!1,(I$LBK0G3]:2;JN9Z][,+3K$*.+.=9/OOSP9* P$2.E]^2"#X?=[S]SW
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M<60 QQT&=FE@-PQLK\-@7!J,FP9=(3FE@7-I2&YID$_=+.:>"[=" BUFC!X
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M6+'-69P(NLWW\1ZI$#3-#V.,9 NG!LCK&TK%RXG:&JPVFQ?_ 5!+ P04
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M7-I;V62J;[C0-"HN)\,+>Q?(9&8#5S;'48&>RH8+R:6K9#AJ>GWD:?2 +;_
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M<TYUZ $#3T@PDF);['*>H18@21$[Q>G^QE:U ^-839M<8"4NB2WFG5SOD&G
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MBQ%_2]19E<$@"L$3K'N"7Z]%NB*%H J8(D/+*O '2(9!MZ7\!?K+$G3LMTS
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MG^3=B=N6I.5/.TNB-,.5-99P:,%*Z.6JAE<NB350WK6<T*R_2J:[;3J4L;)
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M;*586W/;-A9^YZ_ J-E.=T:1K(L=Q;4]XSCM;&;2-I.DW8>=?0!)R$)"$BP
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M>74^"LMI^^)-S9>L. =X4_+C!FN3LD2 W]?&^/:%%'2W[C?_ U!+ P04
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M=V]R:W-H965T<R]S:&5E=#$W+GAM;+59;6_;.!+^KE]!>--%"SBV)=MY:=H
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M(%M!5 >9J+[ 79D1UBNDRZ%4PW14 GJ5Q9QM=K9.N),ZE[-<,2P6 *1_0-(
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M=H&+P8[S&T&H6<@(FM_QP(4@CM"H#'VQ-&MUQQZ&ZVG/C#D' C*-W=Y8U[!
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M!BAV<%*H+921'9(KV*MM<MVDFCJAN4[%57:GT>!LZGZ,NP%AN!'H9G'3?38
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M3GO"UA_-ZA_>K/A#U<QX;PI^7"J)K*0%F)\;XYL?=$#[Y?+ROU!+ P04
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MU%K]9T'_,M3.@-87BG+H!B[ ^N\X^PM02P,$%     @ &:]]5J#&P^DD"@
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M?(*H@D)1.(*J[_I"A;5247(RZ1SGM<DY-DD4(ZJ(*AEL68 R03?"MM0EW-/
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MKI0$6+0 WR^M#>T'.J#[:>KF_U!+ P04    "  9KWU63K [;)T%  #<#0
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MEB[W\F&?GOLO'_W\N*7CL.AQIEN_E:T7)[:^NDI_KZMVX]+W56[SX0:/"<X
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M[!'#IN3R_BW-?0E,-4TYU^SMT6C6%>5:A&%4PO;EX<9N,!Y'JL0M& EI1N@
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MM%%D*,V7#CU(44=([AN$R8.C<$ETPW?<,ZT!%"YJ>9* QZ7W A$+17_2G&"
M"7+:I]MQ[*]4.W[,<6'(:404TZIP(T2JCJDQ3SY@LIA2O%77,*;Y(+GAK$]1
M,,RK$2;%G88>X6K7:0ZO!L#&MU D<_!-NX3HS^,<78M5OJ=\SPSG*4.U#NS4
M=-(\&G*/!S7^V>72OXAA][F*3)7%>5O$^F24]3R3' C&E#TM;<-G@PY@U"#2
M#6#DX^TA4G[C)-I8[/"0G7T)(#Y/"@ 21/AQ+D_+,-W3W_7P?0B96(9>:>?*
M=XN3RK9'DBRK"\S$N5T(W$,11E**40K-N"^-%KL+/N, B%"3&19XDF&!9PPL
M+9&(JT)+ML[A-62(_TCN$5"RS>[GS9F J-XD/)CBQU.].$CYR+6:(QYK4OJ.
M7?1 #8=NU!=$'<=U'IG)39-!;:5T]>"V%/AJR]ZEF6^WEQZ"L5-9:;6MRGLD
M1WOX=FNYE_+/%!)Q,G1$'+XX-9"[$3,7N)P<CX-1%(/"1ZAFZ<65@5#*M-$\
M_4V% F?*W9>XQS#.U6ONO\'-<QB[M.T]+@8]Q+G^ NB1@S@AO8?*Q]5I2E@H
ML<!%F1&J2*%0@@K6QR/$G=[/&PK&-WF&P>AL%,6%>6R9=J>\MM[Q!.EYN$CQ
M^4>SW;U^%ZY3\-[BH\*/>F"X-1>"9;XV5[3B3#"D1@I8*5X\2 [=#/$RPS9(
ME))3 /H[$FH1JB-8B.SLFDZ>^E-Z;AX-)Z$I+<(]+E=C7MY73A,_4<JRID6W
MF,*Q1XI.VN*V0J,780B=8@>?2#):U5O*X):V(E_1^D8R#^_WB^D8O=ZW?#1:
MP.M<D,!#4$0;HN%+="I#/-!3<+ <(1'Y%)T2/71%W-L^Y_Y-H54[6:87(/36
MTBD:Z"\AM\07>CM*[Y8&3W1T[*-Y^A&@WQ=,$AGZ3 ;JU;,^OA=[2$\VW"'E
MP%V($Z*%DONA@^%Q,C_LV9,V&=[I-4V#!F@T_&XK3@[@(2EO7YL0)/,<K@KC
MSNQ#B]?9LM0&GF=?MPN9!@\I>>;IZKYDU2)I0GARTR\> GAL*26G-.'2(RW*
M?/L-Q:SR3IM^RL#A9CM3Y(B4PM73>I4H-K.0B*:[NJC:\0V.S.2A*7W("4QE
M6/W-D*OIJR$?I!/]=_-U?"YS>OEXAA7OF7X($[EV-/X+5QT8_8%?W(=&T!^'
MMZ]/CP4?-E+CID+<>#MVA<,!["0DV2(#= K63XV!2RQK*R,])UH1II/TZK6_
MGL$C_\$2#,%Q05LS[2KZH73SE05-A@<&-[R@4L'[.1?;N*@F%P+FJ HX0D5?
MHY!KO;AL?!UU#,*PM=[6NRMR>=5!I<VU;=WHJ7OQ:Y)=T=$.@L"C"9ID2/9I
M1J 0(/0*2  D>=<=WOX*7B&:O>X+)U$E.UQ%])=G?00S1H)P;UK?+5"O5@"*
M,F[3%WV30(IAYS!JU89!RG@PG8=C80P394<)XX4(GBU\F.@;)R1/63ERUS(Q
MS!;2=)@6UG&_<)V=SN*B0$<*TY V(00<A2CQ$!U0O8\I0R## V ,C$F?7?['
M0<57RL\!.++&_52,;N=YKTUUT2\VN%JE3]1CZNA*4)*0#7/?U8W/%.[DK46%
MW'7T"(0Y9TGB24%+UM?A1+&8(C7AB;P8);)<7)OSTYLAZ8/\\RPE-#M>,&V>
M^QLW5]-7;OY&4O=7E&$^D?WS+6!<PAVUU=]Q^>;D 2G>[Y/U%[PQV.T;#QMY
M$P&%0&4F-YQ1C.*9T'Y>1]>I5/JYH N#N_=K&\UE]_>2!XV-:#+IX!ZX#&3A
MS0M#ITI/)?U[1?*BE&'2\?V1YM(#-G\ 16(Y/Q4C> JY5)%+'D3.#X:'+^(9
M2'HXOH30(])W04\3)W)X25]<:1O6M[VG+>:K+G12RN;J5)V^C6"0&=P;':\5
M$GE+L5+[+8<Z_YHCU+^7 \%)QJC*]2JSY3<BY ^RP06@Q(U^$X4XU* '+OR/
M\^1VG!?1=8'&AC*..&&M=X>1UR,Q%OY.:WM_H>;JH1LU<>D>:CFJYM]U5^9P
MY_3FJ$\ SD2SZARUR@NOBLI?#=>1/#-XE<2@#-Y7R?4-*A@@'=Q:XC4H"M3W
M2)&T;3Q/_^8E8+R-P4V))(C.@=@' ?SF&VS33.OO$EQ-7R;X'.=2[Z(D\[UV
M;49Y^!W7#!X\*/U\JF+0E^]"%FA<$MXL(O26BTK(KJS5_ 9=*&$EKBF$V[;(
M9OG>B882)RL5_,Y%M5CC(S-+NS'E:IY<]^6$?BA P^PAV*=/$RPQ.*J!%;<!
M82M\7L9?1NU@_UZG:)?7B6:*X7Z+&OE?WUU#E(4>\:4<GS="(*673!+W6BXT
M<<9)R2NB#)S+\>F*;'&A/?:P)9)\78.="$=K>!1BM()#RD+Z0T$3P2^5-%Q.
MSJ*$&M"@=LSZI^. 3L-'BHQL<=>KBD^GN1YOTPF.)A%'N?L:E;LT5:X&S-*(
ME.,L 4>2LA(WFRUGT*S1'D#\JE$[ LAO>7%-_!:8Y.1+\,9OGY^4I=!RY4XH
M&R.^-S^XQQ?73D,!!]5=XK5I5K@ZYTM4/,*IX>9QZ=C@'/*F9CA@.AAY]$JJ
MF9NGV*056_375Q;3UU<^F?;4'8AO6YG*OY&I.4$TO#& !+I,>(: C<W,OUR%
M+4\P2WB#"P;7=[)SU//2,1J1"@HV*'&V][H9EGVQ=B=R(TOE)0Z:!,;V)(E?
ML'0<X^N[)O5R @55A>.;GG=AA_D8]1]'[V/E61:\=9:OY5:MO)HU?!O>;'LM
M[W/M'Y?7XOYN\*(,)%XK6GHY?_'L+&WD3;/RH:UW_';79=VV]9;_W%A#1@T/
MT.^KF@(E_8 #POM^W_PO4$L#!!0    ( !FO?58BT-4"X (  "H'   9
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MFT">Y0VU-!UKM27:62.:6_A4O3>2X](U96$U[G+TLVEF#'9^7FM68&XDVV@
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MA@]:$[4"<IMI'4P><R,%&/?>)]-;ILTN+NE%#:^)6A2=G38Z-]&^ZP]WS%N
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M4K+,-'= $N!Z@/I]PYA\N= W:,ZXYO\ 4$L#!!0    ( !FO?5;.S[YBZP(
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MP@O>N -P.WM'LP^_)6)-,XD8)-K2.QMK7T2UM:TFBN?E=G+)E=Z<EL.-_AT
M81;H^PGGZF5B=JC-#T;T%U!+ P04    "  9KWU6U!-F"IX"  !\!@  &0
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M3G@TA)XN"",\0UCCAG).^:9/X"!$OT 8T#;IM$T&M;FBV[JB,R554&Z44L*
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M;GVZQ_B.[?E]2<7FL&B-Z QI>VH(EDM[.Q=3>8OTCH_Q'=OS.\E$S+9JCE7
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ML&);8>_4_@.T]8P<7J&$\4^R;WVC@!1;8U75!B.#BLOFS1Y;'0X"*.T)H&T
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M7'0YQE)T,XX;PZK:C\"ELCA0_7*#-QAHYX#G*Z7LD^&F:G<GYK\ 4$L#!!0
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M^'<"CM0.XVV0ZN#.<#[_<*2>;8O4T&$_[,)^)U*[%+A,8C,)4RJWX_>V3+:
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MF 3!##%=;L5T:143>]-#1Y0KO8Z.0E4.)/6L13Y%":'I:J4'P/;3K@3%35W
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MRA)(?@;P=0A5'.$NCE'H1!Q#W$!-_ &%01@Z\)I57IH6K_4"WH1FE"T9>I@
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M+XIVJY@HGML69\J5;ICL<*%;5!!F@_X^XUSM)L9!U?1&/P!02P,$%     @
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M!!( 4P_(^PM*Q>Y$&2B_N$S_!5!+ P04    "  9KWU6,<Q2B)8"   /!@
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M&Y0-P/<;*<UA8PMT_P'I7U!+ P04    "  9KWU6/ ;0<Z4"  "5!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6RU56UOFS 0_BL6JZ96:@,AK\T(
M4M.LVJ1UBAIU_>S"!:P:F]DFZ:3^^)T-8>E$HGW9%_SZW#WWW/F(=E*]Z!S
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MA[)E6+[%-C\1=)-M"9U3(6B<':X)7A"6%I#?+RD5AY,T0;G1>?H?4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ &:]]5IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  9KWU6>HD?C[X'  !!,P  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ &:]]5I./_/;$!   K!$  !@
M             ("! 1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( !FO?5:L9@(B:0(  .8%   8              " @?L4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  9KWU6K93"UM@#  #5
M"P  &               @(&:%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ &:]]5MC&%2=S @  @@4  !@              ("!J!L
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !FO?59,R+)5
M/P0  '@6   8              " @5$>  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  9KWU6-4K8!*L%  "H%@  &
M@('&(@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ &:]]
M5EGHM8+X&P  \E   !@              ("!IR@  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( !FO?58LB\^*NP,  $$(   8
M      " @=5$  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !FO?59?;!#MU04  #(.   9              "
M@11G  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ &:]]
M5AX/9D+N"   @1<  !D              ("!(&T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  9KWU6KMXT.)P$   2"P  &0
M        @(%%=@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( !FO?5:M_60H00H  ,4<   9              " @1A[  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ &:]]5N/B=;@_ P  *0<
M !D              ("!D(4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  9KWU6H,;#Z20*  "F&@  &0              @($&B0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !FO?59.L#ML
MG04  -P-   9              " @6&3  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ &:]]5A49(%(+'   ^U<  !D
M ("!-9D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  9
MKWU6(M#5 N "   J!P  &0              @(%WM0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !FO?59&&O!W60(  $(%   9
M          " @8ZX  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ &:]]5HUM63/R @  Q 8  !D              ("!'KL  'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  9KWU6(<(93ID"  "Y
M!0  &0              @(%'O@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( !FO?59,MBBDWP(  !T'   9              " @1?!
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ &:]]5J&Q
M692Q @  )P8  !D              ("!+<0  'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    "  9KWU66IVHZ,4#  !@"0  &0
M    @($5QP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M !FO?59B@#EK?P(  '0%   9              " @1'+  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ &:]]5I%&F> J!    0L  !D
M             ("!Q\T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  9KWU6$%I@@UH$  #O$@  &0              @($HT@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !FO?5;.S[YBZP(
M &P,   9              " @;G6  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ &:]]5M039@J> @  ? 8  !D              ("!
MV]D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  9KWU6
M#Y(]AE,"  "\!0  &0              @(&PW   >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( !FO?599,F8XWP,  ,@4   9
M      " @3K?  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ &:]]5I>6X?G' @  4P8  !D              ("!4.,  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  9KWU6(+5RC[$"  "9!P
M&0              @(%.Y@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( !FO?5:H+9GD'0H  /YW   9              " @3;I  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ &:]]5E8K3EO;
M @  O0@  !D              ("!BO,  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  9KWU6OS IM 8%  #X*   &0
M@(&<]@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !FO
M?5844"[S90(  ,P%   9              " @=G[  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ &:]]5I[$_,1Y @  'P<  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( !FO?5:",*)8#P,    +   9
M  " @=$6 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M&:]]5A>DX-[2!   ?1D  !D              ("!%QH! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    "  9KWU6,<Q2B)8"   /!@  &0
M            @($@'P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( !FO?58\!M!SI0(  )4&   9              " @>TA 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ &:]]5L8*3#U5 @
M$@4  !D              ("!R20! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    "  9KWU6XP\&K<0"  ! !P  &0              @(%5
M)P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !FO?58-
M=@BEC0(  "\&   9              " @5 J 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ &:]]5N%_[8[$ @  , H  !D
M     ("!%"T! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M"  9KWU6419[Y$D#  #'"   &0              @($/, $ >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !FO?592#+[DZ@(  !D(   9
M              " @8\S 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L!
M A0#%     @ &:]]5G(_IYBH!0  ]"P  !D              ("!L#8! 'AL
M+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  9KWU6VZ?5^RD#
M  !*$@  #0              @ &// $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( !FO?5:7BKL<P    !,"   +              "  >,_ 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !FO?5;$D^/@D 0  .0E   /              "
M <Q  0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  9KWU6\R"+>>D!   2
M(@  &@              @ &)10$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  9KWU6LFA)V-4!  "_(0  $P              @ &J
L1P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!! +X1  "P20$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>87</ContextCount>
  <ElementCount>334</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheet (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheet (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statement of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statement of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statement of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statement of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statement of Changes in Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statement of Changes in Stockholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Recent Accounting Guidance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/RecentAccountingGuidance</Role>
      <ShortName>Recent Accounting Guidance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Asset Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AssetPurchaseAgreement</Role>
      <ShortName>Asset Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Leases, Commitments, and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/LeasesCommitmentsandContingencies</Role>
      <ShortName>Leases, Commitments, and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stockholders' Equity and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/StockholdersEquityandWarrants</Role>
      <ShortName>Stockholders' Equity and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AccruedLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Asset Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AssetPurchaseAgreementTables</Role>
      <ShortName>Asset Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AssetPurchaseAgreement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/Debt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Leases, Commitments, and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables</Role>
      <ShortName>Leases, Commitments, and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/LeasesCommitmentsandContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stockholders' Equity and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables</Role>
      <ShortName>Stockholders' Equity and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/StockholdersEquityandWarrants</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/EquityBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Fair Value Measurements (Details) - Schedule of derivative liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of derivative liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable</Role>
      <ShortName>Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Asset Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/AssetPurchaseAgreementDetails</Role>
      <ShortName>Asset Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AssetPurchaseAgreementTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Asset Purchase Agreement (Details) - Schedule of development milestone payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable</Role>
      <ShortName>Asset Purchase Agreement (Details) - Schedule of development milestone payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AssetPurchaseAgreementTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Asset Purchase Agreement (Details) - Schedule of purchase price of the assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable</Role>
      <ShortName>Asset Purchase Agreement (Details) - Schedule of purchase price of the assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/AssetPurchaseAgreementTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/DebtTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Debt (Details) - Schedule of debt outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable</Role>
      <ShortName>Debt (Details) - Schedule of debt outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/DebtTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Leases, Commitments, and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails</Role>
      <ShortName>Leases, Commitments, and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable</Role>
      <ShortName>Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable</Role>
      <ShortName>Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stockholders' Equity and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable</Role>
      <ShortName>Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Equity-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/EquityBasedCompensationDetails</Role>
      <ShortName>Equity-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Equity-Based Compensation (Details) - Schedule of option and warrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable</Role>
      <ShortName>Equity-Based Compensation (Details) - Schedule of option and warrant</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable</Role>
      <ShortName>Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable</Role>
      <ShortName>Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/NetLossPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/NetLossPerShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Income Taxes (Details) - Schedule of company???s income (loss) before provision (benefit) for income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of company???s income (loss) before provision (benefit) for income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of income tax expense (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f10k2022_cadrenalth.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cadrenal.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cadrenal.com/role/SubsequentEvents</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10k2022_cadrenalth.htm 13516, 13517, 13562, 13563, 13564, 13565, 13566</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_cadrenalth.htm">f10k2022_cadrenalth.htm</File>
    <File>cvkd-20221231.xsd</File>
    <File>cvkd-20221231_cal.xml</File>
    <File>cvkd-20221231_def.xml</File>
    <File>cvkd-20221231_lab.xml</File>
    <File>cvkd-20221231_pre.xml</File>
    <File>f10k2022ex21-1_cadrenal.htm</File>
    <File>f10k2022ex23-1_cadrenal.htm</File>
    <File>f10k2022ex31-1_cadrenal.htm</File>
    <File>f10k2022ex31-2_cadrenal.htm</File>
    <File>f10k2022ex32-1_cadrenal.htm</File>
    <File>f10k2022ex32-2_cadrenal.htm</File>
    <File>f10k2022ex4-11_cadrenal.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="374">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_cadrenalth.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 374,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 87,
   "dts": {
    "calculationLink": {
     "local": [
      "cvkd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvkd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_cadrenalth.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvkd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvkd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvkd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 466,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 60,
    "http://www.cadrenal.com/20221231": 3,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 66
   },
   "keyCustom": 40,
   "keyStandard": 294,
   "memberCustom": 14,
   "memberStandard": 13,
   "nsprefix": "cvkd",
   "nsuri": "http://www.cadrenal.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cadrenal.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cadrenal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cadrenal.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Asset Purchase Agreement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cadrenal.com/role/AssetPurchaseAgreement",
     "shortName": "Asset Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cadrenal.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cadrenal.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Leases, Commitments, and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cadrenal.com/role/LeasesCommitmentsandContingencies",
     "shortName": "Leases, Commitments, and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Stockholders' Equity and Warrants",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cadrenal.com/role/StockholdersEquityandWarrants",
     "shortName": "Stockholders' Equity and Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Equity-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cadrenal.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cadrenal.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cadrenal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Balance Sheet",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
     "shortName": "Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cadrenal.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cadrenal.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cadrenal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cadrenal.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Asset Purchase Agreement (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cadrenal.com/role/AssetPurchaseAgreementTables",
     "shortName": "Asset Purchase Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cadrenal.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Leases, Commitments, and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables",
     "shortName": "Leases, Commitments, and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Stockholders' Equity and Warrants (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables",
     "shortName": "Stockholders' Equity and Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Equity-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cadrenal.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cadrenal.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Balance Sheet (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Balance Sheet (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.cadrenal.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAllocatedToGeneralPartners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAllocatedToGeneralPartners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeInstrumentsAndHedgesLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeInstrumentsAndHedgesLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Fair Value Measurements (Details) - Schedule of derivative liability",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of derivative liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:AccruedConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable",
     "shortName": "Accrued Liabilities (Details) - Schedule of Accrued Liabilities Consist",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:AccruedConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c19",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Asset Purchase Agreement (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
     "shortName": "Asset Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c19",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Asset Purchase Agreement (Details) - Schedule of development milestone payments",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable",
     "shortName": "Asset Purchase Agreement (Details) - Schedule of development milestone payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cvkd:ScheduleOfDevelopmentMilestonePaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Asset Purchase Agreement (Details) - Schedule of purchase price of the assets",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable",
     "shortName": "Asset Purchase Agreement (Details) - Schedule of purchase price of the assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRegulatoryAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c24",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Debt (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cadrenal.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ExtinguishmentOfDebtGainLossPerShareNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:ConvertibleNotesPayableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Debt (Details) - Schedule of debt outstanding",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable",
     "shortName": "Debt (Details) - Schedule of debt outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:ConvertibleNotesPayableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Statement of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cadrenal.com/role/ConsolidatedIncomeStatement",
     "shortName": "Statement of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c42",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdministrativeFeesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c42",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdministrativeFeesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c52",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Leases, Commitments, and Contingencies (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails",
     "shortName": "Leases, Commitments, and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c52",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable",
     "shortName": "Leases, Commitments, and Contingencies (Details) - Schedule of operating lease ROU assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable",
     "shortName": "Leases, Commitments, and Contingencies (Details) - Schedule of future annual lease payments under non-cancellable operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Stockholders' Equity and Warrants (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails",
     "shortName": "Stockholders' Equity and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c55",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable",
     "shortName": "Stockholders' Equity and Warrants (Details) - Schedule of Summarizes the Total Warrants Outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockOtherSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Equity-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
     "shortName": "Equity-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c81",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Equity-Based Compensation (Details) - Schedule of option and warrant",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable",
     "shortName": "Equity-Based Compensation (Details) - Schedule of option and warrant",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c81",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable",
     "shortName": "Equity-Based Compensation (Details) - Schedule of options and warrants granted, exercised, forfeited and outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable",
     "shortName": "Equity-Based Compensation (Details) - Schedule of allocation share based compensation periods",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Statement of Operations and Comprehensive Loss (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Statement of Operations and Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable",
     "shortName": "Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals",
     "shortName": "Net Loss Per Share (Details) - Schedule of basic and diluted net loss per common share (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cadrenal.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Income Taxes (Details) - Schedule of company\u2019s income (loss) before provision (benefit) for income taxes",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of company\u2019s income (loss) before provision (benefit) for income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable",
     "shortName": "Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of components of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:PurchaseAggregateShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cadrenal.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvkd:PurchaseAggregateShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Statement of Changes in Stockholders\u2019 Deficit",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cadrenal.com/role/ShareholdersEquityType2or3",
     "shortName": "Statement of Changes in Stockholders\u2019 Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Statement of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cadrenal.com/role/ConsolidatedCashFlow",
     "shortName": "Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Recent Accounting Guidance",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cadrenal.com/role/RecentAccountingGuidance",
     "shortName": "Recent Accounting Guidance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_cadrenalth.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "cvkd_AccruedConsultingFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued consulting fees.",
        "label": "Accrued Consulting Fees",
        "terseLabel": "Accrued consulting fees"
       }
      }
     },
     "localname": "AccruedConsultingFees",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_AggregatePrincipalsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate principal amount.",
        "label": "Aggregate Principals Amount",
        "terseLabel": "Aggregate principal amount (in Dollars)"
       }
      }
     },
     "localname": "AggregatePrincipalsAmount",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_AggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Shares",
        "terseLabel": "Aggregate shares (in Shares)"
       }
      }
     },
     "localname": "AggregateShares",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvkd_AssetPurchaseAgreementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement (Details) [Line Items]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_AssetPurchaseAgreementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement (Details) [Table]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_AssetsAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Abstract0",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract0",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_BousteadPrivatePlacementNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead Private Placement Notes Member",
        "terseLabel": "Boustead Private Placement Notes [Member]"
       }
      }
     },
     "localname": "BousteadPrivatePlacementNotesMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_ChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Medical Officer Member",
        "terseLabel": "Chief Medical Officer [Member]"
       }
      }
     },
     "localname": "ChiefMedicalOfficerMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_CommonEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Equity",
        "terseLabel": "Common equity percentage"
       }
      }
     },
     "localname": "CommonEquity",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_CommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expenses on completion of enrollment of Lee\u2019s pharmaceutical phase 3 clinical trial.",
        "label": "Completion Of Enrollment Of Lees Pharmaceutical Phase3 Clinical Trial",
        "terseLabel": "Completion of enrollment of Lee\u2019s Pharmaceutical Phase 3 clinical trial"
       }
      }
     },
     "localname": "CompletionOfEnrollmentOfLeesPharmaceuticalPhase3ClinicalTrial",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_ConcentrationRiskPercentage01": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage01",
        "terseLabel": "Bears interest percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage01",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_ConvertibleDebt1": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of total convertible debt.",
        "label": "Convertible Debt1",
        "totalLabel": "Total convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt1",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_ConvertibleDebt2": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of total convertible debt.",
        "label": "Convertible Debt2",
        "totalLabel": "Total convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt2",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_ConvertibleNotesPayableRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable Related Parties",
        "terseLabel": "Convertible notes payable - related parties"
       }
      }
     },
     "localname": "ConvertibleNotesPayableRelatedParties",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_CurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Abstract",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_CurrentAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Abstract0",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentAbstract0",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DebtDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt (Details) [Line Items]"
       }
      }
     },
     "localname": "DebtDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DebtDetailsScheduleofdebtoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Details Scheduleofdebtoutstanding Line Items",
        "terseLabel": "Schedule Of Debt Outstanding [Abstract]"
       }
      }
     },
     "localname": "DebtDetailsScheduleofdebtoutstandingLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DebtDetailsScheduleofdebtoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Debt Outstanding [Abstract]"
       }
      }
     },
     "localname": "DebtDetailsScheduleofdebtoutstandingTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DebtDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt (Details) [Table]"
       }
      }
     },
     "localname": "DebtDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DebtIssuanceCosts1": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 2.0,
       "parentTag": "cvkd_ConvertibleDebt1",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs.",
        "label": "Debt Issuance Costs1",
        "negatedLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCosts1",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_DebtIssuanceCosts2": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 2.0,
       "parentTag": "cvkd_ConvertibleDebt2",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs.",
        "label": "Debt Issuance Costs2",
        "negatedLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCosts2",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_DeferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Abstract",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator Abstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_DeterminationOfTheFairValueOfCommonStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Determination Of The Fair Value Of Common Stock Policy Text Block",
        "terseLabel": "Determination of the Fair Value of Common Stock"
       }
      }
     },
     "localname": "DeterminationOfTheFairValueOfCommonStockPolicyTextBlock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvkd_DiscountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of discount price.",
        "label": "Discount Percentage",
        "terseLabel": "Discount percentage"
       }
      }
     },
     "localname": "DiscountPercentage",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company Status Policy Text Block",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvkd_EmployeeBenefitAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefit And Share Based Compensation",
        "totalLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitAndShareBasedCompensation",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_EquityBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityBasedCompensationDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) - Schedule of option and warrant [Line Items]"
       }
      }
     },
     "localname": "EquityBasedCompensationDetailsScheduleofoptionandwarrantLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_EquityBasedCompensationDetailsScheduleofoptionandwarrantTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) - Schedule of option and warrant [Table]"
       }
      }
     },
     "localname": "EquityBasedCompensationDetailsScheduleofoptionandwarrantTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_EquityBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "EquityBasedCompensationDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_EquityMethodInvestmentOwnershipPercentage1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage1",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage1",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial liabilities subject to fair value measurements on a recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_FinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Abstract",
        "terseLabel": "Financial Liabilities:"
       }
      }
     },
     "localname": "FinancialLiabilitiesAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_FirstCommercialSaleToAThirdParty1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale to a Third Party.",
        "label": "First Commercial Sale To AThird Party1",
        "terseLabel": "First Commercial Sale to a Third Party"
       }
      }
     },
     "localname": "FirstCommercialSaleToAThirdParty1",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_FirstMAASubmittedInThePeoplesRepublicOfChina1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First MAA submitted in the People\u2019s Republic of China",
        "label": "First MAASubmitted In The Peoples Republic Of China1",
        "terseLabel": "First MAA submitted in the People\u2019s Republic of China"
       }
      }
     },
     "localname": "FirstMAASubmittedInThePeoplesRepublicOfChina1",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdevelopmentmilestonepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_GeneratingGrossProceed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of generating gross proceeds.",
        "label": "Generating Gross Proceed",
        "terseLabel": "Generating gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "GeneratingGrossProceed",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_GeneratingGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of generating gross proceeds.",
        "label": "Generating Gross Proceeds",
        "terseLabel": "Generating gross proceeds"
       }
      }
     },
     "localname": "GeneratingGrossProceeds",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_GlynnWilsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Glynn Wilson Member",
        "terseLabel": "Glynn Wilson [Member]"
       }
      }
     },
     "localname": "GlynnWilsonMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_HESPLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HESPLLCMember",
        "terseLabel": "HESP LLC [Member]"
       }
      }
     },
     "localname": "HESPLLCMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_IncometaxPermanentDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax Permanent Differences,",
        "label": "Incometax Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncometaxPermanentDifferences",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_InvestorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants Member",
        "terseLabel": "Investor Warrants [Member]"
       }
      }
     },
     "localname": "InvestorWarrantsMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_IssuanceOfInvestorWarrantsinShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance of investor warrants.",
        "label": "Issuance Of Investor Warrantsin Shares",
        "terseLabel": "Issuance of investor warrants"
       }
      }
     },
     "localname": "IssuanceOfInvestorWarrantsinShares",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_JohnMurphyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "John Murphy [Member]",
        "label": "John Murphy Member",
        "terseLabel": "John Murphy [Member]"
       }
      }
     },
     "localname": "JohnMurphyMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_June2022ConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June2022 Convertible Note Member",
        "terseLabel": "June 2022 Convertible Note [Member]"
       }
      }
     },
     "localname": "June2022ConvertibleNoteMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_LiabilitiesAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Abstract0",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract0",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_March2022ConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March2022 Convertible Note Member",
        "terseLabel": "March 2022 Convertible Note [Member]"
       }
      }
     },
     "localname": "March2022ConvertibleNoteMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_MrPhamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Pham Member",
        "terseLabel": "Mr.Pham [Member]"
       }
      }
     },
     "localname": "MrPhamMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_NetProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net proceeds.",
        "label": "Net Proceeds",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "NetProceeds",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_NonConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Convertible Promissory Note Member",
        "terseLabel": "Non-Convertible Promissory Note [Member]"
       }
      }
     },
     "localname": "NonConvertiblePromissoryNoteMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_NoncashRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash right of use assets and operating lease liabilities.",
        "label": "Noncash Right Of Use Assets And Operating Lease Liabilities",
        "terseLabel": "Non-cash right of use assets and operating lease liabilities"
       }
      }
     },
     "localname": "NoncashRightOfUseAssetsAndOperatingLeaseLiabilities",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_NoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncurrent Abstract",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "localname": "NoncurrentAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_OtherExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense Abstract",
        "terseLabel": "Other expense:"
       }
      }
     },
     "localname": "OtherExpenseAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_PatentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Policy Text Block",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentPolicyTextBlock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvkd_PercentageOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exercise price.",
        "label": "Percentage Of Exercise Price",
        "terseLabel": "Percentage of exercise price"
       }
      }
     },
     "localname": "PercentageOfExercisePrice",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_PercentageOfPriceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of price share.",
        "label": "Percentage Of Price Share",
        "terseLabel": "Percentage of Price Share"
       }
      }
     },
     "localname": "PercentageOfPriceShare",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_PlacementAgentWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of placement agent warrent.",
        "label": "Placement Agent Warrant",
        "terseLabel": "Issue Date"
       }
      }
     },
     "localname": "PlacementAgentWarrant",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_PlacementAgentWarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrant One Member",
        "terseLabel": "Placement Agent Warrant one [Member]"
       }
      }
     },
     "localname": "PlacementAgentWarrantOneMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_PlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants Member",
        "terseLabel": "Placement Agent Warrant [Member]"
       }
      }
     },
     "localname": "PlacementAgentWarrantsMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_PublicOfferingPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of public offering price percentage.",
        "label": "Public Offering Price Percentage",
        "terseLabel": "Public offering price, percentage"
       }
      }
     },
     "localname": "PublicOfferingPricePercentage",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvkd_PurchaseAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common share authorized, Purchase aggregate shares",
        "label": "Purchase Aggregate Shares",
        "terseLabel": "Purchase aggregate shares"
       }
      }
     },
     "localname": "PurchaseAggregateShares",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvkd_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfAccruedLiabilitiesConsistAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Liabilities Consist Abstract"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesConsistAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfAllocationShareBasedCompensationPeriodsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Allocation Share Based Compensation Periods [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAllocationShareBasedCompensationPeriodsAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Common Share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBasicAndDilutedNetLossPerCommonShareAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company SIncome Loss Before Provision Benefit for Income Taxes [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCompanySIncomeLossBeforeProvisionBenefitForIncomeTaxesAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Income Tax Expense Benefit Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfDebtOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Debt Outstanding Abstract"
       }
      }
     },
     "localname": "ScheduleOfDebtOutstandingAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfDerivativeLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Derivative Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilityAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfDevelopmentMilestonePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Development Milestone Payments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDevelopmentMilestonePaymentsAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfDevelopmentMilestonePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of development milestone payments.",
        "label": "Schedule Of Development Milestone Payments Table Text Block",
        "terseLabel": "Schedule of development milestone payments"
       }
      }
     },
     "localname": "ScheduleOfDevelopmentMilestonePaymentsTableTextBlock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvkd_ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Liabilities Subject To Fair Value Measurements On ARecurring Basis Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialLiabilitiesSubjectToFairValueMeasurementsOnARecurringBasisAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Annual Lease Payments Under Non Cancellable Operating Leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFutureAnnualLeasePaymentsUnderNonCancellableOperatingLeasesAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Lease Rou Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseRouAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfOptionAndWarrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Option And Warrant Abstract"
       }
      }
     },
     "localname": "ScheduleOfOptionAndWarrantAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options and Warrants Granted Exercised Forfeited and Outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOptionsAndWarrantsGrantedExercisedForfeitedAndOutstandingAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfPurchasePriceOfTheAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Purchase Price of the Assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPurchasePriceOfTheAssetsAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Tax Expense to the Amount Computed by Applying the Statutory Federal Income Tax Rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfIncomeTaxExpenseToTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Summarizes The Total Warrants Outstanding Abstract"
       }
      }
     },
     "localname": "ScheduleOfSummarizesTheTotalWarrantsOutstandingAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvkd_ScientificAdvisoryBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ScientificAdvisoryBoard[Member].",
        "label": "Scientific Advisory Board Member",
        "terseLabel": "Scientific Advisory Board [Member]"
       }
      }
     },
     "localname": "ScientificAdvisoryBoardMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_SharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Of Common Stock",
        "terseLabel": "Common stock shares"
       }
      }
     },
     "localname": "SharesOfCommonStock",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvkd_StevenZelenkofskemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Steven Zelenkofske.",
        "label": "Steven Zelenkofskem Member",
        "terseLabel": "Steven Zelenkofske [Member]"
       }
      }
     },
     "localname": "StevenZelenkofskemMember",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvkd_StockCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock compensation expense.",
        "label": "Stock Compensation Expense",
        "terseLabel": "Total stock compensation expense (in Dollars)"
       }
      }
     },
     "localname": "StockCompensationExpense",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_StockholdersDeficitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Deficit Abstract",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersDeficitAbstract",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_StockholdersEquityandWarrantsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity and Warrants (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityandWarrantsDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_StockholdersEquityandWarrantsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity and Warrants (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityandWarrantsDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_WarrantsAndRightOutstandingMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights outstanding Maturity Date.",
        "label": "Warrants And Right Outstanding Maturity Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "WarrantsAndRightOutstandingMaturityDate",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "cvkd_WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired.",
        "label": "Weighted Average Remaining Contractual Life Years Canceledforfeitedexpired",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Canceled/forfeited/expired (in Dollars)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYearsCanceledforfeitedexpired",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_WeightedAverageRemainingContractualLifeYearsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Remaining Contractual Life (Years) Exercised.",
        "label": "Weighted Average Remaining Contractual Life Years Exercised",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Exercised"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYearsExercised",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "cvkd_WeightedAverageRemainingContractualLifeYearsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Remaining Contractual Life (Years) Granted.",
        "label": "Weighted Average Remaining Contractual Life Years Granted",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Granted"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYearsGranted",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "cvkd_WorkingsCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Workings Capital",
        "terseLabel": "Workings Capital"
       }
      }
     },
     "localname": "WorkingsCapital",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvkd_stockOptionsGrantedSharesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options granted shares term.",
        "label": "stock Options Granted Shares Term",
        "terseLabel": "Stock options granted shares term"
       }
      }
     },
     "localname": "stockOptionsGrantedSharesTerm",
     "nsuri": "http://www.cadrenal.com/20221231",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r277",
      "r390",
      "r413",
      "r425",
      "r426",
      "r439",
      "r443",
      "r449",
      "r488",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r277",
      "r390",
      "r413",
      "r425",
      "r426",
      "r439",
      "r443",
      "r449",
      "r488",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r269",
      "r277",
      "r294",
      "r295",
      "r296",
      "r389",
      "r390",
      "r413",
      "r425",
      "r426",
      "r439",
      "r443",
      "r449",
      "r481",
      "r488",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r269",
      "r277",
      "r294",
      "r295",
      "r296",
      "r389",
      "r390",
      "r413",
      "r425",
      "r426",
      "r439",
      "r443",
      "r449",
      "r481",
      "r488",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r173",
      "r278",
      "r460",
      "r471"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r173",
      "r278",
      "r460",
      "r461",
      "r471"
     ],
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r474",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r448"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent": {
     "auth_ref": [
      "r15",
      "r482",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer.",
        "label": "Accrued Environmental Loss Contingencies, Noncurrent",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedEnvironmentalLossContingenciesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r103",
      "r114"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing activity:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r448"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Paid an additional"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r468",
      "r469",
      "r470",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r56",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of placement agent warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdministrativeFeesExpense": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.",
        "label": "Administrative Fees Expense",
        "terseLabel": "Administrative services (in Dollars)"
       }
      }
     },
     "localname": "AdministrativeFeesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r24",
      "r35",
      "r95",
      "r248"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r248",
      "r364",
      "r437",
      "r438",
      "r465"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Interest expense, amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r446",
      "r501",
      "r502",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Agreed to pay"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r108",
      "r130",
      "r151",
      "r199",
      "r207",
      "r209",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r337",
      "r339",
      "r352",
      "r448",
      "r486",
      "r487",
      "r511"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r127",
      "r133",
      "r151",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r337",
      "r339",
      "r352",
      "r448",
      "r486",
      "r487",
      "r511"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Direct transaction cost"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.",
        "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r37",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash \u2013 end of the period",
        "periodStartLabel": "Cash \u2013 beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r94"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r64",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r221",
      "r222",
      "r424",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Leases, Commitments, and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "New Issuance",
        "verboseLabel": "Stock options shares issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsShares": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.",
        "label": "Common Stock Dividends, Shares",
        "terseLabel": "Common stock, shares",
        "verboseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "CommonStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r468",
      "r469",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "periodEndLabel": "Outstanding, Ending",
        "periodStartLabel": "Outstanding, Beginning"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Company authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r448"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized, 8,193,875 issued and outstanding as of December 31, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensatedAbsencesLiability": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.",
        "label": "Compensated Absences Liability",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "CompensatedAbsencesLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r84",
      "r137",
      "r139",
      "r145",
      "r407",
      "r410"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r92",
      "r93",
      "r212",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r46",
      "r47",
      "r92",
      "r93",
      "r212",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit and other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r0",
      "r101",
      "r110"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Total convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible promissory note (in Dollars)"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of debt outstanding"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible note payable, net of debt discount"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r0",
      "r101",
      "r109",
      "r118"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 1.0,
       "parentTag": "cvkd_ConvertibleDebt1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible note payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Promissory note payable, net of debt discount"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredDividendsNetOfTax": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r184",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The after-tax amount of any dividends on convertible preferred stock.",
        "label": "Convertible Preferred Dividends, Net of Tax",
        "terseLabel": "Convertible promissory note (in Dollars)"
       }
      }
     },
     "localname": "ConvertiblePreferredDividendsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebtNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Convertible Subordinated Debt, Noncurrent",
        "terseLabel": "Convertible note payable, net of debt discount - related party"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r20",
      "r391"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r467",
      "r496",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r467",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r318",
      "r329",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r467",
      "r496",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r149",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r57",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in Dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Conversion price percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r96",
      "r98",
      "r236",
      "r365",
      "r435",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount (in Dollars)"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r13",
      "r96",
      "r252",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r13",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Percentage of conversion price",
        "verboseLabel": "Conversion secured percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Non-cash debt issuance costs - placement agent warrants"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r467",
      "r497",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross, Current",
        "terseLabel": "Debt issuance costs (in Dollars)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r97",
      "r489"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r467",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r35",
      "r82",
      "r319",
      "r328",
      "r329",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Total deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs",
        "verboseLabel": "Note offering (in Dollars)"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r467",
      "r497",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax asset, net of allowance",
        "verboseLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable",
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and other temporary differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "periodEndLabel": "Balance ending",
        "periodStartLabel": "Balance beginning"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r35",
      "r53"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow",
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCashReceivedOnHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period on settlement of a hedge.",
        "label": "Derivative, Cash Received on Hedge",
        "terseLabel": "Cash proceeds (in Dollars)"
       }
      }
     },
     "localname": "DerivativeCashReceivedOnHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Simple interest rate"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgesLiabilities": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.",
        "label": "Derivative Instruments and Hedges, Liabilities",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgesLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOfCollateral": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of securities pledged as collateral against derivative liabilities.",
        "label": "Derivative Liability, Fair Value of Collateral",
        "terseLabel": "Derivative liability at issuance (in Dollars)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOfCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r279",
      "r298",
      "r299",
      "r300",
      "r305",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.",
        "label": "Disposal Group, Including Discontinued Operation, Cash",
        "terseLabel": "Cash provided in operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r146",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r176",
      "r179",
      "r182",
      "r183",
      "r184",
      "r188",
      "r344",
      "r345",
      "r408",
      "r411",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic and diluted (in Dollars per share)",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement",
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r146",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r179",
      "r182",
      "r183",
      "r184",
      "r188",
      "r344",
      "r345",
      "r408",
      "r411",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Income tax position"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r153",
      "r309",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r493",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Settlement percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r124",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r162",
      "r170",
      "r172",
      "r191",
      "r216",
      "r268",
      "r301",
      "r302",
      "r303",
      "r321",
      "r322",
      "r343",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r375",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails",
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Authorized capital stock shares"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Shares amount (in Shares)",
        "verboseLabel": "Warrants issued (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExtinguishmentOfDebtGainLossPerShareNetOfTax": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share impact of the gain (loss) on the extinguishment of debt, net of applicable taxes.",
        "label": "Extinguishment of Debt, Gain (Loss), Per Share, Net of Tax",
        "terseLabel": "Exercise price per common share (in Dollars per share)"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtGainLossPerShareNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r35",
      "r60"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of derivative liabilities",
        "verboseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow",
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement",
      "http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r350",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r270",
      "r275",
      "r350",
      "r386",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r270",
      "r275",
      "r350",
      "r387",
      "r435",
      "r436",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r350",
      "r388",
      "r435",
      "r436",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of financial instruments at issuance"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal and state statutory income tax rates"
       }
      }
     },
     "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total Financial Liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffinancialliabilitiessubjecttofairvaluemeasurementsonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "verboseLabel": "IPO [Member["
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r21",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r152",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r152",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcompanysincomelossbeforeprovisionbenefitforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r310",
      "r311",
      "r317",
      "r326",
      "r332",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r171",
      "r172",
      "r198",
      "r308",
      "r327",
      "r333",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofcomponentsofincometaxexpensebenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "terseLabel": "Aggregate amount (in Dollars)"
       }
      }
     },
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r306",
      "r307",
      "r311",
      "r312",
      "r316",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax benefit at statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State benefit, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes.",
        "label": "Income Tax Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) in Operating Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r97",
      "r105",
      "r144",
      "r197",
      "r363"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in interest income on deposit with financial institution.",
        "label": "Interest Income, Deposit with Financial Institution, Increase (Decrease)",
        "terseLabel": "Financial institution depositor"
       }
      }
     },
     "localname": "InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentMaturityDate": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of investment, in YYYY-MM-DD format.",
        "label": "Investment Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "InvestmentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future annual lease payments under non-cancellable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r151",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r338",
      "r339",
      "r340",
      "r352",
      "r433",
      "r486",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r102",
      "r112",
      "r448",
      "r466",
      "r479",
      "r506"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r128",
      "r151",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r338",
      "r339",
      "r340",
      "r352",
      "r448",
      "r486",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Fair value of financial instruments at issuance"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofderivativeliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r31",
      "r33",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "terseLabel": "Cash used in operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r18",
      "r36",
      "r104",
      "r115",
      "r126",
      "r136",
      "r138",
      "r143",
      "r151",
      "r161",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r181",
      "r199",
      "r206",
      "r208",
      "r210",
      "r215",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r345",
      "r352",
      "r434",
      "r486"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAllocatedToGeneralPartners": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of net income allocated to general partners.",
        "label": "Net Income (Loss) Allocated to General Partners",
        "terseLabel": "Net Income (Loss) Allocated to General Partners"
       }
      }
     },
     "localname": "NetIncomeLossAllocatedToGeneralPartners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Guidance [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r125",
      "r159",
      "r160",
      "r163",
      "r164",
      "r173",
      "r174",
      "r175",
      "r213",
      "r214",
      "r217",
      "r218",
      "r323",
      "r324",
      "r325",
      "r342",
      "r346",
      "r347",
      "r348",
      "r353",
      "r354",
      "r355",
      "r366",
      "r367",
      "r374",
      "r376",
      "r392",
      "r393",
      "r394",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RecentAccountingGuidance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r0",
      "r101",
      "r110"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable": {
       "order": 1.0,
       "parentTag": "cvkd_ConvertibleDebt2",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Promissory note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofdebtoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r199",
      "r206",
      "r208",
      "r210",
      "r434"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r190",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Schedule of operating lease ROU assets and liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/LeasesCommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleoffutureannualleasepaymentsundernoncancellableoperatingleasesTable",
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liabilities, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent",
        "verboseLabel": "Operating lease liabilities, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/ScheduleofoperatingleaseROUassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r103",
      "r114"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofAccruedLiabilitiesConsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r23",
      "r116"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "totalLabel": "Total other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development expense (in Dollars)"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable": {
       "order": 1.0,
       "parentTag": "cvkd_EmployeeBenefitAndShareBasedCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense classified as other.",
        "label": "Other Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForOtherOperatingActivities": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for operating activities classified as other.",
        "label": "Payments for Other Operating Activities",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PaymentsForOtherOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForPurchaseOfOtherAssets1": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid to purchase other assets as part of operating activities.",
        "label": "Payments for Purchase of Other Assets",
        "terseLabel": "Purchase of assets"
       }
      }
     },
     "localname": "PaymentsForPurchaseOfOtherAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Founder shares paid (in Dollars)"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Investment in property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r132",
      "r219",
      "r220",
      "r431"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Total proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of promissory notes, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds of warrant exercise (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r54",
      "r113",
      "r409",
      "r448"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r276",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r123",
      "r379",
      "r380",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r276",
      "r379",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r75",
      "r122",
      "r519"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable": {
       "order": 2.0,
       "parentTag": "cvkd_EmployeeBenefitAndShareBasedCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofallocationsharebasedcompensationperiodsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "In process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement",
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r62",
      "r111",
      "r417",
      "r421",
      "r448"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r124",
      "r156",
      "r157",
      "r158",
      "r162",
      "r170",
      "r172",
      "r216",
      "r301",
      "r302",
      "r303",
      "r321",
      "r322",
      "r343",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionCustomerAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for incremental direct costs incurred related to the acquisition or origination of a customer contract in a transaction that results in revenue deferral (that is, whether such costs are expensed as incurred or deferred and charged to expense in proportion to the revenue recognized.) Also describes the entity's policy for determining which costs are capitalized as contract acquisition or origination costs.",
        "label": "Revenue Recognition, Customer Acquisitions [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "RevenueRecognitionCustomerAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Received from proceeds"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofpurchasepriceoftheassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Per share amount (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r212",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities consist"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of allocation share based compensation periods"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of derivative liability"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial liabilities subject to fair value measurements on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of company\u2019s income (loss) before provision (benefit) for income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRegulatoryAssetsTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.",
        "label": "Schedule of Regulatory Assets [Table Text Block]",
        "terseLabel": "Schedule of purchase price of the assets"
       }
      }
     },
     "localname": "ScheduleOfRegulatoryAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of options and warrants granted, exercised, forfeited and outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option and warrant"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r64",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of summarizes the total warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Initial public offering price percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number Outstanding Canceled/forfeited/expired (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number Outstanding Granted (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock for gross proceeds"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Exercised (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price Per Share Canceled/forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value Ending (in Dollars)",
        "periodStartLabel": "Aggregate Intrinsic Value Beginning (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number Outstanding Ending (in Shares)",
        "periodStartLabel": "Number Outstanding Beginning (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price Per Share Ending",
        "periodStartLabel": "Weighted- Average Exercise Price Per Share Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number Outstanding Options vested and exercisable (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price Per Share Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Options vested and expected to vest (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number Outstanding Options vested and expected to vest (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price Per Share Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price Per Share Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price Per Share Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r280",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Exercisable price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of amount"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate Intrinsic Value Canceled/forfeited/expired (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionandwarrantTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Options vested and exercisable (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Options vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years) Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Price per share percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Exercisable per common share (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "terseLabel": "Bear interest percentage"
       }
      }
     },
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r61",
      "r124",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r162",
      "r170",
      "r172",
      "r191",
      "r216",
      "r268",
      "r301",
      "r302",
      "r303",
      "r321",
      "r322",
      "r343",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r375",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/RelatedPartyTransactionsDetails",
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3",
      "http://www.cadrenal.com/role/StockholdersEquityandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r191",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of investor warrants"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of founder shares (in Shares)",
        "verboseLabel": "New shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of placement agent warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Equity-based compensation - options, restricted stock and RSUs (in Shares)",
        "verboseLabel": "Restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/EquityBasedCompensationDetails",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r61",
      "r62",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Number Outstanding Exercised (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofoptionsandwarrantsgrantedexercisedforfeitedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of founder shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of investor warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r1",
      "r2",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Equity-based compensation - options, restricted stock and RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r52",
      "r448",
      "r466",
      "r479",
      "r506"
     ],
     "calculation": {
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedBalanceSheet",
      "http://www.cadrenal.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r150",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity and Warrants"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/StockholdersEquityandWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r362",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r362",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r362",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r383",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AssetPurchaseAgreementDetails",
      "http://www.cadrenal.com/role/DebtDetails",
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Operating loss future taxable income"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r192",
      "r193",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofreconciliationofincometaxexpensetotheamountcomputedbyapplyingthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Pay off (in Dollars)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ScheduleofSummarizestheTotalWarrantsOutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r178",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r176",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares used in computing net loss per common share, basic and diluted (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cadrenal.com/role/ConsolidatedIncomeStatement",
      "http://www.cadrenal.com/role/ScheduleofbasicanddilutednetlosspercommonshareTable"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44250-110382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44264-110382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6501251&loc=d3e52485-110419",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226013-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496177-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r452": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r458": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r459": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(1)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19366-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001213900-23-024260-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-024260-xbrl.zip
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M8*M*+7=17WPD2&='S]"P?I[*A#Q+6=\J;(4%<C_,QI+H40Q?O.8B5D#>7ZB
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M1W?N>=_ 0_J>&3ID :F6_Y].^KV+BXX9L%?!J,=&^EE5,] K4*EZ_MR?>-V
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M^&/8LXT!4(:)<YPKO2_F#'!,8F'G^3CWT,Q7F[5Z/??'[X;QVX=_Y?/&!3A
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M?BPF!XNEAJ1H4,A).T.)3(4*)[47V]R)3>6-DF$E1-C;H"8,,748'2NY)\Y
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M?'CUEGR7*?T/MA>0Y?[#JPC'^XV/HA3.8DSC*:#"J-+(U:9WD=1KWB'X!Z@
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MEEA_H%(K=^/PV+3+!,SOSO(<LL.F4]IS6[,.U-,P%Q&2$"0''IA*DL^(]CI
MSF1+_/TENHWI*]PM#J+A$#*2HSUTQUX1T=9DW&&<,1QF)7Q51P[5.7F>7 \
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MAVN&*WR:KQH?NM6M"A8J]TZ9Y60;>^43-&)6F,D2SV8KRT]?AN$97OE3A-U
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M):=N]<<W=&AZ11S]VO\'4$L#!!0    ( !FO?58_:\JX\)H  ,^I!P 5
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M?H6+B#+U.A=K>#+X5[I;7"_/P]B+_;*=&YS;Q6V1L=LE:D_KXBJ[)FZ:RG2
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M:Z^25<8>&"WE7R41,?<S>- MWT&!Q/1)1?UYK3>?U,5,YF-QXW_O;9+L.\3
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MR[*E;N+VC5E==E@]KZLV7<G"_V4;IN1THEU]L^P69YCP8D4<'*Z_ESS9PN#
MHQ,%)#B^"UBH!$;]1 Z<XW77EWIA\,6(@W9.>YI.>@\XP(O+7*@5XG3J:_#5
M*,1'FFD8DPUTUEI+34\KFZ9#OLWS[<Q+H1 K*^M]3L-HF\L+_LO/ZQ(GL(+H
M$)<VCH0*T0)1$FS9ZH5ME]5<G6Y35@X7)D5KEBO\B?XIDU:>T08U;#ABXXN[
MN.7A=( ($/:%\XI//5JE87U-+MF5WS6T865.;G>&C'Y<16$$V3$79;@B D0R
M4%!J.:1?/Y2ETYZQ_KK9B=%I[%=,@MA7EQ-K\Y"XQ;D7QC@H]T[U65U^C:K#
MHMVTR0GCQ62(&*\BV";CB^39>9+B\#&^]YZ+I%KQI* T&\^&H6(<C?\6(]'G
MQ=@O7*?EU:0)D_,ZW+"\'U79M#K/W!T2YI**W#!)=LJ->)1TB82CP0BK[8H>
MDC2 )]IQ<)RD:?*)+&.MPE]N(*I&'DAJ=9TT)^J@3&A#Z;'#KOFD'R@:6"PK
M"K'-O5A6P85A03=7Q;*G.$[6H(%)VB5.[E-4?NOPN>8VXBVO7DJ<Y=.HE2XE
M_RA_5QR6$ 9*B5:P2H%TZT7]\L?P[^H/57U2";6LO*!PYY9EUF*&5A:Z!ULM
M''KE0UE<2(EL!.LP@ZZ7W;$U,K(15:O'"@-LEJ6I25QK2>KRP[K_R@Y=]IKC
M*=XD69C_%.:KXEZ#%T&_J3#?0M)L/U<K=W,+XX1!/4 %7/2) $859,2!!HNF
ME>)VO& '\4;L/P]FMM5.I<R_*4^0-UWN7?6AL^#W/L:M52@FR8Z=F:7YO]][
MS^%ZV]%CM_BH'::PR,X6LCPK)918]*? N(3_05WUDQ=!AHF<>'D:^L2C@#_
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M?QV[M(RDM.BR_] J^VE(*(PU@EOL(_?!+1[95G"K38G-X%9'$;RH^E)T&>!
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M119N E;]^2".7YGRTUT-AGX)AL.0< OK[O*+.;0PA%=:= H'C)ZWT2W.<%^
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M> ?/'AYJ_@#E;(..6M.<V?9#'RVYWH43,%:Y0H02N\=M+O/7PWU5[_(2RB%
MPO-TL+];*L+M+>$T?1'^2=SF$43B'O1H[M!6]!WB8D7E9N"H8:M9I0FJ\.<Z
M@A'4JI]%806)ORI!QK_9>R2)^85:NT'AIY 0%BS5FD0;6\X95+5Z+:,)PVF'
M^L "_<@32+L"?6B6)I2B6JY\<R]XR^LGN,"%<'.SOWOD/2Q!&^H0J<#VAH,(
M#S&@B\ XB/E@(Z4V8<F>A:P8B3&O8BG%@]D! 5S^E+4Z9>IXN/R(ACNX_,FZ
M'DF+@X2(&(KR86+I#MOE$Z\?E!;WHWV$^SDK7V2\<Q-K(-(C,#4$TV.H6/-F
M5<<IGMC1"9K+)\(GRY&HH$01G&, .N)UHZJ]1*1H*^1#V3JU)7B*&NSIBN,
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M9WP+%L>=.#4"&+868OE9H$%8H[AY)-MD!@BI%J;WC&PLZEPDA]IT0L!05M/
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M+*:N[Q+(CJP10#J+F( X&^*-%'='7\(]@FH(7RC_\=11M\R4G4OBB(O3HQD
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M1+VTUM,B$&0 HTI=]2UG*LOSLC8TM%SZ)W&J^]J(N1@T0YTY0ZOHUM.O[DA
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MFC-<4ERGE3;S8R^.D2LOSC8*@NJF9(:6G33Y\8"M+V&PE+M^>XS,\Y?M>CE
M?(C])F3HGKV&B++?D9NO2IN/^=$5NB;1(YV3)7Q=NAU'[+G4!'=2M%R6,=Y%
M^#=[)U2GZ&HW0+U?8C]?_PS[^N=&['Q"B&>^MR4LI%RU;OV0*-QZMPPQ@"XB
MK?)NDP+&+?C/D4>Z =,\PO!708L$L)Z\/?6C("26<Q\_/T/N7<N.O5#!6Z
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M\O.(/O85<7 -;U'#,3VK9CPX"UR7:(F3_0W"(T[(?"XR5N%A6*[3;2@V RL
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MQ[8Z&0']_:TW;Y,43>/VK^YE,9EXZ>PQ3^?;:C"S9"UJ_[7[<4H:Z"L<0&.
M/7F!*J\V1@]_=*]%-W4EOD=!]%9E-_0^O':O9E/8C7?)C4IIN-<N=IKB_?J0
MX'Z$E<I4_4O:J>^VDG8Q&=-_/#<,?MK2Q7=T11^QG+56D[>6O6EAC<#[;KPT
M:+]+DL\8E2FS!)ZT ]2/H5E[^*2C$MC*<1P7P"@N#'HB2@2>#XF%;6Q'X0AR
M?>5AP:O?(;00L,\SS"JD#8UD0RU4- S;"T;=1'FQ8/8(D^3A^H?'S=VCI%'-
M;LM!3)P)0X 2(H],J_JXGE=+;$Y[B-[9/9OB$$90TUCZ8:<R$J'0A/$U5O%@
M3PT$&B'HH33,/K-.5,2"4H-C,@[2+?N%"#:RKP@KJ,UJA.J+@97B[N."SEL.
M:A5R7AT]25U49]H8V+]PK5\<FY_8U6'F9Q3*+W]:^>VA^>E\JIOS4*EN9B:#
M(F=4GRA+K(U14:9N",>&B*M.SPY\FB431'K"]-194L#?8N"E"+XWG-UV  C
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MDN+T;63];BCNVZ$X_#PI,EVRA<Y#!#G1D &"QX)%],3?P)2>BH&$1@[+3X0
MX'3"LD#7RDO<L+H-X<W/X$+YK+^IV//9UQBXPP)EJQMA_TL6GD127$5HF=3&
M7X0_FO> 5[Q(K]T-_6WH;U%X;U!Q^DRQ=)MQ3R@5XCI,L!; '2OX>.RCBVB8
M>@43JS= D)K(NR',$L812*G^$TD4/]]PO@WE->>O>H,PPD09A+S0Z:HB3%UJ
M,U6HC%W? P3/FH1QF(T1L&I8D;MN!J=).85A[ 7J/P6_YY[.Q@WM?7>TIRO&
M4BS.IP(1*]V>C5E*QM\D+VP(Z^M=<N2+T^6J ;8R#P<%:F:M4H=KF5Q\BK!X
M$0SG>U-FC)MP\8;,%LI.-9E&R4SA8P04J5'Z*.LOHM:S+<LH(.YF&@V!: T0
M#(12N^(1!BY",#+"3!C?ANPV9-?H_[WA"#&&&B03:UA$KLKPR$ W8X >9F.@
MC_F*D[::]#Q^B. *TV08YJ6B)RQS0X,;&FR4L AOR<DOK+WY211Y@T3#1)"'
MKD&C*]TC2@M@37Z31.J9M$6QH;T-[36+7?'-(4(CD)EDH;90>B*QM70^JL7Q
MX F5$\L;2E=E07K<$-F&R.9G@ AQ23Q*"+7RX^_GI^W>D3N*D@'H<.R <_TT
M1*QZ5-[""1Q6SKP+V&)<@D\!*]P0V(; &NJ',% ?8A:\#F:5"7RI 4S%0'^>
M*B_7I1U>'$X8IP#1#L/8AR\%G=Q/,D*'?S)BF\_V>Q)@G+\Q2K_&7FQKB!P"
MS%EW7)LU!Y&J0,B(6*>+>=__$=),3?1[.=GEI&9^5@H(0<5A@EFQE3Z_G]7,
MS0B< 3$_!>T]5I$PIA_O#?GWV#FN&])Z:GPRPV>Y/\&?!J,[24? D3G2V[(K
MC>U*/:N6F&F..7N8;2AK+2CK?&C"92#1F>\L15X8GBU"W2.'4,.!)8T0^#]W
MBS)EC_%([7PL/1[[J#?$].T3$VHU!98A9;,L5Y.EZ$B:&5A8V*@3"@XV<"1L
M2E.0'P9)1KJ*4..C!#8F9@"CF#R&+!5];<!L*.O;IZQC_S]%R/C7C)U.]6A:
MVS)48U+F2OADP4O;T,%:T,&IHB ZG*OT.UN*QR@_B9,)P@5;FKK!Y\\DZY)P
MN&.%+ ;^JMTCU48I&W#7&D[]>9P#Z2KNF_,IQ?N7SS8&[3=]V<K,OB+&#5SJ
MKF%B,^,?,7Q"2,V@=-3$QCC"G#\/6TBB)II+][LY>+<-]_[V">HJ02A)138!
M\MFE"(JALC#1 'V'%K>9"K=!'2#.5%3)OG*'*=C,V+,K$:4 B]NX5>N&JM:"
MJ@R;\K$-KG0HII:DS62B+59=:\%M4:L&1QY.E&O0KU:'4#8D^4V0Y">69T!I
M+K?27LX1+,!8O\64]T<]VSG/A<V>?Q=IF 4:AX,M'YW:3#^\1E0  =-"+*W7
MSZ:MKG%(;U6;IWR:TZ4LH"M_+G)'L/729'>"7A9"#R^=*I3W1V\$R1O[FX32
MM2>@/TIH4FR@)U LXEN3YCM-<C7%1LC8E=5J'0EDEJ31)A%OS4E&>$ZNTDE9
M\5H6TC! !+(CC;3'A=C7RIU*5SOM8'F.]+DG;G.YR(MR@[G5XW"*@AM=*B?4
MBM*YQ%:4Z^Y)V=RE$L@MIM@%W@WN;9:G'N73B.L$/2/U3J6&80L^-#DXL2 S
M0Z?+)A%ZW6D&BX:\6$ML@JL/N#WZC3))\5J2&U\<4E$44FLB:5[N?O"RP/N/
M[BKJOB>2VU#/>E,/"AMF(UQ[/?8RH!<5N_ JM VBF7N-Y=MAM$&]77-2.!^Z
M0^\Z85#:5&7*2_TQ2A.NQ\^ B:!B7V2FAH>$%)54)S4R$L<$1>PVA+/FA(,\
M),%<,845A$&8*BDFY/J8,/;#*0@4HH]Q$@581JB^8#E-5NU53I6(2>2B X)(
M2E)E-P2TW@1TC(WLI6F\T #VHO?Y]'7K>$DF\\<)Y@.!,@-Z#9#1!+::6@,#
M^9%JXR?I-*%@#WNRR.-E.[LVY+3>Y/26BZRX1!1[)=K6DI9,TQ030!B0D&PK
M%EP:KL'ZR89<UIM<J./XV$LQ>3%(_((=X@*%FH?MW/NL2"(A7%:8;4JCUI\D
M3B(OG&2""12H"6LHNDD<,@BCY7!L3K0?$E!@?Q?B+/>NO3"BT\*.]!NR67.R
M^4-I(&6,DL3DVIT"1<#V(P9D8-H>82EOII10!DJK#6FL-VF<B'(Z49,!,@K1
M,ZQ2KEQYDRKHCU6+8\IO/.T9]C>FT?= -[KZ2TIH+&-9UW8%7$#K>FA$<<8[
M49?)@J<O:E2#4FL=*6?YW**O)Z]E>YVN,(FA0P^> $:4$I<1? JA%LGBG;$Z
M@WPK4]$UVU:L[!! F1\EU"NWDE<"&A3,"&0?!B52+Y:(+S*V)& -BZ'?<5A*
M2XGA;,GI"+HV(MKZF-I)A(S58X&7!O<I%G^F$.F3Y5(]QIV\I0?-WJ;=S%R[
MF?ZFW4P360W,/)I2%N@_GAL&/VWY_^IV^TB'WIN''/T\5Q.@)/?GLESG,7(G
MGB-UY".(I^M0W:Q$-L@C#2?2:)CX!;)_2F&DO 8J/K?:VGE@:,$7#J;%>E-I
M'9)P:_< 6[N#Y2Y&>TLZ%L/[J+9DC/B^"!"L@<ZY9A7S+<9I,ADDH*0#$\HF
M[O8@2A+0L*(DSW;(EX@ )QY6D84CRC(W36L=F@!(NC;(J1&*P=B+4"ZBDM9"
MD79V>7'*01&/4&#=83A(0;ECQ\)VF#*62HI /6D^4%Z^0[\[?AL..BYL3*9\
MB>XKDW&7V/U.D]@YGL(KW5[+[7?[??<Z]*B?3Y:AA[-(_3&B 93M?<AQ_LO9
MY2?WW;L3W-.;<1(A+MH-;A96;(>P7.P/.'1_@37_"1.]4OXX3J)D- -FPM[U
M$W&YPSHZ]#H'7@>BFQ0!GB]-@52&LPRD?^+^'":?L&;3:[GGL=_A':*O$ _+
MCXJ@?N)43X0O@J/DV<MA#E2LAB&IO: 3!R'Y9<+8X1Q_?$)_W+KG*NB4]*,G
M]&/W_!PWR=U&P#A%63K1S+QO!S=/GT^$^DY:KK7E,/U1NI?>;=3+96.0-%7Y
M. 8\>H>O,]FSSKI>]:MJH]Z8W*U^XN$E0(,8<U@*+/#UZ$++)J(;EGKXRNG"
M0$A8'N%5J)3RG[U\? /Z:HZ\@%S\8"&)3Q^(&UW_?AH.4&V%]V8N<1IQS510
MBX0=9"&[^>@B.M:TRVP)3+NGXX5/582\Q=WN]7;<<0&;4T=_UB5*G&^-  K(
MCJB%2')C4%8YX;\*18AW'%W1O5:WN^L@A[L.@P)?N=T_."H;:-_ 1O!2A.?!
M5D; B$"["K_ =L3YF ?I]6_[51(K=P;,"._F!-24G0[<5?<3,1%@,?07IT\O
MX@_[+W;KBVW9# HW3*IWHQEOW0W8?*#P1%2?1?L'RLY8P,K Y@C0H)7V H+X
M:>:+'->',X+QG,]A$*M9A>&>_'I*$\9S+>='TVJY9^]_OC@^.6L? ]_#!R(D
MI"RW9\M<FD8YZ!Z6XXZ]:^1-9+@HFC1!]T4SI]<Y^($)![A2%++94[[0+",K
MB%8#9L 3[]^8M!<I13R/BI#&>!9T('&BZ1!NATMB*^L T\(L03VC )O+!$4J
MV%N.K'%0Y#0O.L@ SG4,#U'L-"3,7WC]("5D.#C==(QBZ\8C\@2^3_/C,.LT
M 28UB-"W;7)6Z;*8I:TMDP+RZ7=[1ZV&JIRWJ!K@89VBNG$<4!5.S@*DY<")
MOCT];G'4*"#*GM)Q6.0HQ"CJ2:WP5=>HX8F4W:2!86@IJ?68DG%4F[:@SN"4
MGFA^![D=&T>W&E2CZLP@;AD8/93 G8#8D[3"YOETW..,2^;,:[AC>H9#.DU#
M4C%H.4$"645!;&_0-+Q.<LU,C/\\3#/L5A@-<<6@Z>R!VI'<8./MEEP=']CN
M@"X/Y41Z_%XO=YC)6^LV.9(T6UZ2K("T+E1'077*"H:4*-MR-_9;)G=;[):L
MN90HH"( 2\,""0=S&5"!,X*#M!L-ODT:B #1*J8B%@;3!'/M<>XD%_5N4 1A
MG6_@>TI%*^\A$M<(SA1/RU;YM9JE+^#'4U"XJ[=J60O@5IV?#PGU^E(_<*_L
M"68.S $]5SD#V+#"0?<(Z8J)W[)++&*!,4<QZAXM;HUC3S?%'XNHR[B?O$:R
MT&R#G@"U&!5Y+W,\_7CE:9F)]"L;JAO2.#SD>5U0,;KN5"4@XTQ58N>2UX>+
M NJ')4XT@]-JFK;7X$TLGR7R(4HZS"0F $A<S+7*;&4?-6A89)M4#G81XF)I
MU+)OE8T?0.(39Q90<^FAW=ZJ@+N6&HRS&R^\9@;)#$ZESI#@[TG:>E_$1!"7
MI%9A=!HDKYI.E#*F$=!R$>6Y00*;@5% N.XJU01KM'J+A=BN4@<+K302.O#=
MH<H% (E.!V9/D"4X- \IQ5:N*;5A&#?0IJP<JBR'K64,:],JXM:^7QWG;9$B
MLT%]KW7W&L7*)K(:%1Y=2N'^-G_$_')@ BPIN<\WGPO\[ ,R.(U!1UP17NRD
MRE>HXUC'O;8LSC(I4+KJ&T2B2),@F@4DEQT,\\#Y3A002X)1'>MT[F$=E;];
MUDZ:8U+. AM))_/1<>OQLHG.Y$O5$%<C"H>>,:Q5.)?X;U# 43F,9TGE01+,
MI'-\S"HJ,+40;C->'XR<QD*,K+GZ8/6DU5]WW/>X3"9/O3:;#=T8!2PG-&78
M"J#GMOG![V'NP3CNKVBP>J,$M3YFTK__>IRUQ.T04MBMNH7S.UBU,EO$M?6&
M_5E:I1$Q+W/CS<E]CD'OTYZ$DQEH:?@N^.L_/^WM=QV6:FP+T2<MO1$J_G.&
M9&M> -_W3XYH9^&ON\>@4?T\$T7P5NJIV'?F!$@HH4(\@65DI'3Q#"QRJ"RN
MXW[20C7W/E/-$T)/HO"9*.W($\F)4I.044G \,SU(F'F=/IC3!*E[Q'%"=U0
MVD(<%K'/O =U1"O([K%Q'26>V7>S1HRULEA!\S2/@!G[GWDVR1!D.%K70<:6
M%1IW(0&R,OFA[JFELD"2.:@HPM-?8!\'11@%[8)J_]!.$UN;Z9+LUXS!+3#^
MY2-GF=YGIVPJDD,G95Z.05;FU$$_E8XJ*UR$Y\_JTQ)N;@\E-F7J3</ /E]*
MG]+O(_IG6894]H*N**P?02?E!4R4*%(*GWV)0A-M;)A*Z+;H/$ S6!.D3QV/
M8#.C+'''(?G=:"2S\_HHJ^ON4)FEAK^$-P0AJA!.7N?$XC>&V0U!HB8W<&SS
M##2@2BH_+_61ZFATK<*Y,R%'ASR)3\1)W):;*S_,R (9P+4"D4#8JQR(I9GH
MRR9I:>3 H/9/N*?FA1FHGES3D8=@"2E4,N#V9(:XY5*I+R%Z/RH5W YQ6[!H
MQUHO1)%5O;??@4QF[Z16A8PKM^5>:TG@E)( &1'Z7A*@O7;@A80J8_LU9??H
M,@JI@HF*/%@+GFJX AMDVC8'*XWD@&+7%XH=>PPV?ZCPFFR&AS9N\+6P+K+T
MC1QCR694@9!_[M"^D:YI;4'+52&1E(=3;P$A?5:6U(4W(>&:S6UX@[LM&L:'
MC\<GHE;L=$C^NH,H(=9LFD'"=J"B8M[79E ,G'49WB'F/M1ML+*" @=>+IX\
M? J6)(/"/<1>"2VMSVC;#(\$(T7$[.'"X>0R215%=R=.C$0A:36$?S8T]A'S
MU4S-S:;C7ED^H=I>D98!RU[;:[A4FL+^)DUA+DUA=Y.FL**D7=H1:@J:4*#<
M"\RFRE$V4YL-]04=K44<YF[/V?[]UX\7)[T=OO)V)J"H3<B!C:_ <!%DBO@[
MR=3*2C9H1D6E%6U$_B&\9N)NF[GM:,TU)"/#P2A-FS)4.25+38VN/)YE(494
MR7.BK3J;\<(<_!GZ5G!6YL-,I9A,1FF*?L),CQ83PTPP2B[Z.KGIT,7K18Y>
MW8N:V-,\T[+FWLHGY^<M]W?\S_D_2)[Q?S\A-@FHUNX)'!U[(?[';)E1-A7K
M\XB I%,LP]@I==M,46+;M31N(#.PJO!+\-H \LN>I6'VF=9E':<)QM ^V>I?
M-8Z6P2& SN>04QCT]"$9H#3Q,!Z' W;P66H%QX. F$)Q4<.V:SAM+Z+$.]1'
M2E\,ZGH!S";.N ,5_Q1=4U7'% [M<!@S81BI,O?B&Q9,=Z21SG-Q8'GA9(1N
MOY^VMMPL]7_:"B? P/[5[?8Z_YZ.MEZL;=H.:H?"(FPODNL!)<_R\23T6F*-
MD_'K8SV$KZ1"&(,@BDTUNA[D8KT6UVF$4>M^E^+0H OI@4!E3OR0/$/T7K0!
MT4'S!78<FZ4!6;;!8@LL"]1<MCQ-/JN.<V5=0"O)B$>07V7S&C%%E8]]/Y%6
M1PD&H'IH5M'0F;:V3X@FV&MV*K[W$ZEP9M:C/?H4JS@YQ02<<@F@,/;V33"9
M?. <"Y\F4ZWDHZJ\>^@"'X@XJQ:=]2VN(N!IQF9>@=OM[-'[&GSZ'(]VR'R]
MI/2E/7P!S;/;Z2WZ&0V$%L(W?,MO'^[38F,(<1'0.8OP>"XZ*/*TF*"A$809
MJ8V9 )(BE9"IC_M&N5W<MX?<49F[;7QP9(LEG#B6S>* 7'E(&A>7.[COXA[U
M"_9P:O,OF&5&1E(2F'*HOXOTWJ!JM+M^1)Y.LLGHIV3H9:J2\@ ":#9%V:XS
M-\@S'^@DAA36E$S(M:'#)XZDNPQ <!72A<9X43EO#R7J4'+<>!#+NX*=7;&&
MEPPQ:23"XI.=2=@9@OI&4,AW,+/Y!XY%&^NDA+9%P8XQ3%XA)"?U*RY;VMA+
M-39N1BP)SE.,5;P/,M.6Q1\J8AQC5D56M;-]N+? S#+EF+!24N0(6*L-313F
MQ)-HEI2G@5<W#ZV\#YWFB#S6'$.J.&8>L(=*.^_84423@G72UNK5M9P!NW92
MW8K7.I'2*3UEQ]Z0\;D7NP/^T H)5>;3(=MM7J@G U-798??)3?M !0%!PC@
MBS< 4MT^BT)L\[!#;C<SI3(4;[M":!)F7D# J#(%(2,[NP-B]M102U=232G1
MT$\^AZ+0>;F'[WYI,G(H16\:YIPD8!.ST'">F!BCF32>:F&Y;0PAFYM1W3S2
M7D5W,GFBU;PEEDH79Q^.W[6/W[K;5Y2I (.?2:( T86M\5YIPHC=7^QM,)SK
M#QSZF%,>WEH9I[S5B-L7<F8B<*:(WH.!=D<RTS+81V!G:\O@K\Q5(.\V.3E?
M=H\H^'T\@?> 3F[1?HO3?*MR^K#[ R4JR]:WJ&C%: ?SB4,7Q.%/D0@OR377
MP9AH1?!S]+U*Z.SC1A[)B8A$:C&?6I 4@TBX$=E$X93.%!:5>Y'V!U>YEO <
MXA.#66U-M@+5Q"$Q>2%SU34K<@[=&J.;4?Z+<;+1 )9=9^E:M$ 8 'EK^?J?
M45B:[(9LC*<C^J3U+MO(&\\0AQ2M,-2FX" &*D="N/8RGU*J35H@I5\'UU[L
M4S1GI#KN"8G=^J.,1A,"N^3P>4D>.N\(6# S:U@QS&U4O>T.Z45511%W_3B.
M"WWZ%X2L9.$H";^[@UQ:\"Z":*,8#$)=X%:3R[#.L&D6("<\'U__7_L]=R#*
M8J@3VZP**\H4K9*VT4#-8%,O1!%/%?*Z=^=Z\H:E?(\'&]_CG.]Q;^-[7%'2
M_D/I6G,@ BJT$<SFIKH2!_F"N-[<XRST3!-RBP6?C$&-0,[DOE/*)#MQB8>O
M"BJK=7\!@0(/9^X[ULQ:+"MR->+L;YWLT@Y23'B2RE,<JIU@A!J><09A,JV^
ME8N;@5LAHF4)'"6:("I&R)U_372)*?D6^OOL4I"IVD%PX]"LC(*6%(A,TI!H
ML1UGB96B7&RL9)*$48::*?7]>=5[HK"? +V<C4C0"*]5UG$H1;G/(61T1;26
M.0$KBSV_271NO\D;TVN5@AB]C1+/]HL4DT(X5VB*JQD1K:#B* GWK#]_PR+B
M(;V ??$"?C^]JKZJW<:/@S?_+]<XWJ>QT*)BN'LP+8=IFS@AN320"QJ6>"LK
M:QE0A3OX#I\UWAH,"20+^8#3R ?XU_=G!L_5[>.)Q=?[>\"H$.Y !F+$J;)V
MSI8,,Q_%P*RE3\/TTYY+B:5/Z95C4 QT%VY,^!+0=@UDGV&9E>?&!4Z.7*85
MDJ',9Y!>>5EZR!0#C)8K#=# T\6,Y%2COH,I)J3%"MAS2EXFDR5, I.->9R'
MD(9,3$LQ([9(EI(2'SFX1HPKKF]*[7'&%MNP0$=9QN#I&']@[&O;CFQA.09!
M8)2)WS91S"L<^J*S+\"XF4K,E3$PA"2=T:E*5TGYJ(K-$B74P53ZW"H_=[B!
M&7RIZ[3F6B?S3W0FZ3R4%*>V^5XVUI5D'(Q5B+>AB0J626\37)@$W?\,P0%&
M+96R(6*9W4]5^P/+Y>9P*-I;>M_W<]&#E2&)?>XIFXWK(_BX]-C.-/(PT\94
M >FJH&J-(6VSW23=33W$ED49*L%-7U#-];;Q_'186<68+J_S<4N'2VS4(\DA
MHLU<,*=O7=&YPV#@ED$4YZ@*6M/2CQ1(RC$,' H/20LJR8"2LD&[/(VRI"3/
MEIXL%4JX#B'1"I5WT1A\0ZB40:G/FK]+5^"IU89$%WTZ%3\*IW-32OHGPOH\
MT;U(A,5+)Y,K>(5[H?"V,H$<^T06O:.7>UB5,J%D"7O <BKX7#$E0L:X.!D8
MSD#-$KF(DM) BS/45VZ E6MA+EE2#9N4D75W&V\CPO.49%Y^:SG1N2Z4$L_*
MHAHSY9U2]%BU@KS!5J&-=)[ "#^(TAPQ >:R9TT#((VI2N$,]%M9KW)TX1;5
M-I35=-)AZJX&:.2K2DEB2J%*"RTHE.=%1H!! U@TG_4M54K.'55*VEWZR%5*
M3J5*:7V9!UUTS2;NU<D3!2%"(W"ZL>YHAHD!A>D9FYBV.6P M'24IF1)6*(T
M]N[J&GI;RU!'MPQ%:O78E8MSL"P-N0A8 6LPV&@*96,.35^5QASR'7>XEZNN
MJ_W!J(#A(G&TMIPH] 9A%!(*@*3/X[]&HJ%*0\";,574\_VEB"!1>0M.2:*+
M!NV8>RU)A4=M0:6&^G0D>0=PT..->J)U"8JU9>L,KG,G=$6O5T.LT"'\"O"$
M:P-/B,0B]@CS4U3 I]U(!@+"N);Z.J!*+#V> V;0\]$Q?%V&0L:35$56J]S7
M];"6BCX<;J(/<]&'_4WT845)^QRKW\J+;V5;D(M$ Z<0/Y $!'3\S]SCBW]^
MD8P'LL4S!H]B,Z'[LE7%:>&$0TLE'EH)4/7,X0KX#6-Y<=Z/C:^5.C?&>D'#
M%Y>.@UM3<B^PZ2^EYEU=74C68ZVL3%)W6>)[4L=(I=OLR0K*G!(RX:U@P71*
M!:VH'HECH6S:(^Q1\J9X+Q6]URT!=C@"@D6MRX'54'QX'JW&X3JS)HB:/U 9
ML3YG]:,"=<./6L@U9B*B6-.I@ T^0!R#%CO7*"D#;)W)P(NHPH]V@$P<ZZA0
M6MU4-AVEW;;Y"$2=2?YQ=V$K7MN+W[>^Q'W:X?-FDAPSU @8'0'I<!.E<H%Q
M"H'\9PY84=,D1'\B[AXM)0WK@JLV10_+ SUNWP:4#K1#L^;.?B8'.UA;<4<\
M 1U=Q*?S2B1*/&W]W1K:'J:-&/Z NW:<3A10$:;&EGRA=]"2DM6R,G58I0U)
MF$<2P_PXW'3;47$U5I;ND:HI<XD@H7K\ZJG6LEG@Z0GU872+F/(1+:2:<&C'
M&4UVVC",.41'=Q,S[N%?D:*,.=D.RL.0Y%-IYLQS<GA.E:)LS,U#IS 9!(ED
M1WJ4RT\NTBDB7_@<>Z($EYM%:\'XA6!6S/%/25#\#@R&"X6JBWM&O.NI!_\Q
M-*M^XK:P//A;3,>_2E$;/"WQ0%:F1^TC#?<Q=O_NQ05ZO7J[A*VY6R(16>".
M&,-SK"VRPPC:$\7N9ZOVIB86'A*@R&E*VK7F)R 57*I5*7;W?/0V4 =G=%S5
M8F3HB@U"^1(AR!"T>ZC1C1+6HW0ZM%."$]&/A^C[ #93Q,"1=4B*7/=/RCR>
M^R:=2XCD$X=(/HJ2]<2S>>T^\67" :WKA+Y]NDX8A"MS46Z+(:$OOK4G %64
M'6H"P9567Q2,K?_8M/GZK_T.X5NE_(J6X%*25W:4)EE61K7PZ4,<#?_/X;5R
MV%IW,8:P"TSGYMN:ZY95[/2MKF/'W\CV./TN;P]<ED *HK(97GU=BW[R^Z^G
M'?GE.I/,.<'CQ<HOP?$P0+B 1EK6'KJ8Y,H<&X-(Z'1@YW/"3 CV]2;E<M82
M&'D;=UJV^#?[D6/]B#DM2K/]&?A<CCK6)6( DYNV)9C*65DHY%&UI)A<9F0,
MUMOC750>U^.@\4.UN:B[&F!(C?](&=L1Z'^<1:*^D#Y+;FR,=JN10:8D,#I>
M)/SC+;R1S_*RW:/)>E)/LOV6( R2#G^]N[O;[A\<[A_T=VQ@2FSQ2@!+93'H
M8$:AIG(CB.F??<&$E1%%W29A1L$R>]&79R<-]&_.KK9!UG(N]7(,# 1/^!-"
M-H*2ZI@4_*93))J@8R>QQP@I\HO* 7F<$4]!']"/4Z]&)/.'1DE#?_"C>FZ$
MRF%@N,'B&8TPJL!1H9=[=W T*SR(D&]4%X)XOL#$2"/=!CM54]<"!I4E4>"8
MS)#&N]-Q+[$HZ?8%D?^8"$WZN)9\]0#X:M-,>_VN<3?PD,X\5\8O*Q.^8Z[?
M&<O#H#;V61$Q>,O.S#.[##,TJ8R[UM+.<#WQF&&Q@":_LL_=-H74 HOC.'_]
M]4 ^?B%,D5OHB:-E\4L8!S[0^)6)@^\Y%J:%G 9#]Z2,8\\M?@.1UGGLUP#>
M&W_U\RSR;F 4;><6@NK%\ZEU_VN5*W!,$T!*&S'-:!F*D8@<OB0,,V8OF.J"
M@-,4B<\ELT "XZ<*)H%&/OS1>?I&$\^M&L-A>"!\GDDE?OHB8Q%5E Q57B30
M/RG=IJBK![@YSB?S;:DA!$3!\WI/KW78W6L=OMR]35TNLV!976!\<FK%1*<!
M9&EA%25:"9:.WDY%F"NF^$OK@1*E"=LDAH' 3$@<'.\;XWUB1DLUGXS1LJ*R
MLMZ\WNXHSNS0R4JUHY+TA[\3LBIW;NV=5<N$$%]N0HAS(<2#30AQQ2E\0/V;
M+RDX,IJMLY3 =8X2#'R1"D&PH0A'NB@[62J5@06"(6,<C8U)>^BK*Q&($+&0
M*F1-R:_K<]YN!:%"%^AVW%_5#)N>2,<_D0UR(@XE5F>"GIF]>C+]F3X,J0)Y
MOE?C^A?>R(*7KKTQ32?O47IS(NXZMMITQI"[Q/]LOS*!J@><NE;!#Z\"^)/^
M4&:J2B(W]]NNI&0O-9%Z2OGB3A,M'1F6EA62':[I?H$YMM1DR$E>2$4W:D!6
MAN^0FE5A>-"X84J$,-W*@GT^&'<DN\-NH;'41"PH#89BRM%@&8)J-O T_#&'
M*K BIJ$%"5F,=B<+77;>66H>QR=7'R_<X[>O"/VB?6*G;>#+K;PV^.BCH*O@
M6!<VJV*C;QX)8ZFYA%:@A##K)/^_Y>X=]=O",%N8!2(Y+2WWE, 9VC]C:D/+
M_01ZD!HD[9,2I5_/>*F)7%(D&+;;6OTU<&-Y/Z[^4J=P<!@H#MH,[B2( @^X
M*Q@Q/S')^U=V&LV))-Q\I$*\:M2XXYX/75U]0_%G<Z>L-C!_[28+FIT]1#(@
M,Z;>I0"O#34CN&D"W5MJ%M)^AI"I046-V?-;A<NMA-4)X\)L(&X<UB)J5+,*
M/,\S%?EM1.H3B%2^#B5]+B<WYFG9%&ZP(+-[8E9Z+^F$<?5EJHO&(@_N0$WX
M+C6=LET!MAYA_1 F]T'Z*I6#PZ 1HZNP5\SJ<S276U.*PN6X=ID%6&DO6>_%
M4,T=? ?GY_ZNL."$L6&.N2+A5%V'B*6Z_>[WX]-L9VGA_KZLWOV%JG=_I^I=
M=_O]+[\C!):59K,@7;'C'KLXN(;;F6!5&EVYI28S+293U\MSAH<1QR05%+>,
M[UFVR9NJ+]KGC'3M7O.^1"9>XF6^P-!XB#JTG(BGG:SV1#)Y!.90:IF(8J4$
M4@(]],*(ZA]Q%Z6@,P?S?JEYL(F4P7HP%<NJK:;N7'G*;1LQUT%0]1$HAS/:
M-99;'N9PN 7U/P#2'4B;I:7EA[D%6&&..1N>W@D3C8G"H>(RS%,#7Z;"U!V'
MHS'/$+,X9BVS)<N1ZCS&YCR:IE7,;C7+M3'[8'_28JK!UH=@!BY]8<"8A%&0
M(JX]AM@CF$)RC%;2878ZK&<LR$[3%;L"2;S4/.QV+V4>Z8XIU\VDY0RGQ%C
M?#58O:KLEYNK@J7FHH\#CE64=%'10;?>,[AEPER.Y1AA[!?FJQ/4/$<4&&'\
M*ZI'_UL1!J#XQ,^&)+!1,IY R:@(7RPV [MMV2OY@IJ[M 4L0W\B+9]+%5P
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M M4\<[=[+Y'0<"Z](S+F&XC-5N:JUOY.BTR5 @T#>->^>==>Y^4/]4==4%G
M@/N"P[[L].3)'OQM[LD";DE*'X9P1 DH+#FZ%%&-Q:=HL&[G4%Z!J2$MI_8*
M4"/3=*P\>E(&.X*SJ8W%Q8#*"SP?SMIZZ\LYESB0V7M,G+>.GG+?MW?[]-YR
MQQS.%J)/]<;MH$H[20*ZZ>[VWGZGRP/M'<"NU6>%5QP-?=3]UE7DFVH4L@$H
M2=>R\TJCGIABF:O$"53L'ID,@"R4N>"45X:U!79<E(/HQCXG3H/M("OIDIED
MO%9T=E2!^]W7:$6VR8J46@SR;ONJ1=_W7COL4T >=]BC**T7LS$S3<B&1?TZ
MI*O)9I*YF%XZR:R*C"C\K,@=@<D'L.=J,D&N@JR,+-[F7#I=R.,LDU&GW1'D
MD?>QV <7##9X@CL5C]:6Z-ZBN66XI=0Q& &G$S<)W2PIP$[F8H3$]XN4GK(>
MME,VA3)(+E8+-;9+MO":,E#PV'8J%103M,+8W^Y&L\ET#(MKE34;Q$TR-04:
M>GW+J^.&-W/*L\U'@2FJC+,))[.$OJ<L?G@+,=;:"/K:O7863!UL54IEQ+*?
M".9 28SIHK<LV("HP)0)^66]UF0;C=8R;7;'J92^()7#S]0@)9>Y5"$IOE7Z
M%2A4[_,KG<B3A<"FC8XV3;(L'-#%Y.O,#CNGO(4@-8M<3'"L"B!U#'-%%M>R
M:*\?_GQM+]OI0M71=EVVW"%<2L=<RFJ:"Q%_^,6UO[:\N?@^-'/JVJM1=*FB
M@JZOSGAJ?)"4-V3/"[.<D3;8U7.#NK,M**:445O/F&;!TG&/)XGE-6ZNZVO9
MI02T'7,Z.UQWT$1#K(N<4%_C-/F,Y\&E9&KJ7JO0J/3HGS,7R=2$<;U$-MEI
M2:Y<M7Z!RO)D, \G;>U%\[2?L&A@!>JA>]]A/73/JH?.-.I'Z;4W,"".U"E)
MAKW88FS9-E8-X?7BG'[\XF"OH<>UF'7 9D.=J(?F;NB'E(]I0E&F!$L<H.3&
M9JE)+-H.<#%+UT8K:WW:-9TG(VPLG(KPD,SZ,EVR:A=6YE5F\%%< IWMNNYX
MN[)I%(?QT*E4:&>\?E+N)+^&-I6C-A3SRK.=L@2 "GVITB,>2:E5)O,)R%4L
M0[9@H6.P&"EH<N J..00S5[C/6#[E60K[*>7E54A8H-6.'%.[ 1KTM!C"8^#
M+DDLE!1,\@N76P36C[;.J& N29UI!$)WD-@S[/RC98Y1YMIL+)NQJ9)ZP=C;
M?1@,2SGPO\"1]WAL,KWTX(Y-4Y7@HLZVM3BB-T4>3P6O\T10!X^AJIV)XI ;
M%_56(_(Z[H:ZA0-C58Z/U'S<--A\O6>".(!*BB$8%#1-/\6EXV_W&G\;:C*J
M$!S&@9L*1= KU39>J>^F,JP_C_W0Y_D8YF9K!_7S;PG&&X=[*;16E"%6L=YH
MNV^2(@I0&?2("P)%H &<4P$K:M-4/8H_ZG4.\4S[<*2DB]#O1J@>T--M>EA$
M<N1E$P^U5S;]3/6]'<I["Q=LUC;5V7,LMY$SD V)PYN+R1XF$8HM_G-7_CR0
M/WO=E@: T4]T6PY=2F('U00)<S^Y>':7TTOP0<T5:$(!J#\,?8%3HCN&; &K
MS(TM@9Y[](C)Z02SV$-]21$R'[L*174'?0<MWV&!?@&K@HUBY%QQ-U^FSO7T
M.JY*Z0Y5.N ':J.S!P!US,Q4%#A4&<@H$*(JGNHBY#[?X5CR,+#(OD">:\X'
M3)BD&0"B0C86>@CO.PTW0+6<_,-1Y"Q\);].L";,-AM2MN!$FOCH;1Q%] ?*
M^6,>YHCT(K9%=<?BR*AA3UR'N13,P3\4EE&D;,0FH]2;CF=\[R+8-.TW!&L7
M)JM33W!,T.*]4G3 >GAG?+Q<#B@'P/33!*0_WD,\,<;PR-F?/M<YB&MJS\_U
M&7XOS')WGEGNSC'+4A-D%)>%VB"><I%9QA::6+:\!%))8@:#"6/1WT1KJG8+
M:4 7P RC_DNC8&J"A^M6VJ?#,,URO+98"UKE@I5I5)F6F2_22:_K!MY, _:P
M:&9X%PTR@/4<N@#46W!S]^7F4NV1S()B NA8D!#1(NP7_"XI<K<$8O#$^3>F
M[PWO=.2FQW#$O.CZ-LHJ\(*:W6#^CZ_M=YD_E;N>WX2^3GX(2Q"B6LV\M67,
MB+627<4\*&MT=8B)BG<QN4?E'??G6Y--6'^SV4V+_:X5"B+&G:H,53K4CLNE
MT,1LJ[A:P$\,RE=I[NEJYPJ/DA@-4(%Q,#=QHY*/V25L#+0"KVS@;,QN;RG0
M1C8[2I+ >#*,Z"0Q8E,+/@KF/"(L2>"/D2R,,Y1N[FX;R%DJR?$!%5- CSTX
M#6 %^LRR8C2"=8ITE+0V9@43UFSR$FE-*+>:<X2;'%*)=3*!?0DDMF9(9]UY
M[%*Y$/^7O3=M<AM)M@6_XU? >KK')#-F*A>EEJZ^;9:EI4NW2E5ZDJK[VGP9
M TF01 L$> $P4ZP/\]O'CR^Q@&0JJ59J2?$^>]5*$@0"$1X>OAP__F"/A5C'
M0MS?8R&^<ADW.^+ANAWQ<),=(?9[*^QW!S&$5:ZG;X*.-, C>(SHL*Q'[UIO
MV<<@P/MG1XH@U&-/4^AG1ZK^0O0"?)CCAX=G[JO+(*1%=ONV.-8V2_E:;^/Y
M(X1@'/F' "<(M"1RIY4'!@=>7X0=9*J8:SV2K& Z,:>JQV=9.3DHBTGNKOUN
MU+&*ZO%Z?.!X/3X0BRHG\7/'M?2N&%<Y^9HK<CHK 3(H*52PF,QIN&TU(V,'
M@E4T'0>C0F1IHH_=\+@[+:K(T_MK0S(*)1*E)S\_O:NQNPW2G-Z99QV;#DQ
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MJ"!.*52KFW?T'/"TX40)IB4#EI<'.^Y-+KT-,YIGFL4:X;A9+GAJ@E/(SU"
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MB$#K5H7(NU$&$$P1UEJTG8E9$@U;8B0M A&=U!6^(\U\R"?_IKF1TXL;&5^
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M"3E,::7:W'] ;[0LQTE1D=X>YZ;H_N__Z]')\<,?,'^398L)JMTYPY-813J
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M_77"BQA\<)KV+&I2\57O]U.?U&G)""#ULIP/<P%1;= NB)C3+=5,11B^%3E
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M9],I*2]F/4GT81Z.T7,])$=L$,"!6DC:Q@)MW\GV4"4_*NO1.WI&O6A-;6O
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MFNB+[-ZW)A:([Z%_+9:M33(_.P('DL_[ BQT:'YF/RC033[-FK$#;1I\@/4
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M)5=R!(I:^$JZND#F4:LO\##/NA(W')"U2X*@N$'V+;Y(%Z'NE7?']I$<IN=
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MWM3H^ _X?=V>_4  NHU"PF]^^Q\MZ5N+%$KT+[+.MD< O8_2?_'K[@_O%[%
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M.P:UC6I\F$OZ?"P)",Z/@]S15$K-\%P:D2]Q"3E"%,272.) XFE6HZ5")EM
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MO>DYVI\;2!5T;R01Y(8'ZBGAO-6F^BO,'OF :I5*5%S,^.35]8MO/O4]H-P
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M1@0;>)QCC4K>PM8((;?0?45E^7701 N:J>8ZXNB1AO9>!GPV,.(!35(FBB$
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M$<%)*0! 9\E4]ED8VWKR>-Y\E8L1\[ZXF/(YF'+6+?/CQ-C1WRP@9^L3G1<
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MR;Q^5Q+7$KT24'7DR=R%9KM8AQT2[]1N5%>W+6C?JD6TUT#[=UT/3"]'#06
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M12AZ2AX6_S=JT0CVKF]NJKJ7?!HO0 IX"@U995:N&XVRA^"WJDV5]T[=M-$
MIL<'YX4YN-D)]A#_NF\Q)E_E+?@$>3N#WHL>+-"6!%_PR@9 8SHTH-MT\4IB
M-7 L!ZFSA933@M(1)Z:B6>U[?]\44C&A,ZQC"22I'Z3GZ3LDE20*']ATZ;?W
M;8X-QK_3IR$LD0]ESVHC2RH2WM<=6UK!B,P4V+HK46)*F)U>CN69>/;J[DA2
M&*@)EEDRH+S&K72"%%6&_LWJS5HXEW!I(N@N@96JP1"Z6)CFG8YD"LV.,&@]
M>;?EXU<#EWQQ;#V&CUL0[/.@?9&M8&*X0"2)?:J^.C25RTGX$178PTE[%J@=
MWKK9L.M!$'7QWPD(M.LL^^34N* 3%?H1])HC=YI@+49L]_WJCJ$V:[SR0RA8
M#(BG)S=03HR,OD*WUL@JU29G9]79IYM*;9PVL/FPB[<K=!7NV%$Q>""^KT-(
M3I?D\=./WL<!J=H&H1AQ.TJF7[^45#9F!U46U@YYY\H'\8B_S=+-5=W21&"M
MCF]O@*NP^FF1: 'ZCM:*^N+Z_=90;AS;^ (>"J(4C; R'MO#L.KW\=(_P'$]
M!O">OVD8AI9*]/,#Y\9U[E$82K;VY:&0_([>-!ZC0J+)7,,.N)H(5,4NEWX<
M-MC8G4%%,9?>JH1G9$@@>6'>S VIVA6L!5(CJ\=#'0-F%"P/<Y^@)68: DJ_
M87W!:!VBLTCEQF!(>\YE+</N(80V [NY@:Y5]Z,CN1YG$%IA>.Q+8,#P7YH/
M;>,A-] Q4' 6G8>L!46WQN/:(^WR4W[?+( U_G1!T4&36DB*+LWSN63XZ,=%
MKBP_-'%#F^ ,CL<")<0AI21X%5 /8KDYE^^PHYWVO<@JBI?NS9Q/HO$6ZFY*
MJ6<Z@!HPF-&8 6VX87&Z>99-"I / )4&)[<C2>6GG_NXYK-9!+QZD[3<]ZEE
M*SN."G>PURC!(?+!_L@%G)X-<?N-H!E'SB)MZNFH0I'#K"H>$/\2?\_90Y$?
ML-,&H4<T 0\3]-[LP 0"A(AI5*EPLU(X!2>/#!92"?=7%>OL)?<'QS\-/GZH
MH>Y4WD.F"B<3P3LA3D6IP$0%T/+HV+.Z22??QVR;#VV*QW1(2T1#T?^KI4XD
MB%ZA^*,2N*7/"'ZS>B_TDY)1HDS5\-.=FS^U%JW'T^<7>IR;=0:;PR'%15[?
M&9AC :3>SV<3 *P<AO9UMZ9>0.TO'/1*^RB$FVQ: 0YQ&@\0H#P)P#SU')"+
MG2Y$EZ2TOT@! 9M;[P)Y@@N'5O6Y&#[%=K;N5GMI%-0^D2*)^%(\LZX.SW;=
ML_A_]%<72*(\<DA)\7Z"B=I-8%:E>AD\VJ&68R,ZGP,=6L7X&;2E\PY'))"E
M*]TP[=JEKER7L^,LQ[>CRY'Z<@"=!H5#GU9:Q%T&JD=O."L7=_4^YV+2X^ N
MNF6\9QD&8F7@4HKG*:,A=P#4T5A2DKLO%$H$_<H$7QRPY>^[E1TI<?A(MN#K
MH?[;ON=S,*YX/$:X&#T#@I&C@K)[(UR3%?1Q9(357@9=L6JD5TUV$ 3!1PH.
M#_]%>'GJM&V$*_*1LV^DMXQ;:W;]%"-2N&TKAKN-VX$NNY 0F;X)N,\C=MYT
MSM2$(M,'RKYSFT8TON:*N6ONB.>3-< :GO8L#F/7-4S; D<RU3(805QDW>.$
MOE79U'8]CA@I7J,ML]6$)-_5;;7;F^"X?,Y+L<[5.#C=[ &JA=LOA#Z5O)>#
M$Z4BC&LN\H>W3U._]N@I2GB_LN+0-<18LXGR4-W"+BLR'++:T=E%\# \4Q+E
M+^Z Q^:F_'@_7*\H-_[\L\^_4"?'6O/I.G3JW4@>D66')FZ8OHMG&)(;*[ S
M"8*\]A@I;B^TUQQX "L,X,G:]&E@B^<7L,4$;/';SRY@BU^H<2,LC1%,+?X/
M93V/H6%CI%)D.M[XAS6)3H=JV/<C,&GJGP#)QZB%@D&B?,'Z1"$J5CA^+9RR
M)RI,'TTEN[ !GJ\_,/A-07?>CR)?(LM.J<-XY,NKAA!D_$UE$&2=<?%$1R];
MJ#-(&1E^F;QR(M(Y<4H9CL^.S;S0=NX*\;)H=B8UPB5:[EF\GH$5_54Q=77G
M5M:%P/+##I+GG-#9$/>J>,F+E)G'N!'!YX8I77A6N;SOPQ3ZXVK#<E47^5*(
MK'=T58B;C.K_KLD\RP35?^/<NLB;)5NA1M:,"(9:(BGX0QA58A?<5=LA&5IJ
MV>1#-_-MB:W!U\BSU*U+U#[MC-Z[C\R9(N==<#=W/2SNZMN[)).,:@85O,@T
M?$/X6+K+K_H^J87-!7G2I4+^X_BYQ?BY4C-2_XYW+(R0RCGIA\>V9AV_C&DJ
M^>K@SN@1]X'YF^5"9,QVA^+89VCTRQI(BKNV:[K;@_LWTEU]J-?!H"T8I21,
M=*"^GLK=VO"LZ?S[[W^_C@8?78]GZZIN#L5WUR^D_9<K',0Y+WFS,2TI75G?
MO'WS]8ADX/K;>JE5%-ID5$7UZ^4;%/"ANTH7QL,RW")=+=[UE9Z5@!A:SS42
MCW<=DGL8S8M___HW^8@ 8*?.S0<CS'A'<4HU=*W>NTS 2P17U&W.JZZ]O524
MO45O=C1ZW*8Q +D+^(55O/KB/$:G<]APN;ENI56?TLKQFQQ:Q0-C)^WV\8;D
M2G&,TM&SJ]%U'^C5)*D*.#R_PM7B39S^;@,RX4(;VKH%9XF1#:E_J);Q\$*^
M(5ZY#[[<BY7@3OIU>J"L$NE$<\8LQH_/!NI9?U^OVW!0=HC2$^:B&KG#40CT
M7Z@XW_;/S>[+Y[];;/X#!^8B^C'[7> )9JH#A)+[H3GPS&$0-EY@UQ)'@ R*
MU@[!<=AT<"T.,+-E)0DF)?D8T:,5H$=#[O&/FK6$O[ >FTO3/<0QTC,X^6@O
MM$@O9.92K7&L2?-.7]]7?<?C)GN)@>'[X-+A<=T+3'8JWL&-JHFVF-Y4C@:V
M3>,T5UO<B#.S>^@67\<MB+ ^!@ZW%<KJO$1K_GENU,K8+?!X)L7HAKB&!8^<
MH0QMO.K6U*SP3-8[[I#Y5W -.ER6W"E-$#=7&/5Q.HQM+9&C,S)C9FD9O2EQ
M3E &%79:_Y15RY\^X?/\L\__5"[>?/.?!+1TEOQ:C?VZ >@4R8UKG</_YOW[
MO9O':_;2HUWUZ!"F>?PD/O;Z/YY=?_NI.Q=2C^P[^@8!(8B3AK9N-.[FH,EY
MRC5W_9.=_^O_>_WURVOB7FD=?J_KGZWC-@YHB9,*4/ROLD BLVE"\^RV[_;;
M>!_'?4C%,< *X\G!/5.<$,#!$S?;RY<OEQ) ,4,/CG(FX:"6[IE3&?\:K]KX
M@- ",-'M-W1H)(%VVE"@)(B.XCUTA?CPQMZ?/11-#(;/$!Z.PBJ,/)X*F=2]
M^/QWS[[X++[=CC'2?Z8H3U/_+3@<ZPT9I% B$LN3W#'_MH_F\_RSYU\\6:-Y
M2["36ZU+8;E>56T\3157.[,5"[=\BS?4D8DS_&M=H4_>7G_[S;.O/V4N_&W=
M$-E;3=GXQ;NN[PA8]B+^S)KH14-<^;UVJ=X ^B,57[@XO* $/5[T:=]+4:I1
MUT!2\PQ1SD_L(;VB'[AY;-)4RC3\^@K"EI-9'N<(ZEW7!A1[Y:\_)3N44>#\
M,8M::'\GW:O*N$GXEZ_C3VZ6\0>^^+R$@3U??')#%1>ZT5=XL56R1$Z(QX<B
M4;'?41^HI!X^?;*6^2H#/[?59LQ=88P6RT,Q=!M+_%-[JE3X"7+OT,G'0@T^
M2UPVG%--U+;/ ["?IA5UWGH\(2BJCH%4C,96W.PL(;50S4X^Z_ <+CC(&T?R
MH0YCNKNCK*YAQUY1P>,F,+G/ 5PM7AODQO,L4;Y&,VO5JEJ'#1>YX[]K!=!U
M#@.GN#+I).[TW"^;^!6.F:+C2(VBS#Q<C 2O.3G%N2#]3,EQ9MR@$LUZ!'VB
MVL7FB"=[3_"_: @]RCR)MB4]S07D'@U *8UC\7E*F7"47GDUV!2KZ[]S&3J;
MQ=X@+%BD'3*,NW%4F@B%AT+QF"+_XSBKGNS._K9:\5PQH5K*5$E (3N.M\)0
MN&QOPK^4B=2:FQ/<6HN@3#G:4"HQ0>4YS/-]O=[GFZ"$=Q%#UP6YH>LXX)[P
M#U1=X8ZB0GL\#/"@>1?1BRX]*1O#BQ(&)Z4R\ +;O;8I:?-/W )$YA CR"WC
MGG2+5;3-&02%-RJT1TIX8Z1YZ&KQ35/_S[ZF!%.&NJR\/@;?0E_%,'S7-8M7
M4&U<O(U?6\9 KMK4W3I&?3$\_/ S"HJNLJQ-0D*\K=KNIBX77U4Q".YY/5[?
MQ/L[_OEU'V__'ZJ/&F87[@C V"]>QO_=W(5Z4R[^;]QJ#1(/^0.*F0?\6]5&
M7[4%&9,_4GE ;ZO[ZC!\U$"^KNIZ=5?CO=X?NCC5%=$UB+UF1UQ!_ &$E7=(
MBSO,-YSKE$^Q:X-H._#Q9<]]6*ONMJWM !32!;43I 80[*>V*THH*4$\N+O@
M$Q?NIHA[))YDBUOXS\QFPS]L*6 T&DA.QLU$F5H1K4]S,:D'?VG4'-/G VHE
M?.OV6YR1Y#PAW;*9.4,G!<5]XE30-8C[\\OX+W%*M'\1UQRNUG7>1$N[S1TI
M7_+6J]XC1: DA7)G5^O:)<&Y'H,P9H4]E&:?+SCU)%?&Z$,O!8D+[L/RE7PU
M"OEN;AW\0_,Y0N"B\S1LM!_P5@$.OF.-*!H]JFK//+THO<:$!6<&<,-G;-T7
MDOU-E"J#!TP(U (?9S$Y.1[1T<E\1OQN-W*@ZUMY?Z</W/G [I4B-N/%V'.^
MD.3RXI/NC<"A4Z0SC4?:26(H&L<"%[E<9&I4I?QCW]\==G<;\3_H[[;(WS5A
MEUR?IWJCGH9+^.*"2YCB$CZ_X!)^H<:-R RE,G 0A<9YZ?/NXAC%C>N XY]
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M%J_;@9><,#1"A0IM$3;HS(Z':,AXRZ]'&*AD^\\_^_PSZ(Y%6Z)\V0M\E4[
MZ<8IF/@ZJ7]HU;A:_.ZS?V)$QAXXFC8[7'ABJ370ML--#?X#0&(:]MV9MB;N
MGO[  M7Y',HIH7NQN*VV)9]P[PDL*&(TV$W//_MRW;7['4H_X8K^YO,OZ:CY
MJB;X^!"/L*_V:[0L)Y+9/R[2G3_>++9'^6P^I.E3D3I>6DQ"G)4_?&8(,CNO
MUKJCEW&AVU9$H<$Y0Z=@YB5[QRKY@[3DVT"*-/:BX!XAMPGW03SXY&T+6AAE
MD)0CCLH731.=N6B^^ \]6/.9ENZ0X0[_D1VY!*/O=2GD (Z&M>]W+.HV[-@J
MZ4911"2[XB/DJ?RPM-N[;A$%RN9NN81GU*'' +EYOLG7<AE*NJJ[V07 YO'2
MA;V@_?JV:^K50?#V+ N8Y!?)!)%XDD@#@@X/: .H-\M]/S"NOT],=5SKUI>O
MQY],%C,^%A9C!8O!=/7<TV2 <J=ML_=\LJ?UNT?.)SXDA)\,32-]%\.DMDB]
MYM+V^;+U.@-R:A(+("'JY*"Y[;N''35$^XA2BH)FXWSHSXZ&JC8#+9^Y^D75
MD@+#30A4DQY3=-@)([H<:#+68W+&.TL(Y9TQ7K@3BS.G!F(4_PA?+7(]">(
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M^-7B>W)%'T*1:\C%CR*?R7.6>>D^@>1Y=GSZ2W,#/^R8A34^0S'\FN/D["'
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M=204*$:A .M9S\9[,V/02AI.5*&5@P]"$8C>,V)@,ZV<RM/U9,^.TX"(?[@
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MQ.KVNZ$69?><2)!VHP]AU ED1+1&]4B0Q1^F@T3R(V/VB@WG8D JN8QG0<X
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M>R@3)0'.J6<R=)S&?J:CK5<Q</L(3)A=4.J7GG%KO6SSZ1;+/^!U*T03E/I
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M (I G]2US%MXM$S?[7<44CH<BW25G#0()G$7(!TQ\\I%PX_]B&IH/>A5041
M.II34\:  <2?W;?&R4M2$J73=C.1440@HU19L^MN R*6R\8[AXV7'"*E9SW-
MX.B"4I$,CNYRGQSIQEVTY8'%M7:[$#R)C!. OPWM2OTH)VIYTG!F4JOQU6;B
M\ZYG+E!0N_4-T[EXW%P*8G]2#.QE+_S<>T%QJ3N2LS\U]3'=#BHY*I99+4';
M'$(];'Q./\O%"*33BG>G#H)S.4J!2D22.Y%OI2$DG4C3E(^#V!)KW4A527@O
M2*8[K$]EU3# W)D >;\;*\XP183\A6#S)%Z,!]NH&#HE-(1+8+<X"U>I$]X<
M%G,,H0D0K)"_J\7W=W5CE"5)'0,4@X8HA*GKHYGQ6TMEA,]6$O3D7G!V$/L%
M\D^JO0L*1%3.@#IN6!QT&D=P$ TS<]2WF:1ND4!=7OG'0V-I%@_C>O)T"D?2
M/O4N?Y1@H)7ETV1RE<FJX#=F_F3(@1AH>MT]M'&T+8=5D_$YEJ*^0NYW57%Y
M'#V$3?= WW=H.A%HYIYF<69CX/9TM1/>W:EFG.V,#+5.E2YA1S7MX$)F6):9
MY+%+!<-.!9_$0#_L>HO$%>_9^"H-2VIQA'S;UCOHIRG4O3A*TT:LIZ&]W=V)
M&BM#:O7])J!Z/F='=> )UUO*'MG+U6V!!W:0$@;ZF;4_GZRM3-2Y+)"SX$U$
M&M@2BEQ%[,C=6[=R8G:DN;[8A,T2)A=7BU4I-L+IR\ODY-?!\YL_:_:[15KC
M=+]#J26@BX\.8";SH]$]=/U['2GARIJ&#=GX5[A0KVF2#N(<@08CW_J??=6#
M1[=EV80T384^RW63R$YR \=#O^JJ?HW_^)H(L2!^G)^ [K4I [\)Q/AN>WAM
MW^-[03W^[J:P?RHE5?J>'KKC"R#)&K'1QVN' ]3_V7?]?F,_  [<N6%B$7=9
MD#'-P.I@"X7[^W7F"8BS7=7]TSYV)3%H>T=FEM,AUB$ ?9_H%=;K>,T&4JQA
MHPHD04 62U=S^BH)15ANH?/7878LCT!K&1DT5 N9&M,IN,1[F'\+'@P4BL 3
MK;21_$A6^B#U(] A.4'Q]@:JJ-@IFHG$B&'2&P+&F.Z,-FN8)0]HCN #9[WG
MLZ20?]2Y*Q6V,SG;2=>\(16$BORK(YKJ-C/B,'$$H'^9]7F(0VGR.83?1Z)+
M?A;RK>WLS[C;)A$[\<:P*=S%]]GY-Z>^$Q%>.X3= C*N:0N*&?B6@$*2"5TO
M2S],93%]*Y-L0C%']JP.W,X23\DFJ.M*7K.MC9W]U!(#[W1/[C#)P[2LB8WN
MEG@,(-F,7!I+,Y%L[N*6#\D@>JB5FEN^&^I!R=QYUJ R+D,(<4O L1:[-3D<
M>1^90WZI0E^*/@H\5_0(3. DU[4$TK+N]@.)E/6;;-Z>[''TD;$)K82$)2I)
M(W:NHJ*N-XH^1X?5H/\E:5T?O>!ZX+XO/H4XOHJGA\K:\R5E#7D/=T&#95[/
M8ADL\J&#:UC=A?6^":SO1PHP5XL7H\,.>G?+H*I*K*&TN*_BV-E19#&E"9+7
MK%[CNE+>#$)PS(/*L4,JA6N8KX3!F)MJ!B82#6]%8=<D%SP2B\E$[^J=*B@D
M_9N"]&_HF6E(*M2KC-+W=328)5W@^1#YCAZ/D"9R\M.E( B@BT6J315)WM.E
ME01OB:=N\D#6!TH#]#)G6LM]I/IUM7CE8U4,'(*OZFMB0:VJZU7(G$ "FR^K
M,E=M"O$I8,!OQ3UVEUAJXC.;&#*R/.0ZK*BS.E_6=HQY_63X5"Y&)/QVAV(T
M3'%W<OT?:;]V1<$^DRQ(F-DL^IZ1@. 3C6%',S7WG<SDM_L>>PH.8.E]WQEK
MW^ =\Y&1\,4RA):US:(E_$VWBZ]K\IU!CY,\E@DFE(7T0$Z_A[])/$&TK&W7
M/K.1C1]%9@$].G9'I<8J=NDZC\8;>X 2G[5M\J>WW58*6J7J?OR ()%FW)EZ
M#F*6@#4&K[>UQ(^K."FP6NMO'>_^I! Y6ALRGC;N5)1I!U,K30^*V[4VX7@6
MY+;Z+O1([=Q+?X]YX3LSL%\.6XYF92=KAZ F"!BML!?-V[;&WN-Q(T1J#&4Y
M.#8RW4-(\Z?<J\+SBQS:?54WE#KGM\9M7I"5>=F/H;K!62U*AG$HJP/SN#>(
MNZ[MIC*1^6#:XK.>K[;A\B>X5I=21.[=LN,D2U4,2>GQ_O^Q]Z;-C1Q7VNCW
M_!45#CFB.Z)(D^Q-&GD<0;.E&7DL=T]W>_3&O7'CC0(J092Z4 770@CSZV^>
M+?-D+2"II261^&*K0:"67$Z>Y3G/0^F,Y3@'<D!MZ+&TX]\+O7UQ1&^/T-LO
MSH[H[=_'4L>;7X'Y*9"Q%ZU=E&%5L GC_AM$K?E,0HLI69&L<H&RLU4"T0'A
MT:P).7EMO3BZ0Z^H):&1*6U4!4 :RX#']OSARXE 3N42Q]C%V^4*CM++98?1
MY.5WERF$K1CG4*70E-E.2@XWZ)X-YRND1:;GS1W-$F>1P^#NPEU'&'G#B:SB
M$90]=Z=<M%SP 6@QX276O7MY4"*K\A);G*#7,57/%6'+?+/L\%$7(JXKK4GN
MV2DWZ1<=?S5%H6SCXD1W+.^Y9$("Q$IL.)21W(GJ?MFQ3[4$,]"B?A^6?9P[
M@D^]RSK/V19P<\'503':H8#<;EUO2)"3W6>4@ YR.F[<0 F3;^VBH:U5:2)0
MI*4V24UE2]+N,CL#/QEYWEK*ZZ!S0O5>YRP8-4?:SZ3C'O@6NN+$Q4P65.Q+
M>"[Q,FF?!@UAF1E(7N7.,J S(],KD^!6$@B;->@Q-3UJ@.HGH/RW>S)WS6N.
M.^P/18MN'/KS0@CUO?.WVYS39Z(X []$C\A#0;QL.1'HBX!?0'^Y[[HGKT9V
MS!RP8UK97$W;"OPJTG6T+G#MI$;(5BS9]NZMEEA_$C5B57%8BOK-N$#[27TM
ML66?]N3Y#UYON#RJ_<D[CI7>@>C/KW ,_JIG,"UF6;E9QT;"K9F/UKH[VPIT
MN0=5(VAB;3$G@;97V;2P6(/"820/Z.49[R%;&U49IR+!.ZD-3]ZF)8U)?*8'
M?Y:_Z?5,)B!3CS10F)WL  8@EL^SH)L,#P0\Y5;.[ -:@+J$ 1\]C/A&[A(F
MZ8$,W=YP1ENIBXDHLG,AN&I"51:X&NML\KG%.LT>DS):E2FW1#M3V[CK_'>?
M.1O[=IUM2,[L:EW85?+5#W;98X[N#18G&UU"P*,J@_I$VS?HD@(=W7+O"^?%
MRG(P;V8N)U+'^HH@(75Q]B5L&-HE^,'YEW2]P<T*SN1@8I^UP3D5CS>@-9S?
M%*T[;4X-N&:@F8Q^D$AUXE$B-7V<4;>BBKS'Y"XK5#,N9ML0NZ$2J :-:3VI
M@^S%MMAB1)_ZS('RB)D-;I0 ::8]Z0&38%3/F-^C:523&!(.#KQ\YO9[N.4)
M&R>LG/=GM8J=LLO>VS*A%)$SCLB[E$CPZ%P^\#VJ#D$M4 W'\7<_$T?"S_#\
M]E?H/-QD-%WAUL;7T]%QH5-'G@,H/BGW_2^W;-T)XYXT(!2BPHKS/4$?]X<,
M5J//%^+R@HT4?N^'0GX?:^&V9@4Q.)@B%"&$O'#(]XJ^?-4#&H& E&%7 61B
MB]+E%.ZT']V<T+FDRC[L/R, CK3 <C>-S?XT>8-+/GX>$S1YV8MGB41Z0SO[
M=FATKL&QA&WD 6-*%E,PQFDP\BAWZ).$Y#%F";'1F[7SB*%@P^,FSPW6O")K
MA[6L/>$VX/"7?#P#)\@AK9%PI:\*[ZHN; </"3T)2S9\$)=9-''P&:RKT^2]
MBR>,-V?NV[!4W*BV" =E9P-OE6VW-BLYSH(3Y01'"!+-P0N@Q\;V9]:FEKRN
M)S(<J!LKG\C0TDSDNF'<0>K;%YH2+C2!3>,Z6XP1HF7%-6IX#MBXX6((79&U
MC(B440R >I5E:25PD<KN7I4=7-2,--SN0&SQ>&$TT>"[;H;Z\IIJ!5L(K &R
MY7%%@E! &&!1N5G:L/FF"QENS7:?!R 1G%2[BB,_'QS7?;?MNVD5; W,T$XH
M#W@TF\JL(6[-S2MZI>)/P-SZ_>)F6US.L:<X6QI:^$W_6'+/>//A@>*S9U(*
M$@^H5L2EJ?@](Q)09>+)L40Y'<(OD%+P@W>Y+]$C^Q;7_\6K%(A@GZ5D>@ N
MX\Q=.-H,G"2(LX-0Z01KJWCXNAD!LE8NOT*7A;C)*ON YBN:/;VGU/%-7C,5
MV'Q. /Y!QX4U$X<%"=7#[P:IA'1>>3?RZ*:B.H A<.$N]6TU^,"PQ"+G0GD3
M@R"&4B!B.=M]V]D-PZ4#2CM -P /"WIPD:'/W=D,Y2:,5?&<HC5*/H;AI8IW
MEK'U*"> GV$@0"/# MB84;/7OE=/&#?L43;X0?;F\-Z@R.M^#3$A'AY&3FJ-
M'64R'L,J(C]KM4\%.W2_5G;RE3#6@^O<@#T&0P@1S376TU5L&!H(CTOK$2PM
M=7AC$V!USR9V?1I+ZYX^ W>(E'1G?T.2TWT754= =4/763 "TI+4]]58/"[:
M1[!H!VA]\!3O?;9.>+B2$%%>9! A"15/[4LB9"D'_/MC:1:]'QCIV1&,- 8C
MG1_!2+_1Q?V:; K8!\GM!M.@>*TI8C;R'97<T/F,+*%L+5?\J8^G$I!WSC&A
M3^(-THOZ%.53FI*#[HK"C8TIEU"^)_)=<! %N5)4VK>;2 Q3<]1VO6\QPAA>
M78,#X!E+EH6!7@,H\69H(]NN-=)V@'G=3B44?#0>NH.4S^ 'E2"H;K #W)/?
MFD-G7:2B@< R6WA4=5E*^U&L72R=A_$]#24.D>Z[?:323M^L?.*E+&3$0=ZL
MAV9$R, N4-C'#>1U!IT021^2S2Z,P$[V!:!L,/TKUPAT<GMJ2N'2AE";3!?[
M'GGQ_3L4@^$:\UK57>J)23(3JDDA/0" =7"RHP(J%FU"X7@631'RA/@X*\)N
MT:,4*ZXQA8R>F<CHS4':!]4X7;0 4!,M ?F9^VL+F4V^J/K8Y^NAOF&AP1,[
M-:"7Z/N>:A.0G*O[2F@G H=M7\':)I \=4G(A7G4TKB)(E4U4. ^R*"O#RP4
M6O'QYEF66;%A)31ID5%E&#<TN276 #HA])W47ZB+*X7^OJPH8:*@835K<*/D
M0-*%G=2\3*1D24^3 N. 6US8-6JHKU,](17OP'=8(FF0NRJV7</T7.'3#U7[
MVM99<C=!A.HC0G;HQ^DWE+@5D=<,^TBH>L,=K1K:8^#]Z,1T$PM&6(S*W# >
M,C584,5FTSL;F B7:[ZZL=!=%0$;5EC9W3%9"%XT.N)FXP-U?+U#+'*I*%,V
M0*. SRK]GA#_0N-\:H:O''?Z';/!#S)NS2V5S<"-V4#9^#Y!ZXJ!I=,(MDE(
MC&K9\L;ZF-9[#"L-@ ;.9OT8(9(YVB-('<-YI)EGCDGB1[&:V+^BR/B>I8=M
MSXT3&)*I,U7HD=PQF1=9X'H[+JG'L*0@(Y(WV0[Y_'Z*?8HDCQ J5L'8AV:=
MN'AZ7%V/876-TU/W66'8XHTA"]&?41=(60@+^'$-/88UE$4RA/=:0"% !%3_
M^:LO6R+$$*25CQJ/*^DQK"2=O]C4%0)I[U?7WF$O(Q3')\\\X88X+J?'L)P4
M65(D3G%/@0O)(S36O2U4N(-+AHNJS* _:Y0)=3_;U)X5*;#''=?>8UA[TE;&
M!"S'27\,DT[M/5*!NH^-$;(O#P-7%1V=JORD8@7'M?3K>M460G++?,#WTV1:
M9UBZ+);VL<"MWB P4X$BB "0ZU %\: &*D S+JF%7F+H.8O:T2 TIKS<LMX2
MYSV0HR#4I)8*7ZC6!=;WF;H=%Q"Y?]@@8^&Z6!0SG#G3G;Y#*  W2'@\ +:-
M^KX-1)9./)!_:X.O)$QFY,HH_CL?DPWR1*?)9=FM46 %:Y%^I)?K<.V4&0S=
MNP>9LH4'3R0!/&&&0@09DI]W;J+S:R'L;FW7E58(XV"J-L!Z2Y=&&EBFS[%$
MX(YLL\P+263NOH=4IERZ^K!_U=@?EJH\B1533T07?B-K@!I;)EK1L4",+8)
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M,$+LO/,Z,H+8B5K\1%:)H!P^U)15M7(._VXR52)[69X7!@-G.80RV)$&Z'S
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MFV$02DVMF,V 1,AF-P50CF+J$F.X:@X-%M&]^WCF34BV^8ZGT/'53J>%0D;
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MP=-SKS=XNR9#+4F:!K/8!UIK?EEN'% _$3@#_XCG&M7ZV(?IA'V;<#-U#'W
M3"N73+FW);P8#"^3^P\7&$TZ+J/'EL%1Q&6P%6P^N1&,W@@P>J40KAW8<P_>
M;KY!CR20^F(FM.W(%'T8#8L14Y0EI.X.*SS\W/Y ^#>]B.>FQ7/P4'0G"G^$
MU*<6 ]T+5L?-/2;TAE'C!\_EV/+"B_!+:#%0]=2CQUGH0>#?QNU=X.S2'TR[
M)IX#3Y<.Q@U(-HM-L,@>0V^=O>$KZM>928%D0-3*KT9>)+CK]/N'&PS*T/++
MM\/Y0HP+'V!PCD/-1E9>(NS;C*WUZDODM+LPRD; Q!'Q]%(@<\LH4_AO/__K
MT_^>OBBJR8'@#PMD;/BWY.3L]**HYB>#.B"7[GS:0C157?_['\[^@/]NM]E2
M_OTCG_@@[N%+MX'R;@W7._NC,\M=([<!K!)$\/)F[BHS<V[^W.7R*[Z:>]\7
M\,)__E.7_V7NS_'E2KM"_,(7+U]]\>7P=Y/WS7S=AY-#03.=?(-_];4(6@JX
M*:Q$NH>;@:Z!QX09.*Z1![=&I/6S+)R]1I*)*8K9W^^J^'6>YG[(L2^.R+$Q
M<NS5$3EV-)B_08.9>6>8\J7>YQZF/SRGSM96D!6&SYE1AZ-<=,TE^[]HZH]0
M0Y3<!<=QB.>%/ X'Y> WYYC( 8<;L!UMAXT>@$^AP,)+04<-Q9GO\B\AT8[P
M';Z55Z_A,,!9^[K*L<PWF9(;/M3O[4PX+OR?Z$UZ*&-EF=B$]7("R;@L%4H%
M[;\$_,]QF3R*99);(KC*=>:0Q 85X$^%O+!4J"-6_9V)I<AX1=PSO_ B^NUF
M S&=A<<+)8*!>&I5]E >[$(!>)NU76J0E I)FY",S5;)30W9IM)Z1.'"AL^B
M,6;PHY97#AI8?"Y%IYVG]AL0O -AA6U/C8S7-_XJG%?R:7%D_=#0P=$]0'],
M]-7@BT0S1RJ<>ZP:0. "MQ[J,B!MAOO8[*"F( ,FW37=VJ?*/8&G8-KD@4Z3
M\.10LM[VS7*=22Y\ICXE]0FI#11210#P!90)%C5+>/K+X;12,64XS_><P@E^
MP+JZKF$[7;WYGV]>GYQ_89Q=SNVF6.+U450N!R\DR_V[>$D?3W:I1X_J*M%W
M ^.IQ]@JUV%1U K7XHL$1NA.D M ,&0 ^ 6/'T&KR+;&;UHP&  ?NUYUMJ+!
MZ:MA;=\S]KO_0,!3M61^-7^S@&LS2DZ<&:1;=4N]!;BKDA^05SEGVHLA!G9<
M*U, .D0^(.<C(?[VAL3]U,#YFL]HK0%66W:_T+ <,WD/\U#E_*WG8621LV".
M8V3UT2-_#*N"2]$>X@.J=U!*7JX+%^+ISG]9'JGJ84@-,X1*HQ$39;FSQ-F7
MR@OR,6T"0@JKI;]L .:KQB7Y)O!5<5-)-EB;*;-5+6VQA0L9W56!C1_$>H6L
MIZ+<*J14.O"F:P<-.WX;A-=@]%%1NRWV-ZUFJ)J.&^4Q;!2M'0MK 7N U%H#
M!'KX=[163*R$$:RN]!)Q3QZSV!W7TZ-83Z+;A RLV,44;)AP*T[44288N=*I
MXUL(G=NL9!Q.4.L)!!K'M?88UIH_>V.E5N[:D 7E6R99M,]9)@-:O%T;$_/8
M!H[)X])Y%$M'626M=3ZO#B'$+KZ5];A.'L,Z4;1N6/[IFIZEBU<@KU)VZR7V
MJS/]*LE!'-?&HU@;R/@XV882,<P!HUL/,A[8C030M?ZX0![) @FQ%8D]1 I(
MA?OS34"Y*MZ2%B#GO?=U%=7 <>$\AH7#^6TO&]-Z*IRX3E /F]%%>HNI%+G@
M<%PTCV'1: 9:KSP$9$D;R= TEC*5>>9U7D*IV3!.X6AB'L5JH?R).Y-*]UK.
MKI3U\N-D ]MQ.3RJY3 JI4*;..HB8<LT<,("'ZP%&B1B*G->"3(8:5P!_G1=
ME[D]NBR/8P'16DCFUQ&K*2CP4M8T&0=)QT7R*!9) U7++L1#L$B"KR(5?&=,
M_H1$"=RA!6IN0&!,<!@AZ6TJ$E;LFOI8U'\<RP<;/NN0X><5]-'N-8U&S+'A
M236.,-O'LDSBM N1XDB_L"#][ _;L@Y2N)S;=1;GNEB:>LMDFYXW"OO[?S5\
M[:^@Y:JAB[%:>PQ>;,T8O8B_;9,(NIC>";M(Q)8 ZD.YOKKL-P-4*J,;T0T=
MPQL-T<&A%&N#8&FB9KX_Y)$E%PCS.8GV9'0B !Y;VS!9(.H#N[N9VQ"**:_+
MD@N6V#HR]82>]A:QR\!*!(A=:@E7U$0#P"?0&!4=, T:(34*Q!,[E!=7(//1
MU!"C+#Z8FAUD_0^O!90:S.BD'F2!7EZG>:6&:GHCVB2AJ2)MK77/0@<3^LDB
M>C!67$Y%(B'8?M9U!NZ,CO1+$.KL-1-H+?N6( :)34,.- T=O2CK!SP6SHW[
M=&VZ!SQV;8ZZ-C\_=FW^/I8ZWOR;E;(_ !<1PR]I4J9#-<@6U2*<R68-$/1
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MUK*QSM Z*QJB/IHO^:?2FCR#LSXNQ\>P'+V0%'<[8.#H[!,X^JC<DT,2!_(
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MS)+ LOA]GR.MC'HM>1ULH%%,K[K (@AG2&EOMF6]M_;A,P7]*)R)N<^Z3I,
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M-G/XH<.*12ZP)S\,PQDFZ^\OBJ#/C34!/PUKGR.X\R_$?>VW@&G5M!-R;<E
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M[178KVU&!@ S !:Q:DC:96]L66]I5P?REP['1?TLN!WN<+ MUO'=U?EDT.5
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M[9ZPEYI4J,DZ(F\(LHJXQ,2-U'."#J/:/06SU1.3L6G)U+H%J^%,2^>H#^,
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MUW9[/2Q/\6QCKC)^%?6D183E!6ON>U:&U9)DS'3(6 *%.G^F ^41;![9IJ<
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M#A7JH3L%'QV:\3O*<%KJ:N!BUPXW'',9<U0A1:=KEXDR,_!?QIITJ-:&Z\S
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MCO9*?R!(E'J!15AE>=YP@"NR,J#8E8R$4V07X&6D0?8'N%UZ#Z_R)1GGWIW
M!']8 UA!,(?';^%<D>]V'\?<"'E;.0@68=++,,,>Y:X8W,FP5>VGI+[./F]'
MVF9ERFGQ6J9F53'3S'IFQ9AN([\HV@0EP+5![A&%B+%B-%SB@%H89<0HW4AX
M##I!/'ATX;ATB5:"H-0JGADHP*E##G'1&48G=H !UZ@[LJ4N1V?X%5C;3]C#
M'G:)G4#5KB2Q-P2M!_K-"RCXZ9@E$'&''%JID<4>$^X V>09;F@\P#8?P/@(
MGP//9K&%F675))"X1-W' ,X3H2,>8E =CN%>DQKM)#'"E;U8,ZI0L08-!EXD
MHX#O!1@-'3E(=3]X'*4@1JX4:2GZ"&=,I_<'?L8A:OP4"""H(-^S0 Z&Z!</
M12D.]-UJY]T:YW'QXH[FT9S>[9W_@%;\5EU#.6\U9V)40P1G>=BJ/5X9Q,Z!
MA>U:'.K6K,*ZT3/GE9R5;8(&O]NI;#W%.! 33;XAV8A!'.%?+$[PH*.*_B%R
M2)+SFG($RR]X+.QNT83AD4]N$%*2C$,\1!DJRAS,#J7]_&?N"T)N[R-FKO*Q
M@6\5$,?!;^Y??F*]/[^^^(VHA]"!(XS,8_Q,^EM*.C!"$ ^3+C.8$7$A"$O@
M8?! )LH$11%%6E**:L#K:-2@\*LI"O"U.'#4^#1$Z_*;WQU2ONX:@7M^4O;/
M/!_Q0;2:B**A.9$=!7N,K\46.N.;0&/#+V-9'T>Y:/7DSSN];YR-Q2%RS9-Y
MHQI,NS_>BN-E>G^FAZT\TH%7+10Z^H<QCITA^+.U./2J>5I[69A3E-9R;>A*
MH7:*^I2" Z"C0Z+"$/Y@LA36 #0L@GD]1<:&!&E8@.]FBJR&.<+\(C09,87H
M^FN(LGJ0U"S'A*R@VK-\38J:%5Q\NGM@;:I%8Q[[.%ZCQ[E@A'YFISUSV5X<
MY=5JS*D]+^ S3U0Y]E*56?^$5>O)_,T&+>I5'L_;J<L_6XNG\UO-.G4YD^RL
M14?F2334D2H,\ "J3A!VL:4]/XP%$!3*I,VGJGHOGP\!K..((7T^:E"%'J.(
M;&^$SCBJ,\^CHD7]Q:)B%( 90\<D<F$EON=SGFWLT00!3-.X&[B*3*/<D!5?
M7,CH9F8>LYCC\PMSY+!CD-#G+?D\9YVE\1-%.G.0HLKC&N<LOU04QD#18$40
M@]7XA'$K#,WA^3S "DA:FH*BEIL$Y.^3^>',8@ZASR>&#WV(@G\SAP[G>R3M
M^EZRT1\JL\A&[AAF:-3NJ)*8Q'^$;\/D+"IXY_!;Q3K@_0J]_G'1P<G'PXP
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M\!C'E/EC!@,QF)@;[&*-K9V;7^I"Z5@$*B?Z6W24P9:*G^P077U4YVT[]D,
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M*C;)9!S+)QP-AE(1*:Z'XGT@\@D&J2N*30OI:S,B%L!O*6;B9]IPZC\H?DG
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METWC#K-O7^AZ6BFA52B61/N*#ESQ0G\L.++'%RH=(A&\"PO* U70%NX5>*7
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M^JIDAY%!!0H^8Q#E@2:]PF(]UG6J.P272"YU[,7H@* /]L9[6Y>#KTI_;)[
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M_CMUM&1%F-?@,T3QV)MF1SOW9*MR'(N@(,I#!Y28 TM03:ZL25,77%1.<O(
M^)M6@#@1\B%&"OE6"#N+N)R0SA^E$35F860XC9$A7H?&/UY#XV^Q-YDTOKQ.
MM4]7ODZM 9ZWHCM5!YIG7*90K('?$T)NJ[]7&1_CTB%=&Y6_9/WN)D"7!_OV
M[S A@ :^94E<%! *?<LB&Z 6PF$:E&90<W#JB#W _6JN:FRD:3(A'P+6A,$1
M@I?];WE_@$=2IVM6>193WDZFRS18RY=L'ZQX%:*,U=,ALB%=DTHG_AQ$<&7I
MV6)+\W6@BR<[C^4L'6\&<+&YLU3K*_WJSX+ _LOS8P(->RQGZ7B%=/QZSM)\
M5+\X%RZT%<9>R_Y'# 0P&>^ K\4_SV<]1.UK:#?Q!8U:VK8OVBMGFU#_>ZS6
M>L'P0C6_#\ +62/AM-Q3'RGG=-:R/PE0R/ (8WT<KL@M<=OYIW*R<%-IJ!5/
M4V6B5F:&351%<)\DG]"S;8=<D8+=]0Y@BT'_'H\;(W '(0$J31NK@3C A(RH
M02+#VJ.@HI'ZP7 AZ P/HV7TT);]$7Z5_=V7XFF^ ,M:[@*")T!3:4)*#."B
MB?%U<C;Q3VA#Z%0<BV!S,(.%=\<#'Q:HY@DJK +>%J[^.?A?&V&SH_78;(NA
MKZN L$&B(8-T8 R_=WMAGQV!2_>IS!56CNWL,MLQI@M/)'+E42,,B&+BEMUC
MG!;P*.H^[^D&$_X8>9$S3DH0EHQ%H\ 8<!%_F>J&#KQ'P<8\JL:*!6/0Y2X<
MV*^&^#G?)9J*1*&)X9OL(>7Q;@8^/ <?&$LA42$!^HFJ2K$V1]\R\(:2DSN.
M"PC];8UA1CTV)"3AZ !WP NFW($D1(;G%*K)G#X]+!X+M3??M^2CZ?",;'PF
M9[CQ.P1?(PF$C[0[MAS5*0^Y]&7U-?U)W N-Y,3X"1=3RK(W=N2MW-HXBR%!
M+Q7LE=8G6 3)VH2<R.;Z(G<TF!$1/L.>X(((9U.^(T<3_&I<N9E7HX".UU-
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M[KB@9D>%TI)OP+!=JN 7V/R(;<:RK)6(RU^4PW@\V55ICOH"TN"T=QMS=)/
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M!896 N<TL=]0 .[M"V"3.7[?674<$[=>J8_ZB_51OXD^4N3&<%C[AU^.6V7
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MIPGMT9(Q6PS!#MC+]/P4 QT!G)F/9U:,B#^':,>R)]=M?'*=#44^BF]ZCP>
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M4?6%_>;B^O;Z+;)%\4)Z@+^XXWE2'R-W(A["Z)O]IG/8[KZ5X0KL7E$*0&Y
M&DAT]M6J<WLJMNY5D32NIVD^D, DMLHD?NJKQ'2."2@]N?GTGZ^EJ&0&VR!O
M6M1& 0P1)RHLR@&'44FK2.0O/H"A0.>%8W1W.(R*\-2XU<Z 5AEYT40CM*4,
MX992Y GK[R<"]T5=7 _)6$?ELUCK/Z_?W^*-??/GLTU%3K$<(XF^(')C;3=R
M@^MY9*-UF4V3 R4=84@6F658@X@2R3JV(#15^'*Z\TU-JL]N'[\9Z:R"_$FJ
MMXJ40K[IEP!FE$^"5T[2(QA!!@/!UP?ID\TT=E)HE[[@5"JMVKWLCC):)Y;Y
M1>N1*T-9?,F4!?>9&+4C(!'1Y&4$+Y?7NS(\AZ'.O\ =22>W8*;'__L]:$98
MP<V%L[S>=8S;07/FLWK8K!=/@']%9 B8"I(LQ\LTRQ)W;4*%(D(<;G3ACJRB
M)3';08J)+Q99>6]/8S-L2K?I23FXSLM\<GDKU/,<;ZN>YWW+IGX2D$B=U'MN
ME3S/J"[K9*/G6+D6Z6OP\5Z8%1?@5"C9_QA& KYD_Q.L<CST!@8D[HV\!EX%
MC!B+0&E;<D)J5O^H?((O_ S*J(<)V@&&#!Z)9RIWVJ1R^/R=?4VC@N.?\?TR
MO:7+B4]/7F0]\2K5Q*<G^VKB]<6NH,).MZC"F"-(?]WTOGRUKZZN'@-33;VV
M(07.MJ_$,Q7>/D05KH/WI>(+"I98%Q(;6]B_HMM%^;-F6GMK31 ;\U4,S\3N
M];$@$)W$:D)DI-K&2K:WQZ^YB=V<#Z%X. 7J<A576% #)TRM0%0X(S=L<?Y(
M424K!<S*";E@";1*K.IP&$NK+7L!J:X62\#XXCUR)QYE4K,RI!@A1:E<8)85
M%<D%V%02(-]OJ?<OMJ8;/(BE$DDK3<_6=K$\CWO9P=IS)QWEAFC)E7:[/V93
MG&0?69>G??T#YT*;9#W@P_MYT6[HL['WMU 3H1#$#LPHZPY\ZB^5(YYJQF 9
MXX8+"SW<[#(5!]2OL#%9CRL76V.8-DGGWMUK(O/)X5/1^4:F&HO$;C";#;R\
MLL NVD1FPS>YBW]XORRV>=XO33GJJ?AE__['?7\S)E]M#.83",+_25UP/V[&
M[F27B+PL83:OYH[/GC,]ML H%V/7 Y<Y,(K32^IS%3G9"2GXW4W EW^P;_\.
MD^=\[IN7@Z.]'!3EH+HOXP7;B,LPO?/A?OLIC,$Y#9\S0VQ>0$Z.GC,]MB8@
MOPL<>.6O:!GJ1SCO'D'W[W_)[]_RX/LJ^<S/%3\OCQ\_WWB$"N["G\/@X,-D
MZH<S(?8WX/W[U[\![X3O\L]P'-A?6O;O:30=SW:)C$_ONIQVGC,]MN'H2K7W
MDIWYVP3+4>S_$;X(OH6C^)MXSDRP]^=W6RAV@N5_]6=!8/_E^3'F+)[OX6[!
M AP_9WH\.K/G6N VDWQOGQZVL/QM0>D*..B*7LHAWW 50/.%9"D#QRY'A<MP
M)EM;\HZT#V;TH*$7L8CN$0TGSB!>RI%R*_:P<(ZJ5**)["A3R+/FA*%CU9_V
M&[>>>F$:^S/C)34O,(Y&EF^_#]UHR*A\JL $*YU&(;<"P1\^Q%,1A?9[+X3-
MP%<='&G=LM](3#C^LQH3X^AN6%R2'7.;FWI9(@9N-'(C[,SY?.G8O%V/"W 4
MU%&@1L\=MH\M+$'W[7^F/F'@'SHX5HNG<21P(CAA2R39.':</WT74/.:FO*F
M4'ZP23$20X]VB*7Q#"XEH9PNA>\^8#T.]@X!G;#O+D4@J5B(;PRN:3Y<4T77
MLW-?+9T'/"\P3L)E?'D_D<7SV80%"8> 4",B>Z3#O5YZRS:30*/SP>_:+1N!
MKNV/HA_)\0#M#CY;CEE RCGV[U&+V>^!5H&@@P&<*+5<7O[O+_:GWM??KGJ?
MU3 CV_=&PHX''M9NXH1R'^PV4",0/O+[-R'G*,&?9RWK!CLR\97_#AF8)?=$
M8N"4^HYHC*W!EHO314B*3VXR]N!CM[,X$9.860X7.?3N:.H6-=N[H'AQW$2V
M/-7'AF_4K=G$M0.1DA^";0] (R :D;ES>*@H#/_L,K2%_,.9_@-0]V$LIU6H
M5Q!5!QE,SN7_<B?3=U^L"XW+Q3VP0%WDLMQ9$9_0*!S[O3L8"Y]%I!=QU^\'
MX)APX@UDV]\?%Y]Z3H&0+@,=_(ZRA"HBFL8:H]G^2UA]X7O@T6=,X,78$.8S
M@!F.,\)'V;(IM$()&,V]V%%CSOGNIR"W(L8&6!'=J?((HP&=T0\0_FX8N1["
M:5N(N! 1:SEV@.,X43M0+XO"A-"MP!\O>XX:#8"?RJ97P4(2'$K '\UTB3$\
M@]^,*Z;9R#1 ^UL0/H"LWV&UW%R.(*@RB4J":B7<2EW=4YKS^2\W\YU.'=38
M2[?;)A%J+7?60:J4%INRW]V9-,RDH+4A.T21TWC[J,)9/]-+LA=DNO!/G-%T
M$XG8&RILD;H4(W:3D^[YR[K%87 7JEW,E:,*#WSL[1KBL#AO &H]Q?'B,7ZT
M[X4@1N,@],.[F=)LL"K:RZV8)GJ]A\9Z#:)(E(BR_J R65/A2]'K40<:;<>8
M;Y;UQE.Y[-7G/Z_1WY#&*-/^^?W0A,8(:7$0XX0L>X1W38+?4ENQ?I-(B[3>
MN'Z]F7JE%FDD_T&UJS1W8_D>?P0C^ KT=:SJ#9@6-[,KJ-P"Y$PU;!,7K4X)
M(1+0M:&6.D84PRD"X :!W9^&4XW-IL;XFC2AAL&6]9']"[ ;P)EG>;_AO,R7
M\VG6C!0?W#A!5L8VJ01'( 5WCE4ZS\@=P5NG7B2'J3(W?I3F^#0SQ]720\YR
MC9 @S2ZP*VLTLF_8$V+;C,L Y>\FXHX':J.K9KH2W-O([8QFY;<!RX'.!OI,
M0,E[,$AHM+B+$KN2(U>Y0=/(NV< +;#X0_D"#P$E<8L6^1_P"/CO";E016^^
M4O2_>%/[(HW\3$C8&[)]X:(##^;Q 3S35$J=G%81,\"J.P6O$/P[V-XP'21J
M)>WS\Q.YDJY!:?8C+Y"AR(O(MQ&[:J32OVY^_U7YU;? %9>>N N5!ANX\&\N
M6H^++DT@.8<Q/B(+SZR.G@;Q]/KNX$\,ADUN$\_0]&C.$2/R72'CA5Y,MR#X
M/BC^@S\0HM"5$$_V^UM<><]0E)9VQG[2&P4'&!TX;Q$Y%!$2.2;S OVO, H\
MUUAU'QOV\4D/PO5A$? Y[;#@$Z2/995]K('N1I$,##H?<1N3F9R\W4\4E\(;
MS,_?Z>X5A^$=<P"%&3Z+8QNSR>2?+1/UT9""#.<55@<_(P3)R \?# #!F" C
M(S2##&*CM#.-)=?^6N8KXOYEP[-\JGY#[%AX]4AL[*)D%%J",\G,&1P&C5'+
M)BB\*F>N4)X#<MRZ;"FOKE2'\;)]N@(M:MTZ29:"4R>MXYF*N5R"Z)I/0D[/
M0@G2I\IN%8;X8(O,0=^56$&1.U7FG)KXDP=@TIF-5YU8.F&6<6U$GW$L&GE?
M=(4.@SMX<T3XM6P9!J#^*!;/[E*E]U=<+C@4D95?+#D>!]2O)"T;.C('X'$(
M^$W QE.!0.7)E?EB1/E?_; /7/@;CE>^D(NSC4&+]/!K+?)X?^N!/L1K*.)9
MT'VON+G<*,7"34_M<61X0)VV]"NT$X1G+.,;V*<%AK!LC*V"!"'%__7^QO!:
MX8,A+.Q3,J3EY8FM9C^:^I46K+$>:(GFC4&%*;)EHS*><VEP<N1%5\%\Z:5Y
M9ZY4"M)BN</( P-L;*S,2A;LKH;40WJH <EO[A:#<I+'#($PX7>Q2SY"@"IP
M9^&%"&DG0'XD?3*_M<O4L7(4*XMJ15" %B%WXRAXXS":$116.@*'B2!U$#!^
M.@4'9#!VY72>[/YAX\=0[M+ ^T\J+%AX85^SO M/GA0<%#@9*L(R)8[36B,S
M@A425!GR=7& RDC$,MY*I^D%A.#]^;__L#^YP5T(K*-.^8+21K21S]C]^" 0
M "0P7"8=W/PHO !H>F??#L8A0HYD3R<;3MB:N K<Q^^75>X7BNZ?(IJ 6@>Y
M\'W!A%>/R<(V[UN]%JK2_PE94FI<.?FLUV+12R^:@US0/CS<HQ14H!2<[E$*
MG@>ST\O+!2F.?=G"P>0OW%7%>V%I[P6O3\?LK9S7Q^ZJ2A)FL\JS.:W% 5'X
M2P8&DX&F6P4QRE:G?@FFXVGE',]+N!+^!VQ0[]=\4/109SV*@8T*Q^/VP0W
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MOC*3[TZ9=2H\\5>B7WO9I?035OJ,1OL;Z4L5 H)BTOA<X&CBN$+5EI_'_C1
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MM38/J7TMCV&6[4MOEV;4*GI>J/$]&6-0HW7D!K'LR<56P4'D]4%\LCW%,JB
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M96V.WNYDJWRR Y<B5KJ^W9UHM4XT+\"%JQQ*B>S&4?I'L'GI1XBB#YFPM/[
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M(:,6AQ(J8 2JPY\.(VY-*-4%JX[[;O I^'I*'>RXDT"RO@!BC=H).P1$=WS
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MMLR8]&)8+)9G8)QUTEO'/D:10/]"_"_M0<98\L$8$7Z&Z(8"9L6/74ASK11
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M&RVN-/4OHWT)4R7X0K60(CZLQ(B5=")QQ7!8@<;%10OFV=5G!A%FI72Z(X#
M R=MM$SE3QD1&C&*MD?=]6&=I79)_;#1<OTRVZ3$\1I5?)1OV[Y[=VF&_)@1
M&-2%G(Z7]+'4ST,XKTQ/LZ$!Q<G,O*KODY@=V<26ZG-V0QE3@W*A%'RN=(C
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M?B :*D)-Z>L@E%>A#7:GTM00.>&&!UQYKL,2+)+(DM6B.!R\MX97NH\3SB!
MI(:<$?6"8BD46Q9B)FBU%Y?$87<TLR!6BXPPN1-R-H&T#PBR@-_S0[X<K,M
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M\^S-F6!'E=RM9GG<Y:T=<?- SB+@3[I(1Q"\':8?N;&'\"OTU91<O^#687^
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MOY088_PB?OB22TS ;B5Y&MACX-WMD=%;-=+7.C)JQ: ^I7X2&J/323KH#*2
M*(K(<W%R,Q7\AB))EWC96-(FC?8-X_Q5Q1I2*[FK.V-QI\-SKZI6EF;%0[0T
M8N%57Y5ED6JB";2%A+#NXEF#F9L\ 9,P93N;(DI8^5IGZV-O66'?=Z330A@9
M:>SN=9!46$<"S>W;ZT(/=1>$R?16Q;>"(K&4C^QYA8V_G(N)9!*KF<#MZ5@Y
MZ^*L+#?(XX<#U;*4]E<3EKXR^4)?-UR2MDS2AR3^;APE/I["0W4H-'WY*N83
M@T<[_U2S<WV:KK5B/5XP2P%53MB?7&.3._R][H8_;!P>W=]D7A;4Q>QD]?#M
M'CVYJ_>UP\5C*M9[OD%<Q#RX8<W]8SPV>QS_E1U@<V /S$'I^W[W!$Q$+Q[Z
MXS5<=[=:\.O?=KO;&.ZY-IYXS-\-\=UK(W0T>!KD\49!7O%$G#BD;.-0CYH;
MQ;HAFOZD+/PIJ+?1[%-F\<-7\&N"8)M#T1YSB>@SM;%I>RQ%Q+P[$>1T:LMZ
M+N_=_*ZWY=A3CW?>]'5XN=-W[Z@0W#UBPNYJ*BRBO7*D=R_8?QSJ/PS?*'*D
M']"X7]30#V_^#U!+ P04    "  9KWU6*_DOK@,(  "<,P  &P   &8Q,&LR
M,#(R97@S,2TR7V-A9')E;F%L+FAT;>V;;V\:N1;&WR/Q'2RDNTHD0@))JKM)
M&HD0LD6;0@14VKXT,Q[PS<R8VC.D[*>_S[$'F!#:TET(NRUYD3#C/^=X?'Y^
MCCWDZEW__?UUL7#UKEF_Q5]&/U?]5O^^>7UU[/ZB]#@KOKKIW'YDO?['^^;;
M4J#BY()53\8)Z\M(&-863ZRK(AZ7W8TRZPDM@Q(:HNG#][:[9!'70QE?,*IZ
M<LD2\3DYXJ$<XI:6PU%2NKZZN6Y^'LF!3-AIM5*[.KZ!VP];-/A+/##CRRW9
M\$2<"&U'U6AV^ZV[5J/>;W7:K'/''KJM=J/U4+]G=ZUV'1_QJ7.'&LUN?M3;
M]>KA0[?WH=[NLWZ'=3_<-UGUE!]5SUBGFUV>^_;RCO7?-8N%7K/QH=OJMYH]
MUORC\:[>_JW)ZHT^E5=_/3TKOY[C]1ZKWW8>^LU;EA\#'+3/]_2DECG->O7N
M3;W=[!UU_KAO?BP6,G]K)R?;C*Z9JUL-K_^E)I'!M'3=*K/W/$E&Z*/WITK*
M,*^IA"4CGEQLV_K2&/OU&T1.HWE__U"_O6VU?WM;.BG9Z]Y#O3&[_HN>'"5J
M;+V9WQBH)%%1=N])^LF(^COY#\*DWYV9F=#S\'@X\QV]?&$P-(#;6;.LNY-*
M[5S&SQN$(J#EZJZ#P,N-Y2C@D0RG%]\:C:UKY)_"#;YT7:U<'5-GM$K?7N=\
M6.GEYNRVBH41GPBFQ42*)^$C9*1A/(Y3'N+F6.F$J9C=*1VAQ='O3 6LP7TM
M8I3W1T+SL4CQ;&&B%7N5R_PH2&CZ7?I,(7&]@0ATORMG+Z8C>S+931G[@OH_
M<E7W(;J14*GM*$1ON!%^L8 HC*;L,59/H?"'HNPB-0M17Z'+6"7,0VLN8T3P
ME*5QHE/!3,(3$2$@*'8Y)@4KLT3T!MS#+<U4A&PC4:[>BPJQ\(0Q7$^I2L0?
M1;& A7;1J<%-'][ 9D@I!1FA"I[47AJA6HSV<,47FCV-I#=B)J5?B_9/0HNL
M$QI!)$THN"_C(6(E&6&$9BP\ZR'U.X9ORL<X$3#T6 ;3_(/8\_?C\G?ZC^-/
ML$#&"'""91'09<#G,X5BG2N7<0 -X8E$/S+VPM2'V ":7/"609S4X92-$?/$
M*W$<A@L@,Q2,0W#1-Z#W)?5<IBII"*A H0(JUIZQ#GG<C%@0JB<S0U2+H32)
MYK#$Z:9S'&Z6<Z29F3<OW-VS]N.R=K8CUI!1%0N+N/Q%FT^INC0935E:3]*@
M@D#BTD9LBW$M+!R(=3D(!<4P$R!R$$HSHNI4+8(NDC;2M2^-%RJ3HATIIE:A
M@V2LE2=\W 9C!X#"%Z#,17[SLS?B\5"P.L2HFX88E]TMGA^(0]O6;A;IREU*
MV@'%CDXRP$BQ<M ZB,B9KQ@J%IY9"IY9"F")1KK,,FI03GNQYW.'?)9>H/.*
M^/+#W>![*PRZ)K6T2=ZW*2M3 NKQ% K+UFQ"B>!  !AG*DLM5:K1 21K(HT5
M0M02,?5#8LF3A8CFA5B+D%L$L^1R05$Y$VDJE-!3.&-4*'V>6$\'1OJ2:TDC
MD"X%MJE!3#VEAB$KM4N6L3FLU4UEX I0@%!3JS&G&$M#3H*/@5DO%ODMFKAL
M.9_EX]- 4$5(,MH+_S4D^.R_E3<$RQJ(5]]4:N.7AXI[Q+> ^."?@?C:*O>"
M]/7U<2W@@;FB56(B?>*8&Q5S2@6XP2) FU""FVM_QAG0EWP@0YE,*1]>99?6
M'8NDI<VM&,^JYC:Q-N/X[$94+(Q3/0;OQF;PGJ>T;SVP^]FAB)&7AZ >)6),
MZPE5P6;=D8UU1XZA^7NV?UJVO1VQW9SP,"6%<QM,$038;<H) M:LV#3.D_,U
M--M=KMY'6I31$')KW&YUH-*$C$$O5[FP3EK!Y[4%;<:#%6='[/G1$1O0/I\.
M>^WR)-RS@$.7Q0)ZW]/XL]+H[TII79@3C4O T.%NMD>T)2NI_ Y]I?Q8>5ZJ
MB8I<+OJRUV(A4B9! ;W@0V<&$\L^I<AET??!%SP) #B$;ZEVYKD'ZNS!=/S\
MK<NA<VO$S3QU)\FTZX'P(?<07/M$,J6?LE ^BC [IEYJ4/[;#^F2[=> '_G
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M0=^Y"]F"*6BWZD:O,4#9TU=<\(0OTJ3[2FMXE"LJN[ @WJ>E%!GW:YZ(A.S
M*F2*YNY:SLP=7@TMTQU.QC"]F<UOS+%;+KF3?>??2)SQ.]S4YW6K#G/'R@4:
M[?-F]0B4F7,P[<G4=>QCV[-BIRZ:[V%R!>ZU4R[-S=G '#OSVN2OD7,+IN7J
MKE:SV7I%PI\5^ZKL_YVEB@7K)Y8?<O $Y]133'!8,16""FFY9'*>D0AF-!%2
M@0C (KZD')O<D$J2T$PQ#S4,N5>'4YP")Y'_.1/=&5VR5$G"U8G,&\X #5\)
M&:,SM3\@$%*O &M*)%#N4Q]LZM%X026TC2J>1ZL%)(6 1=0OEPI%Z*R72:88
M[@3A/CAW7DCXDH(EXIBEJ5:/7SW2)XH"BJ2H^FMEVI="%4JOPI\9VH!I2.(J
MGI34>U6%)),IMBM0 G:QA_AL]R@//JV0^")1*']_?#%(<X?+Y\*)7!!.T]KD
M+J)K,+U\.S5V5>PG^;1X#9^X6*''2]IY,Q8>H.B:@Y$#EC,:34W;'HX_7%::
ME?SW?&I:Q>__*+&F1)++W#4LA%(BWK:MF*]";:_Y&\:S.RN6^:(/R2-1X11:
M>=1+?3WV7+N8MC779+RB;V"[_TA?O77.^-?&(AK@[71JG#V<\^B*&!A%O 19
M%*TQL.(DTL#N();T<\8DC3$II)J"=(-+N62T3PD&B@3C_-0_VZ%SS_R.]RT_
MQD7[75='0BY-5Q/N3+NFS^P7/<=$3^O'Z6$<LV-,\@R"65D1QC&_L$U:*] B
M3");B:2IIJA:+F$_B2+<"+QH&"9H[$F0J[2:3PL8)]S3[6C19[EMG4!Q5!9M
M*!0)9G3=D1;@W2?Q^O'SM<_30]Y>+'$/'=0BI$^EUA&1)*5XFV__JN15_=-D
M5;:5_W,'W[N:C-U]H;6 Q"Q:=YZ3FH]-V3]TXUFE;R,!'3B<O8]$>N'&B=9%
M?C.W>PUMO;][N/;_[N5@W7E\>6NB41A?5EJ[<]\>8)$<!A'"!4;]'#E(1<3\
M[T3_X<0VTL9>D0'[PO.(VF+T[2;^:*K:$?L^SW4'$UY$VQ/G_&*)[]Y:X8:#
MIT6>'U3DF,2T\TI*VP9*/6"XWW/Z4Y@>*85'@=XA1;A,1?0[J? 9$0>$Q@JQ
M'L&!>4UAA8P&6*IBV:K8%PJ3(&#X;]7AL]XOQIXZWF+JVW!Y.I4,"\X$*\YO
M2#A['(5=6?G31>7#,E$7KOKUZN9]JWXM^R]02P,$%     @ &:]]5KR]6GLD
M!   OQ,  !L   !F,3!K,C R,F5X,S(M,E]C861R96YA;"YH=&WM6&UOVD@0
M_H[$?QA9NHA(O%.J"Q D8\P%'04$CG3YN-AKV*N]ZZ[71^BOOUF#"4$H;:[0
MY*0B)/"^S#PS\\R+W+ES/HVZ^5SGSC;[^ OZTW&&SLCN=BK;7]RM[+8[O4G_
M >;.P\B^-7S!50MJU4B!PT(:PYBN829"PHO;A2+,J62^@1?QZO2U]]H0$KED
MO 7Z:+4-BCZJ$@G8$I<D6ZZ4T>WTNO;CBBV8@D:]7.]4>@A[>D&%5WP11^T+
MZ7 I5U2V84'<STLI$NZ57!$(V8+UBBF:FFO9,V<X&%JF,YR,87H_F]^;8R>?
M<R:'QK\1N-KO<%^>EZTRS&TK!5AK-*O%=X#,G(/9GTP=N_^"S]X 5^:GF^I'
MF S N;/SN;DYZYEC>UZ:_#6R'\"T'+U5KU8OR>]O@KTH\_].8L7\S0OJAQQ<
MP3EU%1,<UDRM0*UH/F=RGI  9C024H'PP2*>I!R7G!65)**)8BYB&'*W# 6\
M E>!]R41[1E=LEA)PM653!>N 04/A S1F-*?X NI-<"&$@F4>]2#/G5IN* 2
M&K4BQJ->!Q*#SP+JY7,9(C363213##U!N ?VH[LB?$G!$F'(XEBCQZ\^Z1%%
M 4%21/T<F;8E0X70B_")*#RPAOE7H8H8*ZF]580HD7&"%H 2L,\])-#.2VGR
M:8S$$Y%" P[/9X<T\Q! "IW(!>$T+DT> [H!TTT=JHE7Q'V27@LW\)F+-=J\
MI*TW8\,1&1VS-[+!LD>CJ=GO#\=_W!I5(WV>3TTK>_Z/$$M*1"G,_<)"*"7"
MW=J:>6JEY55_PXQV9IF:?W207!)D1J&4DU;J]MAQ^MFUG;@JXX;NP/WNB;UR
MO<GX<V$!];$[%6K7QW=.:L34R#+&3X)@@ZD51H&F[)[&DGY)F*0AEH58LR#>
MTB6?JS4*!%-%0JU9\*[WU'EB_9[Q._[4;AH?VCH74FAZFG!FVC0=LU_L>4_L
MJ7\_>QC'^AB2M()@75:$<:PO;%O8,FH1)I%;D:2Q9E$QG\-]$@3H"&PU#$LT
M[D3(J[B87O,9)]S5ZRC18ZEL74+Q5!)L62@BK.EZ(\Z(]U3&R^^?7X=\.N;;
MJR$>4 >Q".E1J7$$)(HI]O/=/R.=ZE]FEK&;_#LZ^(/)V#D$4_))R()-ZUMP
MTK,Q^TJWZ(UN'Z/<PLXEW174;]*&V>A4M/CN+E+GU]G;M$ZJ &NBG3^^->I[
M3^]<EJ5C+\!P0JW<1,_'(F"><49<E;BRQ7+8R ^1IJ1]5:2.TOIC6D#.!CBC
M\"E?/E?\X8WT-L^J=TQ"VMHJA^_1WJB=5?WY:/%S8O&_T^(P%>##I=58*T9]
M&.P;V<3W&4[KOT+ZHUI^%O3"5#(,782Q>XJB'D),U\5.KQA?9D&]/AW5_>#Q
MPV/'\2"A1QO] F[[1DZ_N/L74$L#!!0    ( !FO?5;,/>68]1<  ,9O   ;
M    9C$P:S(P,C)E>#0M,3%?8V%D<F5N86PN:'1M[5UM<]LVMOZN&?T'W-S;
M3CHC.T[:M-/8FQG'=EO/IK;'=MJ['R$2DM!0I$J05K2_?L]S#D""$F6[N4WO
MK#:=21-1!'!P<-Y?H*.?;G]^^WHX./KI[/B4_E;X[^CV_/;MV>NC9_(W??O,
M?WWTYO+T'^KF]A]OS_[V9%+DU2OU_&!1J5L[-TY=F*6Z+N8Z'\F#D;HQI9T\
MH8$T]"J,J\R':D]G=IJ_4J6=SJI#-=?EU-+'@R>OC]Z\/OLPLV-;J6_VGS\_
M>O:& +E:F^*Q2T<STZL'AVIC[2>OO\S';G'XB=9(3%Z9DG=U>G9S<GU^=7M^
M>:$N?U W9R?OKL]OS\]NXBU^6A"NSWX\O[D]NSX[55?OKF_>'5_<JMM+@,)0
M/7\!P&Y_.ON$2(^@:3&@SO[WY*?CBQ_/U/')+6!X_OW7WXS4\8TZ_OGLXO3L
M]!,"]%OM*CM9?6(Z:%8YT6EI<IVIVYDI]<+4E4UHAO,\V5=/JYE17V;I[W5Q
M>%+,%SI?C;XL^>-PX)\O37@4WJQ=\T3G:7A:U*5_^I6:::>*W*@DTX[^-5'.
M)'5I*TN;*<W4.CH1DZHZ3TU)>TDJ6^2"#:((>AU@W31#AH.S#\E,YU.CCI,*
MW\MIT2)Z;FB.M+.1^.4 T4@M9S:9*4O0U*5*BOF\R)6KBN3]2"UTJ>YT5AOU
M/P?[!P?/U8*@<C-=FLZ\,F@XX%%AXOW=(!)BCA]-3O21[0[A$[VK29%EQ=+F
M4YR\5JEQ26D7(+= 9G--M&AU-AS0WW,FUG4*V2?6H>$\@ZOGM/:*J#M;,?6G
M!<&9%Y5:U.6B*"M5%6IL,'Z1F<KLJ_,*(UT]_HWH'-]BU.\U03NQ1+DV5[9R
MBH24+4VU&@[&*V*1"?%'GAB\#FA.3$E[L@G!"@")=PLLIGDC'2:^Y\66%P !
MIGVSRO32=2:01\VKPX'1Q#8TE? />,(VDQ+X'6C!D+DR7IEZV.>%J^@=B&%U
MG.>T<75M&%,$^P]%.:<#W_O[OOK5$!(2&J&)=5=%C?&ET0SI<'#?QD;Q9K W
M[$<O%AF]/LZ,6I3%G77T(DY7: ]OG!H:@ UYRE<G$5+?ZN6(J*=4.DTMGM#W
M-J<'<_Y^=]C^Z/SUB=#Z#6C]Z-GYZ]T1 413.&!=5[.BM/\D>B6BLLZ1J/_N
MY>C@X !_1-2#-H:#+MO_5&2DH'IE L\+IJTRF17J[JZH#!,-,XUH$!K;&3<S
M68J'Q!%%F?+;($:3B1;T:PT'*8F#I"I*H6B=9:J@]TK(JPHPE>;WVI:0;#SO
MC$%5.A&&,!\20WA9VFI&;[I%$#U0E_2'!([GSJ3+5[8C6:J9KH8#G=&"BN#T
M:A7@+HHE 4&JLV%^^L#FK<.; FHC4,FLH,4J5]%6 +&,@@4@.+$BBF<MNET-
M83.9$-QXBTX<9@!]L3YT_1CX"(!LGB!O=[RO+FF[$59+CW018EHM,A(]F:U6
M03-@*J<23>*+7L"3"-,$S<:RNF*4:A%R<V,J;!:[B<:)],7J4!KQ'$D]KS-"
M_!TOC:&"T X=KM-@%PR(68SGW:?VSJ:T>UK2\AFPQ337*^BGU)!M!C1.RF*N
M*N(LC.>_QRN1IX4NF5)/&YQY795:TJ)&J+5F>VQ"EAQA)#-3(E1"YIVV&8M>
MT($A&H<*):K1*QP%1O0 AVT%3NSGMTB),A&6EFBM;U(BE?PAJANU6HVAA);.
MB8OWU;L%[ZQ4F24>2X47"A"/<T56"X>M$>R]\H%LB_9L-/21(@ZC?Y 6]#P/
M!B=;V53@[+FV.2!N\3B1Y:O2CFMAS:)#5<0K8-((%Y@PLWIL,S&["0G#0:,)
M&[G3V:)P:GL(Z\P68Y.('>*!249.]SYLS/0="!XSFOD"-$ZF!1UG9(Z5M/&4
MOZ1/0OG"*V&L%R_@E"*_,S"U9L:N+61SMK!67@2U?H? J,>.+179G =E./!3
MD_5!PIDV7V<5B)T,1BOG'62"A2]I7!4^FP]T*&M"F(R]&4\4F0[W$/;8B$9*
M]X>#\[P9)!061.KD05IK>4.PYOE<IX0I9\"409J.5_?,+8"RJ&5:8,G;1PM\
M^$O#ZY!937H7*@0KBWZU.2\RJ:NZ-+MC+I'!6L]IC%?7NV,J03L&;QJG""IG
M"_\^"X&, RBSOF%C,<=9XJ1&R*7.,^,<J(8XV$%0$94LP9_$05ZHN]@2@@*'
M]9&+6IP ^4*\)\0$S(4G9)00B"LF68X;5![2QKY_6I2C0(_F#LN*Y.J;IO7G
M6.S\1M+#I39I.7)"0@K.@DAC8KB$IPCR]-0_9G :"!J3B)$C0YS:!O!74$4B
M79*L=LW.>9&G]BLA"+ G@6+O!#<Z"6*44)X8PT)Z7!8U,3FK0TB-L9GIC CB
MJ8UG\4.A?DH^"HW C9T#IG$9',")3>O$PO=-:QA)2V\X 0QO(4"E$J48^@>)
MUJQ8&=XZ.72LDT@-,LHYSA3..WP$BNJR(T<9SD<!JNF46,77I:MU'ED(D>>G
M8J=O.-CJ]14?PPD!_GMXX5#Q\=UM;(BX:'-'4[(!2,_43HB5*&):D"C/!>N-
M+H)R(<FN+8GOM$B(]G*SE; . SNF/*DWO5()9MCF?-998BMC$0_,2=JS=;'R
M)K<<$2@UTS 9)HUF$L]EC:4\VP0J\'*!%-!'2888!*\ /0NP.L]C)J25 R\+
M"SM;\7)>4O!V.VPL+L0?)XV'9*3.7-$5E'V"!LYI+#;>Y9;F$%IB6/F;XSF)
MA$3?)T%8]YM@R0:KCP-61'-5E[UT[7A'@?6$+(<#"=UVX[0(N.ZKBZ*"V]D8
MBKR7HC33@CZ->J%JS=)&^B)\PS+"U7 YPBG2 X,H#()-.<G\8.&R_&"Y1)Y)
M"$QAJ6[DN(Q,0^$S(*1Q KH$X40%M,#&E,O[G FY$)%\K,BX7W62CU:G7;=3
MZ$..2+;@5',6;:!<R )[9O]NC$ !FZE@$#_,YELX8=2)5K9Q-()J5PRY,/]_
M[>VI'ZS)TE?JBM34(4WR>PT/@=92>WL^/WET>OY+ $2FWZN*!;WR8M&D$O?&
M1545\U?J6SP;%R4AM'GVAF7A\_V7!!,QGDT)A*ONC QPO/^C9[1J#P#0R._W
MQO"J"<H%0QT#]6T/3 #TCRX9H>89<"/H^+<_^3>OC\DKW[O5[PWTJ;IJ3(3/
MMOP#>HJ4<T7B/[:J6!J)"YAI\BM3.(DC'RP)P?R@=Q>Z) '- DDG(7J)2<LB
M SBU0Q9@.# ?)%[I-:&+[;A1E(B07 R'=<<F*\AT6]HLBU=."E,F$-U5..Y%
M"4V6& Y3VERGQ._ 1O/"V*82*W FBI=(O) 5M3B[$F]K$Q8+DLUXS1GSWMLL
MLD?3W2&^F)"Q5JF<-&)EL39':=D\#R&W)DSIMSL<D,]$>[3DOC"ZHQA%KNP<
M<)H0^8$BZX1>O55$T#@.+6#81-_!8IUL&-V(-BYIF9)5]4KV/ 4..2R]"6(;
M#\;>XF-O5_2$XHKYFC;#7AB475$LG%#I9+1?''R][GR$C--PL.9\[&3V)3(F
M'D+,5J]L7]VTLT"*00Y)DD.DPL;,9#W=<:)#DU<X)A.&S$G.O32'$)MB+)1,
M/M738-+ID!$=D_&7(VQ!%O+8YG$J53@7+.;?#>'!$"43,@]OB_%=&F^=K8PF
M#F@SU$!$RK(HN  B5(CI3$)RF5F]=X%1B*S$(<KN*XJ<+\(9'D(:0+"3,&+X
M?;:41(C.@D3H8?.BA-7?+-.'%DZ1\TR2V$:HFS/N8X. 9$Y'NZ^.'X-8TDPP
M?1$!GA=(HDA""0:W&^%PR,V9^JP4G3],*@]!?E=D=T!GW>:"'W4ZX66G,U:.
M<[*O<!0Y\<,7 2\2HM]7Y[F:"J4"FOQQ*UCQDSDKP Z+G"\)]MR04K:<.RF6
M'/I__O(+O,% ^+7CZ+M/$/GP+_0VO*&-F?5D0MX1ZW!1,F701AFGIMJ/XC$Q
M;:S/LE.B^00525)YL9G@VBWQ>]G/Q];Y/%DJR1*62%*IA< _.99W(HWH\1YD
ME!@3(T]!3577V."UD$+E*"&__3')U(T4+D<LX[SX3A$A^1R+@N0,6VAO@A@$
M&U\4<R\)=Y 8[_,MO#3-8-I.D08'+2YB/(UC/.4MGJ3@(@H-MJ0.B=8Q;2.Q
M'2P&]=*74M ..R0)6<["EK.W9,3,;:4BB,H.$ C*=,9_63H6^J$,H(I#?&W
M4RR(] ZA5@2^;.*3YL5DY+6@6"1-Z=%P0!@BK@XF0ZSD!;SP38.Q#JPH E@:
M3C?'TZKNK#(3SF=]$F/V ^Z&@Y>=X"6,+2XA(,5ABU2E-;MXXK'U0T,N0 V9
M8*+0=#<QP-:01/6<6!0(P7% BLRFM%B" "1TS8?DG*<#5F:"4J)5<IYD3;_!
MTKKW<1Y(%IO0C%@EG!H[E&/QX42O^T0[;4R"Q17GN#ZLFD)"HENN&\O)*&N'
M-00*ZI6M!DBZI(":-U*ZO+]B@0J!.H<<Y0H"MRAR1E"']&1&3Y?K-+\;XD/D
MYIM,Y^_5R<R0T7/5Y*-WL&YMB^I&6763N6]*V2 GU^JI<M;3P7[T27PMI),:
MZ'.DB=CA\*E[\:)"V454UM5PTOHB(%>4_T341J:P]R-VB^SX)'[1"0EI0N3N
MD=KC%+,7T!"UJ'1#SG"+J_A45'2U8>=])0$?"-6[@$[1YV:9M;F;9J:97>R6
M!+N)E/6Q* 02V+^6MB)C@S0!9S__0PCLX6#T PGU;LXT*A#P!EWJ?=@YL)OZ
MPGP$>O-0X]@MH:LXJ]RIWB0_A-Y:&#CGVRHZF::9'9KI+6V'<_;0RZ;$5SZ!
M*7D;D:A^OETA\$?DU%X<JDN)V+W"8MZ,/"39FM7X^J]*N3U^YYN=9-ULVT$/
M.)Q5B]$0$'"H;E<+VN=QJ<<V.5071-R"I(L"6W_12;J%4?CF<T+P$\MES^(_
M"TNRU1/)ZO\4G?]_RP]NU+$T?0AH!X17N[3.M-*9A'"&@JLU^=I4N/0*643#
M5:)#Q');VNQDIBUYMDWA;M\[OF3K9&;-1)U],$G-M4274L.V*V*9Z?LXM$%P
M8=<]O52L\*25:K=H_O81'5]-'&,X:,W>)D: 8#H'2^Y\IP_2J[3V;T49!3I]
MI7=?3PHL%%\$9UW+!J$O!^56<;<>QX\(E(=JB(3[FAQ0[RP/%B*%2;R'F6AG
M? 7=J(F/(>\R91.=S2JH0U(#4A7G14"H.O=2@HOZ%T9GH<FFP59 X-9D4P@3
M]V!=@CU1T3H=4&806O[V6_7BV==?=(/.OF  '53K)M^2Z_3'"#/;J>6&E4*"
MU))9[PTK[HY@>&O)-/91)'! 4TP'Z7Y.)SC/A69$,$R":!2?+4J;[(J0>,@9
M#LK-KN-FXG5)MVO/-#JE"(CSP<U)30J,R(R @%!NG11/]0])*NEFV0!#3]'4
M(OU]OC]#:AAS:;CGA _'&4-5-_>2U&4)*'K E:2HS"0!<2E[81G6.UF# ;$7
M>N:<HU (Q8>H!H&@H3.20ETM=8Q:4C]L%M"8]6W&]4>^)*FY2Z#!&VH55=Q.
M@R+K+I[C=S^VZCODJ3=JHD*XV42)?-UV9$F[PB;%-$B:</ N-Q47W.LY"5KG
MJW[@@OJJ3B!>0G2A)J)3I<_1%>Y[]XNPR1-*]+6+BCO1Z2VVFJ=03YFACY+.
MT;=F\=)MW:U/5DCW7$S);87PXXC9<']2:./H%'UQ-3/'OZ7E GCSW4LA:]\V
M,VT(><)*U"<A]<32C\<%7QM8;FJ<>_'&)[.E*^)^?+O[*EBX$X85%:M>#LWZ
M2=@D"ZLW&BN0%%DH.(R,]/!QWKP&/8SC&'/]<ITMF)0GO@#:ATF:F,1*BN&B
MV+)7H!&I[P\'Q^V^ML_/Q6BX0"-N5W3K_8K[ZH>Z!.F,.CT;,4OVHQ$K#P>]
M2[_ZM-K!/X0PPJ0'^R]>VGQ#,=T>OWE[ID[.WKZ].CX]/;_X\6]/#I[PYYNK
MXY/P^2/!NS?D@&JDM)IAOH,O2+W?7H=ET"M)7)Z%#=$L6_0?-G :AOGIPD:/
MGMV>OM[V=7>^S$P01OCO[[_][OO#]7&]"X,J6Z;";1MTY"CYD5ZCB<J*E<XD
M#5:[WF8A7@<W1]U> U:<PV=J^#>EAL1?(^"SN:):2$!-BX)87?M2)G^E#U=\
M>?-$VFV'@SG*4',2S=+TH=[G4F-W9XM,!XN>A R7?7VFG-VA'!0,E#IWH0\-
MQDK;W].G4-@V0(]^J*1>F+(UV*0VK]K_:VGD+PR*.-P!$+F!D\BV2XM.+U;;
M;L6&CN^Y;.V\T$14A!:[Z-:OYFZ>,"=;>^+ARRT'-I2+(=H@]1TE^3(I1HL5
M"B/IMSI/?,\^RN$G$F)PB0B*'7'-'^N&>L]L.. RE> FK?XT3Y0=HW"90#0]
M%^.&B=I>7^_RR=?<].ON:9G<VORXE++Q8DQ8T3YQ%RJDT!J2H^&4'*^Z+$-8
M*>;K9JMP)83%$<SQ$WC#=F)S::U$N53<!MG71KTC5/5K7S# F87&35[WQA+^
M:,1@D>E\+4ZP;1VUOLP&[<(Q75_%-^A$@WL+Q4/DTO?=W,<@'<>;"<'?NA0H
M;CAXVI;C135:FA1GF9M54_ W,7P7DN&X!-A#NHN3P@%*5DY\Z4EX@O=9[-%"
M925UMEPG)Q/1@#O3@D%^>EJSTUY)]Y23>AU?C@:HQU9JQ,.*)C.+&=?MSHA*
M,"<1/2*W:-?*"*TEW_-QA])#K/D5D4PZ]5B=H&;/=S 7-4YIH6W*'1+.5%4F
M74?$-;7<_,,<[I&SZG"IOY,HBO V.,>_\]CJEWL*P+=DQ>4^!MLT6_3Q*-&K
MUT?^2B*Y&\;OB]WR(C<;0:H8C%'3'^R#"/78V91\>RO=8E'K<'MG 9,XH=]Q
MZ-@W:[4AG[8RLH7$QR^0W755MR/?5UK)4.D,<:$<,S%IC<P"7P7D:[BX ELR
M#7P.$9&W?(RS$^D7$D"-%*4CQ'S5+'C_6[F3[^<+'6A19QY+\3A4PS? ;.5Q
M')-1=*)$X B:0+17%7KR/.EP6*2]'3&TU6FWA5]W1#8_IGCBZ\]U$KY.XNO/
M=1+_+_G3UE'H^@D]/-_IG;7Y1X;7'ZHXX,[CMN.T$_;M7'R 8"Y&D&?17*W2
M"I1N2%<TQWI@ETV.%:_()BMIM5IJ]0D1[TDPSA";0)ZPC37#4YH&$>B#ROUB
M;,07$RE4U$[EWD)_/XKEZEN(2S+41VK.T=E@+NO@GOJP6*B9ZT9:+UG;(',@
M\7&2J>+LB6Z *9QS_04B)C:^.X7LA7E;D.\]A"7?X^?#PZ[RUSNWI@!\/(ZD
M*X1R4]>#[X[!%>*_W&8A2F5[PF='Q/UY[HJ)+L6E[>Z5;\[9=+.WW[@2#JM3
MZ!A7N4165E"G<1-@#9/3NP9C@^)%;@II[P@2RZ!8D+GAT\ ,Q-F)OV]G?0>V
M/7+IO"5[D_Z_PF[)\B!2=-(>VK,7N3].DDI<*%GG_KX73G'LQND?5]P72]PR
MDIU*\HQ.1PSW2&P@^Q/=Y]5VMT9V:K]-K5UCD/:=4&^)K#C[WO_F*,W27V'+
M[:5H"23IBVQK!\3XQK'F0HCX%L7VJITU2';D0/%;"[@'"V9/XP=>-QG)X\6B
MU-;AIBY"[Y7<T;D[11/O'IWHE1Y2J6A:;^#?K,U!3(NEDF[PY[.\?7[AUHYP
M%+SU_@0"KMM,]M75VIUQ#V^B"^:L:*N\@U/'01!3<HCS$=#C*E2N!^_?08N)
M3O-/N% VNO250UO:AI\S:-U@*4J#%Q6Z?S9+3?CB-Y;OX>:WW6'/FY[.S-/6
M4)-6C!TJ9/HC/,FRO:]P@@V+4K1-"+IX4S[7<F$T)'^-FW&:F%%X@V]U&8FM
MC.Q;[BLCUF^L''4C(+Z1,VJ3:>XNXUQ!TI@8O@"PB=9X$I>< G>AAKMPHGQ0
MHQ*CR4J3R>UY9;@;([JY(11AADMO25M+!VAJ..TH1<C!I/99Q=WAFUO@;H)F
MI6DP[J_Y]UM*7>X.M]P&*IF$Q(7W-OU.52COZ_P$#*BPP<]E3L:TD9_5&:F7
MSU^0@:QN="8_K% :0[;>55%6&4T\4I?7LK'OOWOQ_)N=HA8V F]6\W$AUL[/
MNGQO_A)CA]8/&_WTBUVN7\%-M)!9[O3V%U=<:)?JW\GT6-@*%0F"B"A;Z@1)
MX8=;?OG[Z;Z_*.;?C!ZV3]@7%/Q3:Q6>O/[F3]Q&7Q#VNL[,7HCB;0NV/K*2
M(AH-&/><_2?NF8R"LCQ;3T0V(!A11O__.,K8 ?+3G.DS_ Z?_# ??K_O7U!+
M P04    "  9KWU6</K-14PE  #]+P  #0   &EM86=E7S P,2YJ<&?M>6=8
M5%O2[H8&&A%$HB"T(%G)&22K@(!*DIPD9Y#<Q$804$2B@ *2HPA(SB"21'*3
MFYQSSM!T?^V9F3,Z,V?FGGN_7_>9U4_]V+U6[55O5:U:5;71H^@9X*JBG((<
M@(6%!3S%_ #T.' /P,?# ^/AXH/!X$N7\ D(R8D(+U\FI"8E(R:'7*>[ ;E.
M2TO/Q,5*S\#!2$O+)GR+@X=70$" CE540H1/G(M?@._'2[#P+UTBO$Q(141$
MQ7>3]B;?GQ[H+P )/A8YEA0(BP' )L$"D6"A6P Z ,#"Q?IM '\=6-@@'%P\
M,/XE@LN8!>57 6PL$ @;!X2+BX.#F?7%S ,X)+BD-WEE\,A4C<$,3N1\SZ/2
M\!GO%C=1J/7O,/&;. =<(J"\1D5]G9F%E>W6;0%!(6$1T3OW[LO*R3]04%1_
MHJ&II:VC:VIF;F%I96WCXNKF[@'U] I\$10<\O)5:'3,V]BX^'?O$](S,K.R
M<W+S/I:4EI575%95UWQM;FEM:__6\1T^,#@T/#(ZAIB=FU]87%I>65W;W=L_
M.#PZ/CD]^X$+"P!A_6W\2UPD&%S8.#@@'/ /7%C8'C\6D.#@WN3%(Y51!1L[
MD3'P/<<GOQN55MQTB9%?;8?"Q+F?@)))8)9Y]P>TWY#]GP$+^+]"]CNPO^-"
M (0@+(SQ0"2 %+ A27<"^JH;[R_ WME+K*WL(I@N'ETG75I,&VV;B0:"S&<B
MSB@%IL_WV$[,T0!39W/CX3S=7F&AOZCRB:8A/AI(,WV$!AH9(GYYJJEI3FQ-
MT&BH=<I48 KPMI6K35;F.'5*C\6QK/7Y,F-YJH)+_&_8,QQ?(FZO5@BC-':#
M-YG>/2?NQE&@?Y,9:;FHTN*5[/7,"5Z8\_38HM^Q(&&!E)!!@SMJ9+''"I3\
MB[P_/[#GI_\G@=E ;__+_O\!.WO(2?%,(Y&5)#CZ7+&?X]-6W)P@V3TJ32 F
M*N'HSG[*F^F]QQ9HH.A=X_M4HL9@H[V'=6)HP) 7#=Q>6W_[#TY.T!7S@!0:
M-ZVS_Y('H6"[:#^S[6H_=C06T5:VDGJ%='FV1#D'@6 I8++YW&OO//6 Q8KY
MG>)WT5,]>F!B1YDB:LZ76&G CP?*</2]#9^KR,'QQM(3?8',^SQZ(WG(]<'\
M7A];-,"L-+M\X5Z/!OH9_"4(0ME2L7^CWF%NA[)S<$U%>?C,_4][[)VE!%A,
MX5>4R3=9]M;.6KD<"C(J^8!O>5S(/"#@,=X=>$.%P)'SPO)JL5<H6[8%N:HL
M\&>(8EF*IG$AJ1L-&/'"^ W?&+KLUJ(4NJ8/]Z_M"V!5[G2B%.)#8.MM4HL&
M!LXIA(T+[Z$>J#I3E,90'Y:ARURMKSO$UBC^<?5@-K^5V9?B9;O'3$W:7^A@
M#LKN%^S]N:G$I'5WVL=@?6B@PJ^Y8?V<V#&EMF??9*]R>6D\0OB&)8V+;L/-
MJA&6D\Z9T4.QR[;>5%N.N&^+']5G&[%'=R+%3?>+M(LD=HN0L=PA*8>(8S1P
M/Q38Z#I+?LR1*K4J SZ300.J;6;GC=Y%G6=]EH.GK6_!%VST:."!>-/?_AXZ
M8\-^GJ*^:8J%!A0OH0$Z\(6\I^3V%!JP/$SMS5N8^PY"O;T*RZ0[A"S\S@$*
MWHW+<;-URGF]R;VI:63UMKQ,G6SI_L?,!Q/N':?*$-%/F\2MPD*EALW6QM;V
M-@Y7FRU]_>BA\^8X)0'$X%R(:&%MBR[A67^EK?>LU2Y'<3'O)6&.UV7A&;3J
M A%$%V$&0ED"=\+B"=];5FH MX- M$<4^I_+,3)%G.JV?:][*RIU)6X*5;D^
MZ@\-T1]E0@,O[+,B>B_73.V)2KE-GJQ-;Z#*BJ&?%;AC.$AT'SK<Y?!P%F!J
M;M-WT*=<WPL<+]")_ZK+S@NU0W5P6W-,IAFC 9\HC2T!7Q/\!!%NXR'."#V#
MQSP*-^!LJ*?PQ4WNNE@U.ALZEPOJ7 =!/KX*S07?W!]*1 -Q=/L#6Q?;1S!=
M=<F<F-=L4O,K/R:DUL0ZCOV.C>(/"PV'7<S=*X8YN:*\O*SCE]WJI@\[3D$H
M;-B,(-PZH4MK3\&>0]G6]VI7!?QB1D)FI7/KML% 66SP:LX-&X?U7</\P]'(
MWKS]UVS$9RHRJ$C8H--[C''6]U!EU(>2PSQT!ZDINSNP08^8OXC1*,O/@+%F
M1^M;NMV#7ZSV%_/_[5]:"^7:XQID8X%1NC_;OWP3X5F*2(D_&LC"P6@]$)51
ME^*Q[7;Z8P= A7_-9^X[\<D9OA2<^"R<GW7R?-+/:#A0,@?1AG$6,I0D\5G$
MZ2I& ^=2?]U /$E'&@8/@+4W83QRZJ][X_DJ)^E@7)3N'SSU+R[YY!>71!Y@
MYBY2?FP2\YLRE$].I-:DEG,FSS'&+O<+!5+_-4#,)N5A&*]G1?K0'?YNKI]1
M_/,./1RI&-"I@1<88^;.\_E.UX\L7MA<D&-)]^8=%?^D%)079@[5NRZ3HMY+
MJ0)K[_L/4OUDC'/M+[\K! U(_/7$Y1^HX((D<Y+_(L!O!H'U8I TCEU8_2;O
MOSB,0)'HR20F1"\YGIV^/DTXL/FS ;UGI/RE*]&5?8VJ-PNA"(E%LGQW4#*8
MR0519E.8828($9KKR(XF$;?@9]*>J(;(R="]8_ 7&3GY8 MIV,_J@7\9H#F9
M?T^EQ_3XY19-QCY#))C),IM7H\Y<0,U'X\3G%0,_TW%MK#9I8S7$]_8QDAW"
MON$DS;75E\)C(.Y-MJG R%[#%_2UT%3?'@28UAM#XZ7A945AA@2-Q27AE_//
M$]MK8EW>/WA-G]*%<L5:>_L/,5JSX7/98($N8F]*=-8A=U[JY8'D82LTNEVE
MKVR,R\2ZJ&!3I;Z@;?L@4>B $PUP,A[VBJPG;'_$ $N(2W0Q9^1CVBVSZQS$
MYFU]HHO0PW9^O13\YH;;;+?7TB/OAY5OCA7$WE9+.5C'F8_J0=5XZL+;QRE6
M#Y<014$.2)X=V^OV$Z7MMHR/F.RO8[\(HSR5/L6?]5\=="W<EA^R/_S 1[/N
MLO= 5'\AWP.\>G^>:OPMPB56HW?\<3R2=,#;=_+RH*JLPDM567+@/Y%6$M(!
M#42["%_XM"*[O00]>]NV3UGY82-=1EU]>-/-W*<LAA",Q:G00*R;VW<?/LQB
M\]GIL]V(4RTM:5QR3;JPPD*[.IK\B;&Z51=(?IDC]I:;R!JX<E6:)G:Y01"S
M/&MG'U5KB 96HO3#IAB&8QZ]MBCP$B]U.[IT,S9+J38HX2:Y\;>NCN)WQC7(
MZ4F\"I][DM7<;49XV3GFUKAA'L(!W[4MN/:*8CN>R7_W\K/PES#\_=[^.^'0
MDP3P$3GQC*.!KQ1S;MI[-93Y+'UB>H^]B,T=IB]L-M>2\[+'U\[LCJXIU5#'
M6[>K>)-L$3/D"9:.6I<7.X>V[$RE";9^&K[6_4%>&<8P?U$<$2>ST1EXV&T/
MM^EIR7F6'GJ+D"T]%/AWQ-[C)PSK$$U$-9B@+.JOURW/>R!CWC>N+W$O68$<
M9^.1,=Q7T,!(&.Q[3<VB)#6L@V]G^P+:CLQ#,0X+=G/4MUS.U--FQ"&=4F"O
M^^2-\P:Z/9','PJLL7V\(S$YM)5(T3JAN?MMGGZ\R^S-X!ZU C!S'IJ\YVG_
M:3&!QIHK4_9[,[5*CR^6"7C)"MONB@BM:Y'DKY=XF1\S@CE)BV_UVDI.=[3J
MN]YX'(?BLC'">UQ+7]H4FAA#.W<MLDP]=QV_Q U75NSWVCMYE;;2IB4P&-/R
MT(:'%&4!7N;DJABS_S/11KR:6+D^&?**C&$BRMH/#.TXU<-<1Q_</C:]Y8N4
MH<;Q^)A0D4*9GV6@_5!28?[6@43$LOZQ?[EH#MQ(L8YU,\'%DS/YDW]DSDZ3
MT=>/QX9!5>=UG?VHE,6].PBV]$S_]% VX-_1GPI678UP+L$BRK6KU24!'4_X
M[SPHU/EBT&!G7BU>N9,'$ H+YOR4@ZE"^TY,6F<;=UF>0[IS<213ASOH0R @
M-$!)_)G!_XZ!D#93\1OZ!(3J51+>BO:X3WCX %F8EWM>H;$P9:DTDU77RV^0
M.X5R?!*MZGU% J\W&2Z5B7*F*#.2T#S%)G2C@DC&9DC3!J&!YG6:<:([W8Y<
M3T/AWZSW3HUA<,Z]%_EFSQ3":,-N*!<\/2E2^EQR4CVCEZ_'#N7B*N36G=-.
M)X!'X3>9B$HH&^D>(/:GKZ.!#K433S1@4 0[>)!*?/>/]%5X31T-A'JTK>9Q
M=SHZ8R4.F%XMA,UP%C<$Y=<4>K<>175F90WFU8A9=GWQ" KN %_LN9RH^FG!
MUKL0T4L.*?O6^Y-^4N_[^K4;J&KC?%DW1K@;MEJ[/W5?S#6Z-<XHE:$$RQ\K
M]K1=FM3'G(Q[!&SI_G^ACUIGY>%QN8X.:I!E_"L*COI8W2P;3TP6-BG<#=+3
M*ZJ"MR:Y.!<5C)UB745QU!VVK@^/9>MY%A+,'S_SU]X?9R(>?I=@/1;3KUVC
M]6I#4 ^?VXDYZ1K.91>H)K^0ESU-N-\'VX=3B->E5@[&UVYZG$H^G:X<@3AM
M2[]:^:B4O_K&SD%+M8P'/&I.5C@Y];Z'?U/##ODH:TI>/'U-Y&GH8L']4L70
MD@=U5^OV>PNEN*Q AJ%Y+#G6M)@[E$R>:79(E\F-(S$<BU$4.\71UQH*YRP?
M)!,P Y,\H"KTLH2P8;?^'#]',GZ-KH ]\N?P*3&OM)Z+U"!<=\SI)/KTB);;
M)</ 0)SO0V;)N\&BNSSR59L&Q+_$7Q/HN4JY[V.XR&$(W-*_1&)#9:*N.(G=
M_DF8W5,9ZJD'1^(SH$HX9WKE0(;9DWU6;.L%[;HB(3F02^R&<MKJ$Q^+FA@H
MOY8!8_>=YQ6.K-_/3S&HIJG;1 N\A:;-';YJOJ,:/ VO5=H=#",D&Z'*RP6U
M<)D,)2H'<=J[\3I251FP*+E621_+/0AS)C?1Y8W@\5EV -TX+)YC'4F<YPZ4
MRZ-,CL->VM_@M.LQ,]^KWL>:N?%!8GUH_=\57O] Z54!8OG6]HL&_=^#J+P"
M>&QTV:Z[>\B3I"HS!Q?8L+!>,.LI5[&B_.A[FM$ =H149.%4U:1-V[T\&Z'A
MF4N%#(_N]IWIWY5FW*6!\1O()?I2YF2/&]V%>8C;S(\SYLS"$X9O'0V<G5[3
MT<VPM;8]WCZ9*)<E5^/_W3L7!#GQ4--:C^XBYE7KY%ZV?15[H6-Z6B(41S6^
M.;)NX*M9-<A10,O<O5C')7>WXW8>XZY DF>94(;A$SW;O(C9 H+EAR\Z7=R<
MEAYLWZS8!\DEAGO.QQTRAL48$-US]+!W#]HL9'@OTV0UP0/>R:,> KB:9.BQ
M'XM*X!*(?VP9RK]=XA*WL;]:!\[]P*U4L3\?FSHPU69VC8C4I^O*SMUH>2K&
M10E1B@+6$#>FVD'9.B_;@LX. 0^/VV91U&DD+\;#WT-<CIUYIVI2)&_6'N?M
M\6B>AGQ7EO8]I?N@\+!K]B %;"CK$R\\-]9G*.NTR'^::1?PX&Q#-:DDRA\
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ME]U+]I7(,J@=)\#SV]GRWFWU8J9XEL+.H+HD4H3'.;"FF]DWH5/^/,GAJJZ
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ML@#=3A^*'PVD^#*B :QI-/ Z W6=K@VVOYT)FQ%# [NNJM)@I(!4&!I8GGZ
M!KYXH(&YE?\*\U]A?A;FTZ3MW/++.FL3 ?O'$ E.LV<+363LYC*,T>VGJK(
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M><W5C;'_Y@N$D&< EI((X%8@+&:&BL&O*ZU]0?#9\JD9S7FTNAX&Z%QJ0KG
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MO&0Z7"U\FSY7V(ZK*0=DV78;+,5V7K]]+'8>:;7UO6&H,OE:6T)"D5!VTLF
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MAFZ2V&& <C7\Q $Y<D#]/P@B$>_&]ZC=@XV,IR*KT#%ZOY1!&OH"^:'-D[%
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M6>)@?Z$.Y_?!;Z1RL_\V*=G>&A"N((5NG6DXT!G)&2ENZ.QN:UI?0!!*^E8
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M6%V%V3[1>1&M?(V+PK#F.:.<+OR*LEO.U/BZ6/O2[/N/'9MY@62YG#V5"J+
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M$16>M34T5#2;:MN9.KGA63X^+OVDD?1N[=+[!9&)GI7H<IKI,(<PDY"QTKW
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MD;>QL2WI(T0R8URG[$@#'%6&,$!@]1D:7PK--4(VIE*3H*HL8A:769^X9$I
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M*@;PG8D\51<;0^$Y8X"+XZ,=T(G_S,+;O$5V55;\"X\NV?%^KQ7F+\@/4)P
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MDC*2  (" F  _P&P>4 <>(R"@HJ"_!@5%14-[?$3#'Q,#'1TC&=/\;#QR4E
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M[KG!,]PK-V2CC;?8S=$++(7WX3<4#!OXQ<AN=H9)]\V)&S @]3UF"0R8+B+
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M[[JHXWI+IKRNX7ACG["BQW[N(O%=F,UBO)#(3RC7D@;5&@RX>$L* RK\AV&
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M1MW@MY*$V+N&D9>!GTQB\EE=DL4I(M7T(.I@2C,8.@36+S&?UQ-W??3#CGJ
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MH!*Z.&_00GVH@@5-WRZXLU1)PC?O\DLB#)C6J@ M!0;XI)#$D,Z[SQM)(\(
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MNE>=H!3ADB.55K&L[RKLB=:<2+3=EBC(-U$D$)8\ X?6G9?LOEQP997/6A6
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M9Z$J73S\[76R >C=_CP)@\IO)=[$=[235J6XI&-Y5[>1\X2JZ-V!@[TF*JW
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MTB%=(C$'OG/>][SO6>>L]7U_K?]^UEYK[GWOV=>^]EW[>3#CF'F 3%U931D
M@4" ^=4#8*8 10 /!P<7!QL/%Q<7'Q^/@(B2F(B0D(B6X@8I)2,=,Q,C'0,#
M"X<@%PL;/SL# [<X#[^0L)B8&#.7I*R$B(R@J)C(M1,0'CX^$2$1E)@8*L+*
MP"KR+S?,)X <#Q@!"8-!;  6.0A,#L*T \P  ,(&_:,!_]% 6& (-@XN'CX!
MX95!-1F !0*#L2!@;&P(Y&K4[VH<@)!C4[ **^#<T'Z*RP:G%'F-S,!COU?>
M2J4SM,LA^LPU$)^ F@9*2\=YDXN;AU?L]AUQ"4DIQ?M*RBJJ:NJ/=/7T'QL8
M&EE86EG;V-K9N[E[>'IY^_B^"0H."0T+CXA]%Q>?D/C^ RHS*SLG-R^_H+"B
MLJJZIK:NON%S6_N7CLZN[I[AD=%O8]_')R9_+"PN+:^LKJUO[.T?'!X=G_PZ
M_7W-"P2 07^T_Y87^14O+ @$#,&]Y@7"\KHV((=@LPKC4"AHXSZ%WV 3>8U'
M>0^94=Z*SRZJLTOUS'6(@)I#[ ?GWC6U?S#[YX@%_B\Q^Y/8?_*:!(C H*O)
M Y,#<L AH3/U3&Z+O_NZEV"*C!L:)2;]3 #@>.Z_( )BQ0 !$1'.-S;T&U+:
M8TTF3:%;+Y>-;9RYR2'#YHC4G,<M\J14<V]M(7"60"$DF87I&SSY3Y^V=#%
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M<NN=-6>MH4!R_/./IGOG<MR?F--D/(Q>;GGD&4V+SR90NG5(LC"E%&$WJ7C
M/2CU$WCJ4S)B>=)$G(GTHFC8[><IVN=7P:B9D>UA#*!1TZ0T6=E>@7W8U<^-
MU7=="!NM5(G9ICM7-NV(QND]"A#*B=(@D6!X\?VVUR)AET!VPP$[HJN6CZI(
M,2$X2X6O:;O+HE*B0\CW1+:I7$7D>8(8TBU99,GZ_5C" +OJV)Y85*-A!):!
M[XUU>0:]CMH%/(H^*B>4(3JOWNK.H/,IQ'NQMV,N^61 ?23ZR[W]SW*53>0F
MT$6;!.<$D5[*'U1A LF[&C02*PV/*"T#+4P"=!G<<?-_N_"@'<'WV6W9A8/'
M*=,_F3WPA<LS!->^+<V#>=IN?5MQK@P#I-M#9%M_7_2-F[@=B:7M)DEMP+.1
M[35]]M;@7OJW5@'$%Y\]HR1;;X\3VH*+PBQ("BGO#,7@*ASF)O'I]'=,4IA)
M1R?<?7XT@ 9<$V;%[2SKW*P?/&TGSZP;2$LT_2"K2#4_;U&71TH?RJW3^^%.
MS1HD?7Y%A@*^=GKJMH5:-WM0Z</FY@P55EOAUGY=AP5B\6#G8HIG+:_BUIIL
M+5OE6T8P)*<-@*].2.-+:L%W&$"6%0.TS%W8\Z'WGV& 5#4,\#*"&W3X/WSX
MTZ\?V;K%$0$+HU8)6\;?&KPT!$<_U3-NFU3L':Y) TM3M,?WXV_(;Z7^VKRJ
MOIP<^.QFE1,@G@GLA+%W]QG.\Z;>:4_;W:%Q4Q+XDJW3I&A/8S+O^R(:3:F%
M[;&[$E/T^BG9/.(@U?-D,PWI@P$L?1\+\:.M?L5.OICJ<&0M[U&J,K?R3"N%
M1-EF!DA5#QY6X6$C).2!GM6,9U)'R^-7EU[D;3%B ;J;U-K;X;6LDC)+Y,E'
MK0#B\-.7*PC;PTUIM(6.X5864KD#E"A3IC.7EI!VTE7T1GE$\<'G'H9^-YZI
MD_ZMZ2L_]5<WHIJ[ *_GC$ 0B?*V.@;P3G#NK63NR+[L*</W3+-\Z[CH5$?O
M/Y8,2CB:)^!.QTTB?"35;Z[(6RE2OA38ALNL):R7M7OYCH(2AG<OYC&]6RN4
M?3U*>#B"&ZOY,C)OZLN+ H7G;$W[J8J\PCH&6 H2$C*Q/FB81"PA-VNX9P>R
ML/ W('$5!.I_J"9),1/_!E!+ P04    "  9KWU6'<V\B*<J  !<-0  #0
M &EM86=E7S P-2YJ<&?M>F547-NR[FH:#18([AH(%EP2/,%""!;<71IW;R1
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MLKJVOK&YM7UT?')Z=GYQ>77]RR\0  ;][?D/_<)#^(6$C Q&1OOE%PC)_9<
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MB@S3+H:U#PY #-['13@([5V->=7=QNNAP5H880K:5*)P((;Z-1PHA\"!K'M
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M&Z)E2V1,Z\;$1%^.L>KOJ)-I:.B2B91S' XM=9KO"E!1%D<G8&X'<(WDI0@
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ML$GE#9;?*!(_"F&'?J9PZA(TK6?'6]HBXE7A"Z8+E;??B#>IY@I@?LCJDP<
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MVR;/(Q_P?E,[_8I9&D4NV0\;6Y J68VW>07+1J,Z@%BY_-2P*DWI%!Q1?J1
MQB* %/6<$ PZ.56ZBB]DB\^:VY\R'3_(^]3](48FQFTL7DB^ ?.9A;?I>9?
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M:3SN2'?F\"1,>R;#GA86*T/IEUM>V[IZ[64$_YU_YOIZ+]%\P'=2^NK*#0Z
M-]O3+G""$+:,<-/H1^_"QQW'?S/2%[7LH0A^1QYMWN- @_F=MRJMZ>7IP(CL
M$+CQ>K@:0)!?3$M+4 ;$^2:#)D94_-"8G3EH>/G!3CF.J/K_!_)U_4_DBZ*@
M HZ3:9+)X9 9X9=%LF)R3J:XZ"YV:V[;YJZ>?"+_WG'-L_ISZNJT7NQU=CN;
MK-2*O=OPBEY8\2/5#(L'E]!9K,I4[^&F"O.%*$_3QLN5LP2E5=W1^_*G5)T#
M:@='@BBH-$-='"F#M]6MU^*LD6>@<4_Q\H;&H^QFPX1CDU"-9$D+M\3+L-:6
M7AWC9:,\836^CM=S\9749K"1)WV:/M7R3U.%"OS?97+1/\5P><='+[ 9NB.L
MLLIP-/2)/:G/H[$G9C_8MN$SUL " 28<D"M>+27"P7+#J,;3$VKG&0B-19[%
M%",E3\U&)=&#9?H\9X,BB&!%Y"C.HC=/^H-QW0E=]:+QRPOGE5Y^_NT8W=PZ
M!'JPY&%-)@A,8-DGY=;D['B+''TB$HPH'AA5LC<.?1J?RG'A?-M"$=55W^2
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M+K VQ.:5E/YG*KQ9,8"QCZ:F2!*HYWL^7&U^7,4R7BJTJ_5PO&@_YV2_2J5
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MH@-TDK&Q1>7<FDK% -U*?1C@'+90H],W^=&U'T._\9NC]0[=&&"9V_H[13
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MI_28][)![W@LK$/#C)!XR&HN$Q=FHUM8$CDPV4O@&MVE8]5P 0/42J-8>^2
M:RI]=BZY.A6E=[)Z:^%Q7"4U]*:*JXH\\)X_O]5!,"/_ U!+ 0(4 Q0    (
M !FO?5;=K,DI=!0  $C7   1              "  0    !C=FMD+3(P,C(Q
M,C,Q+GAS9%!+ 0(4 Q0    ( !FO?5:>:(]97 L  (A\   5
M  "  :,4  !C=FMD+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  9KWU6
MYB%P_71"   ?[P, %0              @ $R(   8W9K9"TR,#(R,3(S,5]D
M968N>&UL4$L! A0#%     @ &:]]5C]KRKCPF@  SZD' !4
M ( !V6(  &-V:V0M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( !FO?58A
M?)MP]T(  %DP!  5              "  ?S]  !C=FMD+3(P,C(Q,C,Q7W!R
M92YX;6Q02P$"% ,4    "  9KWU6!,O/2L A P"B[14 %P
M@ $F00$ 9C$P:S(P,C)?8V%D<F5N86QT:"YH=&U02P$"% ,4    "  9KWU6
MS:N*/.0   !Z P  &P              @ $;8P0 9C$P:S(P,C)E>#(Q+3%?
M8V%D<F5N86PN:'1M4$L! A0#%     @ &:]]5D@FA4AZ @  60D  !L
M         ( !.&0$ &8Q,&LR,#(R97@R,RTQ7V-A9')E;F%L+FAT;5!+ 0(4
M Q0    ( !FO?58<F$BY& @  '\S   ;              "  >MF! !F,3!K
M,C R,F5X,S$M,5]C861R96YA;"YH=&U02P$"% ,4    "  9KWU6*_DOK@,(
M  "<,P  &P              @ $\;P0 9C$P:S(P,C)E>#,Q+3)?8V%D<F5N
M86PN:'1M4$L! A0#%     @ &:]]5MHV*C-#!   G14  !L
M ( !>'<$ &8Q,&LR,#(R97@S,BTQ7V-A9')E;F%L+FAT;5!+ 0(4 Q0    (
M !FO?5:\O5I[) 0  +\3   ;              "  ?1[! !F,3!K,C R,F5X
M,S(M,E]C861R96YA;"YH=&U02P$"% ,4    "  9KWU6S#WEF/47  #&;P
M&P              @ %1@ 0 9C$P:S(P,C)E>#0M,3%?8V%D<F5N86PN:'1M
M4$L! A0#%     @ &:]]5G#ZS45,)0  _2\   T              ( !?Y@$
M &EM86=E7S P,2YJ<&=02P$"% ,4    "  9KWU6]?S?Z$$N  ! 2@  #0
M            @ 'VO00 :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( !FO?5:J
M_H &'C8   H^   -              "  6+L! !I;6%G95\P,#,N:G!G4$L!
M A0#%     @ &:]]5I498/N)'P  (R0   T              ( !JR(% &EM
M86=E7S P-"YJ<&=02P$"% ,4    "  9KWU6'<V\B*<J  !<-0  #0
M        @ %?0@4 :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( !FO?5;CS$>]
M:$$  (%'   -              "  3%M!0!I;6%G95\P,#8N:G!G4$L! A0#
M%     @ &:]]5M)I8(;G'@  2RH   T              ( !Q*X% &EM86=E
>7S P-RYJ<&=02P4&     !0 %  L!0  ULT%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
